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Carcinogenesis covers molecular, biochemical and cellular processes that underpin this 
field. The complex nature of cancer means that a broad understanding of these processes 
is advantageous when designing novel preventative, therapeutic or diagnostic strategies. 
This book commences with chapters discussing cancer predisposition and pre-cancerous 
lesions. Factors that initiate or progress cancer development, including viral, hormonal, 
oncogenic and biochemical stimuli are then described, as are interactions with the 
cancer extracellular environment. Animal models are particularly useful for evaluating 
therapeutic or chemopreventive agents and examples are presented. Finally, natural 
products that ether prevent or treat cancer are described. Together these topics will 
provide the reader with examples of the latest cutting edge research and discoveries, 
with the goal of stimulating further advances.
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An increased understanding of the molecular, biochemical and cellular processes 
governing carcinogenesis can only be of benefit in improving the effectiveness of 
strategies used to prevent and treat cancer. Since cancer is a multifaceted and complex 
disease a number of factors can contribute to its development and progression. A 
broad knowledge of these factors may aid in understanding how they interact and 
influence the processes of initiating and promoting cancer. This in turn enables more 
effective preventative and therapeutic strategies to be devised and more relevant 
prognostic tools to be developed. This book includes comprehensive reviews and 
some specialized experimental findings that cover diverse processes that contribute to 
carcinogenesis, its diagnosis and treatment. The goal is for these examples to inform 
and influence a reader’s own specialty by stimulating thinking across a diverse range 
of topics. A cross fertilization of ideas arising from understanding the various 
preventative, diagnostic and therapeutic approaches together with a broad knowledge 
of factors that affect cancer progression could be the impetus for further progress in 
tackling a disease that still exerts a heavy human toll worldwide. 
Section 1 includes genetic, molecular and morphological approaches to assessing 
cancer susceptibility and classifying the risk of developing a cancer. While individual 
mutations are known to influence cancer formation a knowledge of the synergistic 
effects of low-risk variant alleles are also important when assessing predisposition to 
cancer. This section also describes a binary system using morphology and molecular 
analysis for classifying pre-cancerous lesions into either high or low-risk potential to 
subsequently develop into oral carcinoma. 
Section 2 contains chapters that discuss the various mechanisms and stimuli that may 
contribute to the initiation of cancer or influence progression of the disease into a 
metastatic state. These stimuli include infection by the human papillomavirus and 
hormonal stimuli such as oestrogens. Specific proteins may also play a role in 
carcinogenesis and therefore have prognostic or therapeutic value. Examples of 
oncogenes and tumor markers, along with their characterisation in cancer cells, are 
described in this book. The oxygen environment of a cancer cell is an important 
determinant of carcinogenesis and a description of the redox and hypoxic signaling 
pathways and how they influence cancer development and metastasis is provided. 
The cancer microenvironment also plays a role in cancer progression and is the focus 
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of a chapter that assesses the expression of specific stromal proteins in cancer tissues. 
Metastasis involves the movement of tumor cells to a distant tissue and the process of 
epithelial-mesenchymal transition (EMT) is described in detail in the final chapter of 
this section. 
The study of cancer and how it develops, progresses and responds to treatments or 
chemopreventive agents is often conducted in animal models. Section 3 contains 
chapters that describe specialized models for studying cancers and offer key insights 
into interpreting and adapting animal studies into human consequences.  
Natural products are increasingly becoming recognised as an important tool for both 
preventing and treating cancer. Section 4 contains chapters describing naturally 
sourced compounds, including dietary polyphenols, and their characterisation as 
chemopreventive or therapeutic agents.  
This book is aimed towards researchers, students and medical practitioners wishing to 
obtain knowledge of the processes that underpin the broader carcinogenesis field. The 
goal is to inspire new ideas and innovative research directions, so that ultimately 
cancer will be defeated. The contributions by each of the specialist authors for their 
chapters and by Professor Krystyna Frenkel for the initial concept and reviews, 
together with the assistance from the extremely professional staff at InTech is greatly 
valued and appreciated in preparing this book. 
 
Associate Professor Kathryn Tonissen 
School of Biomolecular and Physical Sciences and 
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1. Introduction 
It has long been known that cancer can be the result of a genetic predisposition. About 5% of 
total cancers are associated with known Mendelian susceptibility; in these cancer types the 
clinical manifestations of disease are due to mutations in high-risk alleles, with a penetrance 
usually at least of 70%. However, there are many tumors in which the cause of hereditary 
predisposition can not be explained as the Mendelian syndromes. For colorectal cancer 
(CRC), for example, about 30% of cases are thought to be due to inherited susceptibility, 
which only in part can be explained by the known Mendelian inheritance, as FAP, MAP and 
Lynch syndrome [1]. Breast cancer has a similar gap between Mendelian and overall genetic 
risk. For prostate cancer, the risk is even higher, as very few cases are attributable to high-
risk alleles. This gap needs to be filled by studies to identify predisposition alleles that 
explain the cases of hereditary tumors for which no association with gene variants has been 
found, so far [2].  
With the advent of high-throughput technology it is now possible to analyze a great number 
of polymorphic variants in large cohorts of cases and controls. These studies have been used 
successfully by many groups leading to the identification of a large number of rare variant 
alleles in patients with an inherited risk of cancer [3, 4]. The simultaneous presence of rare 
genetic variants in the same patient might contribute in a cooperative manner to increase the 
risk of tumor development. Another problem is represented by variants of unknown 
significance (VUSs) within the cancer predisposition highly penetrant genes. These variants 
are usually missense or silent changes which are generally rather uncommon or rare and 
thus of doubtful clinical relevance, that make troublesome the genetic counseling for these 
cancer families. The interpretation of these variations is not easy and requires the 
combination of different analytical strategies to get a proper assessment of their 
 The Author(s). Licensee InTec . This cha ter is distributed unde  the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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pathogenicity [5]. In some cases, VUSs make a more substantial overall contribution to 
cancer risk than the well-assessed severe Mendelian variants. It is also possible that the 
simultaneous presence of some polymorphisms and VUSs in cancer predisposition genes 
that behave as low-risk alleles, might contribute in a cooperative manner to increase the risk 
of hereditary cancer [6]. Therefore, current literature data suggest that a significant 
proportion of the inherited susceptibility to relatively common human diseases may be due 
to the addition of the effects of a series of low frequency variants of different genes, 
probably acting in a dominant and independent manner, with each of them conferring a 
moderate but even detectable increase in the relative cancer-risk. 
Our studies are concerned with the molecular basis of the Lynch syndrome, which is 
commonly associated with mutations in mismatch repair (MMR) genes, MLH1 and MSH2. 
However, mutations in these genes do not account for all Lynch syndrome families. In our 
experience we have also identified germ-line genetic variants in the other MMR genes, 
called minor MMR genes: MSH6, PMS2, MLH3 and MSH3. We have shown that several 
patients were carriers of at least two genomic variants within the “minor” genes or a VUS in 
a major gene associated to a genetic variant in minor genes. We therefore speculate that the 
association between weak alleles in the MMR genes could determine the onset of the tumor.  
2. Hereditary cancer syndromes 
Over 200 hereditary cancer susceptibility syndromes have been described, the majority of 
which are inherited in an autosomal dominant manner. Although many of these are rare 
syndromes, they are thought to account for at least 5–10% of all cancer, amounting to a 
substantial burden of morbidity and mortality in the human population (Figure 1).  
 
Figure 1. The majority of most common cancers are sporadic, 5–10% are inherited and arise due to 
highly penetrant germ-line mutations. An additional 10–15% are referred to as 'familial' and may be 
caused by the interaction of low-penetrance genes, gene–environment interactions, or both. 
While characterized by their markedly increased risk of malignancy, these syndromes often 
predispose to benign tumors and generalized disease, as in Cowden syndrome (CS) and the 
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multiple endocrine neoplasias [7]. When the benign and malignant manifestations are 
considered together, many of these syndromes show almost complete penetrance by age 70. 
An inherited cancer susceptibility is suspected in families with the following characteristics: 
two or more relatives with the same type of cancer on the same side of the family; several 
generations affected; earlier ages of cancer diagnosis than what is typically seen for that 
cancer type; individuals with multiple primary cancers; the occurrence of cancers in one 
family, which are known to be genetically related (such as breast and ovarian cancer, or 
colon and uterine cancer); and the occurrence of nonmalignant conditions and cancer in the 
same person and/or family [8]. In table 1 are reported the more frequent hereditary cancer  
 
Syndrome MIM#a Gene(s) Population incidence Penetranceb 
     
Cowden syndrome 158350 PTEN 1/200 000 90–95% 
Familial adenomatous 






     







1/500 to 1/1000 Up to 85% 
Hereditary diffuse gastric 
cancer 
137215 CDH1 Unknown, rare 90% 







1 in 400 90% 






1/100 000 90–100% 
Li–Fraumeni syndrome 151623 TP53 Rare 90–95% 
Multiple endocrine 
neoplasia type 1 
131100 MEN1 1/100 000 95% 
Multiple endocrine 
neoplasia type 2 
171400, 
162300 
RET 1/30 000 70–100%c 
Peutz–Jeghers syndrome 
(PJS) 
175200 LKB1 (STK11) 1/200 000 95–100% 
Retinoblastoma, hereditary 
(RB) 
180200 RB 1/13 500 to 1/25 000 90% 
von Hippel–Lindau (VHL) 193300 VHL 1/36 000 90–95% 
a MIM numbers beginning with 1 indicate autosomal dominant inheritance; those beginning with 6 are autosomal loci 
or phenotypes entered into the catalogue after May 1994. b Penetrance estimates are up until age 70 years, include both 
malignant and benign features and with the exception of MEN2, describe clinical penetrance. c By biochemical testing 
(pentagastrin-stimulated calcitonin levels) is 95–100% by age 70. 
Table 1. Highly penetrant cancer syndromes  
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syndromes that are associated with mutations in high penetrance alleles. Because of 
phenotypic variability, age-related penetrance, and gender-specific cancer risks, however, 
many families with an inherited cancer syndrome will not meet these criteria. Furthermore, 
because cancer is relatively common in the general population, it is possible to have a 
chance clusterings of the same or related cancers within a family. These familial clusterings 
are most likely due to low-penetrance alleles that are more common than mutations in high 
penetrant alleles. Thus, they will potentially account for a larger proportion of cancer in the 
general population than the mendelian classic syndromes. For colorectal cancer (CRC), for 
example, Mendelian syndrome includes FAP, MAP and Lynch syndrome.  
However, about 30% of the variation in CRC risk is thought to be due to inherited 
susceptibility, which only in part can be explained by the known Mendelian inheritance [2]. 
Breast cancer has a similar gap between Mendelian and overall genetic risk and for prostate 
cancer the risk is even higher, as very few cases are attributable to high-risk alleles. It is that 
gap which must be filled by studies to identify cancer predisposition alleles in the general 
population [9]. Localization and characterization of low-penetrance alleles are the focus of 
much research, but the challenges are great due to the multi-factorial nature of cancer and 
the underlying genetic heterogeneity. 
2.1. High-throughput technology for detection of the multiple alleles associated 
to cancer predisposition 
The history of human genetics has focused on mapping regions of the genome that can 
explain part or all of a disease or human trait. 
The ‘rare variant hypothesis’ proposes that a significant proportion of the inherited 
susceptibility to relatively common human diseases may be due to the sum of the effects of a 
series of low frequency variants of a variety of different genes, perhaps dominantly and/or 
independently acting, each conferring a moderate but detectable increase in relative risk [2]. 
Regardless, there is good supporting evidence that rare variants will often have stronger 
effects on cancer risk than common variants. This evidence is based on several works whose 
purpose was to determine whether evaluating rare single-nucleotide polymorphism (SNPs) 
in case-control association studies could help to identify causal SNPs for common diseases. 
The sources of data of these works were generally the International HapMap Project and the 
SeattleSNPs project and they suggest that slightly deleterious SNPs subjected to weak 
purifying selection are major players in genetic control of susceptibility to common diseases, 
including cancer. These results suggests that studies with large sample sizes (5000 and 
higher) targeting SNPs will be a better strategy to identify causal disease SNPs [10]. Instead, 
genome wide association studies (GWAS) have emerged as an important tool for 
discovering regions of the genome that harbor uncommon genetic variants that confer risk 
for complex tumors, whose nature is probably polygenic [11]. These variants include single 
nucleotide variants (SNVs) or single nucleotide polymorphisms (SNPs), small insertions and 
deletions and structural genomic variants.  
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One of the fundamental elements for the success of GWAS is represented by a large 
collection of biospecimens in case-control and cohort studies so as to have a high degree of 
reliability of results. The first approaches in this regard were based on technologies such as 
the Denaturing High Performance Liquid Chromatography (DHPLC) and classical 
sequencing analysis, that provide a high degree of analytical sensitivity and specificity. 
However, the new challenge in the field of biotechnology has surely been to make the 
techniques increasingly automated in order to process multiple samples simultaneously and 
especially more quickly.  
The method becoming more widely used is high-throughput sequencing, which allows a 
massive study of DNA. This is a system able to obtain more than 400,000 different readings 
in a single stroke of about 8 hours. The operating principle is based on clonal amplification 
of DNA in vitro by emulsion PCR and on a protocol of pyrosequencing that, unlike the 
classic method of Sanger, is based on the detection of pyrophosphate released by the 
incorporation of a nucleotide during DNA synthesis. In high-throughput sequencing 454 
instrumentation, the sample may be any DNA larger than 1500 base pairs (genomic DNA or 
portions, cDNAs and large amplicons). The sequences obtained are analysed, properly 
aligned and oriented in contigs from the sequencer software, according to the shotgun and 
paired-end strategy. The accuracy of the data obtained is measured in terms of "coverage", 
that is based on the average number of times that each is accessed (read). This technology, 
therefore, is able to ensure high accuracy of the results (> 99.5%), thanks also to the careful 
management of the enormous amount of bioinformatics sequences obtained, which 
minimizes the production of raw redundant data. This feature, coupled with the 
extraordinary speed of processing, which makes the method also more economical than the 
classic automated sequencer, allows the user to analyze and quantify at the same time a 
large amount of samples. Therefore, the sequencer ultra-massive is an extremely versatile 
technique for a large number of applications such as resequencing and de novo assembly of 
entire genomes, and the massive sequencing of amplicons.  
This latter approach is now widely applied, for example, for the identification of rare 
variants that presumably contribute in a synergistic way and in association with other 
factors predisposing to the development of complex genetic diseases characterized by 
genetic heterogeneity. This technology therefore offers a great contribution to the studies of 
Genome Wide Association, because it allows quick identification of the allele frequencies of 
SNPs in population studies, and to analyze a given target gene in multiple genomes, or a 
panel of target genes in a single patient, even at the level of gene expression (transcriptome 
analysis) [4]. However, the high number of next generation sequencing information requires 
accurate statistically studies. The threshold value for discovery has been established at a 
high level, known as genome-wide significance, which serves two dual purposes [12]. First, 
it needs careful consideration of the power to detect the effect sizes expected to be observed 
in the study. Second, the high bar of genome wide significance protects against the 
probability of a false-positive finding. The latter is critical because GWAS are discovery 
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tools that point investigators toward long arduous follow-up studies for unraveling the 
underlying biology and the pursuit of markers for risk assessment [11, 13]. However, the 
common cancer alleles detected by GWAS account for only 10% of the familial relative risk 
of disease. 
2.2. Variants of unknown significance in hereditary cancer predisposition genes 
Variants of unknown significance (VUS) within the cancer predisposition genes could be 
responsible for cancer development, in particular when associated with another VUS or 
SNPs. The influence of these variants on the development of cancer is often difficult to 
predict [5, 14]. Several criteria have been established for the characterization of these 
phenotypic variants, particularly for the missense variants [15, 16]; these criteria included 
the co-segregation of the variant with the disease and the presence/absence of variation in 
the healthy population. However, these criteria are not always pursued to establish the 
pathogenetic significance of these variants [ 17, 18].  
Segregation analysis is not always practicable, since, often the families are small or part of 
family members is reluctant to participate to molecular investigation. Population studies to 
exclude the polymorphic nature of the variant is often laborious. Recent studies have 
revealed new strategies to classify the VUS as pathogenic. These strategies include “in 
silico” analysis, using computational programs such as PolyPhen (Polymorphism 
Phenotiping) and SIFT (Sorting Intolerant From Tolerant) to assess whether the VUS 
missense type falls into a phylogenetically conserved domain and / or makes changes to the 
physical-chemical properties of proteins [19 -21].  
The program Human Splicing Finder (HSF) [22, 23], which simultaneously uses a set of 
matrices already available on the network is useful to predict the effects of missense, silent 
and intronic variants on the signals of splicing and to identify regulators motifs associated 
with the processing of the mRNA. However, the results of the computational accuracy have 
a predictive value of about 80% and, therefore, do not always reflect the functional 
consequences of the variant in vivo. Several papers suggest to combine the results from 
several bioinformatics approaches especially those based on amino acid conservation status, 
to increase the predictive value of about 10% [19, 24].  
Other studies complemented “in silico” analysis to a direct study of the mRNA, to confirm 
or rule out the effects of splicing variants [25, 26]. In addition, many recent literature data 
emphasize the importance of developing functional assays in vitro and in vivo to assess the 
effects of VUS on specific biological functions [18]. All studies conducted so far show that 
none of the above criteria, including functional assays, is an indicator of pathogenicity, if 
considered individually; it is necessary that most of these strategies are used in combination 
with each other so that they can lead to a correct evaluation pathogenicity of numerous 
variant data. 
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2.3. The simultaneous presence of low-risk alleles increases the risk of 
hereditary cancer: review of literature data 
Genome–wide association studies in cancer based on high-throughput sequencing 
approaches have already identified over 150 regions associated with two dozen specific 
cancers, such as breast, prostate and colorectal cancer, providing new insights into common 
mechanisms of carcinogenesis. Since each region confers a small contribution to the cancer 
risk, it is daunting to consider any single nucleotide polymorphism as a clinical test, rather 
one should think about the synergistic action of different SNP as well as the environmental 
factor [11, 27]. These studies allowed researchers to identify large susceptibility 
chromosomal regions for many unrelated cancers. For example, the 8q24 region harbor 
multiple cancer susceptibility SNP loci associated with prostate cancer, colorectal cancer and 
precancerous colorectal adenomas, and bladder cancer risk; these loci affect genes such as 
MYC oncogene and the prostate stem cell antigen gene (PSCA) [11, 28].  
Another common cancer susceptibility chromosomal region is the 5p15.33; in this region 
common variants in the TERT-CLPTM1L have been identified by GWAS in association with 
the prostate, uterine cervix and skin cancers [11]. TERT is an attractive candidate gene, 
because it encodes the reverse transcriptase component of the telomerase, a gene that is 
critical for telomere replication and stabilization by controlling telomere length. TERT 
promotes epithelial proliferation and telomere maintenance has been implicated in the 
progression from KRAS-activated adenoma to adenocarcinoma in a murine model. There is 
additional evidence for its association with bladder, prostate, uterine cervix and skin cancers 
[11]. Moreover, phenotypic heterogeneity in the breast cancer, such as merging estrogen 
receptor negative and positive cases, has been need to identify other loci that might 
contribute to different phenotypes. Preliminary GW analysis has shown that a subset of the 
discovered loci may be specific to ER-pos breast cancer while select loci could be more 
important for ER-neg breast cancer [29]. Similar studies have identified an association 
between coding variants in CASP8 gene and breast cancer [30]. CASP8 belongs to many key 
pathways, including p53 signaling, apoptosis, and cancer [31]. The decreased risk for breast 
cancer with CASP8 Asp302His was revealed in an another recent association study [32]. 
Others proposed that rare variants within the double strand break repair genes CHEK2, 
BRIP1 and PALB2 predispose to breast cancer [33].  
Other large studies have identified 31.7% of the novel gene-variant breast cancer significant 
associations between 145 variants analyzed. A large GWAS conducted with East Asian 
women provided convincing evidence for an association with a novel independent 
susceptibility locus located at 6q25.1, near the TAB2 gene (TGF-beta activated kinase 1). 
Furthermore this study shows that genetic variants in the ESR1 gene (estrogen receptor 1) 
may be related to breast cancer risk [34]. A recent study of populations conducted by Smith 
et al. [35] has pointed out that the simultaneous presence of mutations in the TP53 gene and 
single nucleotide polymorphisms (SNPs) in genes belonging to different repair systems such 
as complex BER, NER, MMR and DSBR (Double-Strand Break Repair) is associated with 
earlier age of onset of breast cancer (<50 years), thus suggesting the idea of an additive or 
multiplicative effect.  
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In prostate cancer, there are at least 35 distinct loci harboring common susceptibility alleles 
identified by GWAS that could distinguish between aggressive and non-aggressive disease, 
but other studies are required [36]. These analyses were conducted in both European and 
Asian populations [37]. Moreover, a fine mapping of a region of chromosome 11q13 showed 
a complex genomic architecture characterized by multiple independent signals contributing 
to prostate cancer risk. This study further annotates common and uncommon variants 
across this region. In particular, a variant in the promoter of the MSMB gene on 
chromosome 10q13, is known to have influence in the gene expression, and in the protein 
PSP94 (prostate secretory protein 94) levels, showing significant association with prostate 
cancer. This chromosomal region was extensively resequenced and it is possible that a 
neighboring gene, the androgen receptor coactivator (NCOA4), could also be a candidate 
gene for analysis [38]. Moreover, GWAS for chromosomal 19q13.33 region, that harbors the 
gene responsible for the prostate serum antigene (PSA), suggested that variants in this gene, 
including a nonsynonymous SNP, could contribute to both prostate carcinogenesis and PSA 
levels [39].  
A large GWAS conducted in several populations (European Americans and African 
Americans) showed that genetic associations by race are modified by interactions between 
individual SNPs and prostate cancer and that significance of particular GWAS “hits” is not 
the same between racial groups. This study highlights the need to conduct GWAS and 
GWAS replication studies in a variety of racial groups in order to gain a more complete 
understanding of differences in risk alleles by race and in order to study gene-gene and 
gene-environment interactions [40]. A similar study conducted in two European 
populations suggested a list of SNP–SNP interactions that can be followed in other 
confirmation studies. to explore the etiology of prostate cancer [41].  
Finally several papers report numerous GWAS for colorectal cancer, identifying a total of 16 
new susceptibility loci for colorectal cancer. SNPs both in common genes as MMR genes and 
in other novel loci as SMAD7 and MYC seem to associate with different clinical outcomes 
[42], or different pharmacological responses [43]. Moreover, GWAS for chromosomal 
20p12.3 region, a site bereft of genes or predicted protein-encoding transcripts, suggested 
that particular SNP in this region could contribute to colorectal cancer progression. 
Interestingly, the bone morphogenetic protein 2 (BMP2) maps 342 kb telomeric to this locus, 
which is an initiator of BMP signaling by binding to its corresponding receptors. BMP 
signaling can suppress the Wnt pathway to ensure a balanced control of intestinal stem cell 
self-renewal. As reflected by earlier studies, mutations of BMP pathway have been 
described in juvenile polyposis, an inherited syndrome that predisposes to CRC. 
Considering all this information, it has been speculated that this locus might alter the BMP 
signaling transduction by the effect on BMP2 and thus affect CRC incidence [44].  
A different GWAS study assessed a set of single-nucleotide polymorphisms (SNPs) near 157 
DNA repair genes in three studies on colorectal cancer (CRC). Although no individual SNP 
showed evidence of association, the set of SNPs as a whole was associated with colorectal 
cancer risk, in particular the MLH1 promoter SNP -93G>A (rs1800734) and rare variants in 
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CHEK2 (I157T and possibly del1100C) [45]. Numerous GWAS data for susceptibility cancer 
specially for colorectal cancer have been the subject of several functional studies to 
demonstrate the effective association and to test the hypothesis of a synergistic effect 
between low risk allelic variants.  
In a recent study on the genome of yeast, it has been shown that the weak alleles of MMR 
complex cause a weak mutator phenotype, but when these interact with each other cause a 
strong mutator phenotype. In this work, 11 SNPs and 14 missense variants of doubt 
pathogenetic meaning, previously identified in these genes, have been studied. The mutator 
effect of these variants both individually and in combination with each other was assayed 
by testing complementation, in selective media for the amino acids lysine and tyrosine, and 
for resistance to canavanine [46]. Finally, Demogines et al. [47] have used yeast strains, that 
differed in terms of geographic and environmental factors, to demonstrate that the 
association of polymorphic variants, identified in the MMR genes MLH1 and PMS1, 
affecting the same or different genetic loci, may act as modifiers intra - or inter-gene and this 
phenomenon may play a role in both the penetrance of the colorectal disease (mutator 
phenotype) and in the process of evolutionary adaptation (genomic compatibility). 
3. The Lynch syndrome 
In this chapter we report the results of our studies on detection of mutations in MisMatch 
Repair (MMR) genes as responsible for Lynch syndrome. Because many patients with 
hereditary cancer syndrome did not show mutations in high penetrance genes, we speculate 
that association of several low penetrance alleles could determine a genetic predisposition to 
cancer development.  
Colon cancer is a multifactorial disease. It’s caused by enviromental factors, nutritional 
factors and genetic predisposition. Our studies are related to the genetic susceptibility of 
colon cancer, in particular the molecular basis of Lynch syndrome (Hereditary Non 
Polyposis colorectal cancer, HNPCC). The Lynch Syndrome is one of the syndromes of 
hereditary cancer with higher incidence in the population [48]. It has an autosomal 
dominant transmission and occurs in two forms: as Lynch I with an early age of occurrence 
(25% at 50 years and 70–80% within 70 years), predilection for the proximal colon (60–80%), 
and high rates of metachronous colorectal cancer (30% at 10 years and 50% at 15 years from 
the first tumor); and Lynch II, has the same characteristics but also extracolonic tumors 
involving the uterus (25–60%), ovaries (8–14%), stomach (13%), and urinary tract (4%) 
(Figure 2). 
This syndrome accounts for 5–15% of all colorectal cancers, although the true incidence is 
unknown, confounded by incomplete penetrance (<80%), rapid progression of adenoma to 
carcinoma (<5 years), development of extracolonic neoplasms, and the inter- and, 
occasionally, intra-familiar heterogeneity of the lesions [49]. In Lynch syndrome, the 
adenomas have the same frequency as in sporadic cases, but a more rapid progression to 
carcinoma. Due to the deficiency in DNA-repair genes, adenomas accumulate mutations 
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about three times faster than in sporadic disease. These mutations occur predominantly in 
microsatellite DNA sequences, a condition defined as microsatellite instability (MSI), which 
are more susceptible to errors in these genes replication because of their repetitive nature. 
The microsatellite sequences are also present in very important colorectal cancer 
tumorigenesis genes, thus the accumulation of errors in these genes determine rapid cellular 
proliferation. MSI is present in over 90% Lynch cases [50]. The clinical diagnosis of Lynch 
syndrome is performed upon the Amsterdam Criteria (Tab. 2). However, the Amsterdam 
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For this reason, in some patients with colon cancer, as suggested by the Bethesda guidelines 
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identify the inefficiency of DNA mismatch repair complex. If there is microsatellite 
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mutations in MMR genes have been identified in the MSH6 gene and a total of 5% in MLH3 
and PMS2 and very recently germ-line mutations in the MSH3 gene [53]. These genes are 
defined as “minor MMR genes” because they have redundant functions in mismatch repair 
in replication. It is known that as well as being involved in mismatch repair in replication, 
 
Carcinogenesis 12 
about three times faster than in sporadic disease. These mutations occur predominantly in 
microsatellite DNA sequences, a condition defined as microsatellite instability (MSI), which 
are more susceptible to errors in these genes replication because of their repetitive nature. 
The microsatellite sequences are also present in very important colorectal cancer 
tumorigenesis genes, thus the accumulation of errors in these genes determine rapid cellular 
proliferation. MSI is present in over 90% Lynch cases [50]. The clinical diagnosis of Lynch 
syndrome is performed upon the Amsterdam Criteria (Tab. 2). However, the Amsterdam 








Figure 2. Lifetime Risk of development of cancer associated with Lynch Syndrome. 
 
Synergistic Effects of Low-Risk Variant Alleles in Cancer Predisposition 13 
All of the following must apply for a putative diagnosis of HNPCC to be made in a family 
There are at least three relatives with an HNPCC-associated cancer (large bowel, 
endometrium, small bowel, ureter, or renal pelvis, although not including stomach, ovary, 
brain, bladder, or skin)  
One affected person is a first-degree relative of the other two 
At least two successive generations are affected 
At least one person was diagnosed before the age of 50 years 
Familial adenomatous polyposis has been excluded 
Tumors have been verified by pathologic examination 
Table 2. Amsterdam Criteria I and II 
For this reason, in some patients with colon cancer, as suggested by the Bethesda guidelines 
(Table 3) [52], it is possible to analyse microsatellite instability in colon tumor specimens, to 
identify the inefficiency of DNA mismatch repair complex. If there is microsatellite 
instability, there is a higher likelihood for a Lynch syndrome diagnosis. 
 
Tumors from any of the following should be tested for MSI and then positive patients should 
continue for MMR testing  
Individuals with cancer in families that meet the Amsterdam Criteria 
Individuals with two HNPCC-associated cancers, including synchronous and 
metachronous CRC or associated extracolonic cancers 
Individuals with CRC and a first-degree relative with CRC and/or HNPCC-related 
extracolonic cancer and/or a colorectal adenoma diagnosed at age < 40 years  
Individuals with CRC or endometrial cancer diagnosed at age < 45 years 
Individuals with right-sided CRC with an undifferentiated pattern (solid or cribriform) on 
histopathology diagnosed at age < 45 years  
Individuals with signet-ring–cell-type CRC diagnosed at age < 45 years 
Individuals with adenomas diagnosed at age < 40 years 
Table 3. Bethesda Guidelines for MSI Testing 
Germ-line mutations in the MLH1 and MSH2 genes account for a majority of families with 
Lynch Syndrome. The majority of research into mutations has focused on MLH1 and MSH2, 
however mutations in these two gene are not present in many patients. So far, 10% of 
mutations in MMR genes have been identified in the MSH6 gene and a total of 5% in MLH3 
and PMS2 and very recently germ-line mutations in the MSH3 gene [53]. These genes are 
defined as “minor MMR genes” because they have redundant functions in mismatch repair 
in replication. It is known that as well as being involved in mismatch repair in replication, 
 
Carcinogenesis 14 
the MMR system also has other functions [54], such as: DNA damage response, 
diversification of antibody, promotion of meiotic crossover. In these functions the “minor” 
MMR genes play an important role.  
3.1. Results of mutation detection analysis in MMR genes 
Recently, several studies have shown that association of low penetrance alleles could 
determine a genetic predisposition to cancer development [46,47]. For this reason, we 
studied 63 Lynch families recruited from various health centres in Campania (Southern 
Italy). Of these, forty families met the Amsterdam criteria and twenty-three patients with 
high microsatellite instability (MSI-H) met the Bethesda guidelines, in which no 
pathogenetic germline mutations were identified in MLH1 and MSH2 genes. We performed 
detection mutation analysis in each minor MMR gene (MSH6, MLH3, PMS2 and MSH3) by 
DHPLC. All samples exbiting abnormal DHPLC profiles were analyzed by directed 
sequencing (Figure 3). In our studies we have identified overall 65 genetic variants in these 
“minor” MMR genes.  
 
Figure 3. A) Chromatogram and B) electropherogram of the missense mutation c.2732 T>G (Leu>Trp) 
in MSH3 gene. 
The analysis of the damaged point mutations at the structural level is considered to be very 
important to understand the functional activity of the protein concerned. For this purpose 
we used the server PolyPhen (bibl), which is available at http://coot.embl.de/PolyPhen/, for 
missense mutations identified in this study. Moreover, we also used the bioinformatic 
analysis for the silent and intronic variants. 
These variants were analyzed by the software “Human Splicing Finder”, a tool to predict the 
effects of mutations on splicing signals or to identify splicing motifs in any human sequence. 
Most of these variants result in a polymorphism, which, however, can cause phenotypic 
variability, affecting the accuracy and efficiency of the protein function [24]. Interestingly, 
several patients were carriers of at least two genomic variants within the “minor” genes or a 
VUS in a major gene associated with a genetic variant in minor genes (Table 4 ). 
Recently, the effect of polymorphisms and missense mutations in human MMR genes was 
studied in a Saccharomyces cerevisiae-based system. A number of weak alleles of MMR genes 
and MMR gene polymorphisms that are capable of interacting with other weak alleles of 
MMR genes to produce strong polygenic MMR defects, have been identified [46]. A similar 
situation found in our studies might support the hypothesis that weak MMR gene alleles are 
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capable of polygenic interactions with other MMR gene alleles that might lead to tumour 
progression in Lynch syndrome.  
 
PATIENTS MSH6 PMS2 MLH3 MSH3 PHENOTYPE 
9525 
ex4         c.2633 
T>C (Val>Ala) 
ex14        c.2324 
A>G (Asn>Ser) 
ex1 c.2530 C>T 
(Pro>Ser) c.2533 
T>C (Ser>Pro) 
IVS7 -9 T>C AM+ 
013  
ex6 c.665G>C 
(Ser>Thr)        
IVS6 +16A>G 
ex1 c.2533 T>C 
(Ser>Pro) 
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MSI-H 
504*    
ex4          
c.693G>A 
(Pro) ex20     
c.2732 T>G 
(Leu>Trp) 
AM+        
MSI-H 
Table 4. Patients carrying variants in several MMR genes: MSH6, PMS2, MSH3, MLH3; *the patient 
shows also the UV in MSH2 gene (c.984 C>T) 
In detail, we report the case of a Lynch family with mutations in several MMR genes. The 
index case of family 504 (II-5 in Figure 4), who had developed an adenocarcinoma of the left 
colon at the age of 34 years, an adenocarcinoma of the right colon at the age of 53 years and 
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a new malignancy of the colon at 59 years of age, show two mutations in MSH3 gene, the 
c.2732 T>G in exon 20 and c.693 G>A in exon 4, and an UV within the MSH2 gene, the c.984 
C>T in exon 6. The PolyPhen in silico analysis showed that the missense variant in MSH3 
might alter the function of the protein, because it falls into a highly conserved region in 
different species, while the silent variant, analyzed by HSF could affect the splicing process.  
To elucidate whether the mutation was associated with the disease in this family, we 
analysed another eight members. These variants was found in a brother of the index case, 
with the same phenotype. Instead, another brother (II-8 in Fig. 4) showed only a variant in 
the MSH2 gene and no genetic variants in the MSH3 gene. This patient had developed a 
polyp of the colon at 47 years of age. Today he is 59 years old, undergoes regular 
colonoscopy and so far has not presented other polyps. In the third generation (Fig. 4), we 
analysed four affected family members. Subjects III-1 and III-2, in Figure 4, showed a silent 
variant in MSH3 and a variant in MSH2; both subjects showed an early-onset right colon 
tumour. Subjects III-3 and III-4, in Figure 4, the sons of our proband, developed colon cancer 
at 36 years of age and a tubular adenoma of the colon at 34 years of age, respectively. Both 
subjects showed a silent variant in MSH2 and a missense variant and a silent variant in 
MSH3. The MSI analysis performed on DNA extracted from tumour tissues of patients II-5 
and III-3 showed an MSI-H status. Thus, both subjects presented a strong mutator 
phenotype, probably due to an additive effect by several variants that leads to inefficiency of 
the MMR complex. The other family members analysed showed only one mutation in the 
MSH3 gene and they do not present a typical phenotype of Lynch syndrome (Tab.4). 
Therefore, it is clear that all subjects in this family with the Lynch phenotype showed the 
c.984T allele of MSH2 and a germ-line variant in the MSH3 gene (a missense and/or silent 
variant).  
Patients belonging to other families showed mutations in several MMR genes; however, for 
these families it wasn’t possible to perform segregation analysis of mutations with disease 
because no other family members were available for the analysis. In conclusion, several 
germ-line variants have been identified in several MMR genes using a DHPLC procedure; a 
method robust, automated, highly sensitive, fast, feasible and particularly useful for high-
throughput analyses.  
On the basis of this study, it is conceivable to hypothesize a model in which these genetic 
variants behave as low-risk alleles that contribute to the risk of colon cancer in Lynch 
families, mostly together with other low-risk alleles of other MMR genes. Therefore, if our 
assumptions are correct, these studies may indicate a novel inheritance model in the Lynch 
syndrome, and might suggest that the risk alleles identified to date represent just the tip of 
an iceberg of risk variants likely to include hundreds of modest effects and possibly 
thousands of very small effects. This could pave the way toward new diagnostic 
perspectives. Moreover, The same situation could occur in other forms of hereditary cancer 
and it may explain the large number of cases remained unresolved as well as the phenotypic 
heterogeneity that characterizes all hereditary cancer syndromes. 
 




Figure 4. Pedegree of 504 family [53]. Symbols and abbreviations used are denoted as fellow: Arrows, 
analysed members of family; black symbol, colorectal cancer or cancer associate with HNPCC; gray 
symbols, adenomas or cancer not associated with HNPCC; CRC, colorectal cancer; Br, brain cancer; GU, 
gastric ulcer; BL, bladder cancer; Bre, breast cancer; TA, tubular adenoma. Number next to diagnosis 
denote age at oneset; l not detected. 
 
 
Table 5. Genotypes of analysed patients; the patients are identified with number of pedigree (Fig.4). 
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4. Further research 
The Lynch syndrome is associated mainly with germ-line mutations in MSH2 and MLH1 
genes. However, mutational analysis of these two genes do not always provide informative 
results for genetic counseling of patients with a clinical diagnosis strongly predisposing to 
cancer development. Therefore, these subjects are considered candidates with simultaneous 
molecular analysis of all MMR genes. For this reason, high-throughput sequencing could be 
considered as an analytical approach that adapts better to clarify the molecular basis for 
each subject with a significant colorectal cancer history. In the future, these new 
technologies will enable faster identification of the molecular basis of cancer; it will improve 
the genotype-phenotype correlations the purpose of implementing a clinical treatment more 
personalized. 
5. Conclusions 
A field of biology where the “high-throughput technologies” is now widely applied is 
certainly the genetics of cancer for identification of constitutive and somatic mutations of 
putative genes associated with hereditary predisposition to cancer, particularly for those 
diseases characterized by genetic heterogeneity. Nowadays, we are witnessing a revolution 
in oncologic medicine, and the hope is that an increasing understanding of genetics will one 
day unlock the potential of personalized medicine. Clinical cancer genetics has traditionally 
been associated with risk estimation. Genome-wide germ-line mutation analysis will result 
in the identification of new cancer-associated alleles across the spectrum of risk. This may 
in time permit more precise estimation of development cancer risk. The new genetics will 
bridge the gap between germ-line and somatic genetics; prior analysis of the genetic 
makeup of the person and their tumour at time of diagnosis will be needed in order to 
tailor therapy. Central to this endeavour will be the increasing use of next-generation 
sequencers as whole cancer genomes become unravelled, revealing critical pathways that 
drive tumour progression and resistance. In the future these new technologies will enable 
faster identification of the molecular basis of cancer and thus improve the genotype-
phenotype correlations, in order to implement more personalized monitoring and clinical 
treatment. 
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1. Introduction 
Cancers of the oral cavity and oropharynx account for approximatelly 3% of all 
malignancies among men and 2% among women in the United States, and oral squamous 
cell carcinoma represents 90% of these tumors. Despite great achievements concerning 
surgery, radiation and chemotherapy, survival rates in 5 years remain near 50 to 55%. As 
this survival time is directly related to the time of diagnosis of the lesion, prevention and 
early diagnosis remain important aspects to reduce incidence of the disease, as well as to 
enhance the survival rate of patients [1,2]. 
Oral squamous cell carcinoma can be preceded by potentially malignant alterations [1,3]. 
Such alterations are classified as potentially malignant due to the following evidence: 1) it 
was observed that these lesions evolved to malignant ones during follow-up; 2) typical 
alterations of potentially malignant lesions are seen co-existing in the margins of squamous 
cell carcinoma; 3) a proportion of these lesions show cytological and morphological 
alterations that are observed in malignant lesions; 4) some chromosomal, genomic, and 
molecular alterations are found in both, potentially malignant and malignant lesions [4].  
1.1. Definition, epidemiology, and etiology of oral leukoplakias 
In a recently published paper, leukoplakia has been defined as ‘‘a white plaque of 
questionable risk having excluded (other) known diseases or disorders that carry no 
increased risk for cancer” [5]. Nevertheless, the most used definition of leukoplakia is still 
the one proposed by the World Health Organization (WHO) in 1978, which states that 
“leukoplakia is a predominantly white patch that cannot be characterized clinically or 
histopathologically as any other definable lesion” [6,7].  
Oral leukoplakia (OL) is the most common potentially malignant lesion of the oral mucosa 
[1,3]. In a published systematic review [8], the author estimated a global prevalence of OL of 
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2.6%, which is in accordance with the consensus that OL prevalence is between 1% and 5% 
[9,10]. However, isolated reports show variable rates from 0.5% to 26.92% [8].  
OL is more frequent in middle-aged and elderly men, with higher indexes correlated with 
increased age. The most common sites are cheek, alveolar mucosa, and lower lip [1]. 
Nonetheless, lesions affecting the floor of the mouth, lateral border of tongue, and lower lip 
seem to present displastic or malignant alterations more frequently [1,9]. 
The main risk factor associated with OL is the use of tobacco. OL is six times more frquent 
among smokers than non-smokers [10]. The effects of alcohol, betel, human papiloma virus, 
and diet are associated as well, but their exact role is yet to be established [1,9-11]. In addition, 
there are some OL for which no obvious aetiological factor can be identified, and these lesions 
are named idiopathic leukoplakias. It is believed that such lesions are significantly more prone 
to develop into cancer than those OL with known causative factors [9]. 
1.2. Clinical and histological features 
Clinically, OL can be classified as homogeneous and non-homogeneous lesions. 
Homogeneous OL arises as a white patch slightly elevated, thin, white to gray, uniform, and 
can present well defined borders or may gradually mix with normal adjacent mucosa 
(Figure 1 to 3). Non-homogeneous OL can be nodular, verrucous, or speckled 
(erythroplastic) (Figure 4) [4,10].  
 
Figure 1. Homogeneous thin leukoplakia in the tongue. 
 
Figure 2. Homogeneous leukoplakia in the lower lip. 
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Figure 3. Homogeneous thick leukoplakia in the tongue. 
 
Figure 4. Non-homogeneous (speckled) leukoplakia in the upper alveolar ridge. 
There is also the proliferative verrucous leukoplakia, characterized by multifocal 
evolvement, mainly in elderly female patients that do not present known risk factors (Figure 
5 and 6). These lesions are usually resistant to treatment and show a high risk for malignant 
transformation [4,10]. 
 
Figure 5. Proliferative verrucous leukoplakia. Notice the multifocal involvement in the lower gingiva. 
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Figure 6. Proliferative verrucous leukoplakia. This elderly woman presented multiple lesions affecting 
different sites of the oral mucosa. 
Many lesions must be excluded before formulating a diagnostic hypothesis of OL, such as 
chemical injuries, candidiasis, frictional lesion, hairy leukoplakia, leukoedema, linea alba, 
nicotinic stomatitis, among others [4,10]. Because of variable clinical presentation of the 
potentially malignant lesions, when a provisional clinical diagnosis of OL is made, a biopsy 
must be performed to obtain the histopathological diagnosis [12]. 
The microscopic presentation of OL can vary from slightly hyperkeratotic epithelium to 
lesions with severe dysplasia [13]. The frequencies of dysplastic or malignant alterations in 
OL vary from 15.6% to 39.2%, and a rate of 19.9% was found in a retrospective study of 3,300 
white lesions of the oral cavity [14]. Epithelial dysplasia is characterized by the presence of 
architectural alteration and cytological atypia, and can be graded as mild, moderate, severe, 
and carcinoma in situ [10]. Nevertheless, there is a notable inter- and intra-observer variation 
in the interpretation and classification of dysplasia, which makes this method subjective 
with low reproducibility [12,15]. Thus, many different grading systems have been suggested 
to enhance the reproducibility and the predictive value for malignant transformation of OL. 
It has been suggested a possible correlation between clinical and histopathological features 
of OL [16]. Following this proposal, thin and flat OL would show hyperkeratosis, 
acanthosis, and occasional lymphocytes. Thick fissured OL lesions would present, besides 
these microscopic alterations, mild to moderate dysplasia. The verrucous or granular OL 
would show irregular hyperkeratosis, drop-shaped rete ridges, a moderate amount of 
lymphocytes, and moderate to severe dysplasia. Finally, speckled OL and erythroplakia 
could show irregular hyperkeratosis, epithelial atrophy, numerous lymphocytes, and severe 
dysplasia or carcinoma in situ.  
A research group published a proposal of a staging system for OL, in which a clinical 
feature of the lesion would be taken into account [17,18]. The lesion would be classified into 
one of the four stages (I, II, III, or IV), according to the association between two parameters. 
The first characteristic to be evaluated would be the size of the lesion, with four possible 
categories (L1, L2, L3, and Lx). The second item concerned the histopathological presentation, 
focused on the presence of dysplasia, with three possible categories (P0, P1, and Px). 
Therefore, a somehow similar strategy to that of TNM (extent of the tumor (T), spread to 
regional lymph nodes (N), and distant metastasis (M)) for oral cancer would be used to 
stage OL, and the authors intended to promote a uniform reporting of treatment or 
management of OL lesions. 
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1.3. Evolution and prognosis 
OL may persist unchanged, progress, regress, or even disappear [9]. The malignant 
transformation risk varies from 3.6% to 36.0%, and some features such as the presence and 
degree of dysplasia, female gender, time of duration, non-smoker patient, location at floor of 
the mouth or tongue, size higher than 200mm², and non-homogeneous type, seem to be 
associated with a worse prognosis [10,19-22]. Surgical excision, cryosurgery, laser surgery, 
topical or systemic retinoids, therapy with mouth rinses with attenuated adenovirus, and 
photodynamic therapy are possible therapeutics [10,13,23]. Recurrence rates are highly 
variable among studies, from 0 to 30.0% [10]. 
Many efforts have attemped to identify molecular markers to predict cancer development in 
OL. However, the presence and degree of epithelial dysplasia in OL is yet regarded as the 
most relevant indicator of progression and prognosis, influencing the management of the 
patients [9,10,12].  
2. Grading oral epithelial dysplasia 
The term “dysplasia” is generally employed in the sense of a disordered development [24]. 
In a stratified squamous epithelium, architectural disturbances affecting normal maturation 
and stratification may occur. When such alterations are accompanied by cytological atypia, 
which can be detected as variations in the size and shape of the keratinocytes, the term 
“dysplasia” is applied [7,12].  
Despite many efforts towards new evaluative methods, the histological analysis is still the 
most useful method for grading epithelial dysplasia in OL [12].  
2.1. Relevance 
The concept of a sequential developmental process from a normal epithelium through a 
dysplasia, ending in a carcinoma, was introduced from studying pathological changes in the 
uterine cervix [24]. It is believed that through this process there is an accumulation of 
genetic and epigenetic alterations and more and more layers of the epithelium are 
progressively involved, until it is replaced by atypical cells in full length. It is considered 
that the more severe the degree of dysplasia, the greater the likelihood of malignant 
transformation. Despite the imperfection of currently available systems, they remain 
essential, and the diagnosis is a prerequisite for the establishment of the treatment that 
provides the best prognosis [12,24]. 
2.2. Proposed systems 
The elaboration of a classifying system is not a simple issue as the system may be, above all, 
an indicator of prognosis, guiding or at least helping in the establishment of the best 
treatment. Moreover, it should be reproducible, reliable, and as simple and objective as 
possible. Many classification schemes have been proposed over time, with variable 
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acceptance and employment. Herein, three of the most mentioned systems will first be 
discussed, followed by the recently suggested binary system. 
2.2.1. Squamous intraepithelial neoplasia (SIN) 
This classification is a modification of a previously suggested system for cervical pre-
malignant lesions, named cervical intraepithelial neoplasia [25]. After that, this concept has 
been adopted and extended to other sites, including oral mucosa, named “oral 
intraepithelial neoplasia” [12,26]. The term squamous intraepithelial neoplasia is also used 
to encompass all sites of the upper aerodigestive tract [26]. However, there is no evidence 
that many of the potentially malignant lesions of the oral mucosa are committed on a path to 
malignancy. Moreover, the SIN terminology would not clarify the knowledge concerning 
this issue, which would not justify replacing the widely accepted concept of dysplasia. 
Additionally, the WHO consensus group did not favour this system [12]. 
According to this system, lesions are classified as: 
 SIN 1, would be similar to mild dysplasia 
 SIN 2, would be similar to moderate dysplasia 
 SIN 3, would combine severe dysplasia and carcinoma in situ 
2.2.2. Ljubljana classification of squamous intraepithelial lesions 
This classification system was proposed by laryngeal pathologists in 1971 and additionally 
formulated in 1997 by a Working Group of the European Society of Pathology [27,28]. Very 
detailed criteria have been published and this system is more complex than the concept of 
dysplasia, so that even experienced pathologists would require time to adapt to it. 
Moreover, despite some publications, the usefulness of this grading system for oral lesions 
is doubtful [12,24]. 
Briefly, lesions are classified into four groups according to this system: 
 Simple hyperplasia, which is an increase in the stratum spinosum 
 Basal/parabasal cell hyperplasia or abnormal hyperplasia, considered essentially a basal 
cell hyperplasia 
 Atypical hyperplasia, also named risky hyperplasia, shows epithelial stratification, but  
with atypia 
 Carcinoma in situ, characterized by loss of stratification throughout epithelium, but 
three to five layers of compressed cells may be present on the surface. Also, there is 
marked atypia and mitotic abnormalities 
The first two degrees are considered mainly benign lesions, showing minimum risk for 
malignant transformation. The third degree would be a potentially malignant lesion, and the 
last one is actually considered a malignant lesion already. Additionally, the “atypical 
hyperplasia” and “carcinoma in situ” degrees are divided into basal cell type and spinous 
cell type [12,24]. 
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2.2.3. World health organization 
In 1997, the WHO published the “Histopathological Typing of Cancer and Precancer of the 
Oral Mucosa” and in the latest WHO’s classification of Head and Neck Tumours, a grading 
system based on “thirds” was described [7,29]. This resembled the system described since 
the 1970’s for lesions of the uterine cervix [24]. 
The WHO’s classification system is truly widely accepted among pathologists. However, it 
is not able to reflect the clinical behaviour of every single lesion and does not provide a clear 
therapeutic guideline to clinicians [24]. Moreover, in spite of its wide acceptance, this system 
presents great variability and low reproducibility [10,12]. According to it, lesions are 
allocated into categories considering firstly the architectural features, followed by 
cytological alterations [7].  
The architectural features that should be addressed are: 
 Irregular epithelial stratification (Figure 7) 
 Loss of polarity of basal cells (Figure 8) 
 Drop-shaped rete ridges 
 Increased number of mitotic figures 
 Abnormally superficial mitoses 
 Premature keratinisation in single cells (dyskeratosis) (Figure 9) 
 Keratin pearls within rete pegs 
 
 
        
 
Figure 7. Left: specimen of an oral leukoplakia showing irregular epithelial stratification. Right: Normal 
oral mucosa. Hematoxylin and eosin, 200X magnification.  
 
Carcinogenesis 30 
acceptance and employment. Herein, three of the most mentioned systems will first be 
discussed, followed by the recently suggested binary system. 
2.2.1. Squamous intraepithelial neoplasia (SIN) 
This classification is a modification of a previously suggested system for cervical pre-
malignant lesions, named cervical intraepithelial neoplasia [25]. After that, this concept has 
been adopted and extended to other sites, including oral mucosa, named “oral 
intraepithelial neoplasia” [12,26]. The term squamous intraepithelial neoplasia is also used 
to encompass all sites of the upper aerodigestive tract [26]. However, there is no evidence 
that many of the potentially malignant lesions of the oral mucosa are committed on a path to 
malignancy. Moreover, the SIN terminology would not clarify the knowledge concerning 
this issue, which would not justify replacing the widely accepted concept of dysplasia. 
Additionally, the WHO consensus group did not favour this system [12]. 
According to this system, lesions are classified as: 
 SIN 1, would be similar to mild dysplasia 
 SIN 2, would be similar to moderate dysplasia 
 SIN 3, would combine severe dysplasia and carcinoma in situ 
2.2.2. Ljubljana classification of squamous intraepithelial lesions 
This classification system was proposed by laryngeal pathologists in 1971 and additionally 
formulated in 1997 by a Working Group of the European Society of Pathology [27,28]. Very 
detailed criteria have been published and this system is more complex than the concept of 
dysplasia, so that even experienced pathologists would require time to adapt to it. 
Moreover, despite some publications, the usefulness of this grading system for oral lesions 
is doubtful [12,24]. 
Briefly, lesions are classified into four groups according to this system: 
 Simple hyperplasia, which is an increase in the stratum spinosum 
 Basal/parabasal cell hyperplasia or abnormal hyperplasia, considered essentially a basal 
cell hyperplasia 
 Atypical hyperplasia, also named risky hyperplasia, shows epithelial stratification, but  
with atypia 
 Carcinoma in situ, characterized by loss of stratification throughout epithelium, but 
three to five layers of compressed cells may be present on the surface. Also, there is 
marked atypia and mitotic abnormalities 
The first two degrees are considered mainly benign lesions, showing minimum risk for 
malignant transformation. The third degree would be a potentially malignant lesion, and the 
last one is actually considered a malignant lesion already. Additionally, the “atypical 
hyperplasia” and “carcinoma in situ” degrees are divided into basal cell type and spinous 
cell type [12,24]. 
 
Binary System of Grading Epithelial Dysplasia in Oral Leukoplakias 31 
2.2.3. World health organization 
In 1997, the WHO published the “Histopathological Typing of Cancer and Precancer of the 
Oral Mucosa” and in the latest WHO’s classification of Head and Neck Tumours, a grading 
system based on “thirds” was described [7,29]. This resembled the system described since 
the 1970’s for lesions of the uterine cervix [24]. 
The WHO’s classification system is truly widely accepted among pathologists. However, it 
is not able to reflect the clinical behaviour of every single lesion and does not provide a clear 
therapeutic guideline to clinicians [24]. Moreover, in spite of its wide acceptance, this system 
presents great variability and low reproducibility [10,12]. According to it, lesions are 
allocated into categories considering firstly the architectural features, followed by 
cytological alterations [7].  
The architectural features that should be addressed are: 
 Irregular epithelial stratification (Figure 7) 
 Loss of polarity of basal cells (Figure 8) 
 Drop-shaped rete ridges 
 Increased number of mitotic figures 
 Abnormally superficial mitoses 
 Premature keratinisation in single cells (dyskeratosis) (Figure 9) 
 Keratin pearls within rete pegs 
 
 
        
 
Figure 7. Left: specimen of an oral leukoplakia showing irregular epithelial stratification. Right: Normal 




Figure 8. Loss of polarity of basal cells in a photomicrograph of an oral leukoplakia specimen (arrows).  
Hematoxylin and eosin, 400X magnification. 
 
 
Figure 9. A keratinocyte showing dyskeratosis. Hematoxylin and eosin, 1000X magnification. 
The cytological alterations to be observed are as follows: 
 Nuclear pleomorphism: abnormal variation in nuclear shape (Figure 10) 
 Cellular pleomorphism: abnormal variation in cell shape (Figure 10) 
 Anisonucleosis: abnormal variation in nuclear size (Figure 10) 
 Anisocytosis: abnormal variation in cell size (Figure 10) 
 Increased nuclear size (Figure 10) 
 Increased nuclear-cytoplasm ratio (Figure 10) 
 Atypical mitotic figures (Figure 11) 
 Increased number and size of nucleoli (Figure 10 and 12) 
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Figure 10. Left: in this specimen, it can be noticed anisonucleosis, anisocytosis, nuclear and cellular 
pleomorphism, increased nuclear size, increased nuclear-cytoplasm ratio, and increased number and 
size of nucleoli of keratinocytes in an oral leukoplakia. Right: normal keratinocytes. Hematoxylin and 
eosin, 1000X magnification. 
 
Figure 11. Keratinocytes exhibiting atypical mitotic figures (arrows). Hematoxylin and eosin, 400X 
magnification. 
The observation of these alterations should be done considering the epithelium divided into 
“thirds”. Accordingly, lesions should be classified into five categories, as described below: 
1. Hyperplasia (Figure 13): describes a lesion showing an increase in cell number in the 
spinous layer and/or in the basal/parabasal cell layers. There is regular stratification and 
no cellular atypia. 
2. Mild dysplasia (Figure 14): architectural disturbance only in the lower third of the 
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The observation of these alterations should be done considering the epithelium divided into 
“thirds”. Accordingly, lesions should be classified into five categories, as described below: 
1. Hyperplasia (Figure 13): describes a lesion showing an increase in cell number in the 
spinous layer and/or in the basal/parabasal cell layers. There is regular stratification and 
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2. Mild dysplasia (Figure 14): architectural disturbance only in the lower third of the 
epithelium with cytological atypia. 
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3. Moderate dysplasia (Figure 15): architectural disturbance extending into the middle 
third of the epithelium is the initial criteria, but the degree of cytological atypia may 
require upgrading it to “severe”. 
4. Severe dysplasia (Figure 16): architectural disturbance affecting greater than two thirds 
of the epithelium, with cytological atypia. 
5. Carcinoma in situ (Figure 17): theorically, indicates that malignant transformation has 
occurred but invasion has not. Full or almost full thickness architectural disturbance in 
viable cellular layers with pronounced cellular atypia. Atypical mitotic figures and 








Figure 12. Oral leukoplakia specimen exhibiting increased number and size of nucleoli (arrows). 
AgNOR staining, 200X magnification. 
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Figure 13. Sample of an oral leukoplakia showing hyperplasia. Note an increased number of basal / 
parabasal cells and a hyperkeratotic surface. Regular stratification is observed, as well as no cytological 
atypia. Hematoxylin and eosin, 200X magnification. 
 
      
Figure 14. These specimens of oral leukoplakia exhibited mild dysplasia. Observe architectural 
disturbances affecting the lower third of the epithelium and cytological atypia. Hematoxylin and eosin, 
200X magnification (left), 400X magnification (right). 
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Figure 15. Microscopic presentation of an oral leukoplakia showing moderate dysplasia. Architectural 
disturbances extending into the middle third of epithelium, along with cytological atypia. Hematoxylin 




Figure 16. Histological section of oral leukoplakia exhibiting severe dysplasia. Architectural 
disturbances affecting greater than two thirds of the epithelium. Pronounced cytological atypia is 
evident. Hematoxylin and eosin, 100X magnification. 
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Figure 17. An oral leukoplakia that showed microscopic features of carcinoma in situ: architectural 
disturbances are observed in the full thickness of epithelium with pronounced cellular atypia. No 
superficial keratinisation can be observed. Hematoxylin and eosin, 200X magnification. 
2.2.4. Binary system 
As mentioned above, the proposed systems to grade epithelial dysplasia published so far, 
including the WHO’s proposal, showed some shortcomings, such as great variability and 
low reproducibility. Thus, studies concerning classification criteria are being performed, 
looking for an enhancement for grading epithelial dysplasia in OL. In 2006, a new binary 
system was proposed, which could be a more feasible and reliable tool for grading epithelial 
dysplasia in OL [15]. According to this system, pathologists would observe the same 
morphological criteria used in the WHO classification, but lesions would be classified as 
low-risk OL (former “no/ mild / questionable” dysplasia) or as high-risk OL (former 
“moderate/ severe” dysplasia) [15,10,12]. This would provide more reliable criteria upon 
which to rely for the selection of patient treatment. 
Interestingly, in 1988 the “Bethesda classification” for cervical cytopathology, already 
included only two grades [30]. According to this, lesions would be classified as low-grade 
squamous epithelial lesions, corresponding to former cervical intraepithelial neoplasia 
grade 1, and high-grade squamous epithelial lesions, corresponding to grades 2 and 3. This 
system has also been mentioned in some reports for oral lesions [26]. 
After the publication of those papers on the binary system for grading epithelial dysplasia in 
OL, a study was performed with 218 patients with OL, from which 39 (17.9%) developed 
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OL, a study was performed with 218 patients with OL, from which 39 (17.9%) developed 
into cancer [31]. The authors reported that high-risk OL was associated with a 4.57-fold 
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increased risk for malignant transformation, compared with low-risk OL. Those authors 
suggested that high-risk dysplasia would be a significant indicator for evaluating malignant 
transformation risk in OL.  
Subsequently, the same research group published a study in which they identified 
significant risk factors for malignant transformation in a long-term follow-up cohort of 
patients with oral epithelial dysplasia [32]. Of the 138 patients with histologically confirmed 
oral dysplasia, 115 had OL and 23 had lichen planus. From these 138 lesions, 37 (26.8%) 
developed into cancer and the “high-risk” degree of dysplasia was an independent risk 
factor for transformation. Moreover, high-risk degree of dysplasia was associated with a 
2.78-fold increased risk of transformation compared with low-risk degree. The authors then 
suggest the utilization of high-risk dysplasia as a significant indicator for evaluating 
malignant transformation risk in patients with potentially malignant lesions. According to 
them, this would also help guiding treatment in clinical practice. In spite of these great 
achievements, it must be mentioned that malignancy also developed in some patients 
previously presenting low-risk potentially malignant lesions [32]. 
In our first paper [33], we investigated the immunoexpression of hMLH1 (a protein of the 
mismatch repair system) (Figure 18) in OL with different degrees of dysplasia, according to 
the WHO grading system. We evaluated lesions showing no, mild, moderate, and severe 
dysplasia, and we found that the greater difference in the hMLH1 immunoexpression was 
detected comparing OL with mild and moderate dysplasia, with decreasing indexes. 
Therefore, we suggested that this result would be in accordance with the proposed binary 
system of grading dysplasia in OL, as the morphological dysplastic alterations observed in 
routinely stained slides may be related to molecular changes.  
    
Figure 18. Immunoexpression of hMLH1 in oral leukoplakia showing no dysplasia (left) and severe 
dysplasia (right). Advance HRP, 200X magnification. 
 
Binary System of Grading Epithelial Dysplasia in Oral Leukoplakias 39 
After that, we conducted a comparative immunohistochemical and histochemical study 
encompassing those same samples of OL [34]. At that time, the hMLH1 immunoexpression 
was compared to p53 immunoexpression (Figure 19) and AgNOR counting. Thus, we could 
assess the possible association between a protein of DNA repair, a tumor suppressor 
protein, and the cellular proliferation in OL with different degrees of dysplasia, i.e. no, mild, 
moderate, and severe. We concluded that it seemed reasonable that other molecular 
alterations may take place in early phases of carcinogenesis, related to tumor suppressor 
genes, like p53, as well as modifications in proliferation rates. 
   
Figure 19. Immunoexpression of p53 in oral leukoplakia with mild dysplasia (left) and severe dysplasia 
(right). Streptoavidin-biotin, 100X magnification. 
Recently, we decided to reevaluate those previous results in the light of the binary system to 
grade epithelial dysplasia in OL [35]. Therefore, we grouped OL formerly classified as 
showing no and mild dysplasia into low-risk lesions. Accordingly, OL previously classified 
as having moderate and severe dysplasia were defined as high-risk lesions. After that, we 
performed the statistical analyses again. Our findings showed statistically significant 
differences for hMLH1, p53, and AgNOR indexes between low- and high-risk OL. This 
suggests that the biological processes linked to the impairment of those proteins remain 
enhancing from low-risk OL to high-risk OL. Thus, the use of the binary system would give 
support to a more reliable clinical approach involving the removal of high-risk OL. 
Moreover, we could speculate that OL classified as low-risk may be reasonably named this 
way, since comparisons between hMLH1 and AgNOR indexes of this group and normal 
oral mucosa did not reach statistical significance, despite their different median values.  
2.2.5. Other proposals 
Apart from those investigations pointing towards an adaptation of the WHO classification 
to a binary system, there are also other recently published papers on different proposals to 
evaluate epithelial dysplasia. 
As reviewed before, the Japanese Society for Oral Pathology reported a definition of 
carcinoma in situ and proposes the term “oral intraepithelial neoplasia”, which in turn could 
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be classified as differentiated and basaloid type [24]. The main difference between them 
would be the presence of keratinisation in the epithelium surface in the differentiated type. 
Additionally, some authors analyzed individual features of dysplasia in oral lesions and 
determined the reproducibility of scoring each one [36]. They suggested that those data 
might be used to improve or to develop simpler routine diagnostic methods. 
3. Conclusion 
To date, no system is free of presenting failures in identifying those OL prone to evolve to 
oral squamous cell carcinoma. Furthermore, the reproducibility and subjectivity are still key 
points to be addressed. Therefore, robust research on the predictive value, relevance, 
applicability, and feasibility of the binary system for grading epithelial dysplasia are clearly 
warranted. Such research should aim to establish of a reliable and reproducible method that, 
above all, could provide a better and less empiric clinical management of the patient. 
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1. Introduction 
Infectious agents are suspected to play causal roles in a variety of human malignancies. The 
public health impact of the oncogenic effects of these infections is considerable. Infection is 
estimated to be responsible for about 17.8% of all incident cases of cancer worldwide, 
accounting for 26.3% of all malignancies in economically developing countries and 7.7% in 
developed countries [1]. 
The evaluation of causality for these infectious agents as human carcinogens is difficult 
given their ubiquitous nature, the substantial length of time between infection and the 
cancer event, the nature of cofactors, and the rarity of malignancy among those infected. 
Thus, a central problem for the epidemiologist is to define the natural history of infection 
and to identify those factors that are related to the development of cancer. Hence, 
informative biomarkers of the agent (such as viral load), of the host (such as abnormal 
antibody pattern), and of other oncogenic exposures (such as tobacco use) are required for 
understanding the viral-human interactions and for developing interventions [2]. 
Case-control studies have now recognized that human papilloma virus (HPV) infection in 
the oral cavity is a strong risk factor for head and neck squamous cell carcinoma (HNSCC), 
and mostly for oropharyngeal cancer. The risk is increased for high-risk HPV-16 infection 
[3]. Therefore, HPV infection in the oral cavity has important health consequences, requiring 
more studies about these aspects to clarify the implications of a diagnosis of HPV in the oral 
cavity and HNSCC.  
2. Human papillomavirus (HPV) 
HPVs are nonenveloped icosahedral viruses with a diameter of 55 nm, belonging to the 
papillomaviridae family. This epitheliotropic virus has 72 capsomers enclosing an 8 kbp-long 
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circular DNA genome. Although its DNA is double-stranded, only one strand contains open 
reading frames (ORF) that are transcribed. The viral DNA has eight ORFs and an upstream 
regulatory region, also called the long control region (LCR), which contains an origin of 
replication and cis-acting transcriptional regulatory elements [4]. Figure 1 shows the 
genome organization of HPV-16, the HPV type most strongly related to cervical cancer. The 
early region of the HPV genome contains six ORFs corresponding to E1, E2, E4, E5, E6, and 
E7 genes, which encode proteins necessary for viral replication and cell transformation. The 
late region codes for the two proteins of the viral capside: L1, the major structural protein; 
and L2, the protein linking to encapsulated DNA [4]. 
 
Figure 1. HPV genomic organization. The early region of the HPV genome contains six ORFs 
corresponding to E1, E2, E4, E5, E6, and E7 genes, which encode proteins necessary for viral replication 
and cell transformation. The late region codes for the two proteins of the viral capside: L1, the major 
structural protein; and L2, the protein linking to encapsulated DNA. 
3. Classification of papillomaviruses 
The L1 ORF is the most conserved gene in the papillomavirus (PV) genome and has 
therefore been used for identifying new PV types over the past 15 years. A new PV isolate is 
recognized as a new PV type if the complete genome has been cloned and the DNA 
sequence of L1 ORF differs by more than 10% from any known PV types. A difference 
between 2% and 10% homology defines a subtype, and less than 2%, a variant [5].  
HPV has more than 100 types, of which approximately 90 have already been characterized 
and assigned with numbers, and has five genuses: alpha-papillomavirus, beta-
papillomavirus, gamma-papillomavirus, mu-papillomavirus, and nu-papillomavirus [5]. 
HPV is also subdivided into two major groups, cutaneous and mucosal, based on data from 
clinical manifestations [6]. Most mucosal HPV types exist in the genital area, which can be 
divided into high-risk and low-risk HPV types [7]. HPV of high-risk types increases the risk 
of cervical cancer, which is almost always associated with HPV infection. To this date, 
approximately 20 HPV types have been identified as high-risk. Among them, HPV-16 and 
HPV-18 are considered to be associated with 70% of all cervical cancer. In contrast, low-risk 
type HPV, such as HPV-6 and HPV-11, causes genital warts but not cancer.  
Furthermore, HPVs have intratype variants. However, information on variants is limited to 
certain HPV types. Yamada et al. [8] showed five phylogenetic clusters with distinct 
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geographic distributions, analyzing the sequences of E6, L1, and LCR of HPV-16 isolated 
from cervical samples collected worldwide. The AA (Asian American) variant was isolated 
mainly from Central and South America and Spain. The African variants 1 and 2 (Af1 and 
Af2) and Asian (As) variant were present mainly from Africa and Southeast Asia, 
respectively. In all regions other than Africa, the European-350T (E-350T) prototype as well 
as the European-350G (E-350G) variant were detected.  
4. HPV life cycle and its carcinogenesis 
The life cycle of HPV is linked to the differentiation program of the infected host cell, 
epidermal or mucosal epithelial cell. Cells in the basal layer consist of stem cells, which 
persist indefinitely, and a much larger number of “transit amplifying cells”, which arise 
from the stem cells and divide a finite number of times until they become differentiated, 
providing a reservoir of cells for subrabasal regions [9].  
HPV initially infects the basal layer of epithelia via minor abrasions. Viral entry into a cell is 
not clearly understood. It is suspected that the heparin sulfate mediates the initial 
attachment of virions to cells [10] and that HPV enters a cell via interaction with certain 
receptors such as alfa-6 integrin for HPV-16 [11].  
The first HPV genes to be expressed are E7 and E6 (Figure 2). The virus protein E7 promotes 
cell division by binding to pRb, a tumor suppressor protein that usually binds to and 
inactivates E2F, a transcription factor. E2F released from pRb causes transcription of genes 
involved in DNA replication and cell division. E6 virus protein binds to and inhibits p53 
protein, which is active in repressing the cell cycle in the event of DNA damage, and in 
triggering apoptosis in the case of damage too severe to be repaired. E6 virus protein also 
activates cellular telomerase that synthesizes the telomere repeat sequences in eukaryotic 
cells and allows their immortal replication [12]. The transforming activities of high-risk HPV 
type represent a consequence of a viral replication strategy that is driven by the necessity to 
replicate the HPV genomes in suprabasal cells [12]. During the early phases of infection, the 
copy number of viral genome is between 50 and 100, and the viral genome exists as 
extrachromosomal plasmid or an episomal form that replicates as the host cell chromosomes 
replicate. As the infected cells differentiate, the rest of the early viral genes, such as E1, E2, 
E4, and E5 genes, become switched on [13]. E1 and E2 proteins, a helicase and a 
transcription factor binding to LCR viral region, respectively, support viral DNA replication 
so that the infected stem cells can be maintained in the lesion for a long period. E4 viral 
protein is thought to be involved in activating the productive phase of the HPV life cycle. 
E5, another viral protein, is involved in transformation, enhancing the activity of EGF. As 
infected daughter cells migrate to the upper layers of the epithelium, viral L1 and L2 late 
gene products and the major and minor viral capsid proteins are produced to initiate the 
vegetative phase of the HPV life cycle, resulting in high-level amplification of the viral 
genome. In the upper layers of stratified squamous epithelia, viral DNA is packaged into 
capsids and produced virions are freed through normal desquamation processes, triggering 
little inflammation [14]. In addition, E6 and E7 proteins inactivate interferon regulatory 
factor [15] so that HPV infection can remain persistent and asymptomatic. 
 
Carcinogenesis 46 
circular DNA genome. Although its DNA is double-stranded, only one strand contains open 
reading frames (ORF) that are transcribed. The viral DNA has eight ORFs and an upstream 
regulatory region, also called the long control region (LCR), which contains an origin of 
replication and cis-acting transcriptional regulatory elements [4]. Figure 1 shows the 
genome organization of HPV-16, the HPV type most strongly related to cervical cancer. The 
early region of the HPV genome contains six ORFs corresponding to E1, E2, E4, E5, E6, and 
E7 genes, which encode proteins necessary for viral replication and cell transformation. The 
late region codes for the two proteins of the viral capside: L1, the major structural protein; 
and L2, the protein linking to encapsulated DNA [4]. 
 
Figure 1. HPV genomic organization. The early region of the HPV genome contains six ORFs 
corresponding to E1, E2, E4, E5, E6, and E7 genes, which encode proteins necessary for viral replication 
and cell transformation. The late region codes for the two proteins of the viral capside: L1, the major 
structural protein; and L2, the protein linking to encapsulated DNA. 
3. Classification of papillomaviruses 
The L1 ORF is the most conserved gene in the papillomavirus (PV) genome and has 
therefore been used for identifying new PV types over the past 15 years. A new PV isolate is 
recognized as a new PV type if the complete genome has been cloned and the DNA 
sequence of L1 ORF differs by more than 10% from any known PV types. A difference 
between 2% and 10% homology defines a subtype, and less than 2%, a variant [5].  
HPV has more than 100 types, of which approximately 90 have already been characterized 
and assigned with numbers, and has five genuses: alpha-papillomavirus, beta-
papillomavirus, gamma-papillomavirus, mu-papillomavirus, and nu-papillomavirus [5]. 
HPV is also subdivided into two major groups, cutaneous and mucosal, based on data from 
clinical manifestations [6]. Most mucosal HPV types exist in the genital area, which can be 
divided into high-risk and low-risk HPV types [7]. HPV of high-risk types increases the risk 
of cervical cancer, which is almost always associated with HPV infection. To this date, 
approximately 20 HPV types have been identified as high-risk. Among them, HPV-16 and 
HPV-18 are considered to be associated with 70% of all cervical cancer. In contrast, low-risk 
type HPV, such as HPV-6 and HPV-11, causes genital warts but not cancer.  
Furthermore, HPVs have intratype variants. However, information on variants is limited to 
certain HPV types. Yamada et al. [8] showed five phylogenetic clusters with distinct 
 
Human Papillomavirus and Carcinogenesis in the Upper Aero-Digestive Tract 47 
geographic distributions, analyzing the sequences of E6, L1, and LCR of HPV-16 isolated 
from cervical samples collected worldwide. The AA (Asian American) variant was isolated 
mainly from Central and South America and Spain. The African variants 1 and 2 (Af1 and 
Af2) and Asian (As) variant were present mainly from Africa and Southeast Asia, 
respectively. In all regions other than Africa, the European-350T (E-350T) prototype as well 
as the European-350G (E-350G) variant were detected.  
4. HPV life cycle and its carcinogenesis 
The life cycle of HPV is linked to the differentiation program of the infected host cell, 
epidermal or mucosal epithelial cell. Cells in the basal layer consist of stem cells, which 
persist indefinitely, and a much larger number of “transit amplifying cells”, which arise 
from the stem cells and divide a finite number of times until they become differentiated, 
providing a reservoir of cells for subrabasal regions [9].  
HPV initially infects the basal layer of epithelia via minor abrasions. Viral entry into a cell is 
not clearly understood. It is suspected that the heparin sulfate mediates the initial 
attachment of virions to cells [10] and that HPV enters a cell via interaction with certain 
receptors such as alfa-6 integrin for HPV-16 [11].  
The first HPV genes to be expressed are E7 and E6 (Figure 2). The virus protein E7 promotes 
cell division by binding to pRb, a tumor suppressor protein that usually binds to and 
inactivates E2F, a transcription factor. E2F released from pRb causes transcription of genes 
involved in DNA replication and cell division. E6 virus protein binds to and inhibits p53 
protein, which is active in repressing the cell cycle in the event of DNA damage, and in 
triggering apoptosis in the case of damage too severe to be repaired. E6 virus protein also 
activates cellular telomerase that synthesizes the telomere repeat sequences in eukaryotic 
cells and allows their immortal replication [12]. The transforming activities of high-risk HPV 
type represent a consequence of a viral replication strategy that is driven by the necessity to 
replicate the HPV genomes in suprabasal cells [12]. During the early phases of infection, the 
copy number of viral genome is between 50 and 100, and the viral genome exists as 
extrachromosomal plasmid or an episomal form that replicates as the host cell chromosomes 
replicate. As the infected cells differentiate, the rest of the early viral genes, such as E1, E2, 
E4, and E5 genes, become switched on [13]. E1 and E2 proteins, a helicase and a 
transcription factor binding to LCR viral region, respectively, support viral DNA replication 
so that the infected stem cells can be maintained in the lesion for a long period. E4 viral 
protein is thought to be involved in activating the productive phase of the HPV life cycle. 
E5, another viral protein, is involved in transformation, enhancing the activity of EGF. As 
infected daughter cells migrate to the upper layers of the epithelium, viral L1 and L2 late 
gene products and the major and minor viral capsid proteins are produced to initiate the 
vegetative phase of the HPV life cycle, resulting in high-level amplification of the viral 
genome. In the upper layers of stratified squamous epithelia, viral DNA is packaged into 
capsids and produced virions are freed through normal desquamation processes, triggering 
little inflammation [14]. In addition, E6 and E7 proteins inactivate interferon regulatory 




Figure 2. HPV life cycle. HPV establishes latent infection in the basal cells of the differentiating 
epithelium as episomal multicopy circular nuclear plasmids in order to support the viral life cycle via 
action of the viral replication proteins E1 and E2. Development of invasive cervical cancer is a stepwise 
process, which is associated with integration of the high risk HPV DNA into the host cell chromosome, 
upregulating the expression of viral oncoproteins E6 and E7. 
The infection with high-risk HPV is associated with cervical dysplasia or cervical 
intraepithelial neoplasia (CIN). Long-term persistent HPV infection in these lesions is 
thought to give rise to cervical cancers. CIN I (mild dysplasia) and CIN II (moderate 
dysplasia) lesions, in which the viral genomes replicate episomally, show relatively low 
levels of E6 and E7 gene expression, and are, in most cases, resolved spontaneously by an 
effective immune response (Figure 3). In contrast, CIN III (severe dysplasia, carcinoma in 
situ) and invasive cancer lesions, where viral DNA is integrated into the host genome in 
most cases, often display high-level expression of E6 and E7 genes [16].   
The integration of the viral genome into the host cell is a very rare event with a predilection 
for host chromosomal fragile sites [17], but after it has happened carcinogenic 
transformation progresses rapidly. HPV integration into the host genome induces the 
increased E6 and E7 protein expressions since integration results in disruption of HPV E2 
gene, which is a negative regulator of HPV E6 and E7 transcription. In addition, once 
integrated, the E6 and E7 mRNA gains a longer half-life by using host genome poly (A) 
signals. However, the ultimate development of cervical cancer is rarely accompanied by 
high expression of E6 and E7 proteins [17]. High-risk HPV E6 and E7 oncoproteins can each 
independently induce genomic instability in normal human cells [18]. They cooperate to 
generate mitotic defects and aneuploidy through the induction of centrosome abnormalities 
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in normal human epithelial cells, and the characteristic multipolar mitoses in cervical lesions 
are caused by centrosome abnormalities [19]. HPV oncoproteins expressing cells also exhibit 
centrosome-independent manifestations of genomic instability. These manifestations 
include anaphase bridges that may be caused by double-strand DNA breaks as well as 
lagging chromosomal material [20]. To date, information on co-factors of HPV-related 
carcinogenesis in extra-genital organs is quite limited. Muñoz et al. [21] proposed the 
following three groups of potential cofactors in the cervical carcinogenesis: i) environmental 
or exogenous cofactors, including hormonal contraceptives, tobacco smoking, parity, and 
co-infection with other sexually transmitted agents; ii) Viral cofactors: such as HPV types, 
multiple HPV type infections, HPV integration, HPV viral load, and HPV variants; and iii) 
Host cofactors: including endogenous hormones, genetic factors, and other factors related to 
the immune response.  
 
 
Figure 3. Cervical carcinogenesis. A long-term persistent HPV infection in cervical dysplasia or 
cervical intraepithelial neoplasia (CIN) could possibly lead to cervical cancer by integration of viral 
DNA into the host genome and overexpression of viral genes E6 and E7. 
5. Squamous cell carcinomas (SCC) in the upper aero-digestive tract 
(UADT) 
5.1. Epidemiology  
Oral cancer is the 11th most common cancer in the world in terms of number of cases, while 
cancer of the pharynx ranks as 20th. Worldwide, about 389,000 new cases occurred in 2000, 
two-thirds of which were in economically developing countries, and these cancers are 
responsible for some 200,000 deaths each year [22]. The male-female ratio of its incidence 
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5.1. Epidemiology  
Oral cancer is the 11th most common cancer in the world in terms of number of cases, while 
cancer of the pharynx ranks as 20th. Worldwide, about 389,000 new cases occurred in 2000, 
two-thirds of which were in economically developing countries, and these cancers are 
responsible for some 200,000 deaths each year [22]. The male-female ratio of its incidence 
varies from 2 to 15 depending on the anatomical sub-site. An extremely high ratio is a 
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characteristic of cancers of the tongue, floor of mouth, and pharyngeal. Cancers of the 
mouth and anterior two-thirds of the tongue are predominant in economically developing 
countries, whereas pharyngeal cancers are common in developed countries and in Central 
and Eastern Europe. In most countries, oral/pharyngeal cancer incidence and mortality rates 
have either been stable or increasing in the last four decades [23]. Cancers of the esophagus 
are the sixth most frequent cancers worldwide. In 2000, the number of deaths due to 
esophageal cancer amounted to some 337,500 out of a total of 6.2 million cancer deaths 
worldwide [24]. About 412,000 cases of cancer of the esophagus occur each year, of which 
over 80% are in economically developing countries. The incidence of esophageal cancer 
shows a distinct geographical difference, which is more evident than in any other cancers. In 
certain regions in Asia, the incidence rates of esophageal squamous cell carcinomas (ESCC) 
are as high as 200 per 100,000. Even within these high risk areas, there are striking local 
variations in ESCC risk  
5.2. Genetic alterations 
The genetic alterations observed in the cancers of the UADT include activation of 
protooncogenes such as cyclin D1, MYC, RAS, EGF receptor, HST-1, and HST-2, as well as 
inactivation of tumor suppressor genes (TSGs), such as those encoding p53 and p16INK4a 
[25]. Likewise, in cancer of the esophagus, the mutation of the p53 gene is detected in 35-
70% of tumors, depending on geographic origin. Mutations in p53 have also been observed 
in dysplasia and in normal mucosa adjacent to cancer lesions, and considered as an early 
event. The p16INK4a gene is another TSG that plays an important role in the UADT 
development, and p16INK4a is often subject to hypermethylation of its promoter region, 
resulting in down-regulation of its expression [26].  
5.3. Etiology 
Consumption of tobacco and alcohol, associated with a low intake of fresh fruit, vegetables, 
and meat, is causally associated with SCCs of the UADT worldwide. However, the relative 
contribution of these risk factors varies from one geographic area to another [27]. Smoking is 
estimated to be responsible for about 41% of oral/pharyngeal cancers in men, and 15% in 
women worldwide. In more economically developed countries, it is estimated that 90% of 
ESCCs are attributable to tobacco and alcohol, with a multiplicative increase in risk when 
individuals are exposed to both factors. In addition, it has been reported that a genetic 
polymorphism of aldehyde dehydrogenase 2 (ALDH2), which plays a role in ethanol 
metabolism, is significantly associated with ESCC in the Japanese population [28].  
Other environmental risk factors include nitrosamines, deficiency of vitamins A and C, 
copper, and zinc, poor nutrition, and ingestion of pickled and preserved foods contaminated 
with fungi such as Aspergillus flavum, Geotrichum candidum and Fusarium sp. Infectious 
agents, such as HPV and EBV, have also been suggested to be involved in the development 
of cancer of the UADT [22]. 
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5.4. HPV infection 
The International Agency for Research on Cancer considers that there is convincing 
evidence that infection with HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59 and -66 
can lead to cervical cancer [29]. Regarding HPV-16, evidence supports its causal role in 
cancers of the vulva, vagina, penis, and anus.  The association of HPV with cancers of the 
UADT is also suspected. The UADT consists of a complex mucosa-covered conduit for food 
and air that extends from the vermilion surface of the lips to the esophagus. Major 
malignancies observed in the UADT are cancers of the oral cavity, oropharynx, larynx, and 
esophagus. Among them, HPV-16 is strongly suspected to cause cancers of the oral cavity 
and oropharynx. Limited evidence is available for the association of HPV with cancers of the 
larynx and periungual skin, but there is insufficient evidence for roles of HPVs in cancer of 
the esophagus [30].  
In our current research, we found HPV infections in 21 ESCC specimens (29%) [31]. 
Sequencing analysis of an amplified L1 fragment identified HPV-16 genotype in six 
Colombian cases (13%) and in five Chilean cases (19%). We also found that a large 
proportion of ESCC specimens harbour HPV-16 genotype in the integrated form in a certain 
geographical area with a high ESCC incidence in China [32]. In addition, studies on the 
association of HPV with cancers of the oral cavity, oropharynx, and esophagus, using cancer 
specimens from Japan, Pakistan, and Colombia found HPV DNA in around half of the cases 
in SCCs of the oral cavity and oropharynx, and in a smaller proportion of ESCCs. The high-
risk type HPV-16 was the most prevalent type with a viral load in SCC of the tonsil similar 
to that of cervical cancer (Table 1).  The HPV-16 genomes detected in SCCs of the oral cavity, 
oropharynx and esophagus were frequently integrated in the host genome [33].  
The most recent systematic review that included 5,046 SCC of head and neck cancers cases 
from 60 studies employing PCR-based methods showed that the presence of HPV DNA was 
25.9%, being significantly higher in oropharyngeal SCC (35.6%; range 11–100%) than in oral 
(23.5%; range 4–80%) or laryngeal SCC (24.0%; range 0–100%). HPV-16 accounted for a 
larger majority of HPV-positive oropharyngeal SCC (86.7%) than HPV-positive oral (68.2%) 
and laryngeal SCC (69.2%) [34]. Another meta-analysis of 4,680 samples from 94 reports 
published during the period between 1982 and 1997 showed that HPV was between 2 and 3 
times more likely to be detected in precancerous oral mucosa and 4.7 times more likely to be 
detected in oral carcinoma than in normal mucosa [35]. Among the studies used in their 
meta-analysis, the largest-scale and most well designed study was the one by Maden et al. 
[36]. They examined 112 normal mucosa specimens and 118 oral carcinomas, and detected 
HPV-16 in six cases of oral carcinomas but only one sample of normal mucosa. On the other 
hand, HPV-6 was detected in 12 and 10 oral carcinomas and normal mucosa, respectively. A 
recent hospital-based case-control study of oropharyngeal cancer in the US detected HPV-16 
DNA in 72% of 100 paraffin-embedded tumor specimens, and showed an association of oral 
HPV-16 infection with oropharyngeal cancer. The study also showed that 64% of patients 
with cancer were seropositive for the HPV-16 oncoproteins E6 or E7, or both [37]. HPV DNA 
in situ hybridization clearly showed its presence in the nuclei of cancer cells and not in 
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characteristic of cancers of the tongue, floor of mouth, and pharyngeal. Cancers of the 
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development, and p16INK4a is often subject to hypermethylation of its promoter region, 
resulting in down-regulation of its expression [26].  
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ESCCs are attributable to tobacco and alcohol, with a multiplicative increase in risk when 
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and oropharynx. Limited evidence is available for the association of HPV with cancers of the 
larynx and periungual skin, but there is insufficient evidence for roles of HPVs in cancer of 
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Colombian cases (13%) and in five Chilean cases (19%). We also found that a large 
proportion of ESCC specimens harbour HPV-16 genotype in the integrated form in a certain 
geographical area with a high ESCC incidence in China [32]. In addition, studies on the 
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specimens from Japan, Pakistan, and Colombia found HPV DNA in around half of the cases 
in SCCs of the oral cavity and oropharynx, and in a smaller proportion of ESCCs. The high-
risk type HPV-16 was the most prevalent type with a viral load in SCC of the tonsil similar 
to that of cervical cancer (Table 1).  The HPV-16 genomes detected in SCCs of the oral cavity, 
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The most recent systematic review that included 5,046 SCC of head and neck cancers cases 
from 60 studies employing PCR-based methods showed that the presence of HPV DNA was 
25.9%, being significantly higher in oropharyngeal SCC (35.6%; range 11–100%) than in oral 
(23.5%; range 4–80%) or laryngeal SCC (24.0%; range 0–100%). HPV-16 accounted for a 
larger majority of HPV-positive oropharyngeal SCC (86.7%) than HPV-positive oral (68.2%) 
and laryngeal SCC (69.2%) [34]. Another meta-analysis of 4,680 samples from 94 reports 
published during the period between 1982 and 1997 showed that HPV was between 2 and 3 
times more likely to be detected in precancerous oral mucosa and 4.7 times more likely to be 
detected in oral carcinoma than in normal mucosa [35]. Among the studies used in their 
meta-analysis, the largest-scale and most well designed study was the one by Maden et al. 
[36]. They examined 112 normal mucosa specimens and 118 oral carcinomas, and detected 
HPV-16 in six cases of oral carcinomas but only one sample of normal mucosa. On the other 
hand, HPV-6 was detected in 12 and 10 oral carcinomas and normal mucosa, respectively. A 
recent hospital-based case-control study of oropharyngeal cancer in the US detected HPV-16 
DNA in 72% of 100 paraffin-embedded tumor specimens, and showed an association of oral 
HPV-16 infection with oropharyngeal cancer. The study also showed that 64% of patients 
with cancer were seropositive for the HPV-16 oncoproteins E6 or E7, or both [37]. HPV DNA 











* Fisher’s exact test value for difference of HPV-16 detection rate among cancer sites 
** Kruskal-Wallins test value for difference of HPV-16 geometric mean copies per cell 
*** Fisher’s exact test value for difference of HPV-16 genomic status 
Table 1. HPV-16 genomes detected in SCCs of the oral cavity, oropharynx and esophagus. 
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surrounding normal cells. Another case-control study in the US found high-risk HPV, 
mainly HPV-16, more frequently in exfoliated oral cells from cancer patients than in those 
specimens from controls, suggesting an association of oral HPV infection with an increased 
risk of SCC in the head and neck [38]. In addition, elevated antibodies against L1 and/or 
E6/E7 were shown in an international study [39]. 
A review also showed that 15.2% of the 2,020 Esophageal SCC cases tested by PCR until the 
year 2002 were HPV positive [40]. However, the role of HPV in esophageal carcinomas 
remains unclear and controversial. European prospective serologic studies that used stored 
serum specimens [41] as well as a Chinese case-control study [42] found a strong association 
between the risk of ESCCs and seropositivity to HPV-16. In contrast, other retrospective 
studies conducted in Europe [43] and a large prospective serologic study in China [44] 
found no significant association of HPV-16 or HPV-18 with SCCs or adenocarcinomas of the 
esophagus.  
Recently, in United State, Gillison [45] showed that HPV is a causal factor for a distinct 
group of UADT cancers particularly in oropharyngeal cancers that occur more frequently 
in men than women, where oral sex appear to be the principal risk factor for HPV-
associated oral cancers in adolescents [46]. Also, the tumor HPV status may be a strong 
and independent prognostic factor for survival among patients with oropharyngeal cancer 
[47]. 
One important question is the route of HPV infection in the oral cavity, oropharynx, and 
esophagus tract. HPV is known to be sexually transmitted in the case of the anogenital 
organs. However, limited available data suggest that HPV infection in oral cavity is possibly 
sexually acquired: a history of sexually transmitted disease and number of oral sexual 
partners are associated with both oral HPV infection [48] and HPV-positive oropharyngeal 
cancer. Some data suggest that the presence and persistence of an oral high-risk HPV 
infection is associated with a persistent oral infection in a spouse [49] as well as with an 
increased risk for oral cancer among women with a history of cervical cancer and their 
husbands [50]. In addition, other several conceivable ways have been proposed for 
acquiring HPV infection in oral and pharyngeal cavities. These include intrapartum 
infection during passage through the infected birth canal, transplacental infection in uterus 
prior to birth, and postnatal infection by contact. For instance, HPV can be transmitted from 
a mother to her newborn baby during vaginal delivery resulting in recurrent respiratory 
papillomatosis. In addition, HPV DNA has been detected in the foreskin of normal newborn 
and in a high percentage of neonates vaginally delivered by HPV-infected mothers as well 
as in the amniotic fluid [51].  
5.5. Etiological role of HPV 
Studies on prevalence of HPV infections in premalignant and malignant lesions of the oral 
cavity suggested the implication of HPV during the early stages of oral neoplasia and a role 
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surrounding normal cells. Another case-control study in the US found high-risk HPV, 
mainly HPV-16, more frequently in exfoliated oral cells from cancer patients than in those 
specimens from controls, suggesting an association of oral HPV infection with an increased 
risk of SCC in the head and neck [38]. In addition, elevated antibodies against L1 and/or 
E6/E7 were shown in an international study [39]. 
A review also showed that 15.2% of the 2,020 Esophageal SCC cases tested by PCR until the 
year 2002 were HPV positive [40]. However, the role of HPV in esophageal carcinomas 
remains unclear and controversial. European prospective serologic studies that used stored 
serum specimens [41] as well as a Chinese case-control study [42] found a strong association 
between the risk of ESCCs and seropositivity to HPV-16. In contrast, other retrospective 
studies conducted in Europe [43] and a large prospective serologic study in China [44] 
found no significant association of HPV-16 or HPV-18 with SCCs or adenocarcinomas of the 
esophagus.  
Recently, in United State, Gillison [45] showed that HPV is a causal factor for a distinct 
group of UADT cancers particularly in oropharyngeal cancers that occur more frequently 
in men than women, where oral sex appear to be the principal risk factor for HPV-
associated oral cancers in adolescents [46]. Also, the tumor HPV status may be a strong 
and independent prognostic factor for survival among patients with oropharyngeal cancer 
[47]. 
One important question is the route of HPV infection in the oral cavity, oropharynx, and 
esophagus tract. HPV is known to be sexually transmitted in the case of the anogenital 
organs. However, limited available data suggest that HPV infection in oral cavity is possibly 
sexually acquired: a history of sexually transmitted disease and number of oral sexual 
partners are associated with both oral HPV infection [48] and HPV-positive oropharyngeal 
cancer. Some data suggest that the presence and persistence of an oral high-risk HPV 
infection is associated with a persistent oral infection in a spouse [49] as well as with an 
increased risk for oral cancer among women with a history of cervical cancer and their 
husbands [50]. In addition, other several conceivable ways have been proposed for 
acquiring HPV infection in oral and pharyngeal cavities. These include intrapartum 
infection during passage through the infected birth canal, transplacental infection in uterus 
prior to birth, and postnatal infection by contact. For instance, HPV can be transmitted from 
a mother to her newborn baby during vaginal delivery resulting in recurrent respiratory 
papillomatosis. In addition, HPV DNA has been detected in the foreskin of normal newborn 
and in a high percentage of neonates vaginally delivered by HPV-infected mothers as well 
as in the amniotic fluid [51].  
5.5. Etiological role of HPV 
Studies on prevalence of HPV infections in premalignant and malignant lesions of the oral 
cavity suggested the implication of HPV during the early stages of oral neoplasia and a role 
in malignant progression [52].Studies in oral keratinocytes immortalized by HPV-16 have 
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demonstrated an accumulated progression of chromosomal aberrations as well as high 
levels of cellular differentiation [53], however, in nude mice model, the tumorigenic activity 
is possible if there is a chronic exposure to the carcinogen benzopyrene of tabacco [54]. Both 
benzopyrene stimulation and the HPV-16 infection in cultured oral epithelial cells have been 
shown to confer anti-apoptotic characteristics, such as downregulation in the expression of 
the Fas and Bax proteins, as well as overexpression of Bcl2 via p53 deregulation. 
Consequently, HPV alone is not sufficiently to induce malignant transformation in several 
oral anatomic locations. Therefore further studies are needed. 
6. Methods for HPV detection  
As HPVs cannot be cultured easily, HPV detection and genotype assays are based on the 
detection of viral nucleic acids, usually viral DNA. HPV-DNA is detected by target 
amplification methods and/or signal amplification methods. The most used target 
amplification-based method is the polymerase chain reaction (PCR) using conserved 
sequences of the HPV genome, almost exclusively within the L1 open reading frame (ORF). 
In our studies in UADT using formalin-fixed and paraffin-embedded specimens [31], we 
detected HPV-DNA by GP5+/GP6+ primer pair for PCR [55] that amplified 150 base pair 
regions within L1, and the results were confirmed by southern blot analysis. Also, 
sequencing of an amplified L1 gene fragment was used to identify HPV genotype. In other 
studies in the UADT using formalin-fixed and paraffin-embedded specimens [32,33], we 
used an ultrasensitive short-fragment PCR assay, the SPF10, which amplifies a 65 base pair 
region within L1 [56]. The HPV types were determined using the INNO-LiPA HPV 
genotyping v2 kit (Innogenetics NV, Belgium), which is based on the reverse hybridization 
principle. In brief, part of the L1 gene region of the HPV genome is amplified using SPF10 
primers tagged with a biotin at the 5′ and denatured. Biotinylated amplicons are hybridized 
with specific oligonucleotides probes immobilized on the strip. In total 25 genotypes (HPV-
6, -11, -16, -18, -31 -33, -35, -39, -40, -42, -43, -44, -45, -51, -52, -53, -54, -56, -58, -59, -66, -68, -70, 
-73 and -74) were examined. Recently, real-time PCR assays have been used to determine 
the number of viral copies of HPV as well as to determine its integration status [57]. HPV-16 
physical status is determined on the assumption that the E2 gene is disrupted in the 
integrated viral genome. On the other hand, episomal viral genome has equivalent copy 
numbers of the E2 and the E6 genes. In addition, mixed viral genome for HPV-16 shows 
both integrated form and episomal forms (figure 4).  
Other target amplification-based methods such as reverse-transcriptase (RT-) PCR assays 
can be applied to detect HPV mRNAs in fresh-frozen specimens or samples in which RNA 
is well preserved (i.e. liquid-based cytology samples of cervical scrapings). Signal 
amplification methods are based on an initial hybridization step of nucleic acids in the 
specimen with target-specific probes in liquid phase or in situ on cells or tissue slides, after 
which the signal (i.e. the hybridization event) is amplified and ultimately visualized with 
one of the various available methodologies. The liquid-phase signal amplification method 
the Digene Hybrid Capture 2 (HC2) assay [58] (Qiagen, Gaithersburg, MD, USA), is the first 
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Figure 4. HPV Physical status by real-time PCR assay.  
Food and Drug Administration (FDA) approved test that screens for the presence or absence 
of oncogenic HPV types. The HC2 assay uses a mixture of RNA probes representing 13 HPV 
genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59 and -68) to hybridize to 
HPV-DNA positive samples. DNA–RNA hybrids are subsequently captured in microplate 
wells coated with antibodies that specifically recognize DNA–RNA hybrids. For clinical 
validation of a new HPV tests a clinical equivalence analysis is necessary that compare the 
new test with a clinically validated reference for HPV using samples that originate from a 
population-based screening cohort. 
Our studies showed that the HPV genome was detected in 56% and 19% of SCCs of the oral 
cavity and esophagus, respectively, in cases collected from Japan, Pakistan and Colombia 
and the HPV prevalence in both oral cancers (OCs) and esophageal cancers (ECs) did not 
significantly differ by country [33]. HPV16 was frequently integrated into the host genome 
in patients with OCs and ECs, however, the viral loads in these malignancies were much 
lower than those found in cancer of the cervix [33]. It should be noted, however, that human 
cancer is often regarded as a stem cell-like disease originating from a small fraction of cancer 
cells that show self-renewal and pluripotency and are capable of initiating and sustaining 
tumor growth [59]. This means that HPV may be present in only a small fraction of cancer 
cells with a stem cell-like nature present even in advanced tumors. 
On the other hand, there was a significant geographical difference in the distribution of 
HPV16 E6 variants, which was also related to the viral load. HPV-16-positive OC cases with 
the E-350G variant showed a higher viral load than those with non-E-350G variants. Similar 
trends were observed in ECs although the difference was not statistically significant. Among 
HPV-16 intratypes, there is one polymorphism in the sequence of the E6 probe at nucleotide 
145, and the Asian-American variant harbors this nucleotide substitution (C to T) [33]. 
However, this polymorphism is unlikely to cause a difference in viral load because the copy 
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Figure 4. HPV Physical status by real-time PCR assay.  
Food and Drug Administration (FDA) approved test that screens for the presence or absence 
of oncogenic HPV types. The HC2 assay uses a mixture of RNA probes representing 13 HPV 
genotypes (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59 and -68) to hybridize to 
HPV-DNA positive samples. DNA–RNA hybrids are subsequently captured in microplate 
wells coated with antibodies that specifically recognize DNA–RNA hybrids. For clinical 
validation of a new HPV tests a clinical equivalence analysis is necessary that compare the 
new test with a clinically validated reference for HPV using samples that originate from a 
population-based screening cohort. 
Our studies showed that the HPV genome was detected in 56% and 19% of SCCs of the oral 
cavity and esophagus, respectively, in cases collected from Japan, Pakistan and Colombia 
and the HPV prevalence in both oral cancers (OCs) and esophageal cancers (ECs) did not 
significantly differ by country [33]. HPV16 was frequently integrated into the host genome 
in patients with OCs and ECs, however, the viral loads in these malignancies were much 
lower than those found in cancer of the cervix [33]. It should be noted, however, that human 
cancer is often regarded as a stem cell-like disease originating from a small fraction of cancer 
cells that show self-renewal and pluripotency and are capable of initiating and sustaining 
tumor growth [59]. This means that HPV may be present in only a small fraction of cancer 
cells with a stem cell-like nature present even in advanced tumors. 
On the other hand, there was a significant geographical difference in the distribution of 
HPV16 E6 variants, which was also related to the viral load. HPV-16-positive OC cases with 
the E-350G variant showed a higher viral load than those with non-E-350G variants. Similar 
trends were observed in ECs although the difference was not statistically significant. Among 
HPV-16 intratypes, there is one polymorphism in the sequence of the E6 probe at nucleotide 
145, and the Asian-American variant harbors this nucleotide substitution (C to T) [33]. 
However, this polymorphism is unlikely to cause a difference in viral load because the copy 
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number of HPV-16 in the Asian-American variant was similar to other intratypes except E-
350G. The HPV-16 E-350G variant contains a polymorphism at residue 83, leucine to valine 
(L83V), which is associated with the risk of invasive cancers of the cervix in European 
studies [60,61]. Only the E-350T prototype and the E-350G variant were detected in Japan. 
On the other hand, in Pakistan, E-350G was the predominant HPV16 variant. In Colombia, 
the Asian-American variant was the most commonly found type, but this variant was not 
found at all in Japan and Pakistan. Our findings are similar to those of Yamada et al [25], 
who detected the E-350G, E-350T, and Asian-American variants in 52%, 25%, and 20%, 
respectively, of 228 HPV16-positive cervical cancer specimens from Central and South 
America. No particular HPV16 E6 variant predisposed those infected to OCs or ECs. 
7. HPV vaccine 
Preventive HPV vaccines are based on empty virus-like particles (VLPs) assembled from 
recombinant HPV coat proteins. Two prophylactic HPV vaccines are currently on the 
market: Gardasil and Cervarix. The vaccine works by making recipient immune to two key 
strains of the HPV (HPV-16 and -18). Together, the two strains are known to cause 
approximately 70% of all cervical cancer cases worldwide and some other genital cancers. 
Gardasil also protects against the two HPV types (HPV-6 and HPV-11) that cause 90% of 
genital warts [62]. In UK, the Joint Committee on Vaccination and Immunization 
recommended routine vaccination for 11 to 12-year olds, including the possibility of a catch-
up campaign but only up to the age of 16. Similar recommendations on vaccination of 
young women against HPV to prevent cervical cancer were made by Public health officials 
in Australia, Canada, Europe, and the United States [63]. It is suggested that vaccinating 
most teenage girls could save hundreds of lives a year, although, the benefits would not be 
seen until those receiving the vaccine enter middle age.  
In 2009, the Food and Drug Administration (FDA) licensed to Gardasil for use in males aged 
9 through 26 years for prevention of genital warts caused by HPV-6 and -11. HPV-6 and -11 
cause approximately 90% of genital warts and most cases of recurrent respiratory 
papillomatosis [63]. HPV-associated cancers in males include certain anal, penile, and 
oropharyngeal and oral cavity cancers caused primarily by HPV 16 [45, 64, 65]. 
Mathematical modeling suggests that adding male HPV vaccination to a female-only HPV 
vaccination program is not the most cost-effective vaccination strategy for reducing the 
overall burden of HPV-associated conditions in males and females when vaccination 
coverage of females is high (>80%) [66]. Since the health burden is greater in females than 
males, and numerous models have shown vaccination of adolescent girls to be a cost-
effective use of public health resources, improving coverage in females aged 11 and 12 years 
could potentially be a more effective and cost-effective strategy than adding male 
vaccination.  
Men who have sex with men (MSM) are particularly at risk for conditions associated with 
HPV-6, -11, -16, and -18; diseases and cancers that have a higher incidence among MSM 
include anal intraepithelial neoplasias, anal cancers, and genital warts [67]. Gardasil has 
high efficacy for prevention of anal intraepithelial neoplasias in MSM [68]. The 3-dose series 
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of gardasil may be given to fenales and males aged 9 through 26 years to reduce their 
likelihood of acquiring genital warts and gardasil would be most effective when given 
before exposure to HPV through sexual contact. 
On the other hand, laboratory research and clinical trials are focused on the development of 
therapeutic vaccines against HPV oncogenes, such as E6 and E7. It is hoped that immune 
responses against the two oncogenes might eradicate established tumors [69, 70]. 
8. Conclusions 
Currently, the HPV vaccines potentially hold promise for the prevention of a greater 
majority of HPV-positive cervical cancers in woman. Thus, studies that attempt to clarify the 
association between HPV with cancers of the oral cavity and esophagus are important. They 
give us reason to be optimistic that HPV vaccines may be protective against UADT HPV 
infection, and consequently, effective in preventing HPV-associated UADT cancers in both 
men and women. 
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1. Introduction 
The hormonal microenvironment surrounding endocrine-sensitive tissues may play an 
important role in the carcinogenesis of these tissues. Epidemiological evidence strongly 
suggests that steroid hormones, primarily oestrogens (E2), are implicated in ovarian and 
breast carcinogenesis.  
The breast is an endocrine-sensitive organ. The development of the breast from puberty 
through the cycles of pregnancy, lactation and involution is regulated through hormonal 
controls. Epidemiological studies have demonstrated that 50% or more of breast cancers are 
environmental in origin. Epidemiological evidence linking breast cancer incidence to 
oestrogen exposure and the ability of oestrogen to drive the growth of breast tumours in 
vivo is well documented in clinical studies. In addition, the mechanism of oestrogen action 
on the growth of breast cancer cells in animal models and in vitro has been extensively 
described in experimental studies. The involvement of oestrogen in the progression of breast 
cancer is the basis for the successful use of endocrine therapy as a treatment for breast 
cancer. In addition to the physiological steroidal oestrogens, many compounds have been 
found to have oestrogenic activity such that the human breast can be exposed to 
environmental oestrogens from a variety of sources. The link between breast cancer and the 
use of the oral contraceptive pill has been extensively studied, and a study involving a 
million women has documented an increase in breast cancer following the use of hormone 
replacement therapy (HRT). Such findings demonstrate that the development of breast 
cancer can be influenced at all stages of life after puberty through the voluntary exposure to 
exogenous oestrogens.  
Ovarian cancer is the fourth-ranking cause of cancer-related death in women from Western 
countries. The natural history of this cancer is characterised by the potential for particularly 
aggressive local invasion. Unfortunately, these tumours are often diagnosed at an advanced 
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stage (i.e., 70% of tumours are discovered at stage III). Although all cell types of the human 
ovary may undergo neoplastic transformation, the vast majority (80-90%) of tumours are 
derived from ovarian surface epithelium (OSE). One of the hypotheses regarding the causes 
of ovarian cancer argues that the repeated cycles of ovulation-induced trauma and repair of 
the OSE during ovulation, without pregnancy-induced rest periods, contribute to ovarian 
cancer development. This “incessant ovulation” hypothesis suggests that regenerative repair 
of OSE cells that occurs during ovulation results in the accumulation of mutations, which 
predisposes this cell layer to tumourogenesis. There is also growing experimental evidence 
that oestrogens may play an important role in ovarian carcinogenesis. Use of HRT for 
menopause-related symptoms could be associated with an increased risk of ovarian cancer 
incidence or mortality. 
2. Endogenous oestrogens 
 
Figure 1. A) Oestrone (E1); B) Oestradiol (E2); C) 2-hydroxyoestradiol (2-OH-E2); D) 4-
hydroxyoestradiol (4-OH-E2) 
2.1. Carcinogenesis of oestrogens 
Oestrogens are believed to play a critical role in the etiology of breast and ovarian cancer 
through two distinct pathways. First, the products of oestrogen metabolism damage DNA 
by forming adducts and oxidised bases, leading to mutations in oncogenes and tumour 
suppressor genes that normally control cell growth and proliferation [1]. Second, oestrogens 
may alter the expression of specific genes, which stimulate growth and proliferation of 
epithelial cells in the breast and ovary. Notably, oestradiol-17β has been classified as a 
carcinogen by the International Agency for Research on Cancer. Thus, natural oestrogens 
levels in men and women have the potential to act as carcinogens. For example, early 
menarche and late menopause are risk factors for breast cancer, due to longer oestrogen 
exposures. It is well established that chronic exposure to elevated oestrogen levels 
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contributes to carcinogenesis of multiple reproductive organs. Ovaries are not only the 
principal source of oestrogens in premenopausal women but are the key target tissue of 
oestrogen activity. Oestradiol and oestrone are mainly produced by follicular cells. Ovarian 
tissue oestrogen levels are at least 100-fold higher than the circulating levels and those in the 
follicular fluid of ovulatory follicles are even higher [2]. Additionally, active oestrogens are 
formed from circulating oestrone sulphate or oestradiol sulphate, as the result of de-
conjugation by sulphatase [3]. The local release of biologically active oestrogens from 
conjugates and their further metabolism prolong the effect of oestrogen on peripheral 
tissues [4]. Oestrogen is essential to the function of the female reproductive system and a 
major regulator of growth and differentiation in normal ovaries. Furthermore, oestrogens 
are required for the proliferation and differentiation of healthy breast epithelium. 
2.2. Classic ER mediated activity 
The classic oestrogen receptors (ERs) are nuclear hormone receptors that act as transcription 
factors, regulating genes involved in homeostasis, development and metabolism. Two forms 
of ER have been identified, ERα and ERβ. While ERβ is predominantly expressed by 
granulosa cells, theca cells, surface epithelium, and CL, oocytes have also been reported to 
express the receptor. Both receptors are ligand-inducible nuclear hormone receptors. The 
classic mechanism of ER action involves binding of the ER to its ligand, resulting in receptor 
dimerisation, interaction with consensus oestrogen-response elements (EREs), and 
recruitment of transcriptional co-regulators, resulting in the formation of a complex that 
modulates the transcription of oestrogen target genes. The best-described nuclear receptor 
cofactors are the p160 family of co-activators, namely, SRC-1, SRC-2, and SRC-3; however, 
the cofactor complexes that mediate the ultimate outcome of ER signalling are complicated 
with more than 300 cofactors described in the literature [5]. Numerous genes with diverse 
functions in energy production, cell growth, cell cycle regulation, and cytoskeleton 
organisation, whose expression is induced or repressed by oestrogen, have been identified 
by microarray analysis. Oestrogen receptors have been shown to interact with other 
transcription factors, co-activator proteins, and tyrosine kinase growth-factor receptors and 
to cross–talk with other signal transduction pathways [6]. Through regulating gene 
expression, oestrogen functions as a potent stimulus for proliferation and inhibition of 
apoptosis, which may lead to the development of cancer. 
2.3. Non-genomic ER mediated activity 
ER signalling may occur in a ligand-dependent, non-genomic (extra-nuclear) pathway. This 
pathway involves the activation of other signal transduction pathways that lead to rapid 
responses, generally within minutes, to oestrogen exposure. The mechanism of non-genomic 
ER signalling is not clear, but is potentially mediated by a membrane-associated receptor. A 
G-protein coupled receptor known as GPR30 mediates rapid oestrogen signalling 
independent of ERs, which can lead to activation of the MAPK or phosphoinositide-3-kinase 
(PI3) kinase signalling cascades, fluctuations in intracellular calcium, or stimulation of 
cAMP production [7]. E2 mediation activates the MAPK and PI3 pathways that are the 
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major effectors of cell proliferation and cell survival. Deregulations of cell proliferation, 
differentiation, and apoptosis may allow cells that have harboured mutations in proto-
oncogenes and tumour suppressor genes to survive and expand clonally. 
2.4. Metabolism of oestrogens 
There is growing evidence that E2 and its metabolites may be involved in breast cancer 
development. Endogenous E2 metabolites may play an important role by influencing the 
growth of oestrogen-sensitive target cells, both stimulating and inhibiting proliferation [8]. It 
is generally known that both the biosynthesis and metabolism of E2 occur in cancerous 
breast tissues. The cytochrome P450-dependent monooxygenases (CYP) are responsible for 
the biosynthesis and metabolism of endogenous compounds such as steroid hormones. 2-
hydroxyestadiol (2-OH-E2) and 4-hydroxyestradiol (4-OH-E2) are two major hydroxylated 
metabolites of E2 formed by cytochrome P450 1A1 and 1B1, respectively. The catechols 2-
OH-E2 and 4-OH-E2 can be oxidised to quinones, which are putative tumour initiators, and 
the 4-hydroxylated form of E2 appears to be one of the most genotoxic metabolites of E2 in the 
breast epithelium. The 4-OH-E2 to 2-OH-E2 concentration ratio has been reported to be 4:1 in a 
human breast cancer extract [9]. The catechol-O-methyltransferase (COMT), which methylates 
catechol estrogens, prevents their conversion to quinones. There are reports that 2-
hydroxylated E2/E1 are better substrates for COMT than their 4-hydroxylated isomers [10,11]. 
Thus, the 2OH-E2/4OH-E2 ratio may be a critical parameter of the carcinogenicity of E2. 
 
Figure 2. Major metabolic pathway in cancer initiation by oestrogens 
We propose that local activation of the cytochrome P450 enzymes CYP1A1 and CYP1B1 by 
E2 may generate active metabolites that affect apoptosis and thereby promote mammary 
carcinogenesis. To test this hypothesis, we measured the ability of E2 to induce CYP1A1 and 
CYP1B1 and assessed the influence of the parent compounds and their hydroxylated 
metabolites on apoptosis.  
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The previously published results demonstrated that E2 increased CYP1B1 protein 
expression after 48 h of cell culture but had no effect on CYP1A1 protein levels [12], Figure 
3. CYP1B1 has been suggested to play key roles in initiating breast cancers in humans, as 
this enzyme is active in catalysing oestradiol to a 4-hydroxylated metabolite. Cytochrome 
P450 enzymes, the products of the CYP genes, are components of the oestrone hydroxylase 
enzyme system. Elevated 4-hydroxyoestrogen production has been associated with breast 
tumours [13]. 
 
Figure 3. The effect of oestradiol (1nM) on expression of the CYP 1B1 protein in MCF-7 cells [12] 
2.5. Action of E2 and its hydroxylated metabolites (2-OH-E2 and 4-OH-E2) on 
MCF-7 breast cancer cell proliferation 
In our previously published data [12], we demonstrated that E2 can be locally metabolised 
to their hydroxylated derivatives via cytochrome P450 enzymes in breast cancer MCF-7 
cells. Additionally, E2 hydroxylated metabolites had a time-dependent affect on MCF-7 cell 
proliferation [14]. While E2 and 4-OH-E2 elicited a significant increase in cell proliferation 
over the entire time of exposure, 2-OH-E2 resulted in an increase of cell proliferation only 
after a long incubation period, Figure 4.  
Our observations were consistent with the results of [15], who demonstrated that 4-OH-E2 is 
more oestrogenic than 2-OH-E2. In [16] it was indicated that certain oestradiol metabolites, 
i.e., 4-OH-E2 and 16-OH-E2, are able to mimic the effects of 17β-oestradiol on proliferation 
and markers of tumour metastasis. The effect was more pronounced for 16-OH-E2. In 
contrast, the metabolite 2-OH-E2 did not show any significant effect on these parameters. 
The effect of the various oestrogen metabolites appears to be dependent on their ability to 
bind to the oestrogen-receptor. The most potent oestrogen regarding an influence on 
proliferation, apoptosis and metastasis is 17β-oestradiol. As this oestrogen appears to be 
metabolised intracellularly, the direction of oestradiol metabolism may influence breast 
cancer risk in certain predisposed women. Enhanced metabolism towards 2-OH-E2 may 
even be protective, as this metabolite is rapidly converted into 2-methoxyestradiol, which 
has been shown to be a potent anti-proliferative and anti-angiogenic agent in various 
tumour cells [17].  
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major effectors of cell proliferation and cell survival. Deregulations of cell proliferation, 
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Figure 2. Major metabolic pathway in cancer initiation by oestrogens 
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The previously published results demonstrated that E2 increased CYP1B1 protein 
expression after 48 h of cell culture but had no effect on CYP1A1 protein levels [12], Figure 
3. CYP1B1 has been suggested to play key roles in initiating breast cancers in humans, as 
this enzyme is active in catalysing oestradiol to a 4-hydroxylated metabolite. Cytochrome 
P450 enzymes, the products of the CYP genes, are components of the oestrone hydroxylase 
enzyme system. Elevated 4-hydroxyoestrogen production has been associated with breast 
tumours [13]. 
 
Figure 3. The effect of oestradiol (1nM) on expression of the CYP 1B1 protein in MCF-7 cells [12] 
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Figure 4. Action of E2 and its hydroxylated metabolites 2-OH-E2 and 4-OH-E2 on MCF-7 cell 
proliferation after 24, 72, 168, and 260 h of exposure to 0.1, 1.0 or 10nM concentrations of these 
compounds. (*) p < 0.05 [14] 
2.6. Molecular mechanisms of E2 and its hydroxylated metabolites (2-OH and 4-
OH) 
The human sex hormone-binding globulin (SHBG), a glycoprotein that specifically binds 
plasma androgens and oestradiol, participates in the mechanism of action of oestradiol in 
breast cancer cells. The SHBG protein has been detected, using reverse transcriptase-
polymerase chain reaction (RT-PCR), in ZR-75-1, MCF-7 and MDA-MB-231 cells, as well as 
in 11 breast tissue samples [18]. Although the data concerning the cell lines were convincing, 
no evidence for mRNA translation has been presented. Due to its unique property to 
regulate bioavailable oestradiol, several epidemiological studies have implicated SHBG as 
having a role in breast cancer, and it has been suggested that plasma SHBG levels are 
inversely associated with breast cancer risk in post-menopausal women. According to [19], 
for SHBG to be biologically relevant, the interaction of SHBG with its membrane-binding 
site (SHBG-R) requires the occurrence of a precise sequence of events. First, SHBG must 
bind to a membrane (through SHBG-R), and a ligand must then interact with the SHBG 
bound to the membrane. It is only at this point that the biological effect is elicited. If the 
ligand binds to SHBG before the protein binds to the membrane, it is blocked from 
interacting with membranes, Figure 5. In breast cancer MCF-7 cells, SHBG binds to the 
membrane, and through cyclic adenosine monophosphate (cAMP) induction and protein 
kinase A (PKA) activation, it inhibits oestradiol-induced cell proliferation [20]. 
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Figure 5. Model for SHBG-mediated signalling pathway 
Despite extensive years of research, the action of hydroxylated metabolites of E2 (2-OH-E2 
and 4-OH-E2) on SHBG intra/extracellular secretion as well as gene and protein expression 
in extrahepatic tissue has not yet been investigated. Our data demonstrated that 
hydroxylated metabolites of E2, with a potency of E2 > 4-OH-E2 > 2-OH-E2, increased 
intracellular and had no effect on extracellular SHBG levels [21], Figure 6.  
 
Figure 6. The effect of E2, 2-OH-E2 and 4-OH-E2 on intracellular SHBG levels in MCF-7 cells. (*) p<0.05, 
(**) p<0.01, (***) p<0.001 [21] 
Additionally, we demonstrated that E2, 2-OH-E2 and 4-OH-E2 increased SHBG mRNA and 
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Figure 7. The effects of E2, 2-OH-E2 and 4-OH-E2 on SHBG mRNA and protein expression in MCF-7 
cells. SHBG mRNA determined by real time PCR. (*) p<0.05, (**) p<0.01, (***) p<0.001 [21] 
In addition to classical transcriptional actions, oestrogens also trigger rapid intracellular 
signalling events typically associated with membrane receptors. Oestradiol, a biologically 
potent oestrogen, can induce rapid activation of many signalling molecules, including 
cAMP/PKA and MAPK pathways [22]. An increasing number of studies indicate that the 
cellular action of E2 can be initiated at the plasma membrane, through membrane versions 
of oestrogen receptors (mERs) or via other membrane-resident E2-binding proteins [23]. The 
binding of E2 to the membrane receptor causes an increase of intracellular cAMP levels [23]. 
As a second messenger, cAMP is involved in a variety of intracellular signalling pathways 
that lead to diverse physiological effects, including the control of cell proliferation. The 
majority of cAMP signalling in eukaryotic cells is through PKA. It has been reported that 
activation of the cAMP/PKA pathway induces growth inhibition in a variety of human 
cancer cells, including the MCF-7 cell line [23]. Mitogen-activated protein kinases (MAPKs), 
such as extracellular signal-regulated kinases (ERK1 and ERK2), are also rapidly stimulated 
by oestrogens in various cell types, including breast cancer cells. Additionally, it has been 
reported that the cAMP/PKA and the MAPK pathways are connected in MCF-7 cells [23,24]. 
Notably, ERK can be activated or inhibited by cAMP and E2, although activation of the 
cAMP/PKA suppresses the activity of ERK1/2 [25]. However, controversies also exist 
regarding the extent to which E2 may influence ERK1/2 activation [26]. We have shown that 
E2 and its hydroxylated metabolites do not activate cAMP/PKA and ERK1/2 in breast cancer 
cells and confirmed previously published data, which demonstrated a lack of ERK1/2 
activation in a breast cancer cell line [27], Figure 8, 9. The observed reversible action of 
PD98059 on cell proliferation can be explained via the actions of hydroxylated estrogens, 
which similarly to E2, stimulate secretion of a number of growth factors that affect MAPK 
activity [28].  
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Figure 8. The effects of E2, 2-OH-E2 and 4-OH-E2 on cAMP and PKA levels in MCF-7 cells. [27] 
 
Figure 9. Time-dependent effects of E2, 2-OH-E2 and 4-OH-E2 on phospho- and total ERK1/2 protein 
expression in MCF-7 cells. [27] 
3. Xenoestrogens 
Xenoestrogens form a diverse group of man-made chemicals that have been released into 
the environment from agricultural spraying (herbicides, pesticides), by-products of 
industrial processes and waste disposal of polychlorinated biphenyls (PCBs) and dioxins or 
as discharges from treatment systems (alkyl phenols). They are also found in household 
products in daily use, such as plastics (bisphenol A, phthalates) and flame retardants 
(polybrominated organics) and cosmetic products (e.g., parabens, cyclosiloxanes). They may 
be present in diets, and because they are lipophilic, they can pass up the food chain 
dissolved in animal fat and accumulate in humans at the top of the food chain. 
3.1.1. Polychlorinated biphenyls and breast cancer  
Polychlorinated biphenyls (PCBs) are industrial chemicals that have been used as hydraulic 
fluids, dielectric fluids for transformers and cooling fluids for capacitors in the formulation 
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3.1.1. Polychlorinated biphenyls and breast cancer  
Polychlorinated biphenyls (PCBs) are industrial chemicals that have been used as hydraulic 
fluids, dielectric fluids for transformers and cooling fluids for capacitors in the formulation 
of lubricating and cutting oils and as plasticisers in prints, copy paper, adhesives, sealants 
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and plastics. PCBs are complex chemical mixtures that comprise theoretically 209 congeners. 
Although the production and use of these compounds were banned in the late 1970s, a 
significant portion of the PCBs purchased by industry are still in use, mostly within 
capacitors and transformers. These compounds remain in our environment and are 
routinely found in human serum, breast milk and adipose tissue, including breast tissue. 
PCB exposure has been classically thought to alter normal endocrine signalling by 
mimicking endogenous hormone action by binding to hormone receptors, blocking 
receptors, or through interference with steroid metabolism. The relationship between 
exposure to PCBs and breast cancer has been addressed in numerous epidemiological 
studies since the early 1990s [29].  
 
 
Figure 10. Polychlorinated biphenyls (PCBs) 
3.1.2. Metabolism of polychlorinated biphenyls   
PCBs are not only efficacious inducers but also substrates for cytochrome P450 enzymes. 
This enzyme metabolises PCBs, as well as other environmental compounds that enter the 
body, into by-products that are mutagenic and carcinogenic. Notably, lower chlorinated 
PCBs (such as PCB3) are rapidly metabolised and therefore called “episodic congeners” [30]. 
One member of the CYP1 family, CYP1A1, has been shown to play an important role in the 
metabolism of PCBs [31,32]. 
 
 
Figure 11. The metabolic activation of the  4-chlorobiphenyl (PCB3) 
We demonstrated previously in MCF-7 breast cancer cells that PCB3 modestly increases 
CYP1A1 but not CYP1B1, protein levels and activity, Figure 12. This alteration may change 
metabolic activation pathways of PCB3 itself or local oestrogen metabolism and excretion 
[32]. The metabolic activation of PCBs and/or E2 by CYPs leads to the formation of arene 
oxide intermediates and reactive quinones, which can bind covalently to macromolecules 
such as DNA, RNA and proteins [33].  
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Figure 12. The effects of PCB3 on CYP1A1 activity (EROD assay) and protein levels in MCF-7 cells (*) 
p<0.05, (**) p<0.01, (***) p<0.001 [32] 
3.1.3. Action of PCB3 (4-chlorobifenyl) and its metabolites (4-diOH-PCB3 and 3,4-diOH-
PCB3) on MCF-7 human breast cancer cell proliferation and apoptosis  
The balance between proliferation and apoptosis determines tissue homeostasis under 
physiological conditions. Apoptosis is recognised as a major barrier that must be 
circumvented by tumour cells to survive and proliferate under stressful conditions. 
Apoptosis can be initiated via two different types of signals: intracellular stress signals 
(intrinsic pathway) and extracellular ligands (extrinsic pathway). Previous studies have 
provided conflicting data regarding the proliferation and apoptosis effects of PCBs on breast 
cancer cells. As opposed to the action of oestrogen on MCF-7 proliferation, we showed that 
PCB3 and its metabolite 4-OH-PCB3 had no effect on cell proliferation at any time during 
exposure, while at the highest concentration, 3,4-diOH-PCB3 decreased cell proliferation 
[14]. Additionally, we showed that PCB3 and both of its hydroxylated metabolites had no 
effect on caspase-8 (extrinsic pathway) and caspase-9 (intrinsic pathway) activity when cells 
were grown in medium deprived of oestrogen, but they reduced caspase-9 activity when 
cells were grown in medium supplemented with serum containing oestradiol, Figure 13. 
Interestingly, a decrease in DNA fragmentation was observed upon treatment with 3,4-
diOH-PCB3 in both culture conditions, suggesting that 3,4-diOH-PCB3 inhibits a caspase-
independent pathway of cell death [34]. 
3.1.4. Molecular mechanisms of PCB3 and its hydroxylated metabolites (4-diOH-PCB3 
and 3,4-diOH-PCB3) 
Similarly to endogenous oestrogens, xenoestrogens can also contribute to the activity of the 
SHBG pathway and the MAP kinase pathways. Several studies have demonstrated that 
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human SHBG binds phytoestrogens, fatty acids and 4-OH-2’,3’,4’,5’-PCB and 4-OH-
2,2’,3’,4’,5’-PCB [35]. Our previously published data indicated that 3,4-diOH-PCB3 does not 
interact with SHBG through the membrane-binding site or directly. However, an increase in 
intracellular SHBG levels was noted under the influence of 3,4-diOH-PCB3 in MCF-7 cells 




Figure 13. Effects of PCB3 (300 nM) and its metabolites on DNA fragmentation, as determined by 
ELISA; caspase-8 activity and, caspase-9 activity after 24 h of growth in medium supplemented with 5% 
FBS (left panel) or deprived of estrogen and by treatment with activated charcoal-dextran (5% FBS CD) 
(right panel). Staurosporine (St; 0.1 μM) was added during the last 3 h to induce apoptosis. (*) p<0.05, 
(**) p<0.01, (***) p<0.001 [32] 
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Figure 14. The effects of PCB3, 4-OH-PCB3 and 3,4-di-OH-PCB3 on extracellular (medium) and 
intracellular (cells) SHBG levels’ in MCF-7 cells. (*) p<0.05 [34] 
Furthermore, 3,4-diOH-PCB3 is ineffective in the activation of cAMP. Moreover, using a 
PKA inhibitor, we demonstrated that neither PCB3 nor its metabolites act through PKA [34], 
Figure 15.  
 
Figure 15. The effects of PCB3, 4-OH-PCB3 and 3,4-di-OH-PCB3 on cAMP and PKA levels in MCF-7 
cells. (p < 0.05) [34] 
Thus, the anti-proliferative action of 3,4-diOH-PCB3 is not due to inhibition of the ERK1/2 
pathway via the SHBG/AMP/PKA pathway, but rather a direct inhibitory action on the 
ERK1/2 system [34], Figure 16.  
 
Figure 16. The effect of PCB3, 4-OH-PCB3 and 3,4-di-OH-PCB3 on  phospho- ERK1/2 levels in MCF-7 
cells. (*) p<0.05 [34] 
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Others have demonstrated that xenoestrogens can lead to the oscillating activation of ERK. 
Compounds from different classes of endocrine disruptors such as phytoestrogen 
(coumestrol), organochlorinated pesticides and their metabolites (endosulfan, dieldrin, 
DDE) and detergents (p-nonylphenol) can produce the same time-dependent activation 
pattern for ERKs [36]. These xenoestrogens produced rapid (3–30 min after application), 
concentration-dependent ERK1/2 phosphorylation. In addition, [37] demonstrated that the 
mitogenic effect of PCB153 was ERK1/2-mediated. Moreover, they showed that inhibition of 
ERK1/2 with PD98059 completely blocks the mitogenic effect of PCBs.  
 
Figure 17. Proposed mechanism of antiproliferative action of 3,4-di-OH-PCB3 in MCF-7 cells [34]. The 
down arrow indicates a ERK1/2 decrease and proliferations decrease. AC, adenylyl cyclase; Ras-Raf, 
mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase. 
3.2. Bisphenol A and ovarian cancer 
Bisphenol A (BPA) is a small monomer (228 Da) commonly used as plasticiser in the 
manufacture of polycarbonate plastics and epoxy resins. It is present in a multitude of 
products, including the interior coatings of food cans, milk containers, and baby formula 
bottles, as well as in dental composites and sealants. BPA was found in the serum, milk, 
saliva, and urine of humans at nanomolar concentrations. Many studies in the United States, 
Europe, and Japan have documented BPA levels ranging from 0.2 to 18.9 ng/mL (0.5–100 
nM) in adult and foetal human serum [38]. Epidemiological studies have highlighted the 
correlation between the increase of BPA levels in the environment and the incidence of 
cancer in humans. BPA can act as an endocrine disruptor and a mitogenic substance 
inducing cell proliferation. As a mitogen, BPA induces susceptibility to neoplastic 
transformation [39]. 
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3.2.1. BPA action on cell proliferation 
BPA can increase cell proliferation in a dose-dependent manner in OVCAR- 3 human 
ovarian cancer cells [40], MCF-7 breast cancer cells [41] and HeLa cells [42], Figure 19.  
 
Figure 19. The effect of BPA on the proliferation of OVCAR-3 cells. (**) p<0.01, (***) p<0.001 [40] 
Alterations in the mechanisms controlling cell cycle progression play a relevant role in the 
pathogenesis of different types of human neoplasia. As the cell cycle is regulated by the 
coordinate action of cyclin-dependent kinases (cdk), specific cyclin proteins and cdk 
inhibitors, we focused on cell cycle associated gene analysis. The cell cycle has four 
sequential phases: the S phase, when DNA replication occurs, and the M phase, when the 
cell divides into two daughter cells, as well as two gap phases referred to as G1 and G2. The 
G1-S transition in normal cells requires phosphorylation of the retinoblastoma protein (Rb) 
by cyclin D/Cdk4 or cyclin D/Cdk6 in mid G1 and by cyclin E/Cdk2 complexes later in G1. 
As cells progress into the S phase, cyclin A is expressed and becomes the primary cyclin 
associated with Cdk2. Progression from G2 into mitosis requires the activity of the Cdk and 
Cdc2 (also known as Cdk1) complexed with cyclin B, which has been shown to 
phosphorylate proteins regulated during mitosis. Basal and mitogen-induced cell growth is 
regulated by cell cycle inhibitors, which can bind to and inhibit the Cdks (such as p15, p16, 
p21, p27, p57). The results of our study [40] demonstrated that BPA promotes G1 to S-phase 
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Others have demonstrated that xenoestrogens can lead to the oscillating activation of ERK. 
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Figure 17. Proposed mechanism of antiproliferative action of 3,4-di-OH-PCB3 in MCF-7 cells [34]. The 
down arrow indicates a ERK1/2 decrease and proliferations decrease. AC, adenylyl cyclase; Ras-Raf, 
mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase. 
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progression by stimulating the expression of cyclin D1, CDK4, E2F1, E2F3 and PCNA while 
inhibiting the expression of inhibitors (p21WAF1/CIP1, Weel-1 and GADD45 alpha) and 
progression from G2 into mitosis by stimulating the expression of cyclin A in ovarian cancer 
cells OVCAR-3, Figure 20. The results of our study [40] additionally demonstrated that the 
suppression of p21/WAF mRNA, a marker of poor overall survival in ovarian cancer 
patients, was under the influence of BPA.   
 
Figure 20. Selected cell cycle gene expression changes in OVCAR-3 cells exposed to BPA identified by 
real-time PCR [40] 
3.2.2. BPA action on apoptosis 
Studies on the effects of BPA on apoptosis have generated conflicting results, largely due to 
the micromolar concentrations of BPA utilised by most studies. BPA, in doses of 10, 1 and 
0.1 mM, was a potent inhibitor of apoptosis in MCF-7 cells [43]. In contrast, BPA increased 
the expression of Bax (pro-apoptotic) and concomitantly decreased the expression of Bcl2 
(pro-survival) at both protein and mRNA levels in granulosa cells [44]. In addition, BPA at a 
concentration of 100 μM decreased cell viability and increased necrosis in human 
endometrial endothelial cells (HEECs) [45].  
A hallmark of apoptosis is the fragmentation of nuclear DNA. The intrinsic apoptosis 
pathway is activated when intracellular stress signals lead to the release of cytochrome c 
and other pro-apoptotic proteins within the mitochondria, which is regulated by members 
of the Bcl-2 family of proteins. The consequent release of cytochrome C leads to the 
formation of the apoptosome (cytochrome C, Apaf-1 and procaspase-9) in which 
procaspase-9 is auto-activated, thereby activating the executioner caspases. The extrinsic 
pathway is activated when extracellular ligands (such as Fas ligand, TNFα, TRAIL) bound 
to the death receptor domains of these receptors, recruit adaptor proteins (such as FADD 
and TRADD) and initiator caspase-8 and -10 (DISC). Both apoptotic pathways lead to the 
activation of the executioner caspases-3, -6 and -7, which are the main proteases that 
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degrade the cell. A hallmark of apoptosis is the fragmentation of nuclear DNA. 
Endonuclease G is essential for DNA fragmentation during caspase-independent apoptosis. 
In response to apoptotic stimuli, it is also released from the mitochondria into the cytosol, 
where it translocates to the nucleus and generates oligonucleosomal DNA fragmentation.  
In our previously published study, we demonstrated that inhibition of the caspase-3 activity 
had no effect on DNA fragmentation in cells exposed to BPA [40]. We demonstrated that 
BPA acts by suppressing the expression of pro-apoptotic genes, such as FAS, FADD, 
RAIDD, caspase-8, -10, -3, -6, -7, CAD, Bax, Bak, Bok and Apaf-1, and inducing the 
expression of pro-survival genes, such as Bcl-x and Mcl-1. Moreover, BPA activates the 
caspase-independent apoptotic pathway via the induction of endonuclease G gene 
expression, Figure 21. The absence of an effect of BPA on DNA fragmentation is 
hypothesised to result from the simultaneous activation of the caspase-independent 
pathway and an inhibition of caspase-dependent DNA fragmentation. The observed 
induction of p53 (a nuclear transcription factor that accumulates in response to cellular 
stress, including DNA damage and oncogene activation) and suppression of caspase-3 and -
7 is thought to activate the DNA repair process. Therefore, despite the observed induction of 
endo G gene expression, an action of BPA on DNA fragmentation was not observed [40].  
 
Figure 21. Selected apoptosis gene expression changes in OVCAR-3 cells exposed to BPA identified by 
real-time PCR [40] 
3.2.3. Mechanism of action of BPA in OVCAR-3 cell cycle regulation 
BPA can elicit rapid responses in cells via the involvement of a non-genomic signalling 
pathway though the activation of second messenger systems. Our data demonstrated that 
BPA stimulated proliferation of ovarian epithelial cancer cells via the induction of a rapid 
activation of ERK1/2, Stat3, and Akt signalling systems [46], Figure 22, 23. Previous studies 
demonstrate that BPA triggers a rapid biological response through the phosphorylation of 
Stat3, ERK1/2 and Akt in 3T3-L1 cells [47] and ERα/β-positive and -negative breast cancer 
cells [48].  
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Figure 22. The effect of BPA on cell proliferation. OVCAR-3 cells were pretreated with AG490 (50 μM), 
PD098059 (100 μM) or LY294002 (10 μM) for 1 hr, then the cells were treated BPA (8 ng/ml) and an 
alamarBlue assay was performed. (***) p<0.001 [46] 
 
Figure 23. The effects of BPA on the activation of Stat-3, ERK1/2 and Akt in OVCAR-3 cells. Western 
blot analysis was performed following BPA treatment in a time-dependent manner (5, 15, and 30 min 
and 1, 2, 4, 6 and 24 hrs). Total Stat-3, ERK1/2 and Akt were used to normalise the level of 
phosphorylated Stat-3, ERK1/2 and Akt, respectively [46]  
3.3. Combinatory effects of endo- and exogenous oestrogens.  
Recently, an increasing amount of data has demonstrated that xenoestrogens can interfere 
with endogenous oestrogens. In our previously published data, we investigated the 
contribution of specific representative PCBs and PBDEs on the oestrogenic action of 
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endogenous oestradiol on the proliferation and apoptosis of the breast cancer cell line MCF-
7. The structure of polybrominated diphenyl ethers (PBDEs) is similar to that of PCBs. 
PBDEs are a series of 209 possible congeners that differ in the number and position of 
bromine atoms. These chemicals are widely used as flame retardants in plastic foams, 
textiles, electronic devices, and building materials. As a result, they are widely found in the 
environment and can be found in human blood and milk. Some of the PBDE congeners most 
commonly found in human samples are BDE-47, BDE-99, and BDE-153 [49].    
Our data demonstrated that all PCB congeners (118, 138, 153 and 180) and all concentrations 
tested increased MCF-7 cell proliferation while decreased cell apoptosis to a greater extent 
than oestradiol. However, in co-treatment experiments with oestradiol, cell proliferation 
decreased in comparison to the cell proliferation observed for cells exposed to PCB 
congeners alone, and no additional effect on cell apoptosis was observed [50], Figure 24.  
 
Figure 24. The effects of PCB (0.1, 0.5 and 1 mM) and oestradiol, alone (black bar) and combination 
treatment (open bar) on proliferation after 72 hours of culture and on caspase-9 activity after 24 hours of 
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Figure 24. The effects of PCB (0.1, 0.5 and 1 mM) and oestradiol, alone (black bar) and combination 
treatment (open bar) on proliferation after 72 hours of culture and on caspase-9 activity after 24 hours of 
culture in MCF-7 cells. (a<b<c<d) p < 0.05 [50] 
 
Carcinogenesis 82 
Despite the similarity in structure, PCBs and PBDEs had different effects on proliferation 
and apoptosis in MCF-7 breast cancer cells. None of the PBDE congeners tested (47, 99, 100, 
209) had an effect on basal cell proliferation; however, all PBDE congeners tested 
significantly decreased basal cell apoptosis. In the presence of oestradiol, additive anti-
apoptotic activity and an ability to induce cell proliferation were observed [51], Figure 25. 
 
Figure 25. The effects of PBDE (0.1, 0.5 and 1 mM) and oestradiol, alone (black bar) and combination 
treatment (gray bar) on proliferation after 72 hours of culture and on caspase-9 activity after 24 hours of 
culture in MCF-7 cells. (a<b<c<d) p < 0.05 [51] 
4. Conclusion  
Despite a reduction in the doses of natural oestrogens used in HRT and contraceptives, as 
well as the production and use of environmental oestrogens, these compounds remain in 
our environment and are routinely found in human serum, breast milk and adipose 
samples, including breast tissue. Importantly, differences in activity as potential carcinogens 
are being studied. The potencies of these compounds in nuclear transcription reporter 
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assays, compared with the endogenous oestrogens, range from very weak (e.g., PCBs) to 
somewhat weak (e.g., bisphenol A) to strong (DDE). Moreover, both endogenous and 
exogenous oestrogens form metabolites during metabolism that act more strongly than their 
corresponding parental compounds. The results of a published study suggest that the 
genomic and nongenomic actions of the parent endogenous and exogenous oestrogens lead 
to the activation of secondary messenger systems responsible for proliferation and 
apoptosis. The results of our study indicate that it is necessary to consider local metabolism 
in peripheral tissues, such as ovary and breast. Therefore, an accurate assessment of the 
carcinogenicity of oestrogens and xenoestrogens requires an understanding of not only the 
potential mode of action of the parent compounds but also their hydroxylated metabolites. 
These include the promotion of tumorigenic progression, genotoxicity, and the 
developmental reprogramming that increases susceptibility to other carcinogenic events. 
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1. Introduction 
A spectrum of cellular activities including proliferation, differentiation and metabolism are 
controlled by growth factors and hormones. The effects of many growth factors are 
mediated and achieved via transmembrane receptor tyrosine kinases [1,2]. Following ligand 
binding, the intrinsic catalytic activity of the growth factor receptor tyrosine kinases (RTKs) 
is augmented. The autophosphorylated RTKs then transmit signals through their ability to 
recruit and/or phosphorylate intracellular substrates. Thus, identification and 
characterization of proteins that associate with and/or become tyrosyl phosphorylated by 
RTKs become critical to delineate RTKs-mediated signaling pathways. A variety of 
methodologies have been developed and applied to search for substrates of tyrosine kinases 
including RTKs [3-8]. Here, we focus on EGFR pathway substrate no. 8 (Eps8), a putative 
target of epidermal growth factor (EGF) receptor (EGFR), and discuss its biological function 
as well as its implication in human cancers. Given Eps8-elicited effects contribute to 
neoplasm, its potential as a therapeutic target for cancer treatment is anticipated. 
1.1. The identification of Eps8 
To dissect EGFR-mediated signaling, Di Fiore’s laboratory took advantage of immuno-
affinity purification of an entire set of proteins phosphorylated in EGF-treated EGFR-
overexpressing cells, followed by generation of antisera against the purified protein pool. 
With these antisera, bacterial expression libraries were immunologically screened. Several 
murine cDNAs (eps clones) representing genes encoding substrates for EGFR were obtained 
[7,8]. One of them was designated eps8 [9,10]. The human eps8 locus was mapped to 
chromosome 12p12-p13 via fluorescence in situ hybridization (FISH) [11] and confirmed by 
a computer search of a genomic DNA database utilizing human EPS8 cDNA sequence 
(GeneBank accession number U12535) [12]. Similarly, the murine Eps8 genomic DNA 
 The Author(s). Licensee I .  ch pter is distributed under the terms of the Cr a ive Commons 
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1. Introduction 
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including RTKs [3-8]. Here, we focus on EGFR pathway substrate no. 8 (Eps8), a putative 
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sequences are defined on chromosome 6G1 [12]. The computer analysis also revealed three 
genes (designated as Eps8R1, Eps8R2, and Eps8 R3) that are highly homologous to both 
human and murine eps8 [12]. Due to space limitation, studies on these Eps8Rs will not be 
described in this review.   
Proteins with molecular weights of 97 kDa and 68 kDa were recognized by Eps8 antibodies 
and referred to as the two Eps8 isoforms (p97Eps8 and p68Eps8) [12,13].  The exact nature (an 
alternatively spliced or a proteolytic product) of p68Eps8 was still elusive and remained to be 
established. By contrast, p97Eps8 has been well characterized and is the only isoform detected 
in human cancer cells so far and hereinafter is called Eps8. 
Eps8 contains 821 amino acids and exhibits several features of interest: a split pleckstrin 
homology (PH) domain, a putative nuclear targeting sequence, an Src homology 3 (SH3) 
domain, several proline-rich regions, and a degenerated SH2 (dSH2) domain at the N-
terminus (amino acids 55-96) (Figure 1). The proline-rich Eps8 has been demonstrated to 
interact with the SH3 domain of Src [13] and the SH3 of Eps8 was reported to associate with 
Shb [14], Shc [15], RN-tre [16], and Abi1 (also known as E3b1) [17]. The SH3 domain of Eps8 
binds to a consensus sequence of proline-X-X-aspartate-tyrosine (PXXDY) instead of the 
canonical X-proline-X-X-proline (XPXXP) consensus, implicating the existence of a novel 
family of SH3-containing proteins [18]. Furthermore, two Eps8 proteins were demonstrated 
to form an interwound dimer with their SH3 domains being located at the interface [19]. In 
addition to the aforementioned Eps8-interacting proteins, Eps8 was also shown to bind 
directly to EGFR [20], Sos1 [21], and IRSp53 [22,23].  
 
Figure 1. Structural organization of Eps8.  The N-terminal split PH domain (PH*) is important for Eps8 
membrane recruitment. Regions in Eps8 responsible for association with Eps8 binding partners are 
indicated. Green boxes indicate proline-rich regions; gray box indicates the potential nuclear 
localization signal. dSH2 indicates the position of a degenerated SH2. 
Strikingly, Eps8 is an actin capper whose barbed-end capping activity resides in its C-
terminal effector domain and is regulated by protein-protein interaction with Abi1 [24,25].  
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In addition to lamellipodia [26], Eps8 also localizes to other actin-rich structures such as 
PIP2-enriched vesicles, phagocytic cups and comet tails behind intracellular pathogens [25]. 
Two Abi1-containing complexes were reported to have multiple roles in regulating dynamic 
actin turnover [27]. One contains Nap1, Sra (PIR125), Hspc and WAVE, the other contains 
Eps8, Sos1, and the p85 subunit of PI3K.  While the former may activate the Arp2/3 complex, 
the latter may regulate Rac activation and enable Eps8 to cap actin filament barbed ends. Of 
note, Eps8 turns out to be a novel capping protein capable of side-binding and bundling 
actin filaments [28]. The C-terminal Eps8 region (aa648-aa821) encompasses five helices (H1-
H5). The N-terminal amphipathic helix (H1) is largely responsible for Eps8 capping activity, 
while a compact, globular domain composed of H2-H5 is critical for filament bundling. 
Thus, Eps8, as a bifunctional actin remodeller, regulates actin-based mobility and 
endomembrane cellular trafficking through its capping activity, whereas it contributes to 
proper structural organization of gut microvilli via its mediated actin filament bundling 
[28]. 
1.2. Eps8 is an oncoprotein 
Known as the first identified oncoprotein, the tyrosine kinase activity of Rous sarcoma virus 
(RSV)-encoded v-Src is essential for its mediated transformation. Under its influence, a 
spectrum of proteins has their phosphotyrosine content increased and are viewed as 
putative v-Src substrates [3,29]. Intriguingly, some of them including Eps8 turn out to be the 
substrates for EGFR as well [13]. Elevated expression and tyrosyl phosphorylation of Eps8 
are observed in v-Src transformed cells [13]. Overexpression of Eps8 confers the ability of 
fibroblasts to form foci in culture and to grow tumors in mice [30]. Consistent with its 
oncogenic potential [30], Eps8 attenuation retards cellular growth of fibroblasts expressing 
v-Src [31].   
Like SH2 and SH3, PH is a common motif shared by signaling molecules, which mediates 
protein-protein and protein-lipid interactions. Mounting evidence indicates that via PH-
mediated binding to either phospholipids [32,33] or membrane-associated proteins [34,35], 
the association between PH-containing molecules and plasma membrane is accelerated. The 
prominent examples are Akt/PKB that possesses a compact PH and PLC that retains a split 
PH. Like PLC, Eps8 contains a split PH (Figure 1), which does not weaken its linkage to the 
cell membrane. Remarkably, an intact split PH is indispensable for Eps8 membrane 
targeting as well as its mediated oncogenesis. In contrast, Eps8 with truncated PH fails to be 
recruited to plasma membrane and confers transforming ability [30].   
To confirm the involvement of Eps8 in the development of cancer, the correlation between its 
expression and cell proliferation of various human cancer cell lines were examined [36]. In 
human colon cancers, there is a positive correlation between Eps8 expression and mitogenesis, 
implicating the importance of Eps8 in colon cancer formation. Indeed, Eps8 attenuation in high 
Eps8 expressing cells (i.e. SW620 and WiDr) reduces cellular growth [36]. In contrast, 
ectopically expressed Eps8 in low Eps8 expressing cells (i.e. SW480) or Eps8-attenuated SW620 
promotes proliferation. In addition, relative to controls, there is a significant (>50%) 
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sequences are defined on chromosome 6G1 [12]. The computer analysis also revealed three 
genes (designated as Eps8R1, Eps8R2, and Eps8 R3) that are highly homologous to both 
human and murine eps8 [12]. Due to space limitation, studies on these Eps8Rs will not be 
described in this review.   
Proteins with molecular weights of 97 kDa and 68 kDa were recognized by Eps8 antibodies 
and referred to as the two Eps8 isoforms (p97Eps8 and p68Eps8) [12,13].  The exact nature (an 
alternatively spliced or a proteolytic product) of p68Eps8 was still elusive and remained to be 
established. By contrast, p97Eps8 has been well characterized and is the only isoform detected 
in human cancer cells so far and hereinafter is called Eps8. 
Eps8 contains 821 amino acids and exhibits several features of interest: a split pleckstrin 
homology (PH) domain, a putative nuclear targeting sequence, an Src homology 3 (SH3) 
domain, several proline-rich regions, and a degenerated SH2 (dSH2) domain at the N-
terminus (amino acids 55-96) (Figure 1). The proline-rich Eps8 has been demonstrated to 
interact with the SH3 domain of Src [13] and the SH3 of Eps8 was reported to associate with 
Shb [14], Shc [15], RN-tre [16], and Abi1 (also known as E3b1) [17]. The SH3 domain of Eps8 
binds to a consensus sequence of proline-X-X-aspartate-tyrosine (PXXDY) instead of the 
canonical X-proline-X-X-proline (XPXXP) consensus, implicating the existence of a novel 
family of SH3-containing proteins [18]. Furthermore, two Eps8 proteins were demonstrated 
to form an interwound dimer with their SH3 domains being located at the interface [19]. In 
addition to the aforementioned Eps8-interacting proteins, Eps8 was also shown to bind 
directly to EGFR [20], Sos1 [21], and IRSp53 [22,23].  
 
Figure 1. Structural organization of Eps8.  The N-terminal split PH domain (PH*) is important for Eps8 
membrane recruitment. Regions in Eps8 responsible for association with Eps8 binding partners are 
indicated. Green boxes indicate proline-rich regions; gray box indicates the potential nuclear 
localization signal. dSH2 indicates the position of a degenerated SH2. 
Strikingly, Eps8 is an actin capper whose barbed-end capping activity resides in its C-
terminal effector domain and is regulated by protein-protein interaction with Abi1 [24,25].  
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In addition to lamellipodia [26], Eps8 also localizes to other actin-rich structures such as 
PIP2-enriched vesicles, phagocytic cups and comet tails behind intracellular pathogens [25]. 
Two Abi1-containing complexes were reported to have multiple roles in regulating dynamic 
actin turnover [27]. One contains Nap1, Sra (PIR125), Hspc and WAVE, the other contains 
Eps8, Sos1, and the p85 subunit of PI3K.  While the former may activate the Arp2/3 complex, 
the latter may regulate Rac activation and enable Eps8 to cap actin filament barbed ends. Of 
note, Eps8 turns out to be a novel capping protein capable of side-binding and bundling 
actin filaments [28]. The C-terminal Eps8 region (aa648-aa821) encompasses five helices (H1-
H5). The N-terminal amphipathic helix (H1) is largely responsible for Eps8 capping activity, 
while a compact, globular domain composed of H2-H5 is critical for filament bundling. 
Thus, Eps8, as a bifunctional actin remodeller, regulates actin-based mobility and 
endomembrane cellular trafficking through its capping activity, whereas it contributes to 
proper structural organization of gut microvilli via its mediated actin filament bundling 
[28]. 
1.2. Eps8 is an oncoprotein 
Known as the first identified oncoprotein, the tyrosine kinase activity of Rous sarcoma virus 
(RSV)-encoded v-Src is essential for its mediated transformation. Under its influence, a 
spectrum of proteins has their phosphotyrosine content increased and are viewed as 
putative v-Src substrates [3,29]. Intriguingly, some of them including Eps8 turn out to be the 
substrates for EGFR as well [13]. Elevated expression and tyrosyl phosphorylation of Eps8 
are observed in v-Src transformed cells [13]. Overexpression of Eps8 confers the ability of 
fibroblasts to form foci in culture and to grow tumors in mice [30]. Consistent with its 
oncogenic potential [30], Eps8 attenuation retards cellular growth of fibroblasts expressing 
v-Src [31].   
Like SH2 and SH3, PH is a common motif shared by signaling molecules, which mediates 
protein-protein and protein-lipid interactions. Mounting evidence indicates that via PH-
mediated binding to either phospholipids [32,33] or membrane-associated proteins [34,35], 
the association between PH-containing molecules and plasma membrane is accelerated. The 
prominent examples are Akt/PKB that possesses a compact PH and PLC that retains a split 
PH. Like PLC, Eps8 contains a split PH (Figure 1), which does not weaken its linkage to the 
cell membrane. Remarkably, an intact split PH is indispensable for Eps8 membrane 
targeting as well as its mediated oncogenesis. In contrast, Eps8 with truncated PH fails to be 
recruited to plasma membrane and confers transforming ability [30].   
To confirm the involvement of Eps8 in the development of cancer, the correlation between its 
expression and cell proliferation of various human cancer cell lines were examined [36]. In 
human colon cancers, there is a positive correlation between Eps8 expression and mitogenesis, 
implicating the importance of Eps8 in colon cancer formation. Indeed, Eps8 attenuation in high 
Eps8 expressing cells (i.e. SW620 and WiDr) reduces cellular growth [36]. In contrast, 
ectopically expressed Eps8 in low Eps8 expressing cells (i.e. SW480) or Eps8-attenuated SW620 
promotes proliferation. In addition, relative to controls, there is a significant (>50%) 
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suppression of anchorage-independent growth in eps8 siRNA-expressing SW620, and 
reintroduction of Eps8 rescues these defects. Concurrently, attenuation (or overexpression) of 
Eps8 significantly reduces (or promotes) the growth of tumors inoculated into nude mice [36]. 
In addition to fibroblasts and colon cancer cells, Eps8 also plays a pivotal role in cervical cancer 
formation. This can be supported by reduced proliferation and tumorigenesis in Eps8-
attenuated SiHa and HeLa cells cultured in dishes or inoculated in mice [37]. 
1.3. Eps8-interacting proteins 
As an adaptor, Eps8 intreracts with a variety of signaling proteins such as EGFR, Src, Abi1, 
RN-tre, Shb, and IRSp53 to exert its biological functions. The detail and implication of the 
interaction between Eps8 and each of its above-mentioned partners are described below.  
1.3.1. EGFR 
Via serial deletion mutants of Eps8 and EGFR, Castagnino et al. [20] determined the minimal 
region of Eps8 (aa298-aa362) and EGFR (juxtamembrane region, aa648-aa688) is required for 
Eps8-EGFR interaction. Obviously, this interaction is not via classical pTyr-SH2 or proline-rich 
region-SH3 binding manner. Interestingly, the EGFR-binding region in Eps8 is rich in basic 
amino acids while multiple glutamic acid residues are found in the juxtamembrane region of 
EGFR. Although overexpression of Eps8 enhances EGF-mediated mitogenesis, the underlying 
mechanisms are not yet resolved. Nevertheless, the intimately correlated transforming ability 
of EGFR mutants and the level of tyrosyl phosphorylated Eps8 suggested the importance of 
tyrosyl phosphorylation of Eps8 in cellular transformation [38].  
1.3.2. Src 
Oncogenic Src not only enhances Eps8 expression but also its tyrosyl phosphorylation [13]. 
In GST-pull down experiments, fusion proteins with Src SH3, but not SH2 domain directly 
interact with Eps8, presumably via its proline-rich sequences. Through in vitro Src kinase 
reactions, Eps8 was further confirmed to be directly phosphorylated by Src. Notably, simply 
augmenting Eps8 expression in murine C3H10T1/2 fibroblasts can not elevate its tyrosyl 
phosphorylation and promote cell proliferation despite these cells being tumorigenic. Given 
Eps8 attenuation reduced cell growth in v-Src transformed cells [31], Src-mediated Eps8 
phosphorylation might be important for cell proliferation. To date, the residues on Eps8 
mediated by Src are still elusive. Whether Eps8 retains the same receptor (i.e. EGFR)- and 
nonreceptor (i.e. Src)-mediated sites becomes an interesting issue. 
1.3.3. Abi1 
ABI1 (also known as E3b1) was identified as an Eps8-binding protein by screening a human 
embryonic fibroblast (M426) cDNA expression library with Eps8 SH3 [17]. It contains a 
proline-rich sequence at its C-terminus followed by an SH3 domain. The PXXDY consensus 
is identified at aa389-aa393 [17]. In addition to Eps8, it also interacts with Abl tyrosine 
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kinase and is a human homologue of previously identified murine Abl-interactor 1 (Abi1) 
[39]. Both Abi1 and Abl contain SH3 and proline-rich sequences. These two proteins 
associate through the SH3 domain of Abi1 and the proline-rich region of Abl [17,39]. 
Overexpression of Abi1 decreased cell proliferation in NIH3T3-based EGFR overexpressors 
[17] while overexpression of the murine Abi1 suppressed v-Abl transforming activity [39]. 
Abi1/Eps8 associate with Sos1 and enable the latter protein to act as a guanine nucleotide 
exchange factor (GEF) of Rac to facilitate membrane ruffling in response to the activation of 
Ras and PI-3 kinase [21,40]. Strikingly, PI3K was also present in this multi-protein complex 
containing Abi1/Eps8/Sos1 to activate Rac [41]. It is noteworthy that alternatively spliced 
Abi1 fused with MLL has been identified in a human acute myeloid leukemia patient, 
suggesting the role of Abi1 in leukemogenesis [42]. 
1.3.4. RN-tre 
RN-tre (Related to the N-terminal of tre) was originally identified by utilizing Eps8 SH3 as a 
probe to fish out its binding protein(s) in a bacterial cDNA expression library generated 
from NIH3T3 cells [16]. RN-tre shares a homology domain (TrH) with tre oncoprotein at its 
N-terminus and contains an extended proline-rich sequence at the C-terminus. The PXXDY 
consensus is present at aa725-aa729 (GeneBank database, accession number D13644; [16]). 
Overexpression of full-length RN-tre in NIH3T3 cells did not cause cell transformation [16]. 
However, NIH3T3 cells transfected with a plasmid encoding RN-tre C-terminal truncated 
mutant (lacking aa463-aa828) exhibited growth advantage in both soft agar and in low 
serum (1%) cultured medium [16]. The TrH domain in RN-tre possesses a Rab5 GTPase-
activating protein (GAP) activity [43]. RN-tre overexpression suppressed EGF 
internalization via its Rab5 GAP activity [43]. Interactions with Grb2 [44] and/or Eps8 [43] 
are required for RN-tre inhibiting EGF receptor endocytosis. The association between RN-
tre and Eps8 inhibits the ability of Eps8 to complex with Abi1 and Sos1 and attenuates EGF-
mediated Rac activation [43].  
1.3.5. Shb 
Shb is an adaptor protein containing amino-terminal proline-rich sequences and a C-terminal 
SH2 domain [45]. Unlike Abi1 and RN-tre, there is no PXXDY consensus found in Shb 
sequences. Shb interacts with Eps8 SH3 domain and phosphorylated PDGF-receptor and FGF 
receptor-1 (via Shb SH2 domain) [14]. Although the role of Eps8-Shb interaction in cancer 
biology was not defined yet, overexpression of Shb reduced Eps8 expression [46] and induced 
apoptosis of NIH3T3 cells cultured in low serum [47]. Markedly, while Shb overexpression 
reduced tumor growth of PC3 prostate cancer cells [48], Shb attenuation sensitized SVR 
endothelial tumor cells to apoptotic agents such as cisplatin and staurosorine [49]. 
1.3.6. IRSp53 
IRSp53 (Insulin/IGF-1 Receptor tyrosine kinase Substrate of 53 kDa; [50]) was also 
designated as brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2) [51,52]. 
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suppression of anchorage-independent growth in eps8 siRNA-expressing SW620, and 
reintroduction of Eps8 rescues these defects. Concurrently, attenuation (or overexpression) of 
Eps8 significantly reduces (or promotes) the growth of tumors inoculated into nude mice [36]. 
In addition to fibroblasts and colon cancer cells, Eps8 also plays a pivotal role in cervical cancer 
formation. This can be supported by reduced proliferation and tumorigenesis in Eps8-
attenuated SiHa and HeLa cells cultured in dishes or inoculated in mice [37]. 
1.3. Eps8-interacting proteins 
As an adaptor, Eps8 intreracts with a variety of signaling proteins such as EGFR, Src, Abi1, 
RN-tre, Shb, and IRSp53 to exert its biological functions. The detail and implication of the 
interaction between Eps8 and each of its above-mentioned partners are described below.  
1.3.1. EGFR 
Via serial deletion mutants of Eps8 and EGFR, Castagnino et al. [20] determined the minimal 
region of Eps8 (aa298-aa362) and EGFR (juxtamembrane region, aa648-aa688) is required for 
Eps8-EGFR interaction. Obviously, this interaction is not via classical pTyr-SH2 or proline-rich 
region-SH3 binding manner. Interestingly, the EGFR-binding region in Eps8 is rich in basic 
amino acids while multiple glutamic acid residues are found in the juxtamembrane region of 
EGFR. Although overexpression of Eps8 enhances EGF-mediated mitogenesis, the underlying 
mechanisms are not yet resolved. Nevertheless, the intimately correlated transforming ability 
of EGFR mutants and the level of tyrosyl phosphorylated Eps8 suggested the importance of 
tyrosyl phosphorylation of Eps8 in cellular transformation [38].  
1.3.2. Src 
Oncogenic Src not only enhances Eps8 expression but also its tyrosyl phosphorylation [13]. 
In GST-pull down experiments, fusion proteins with Src SH3, but not SH2 domain directly 
interact with Eps8, presumably via its proline-rich sequences. Through in vitro Src kinase 
reactions, Eps8 was further confirmed to be directly phosphorylated by Src. Notably, simply 
augmenting Eps8 expression in murine C3H10T1/2 fibroblasts can not elevate its tyrosyl 
phosphorylation and promote cell proliferation despite these cells being tumorigenic. Given 
Eps8 attenuation reduced cell growth in v-Src transformed cells [31], Src-mediated Eps8 
phosphorylation might be important for cell proliferation. To date, the residues on Eps8 
mediated by Src are still elusive. Whether Eps8 retains the same receptor (i.e. EGFR)- and 
nonreceptor (i.e. Src)-mediated sites becomes an interesting issue. 
1.3.3. Abi1 
ABI1 (also known as E3b1) was identified as an Eps8-binding protein by screening a human 
embryonic fibroblast (M426) cDNA expression library with Eps8 SH3 [17]. It contains a 
proline-rich sequence at its C-terminus followed by an SH3 domain. The PXXDY consensus 
is identified at aa389-aa393 [17]. In addition to Eps8, it also interacts with Abl tyrosine 
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kinase and is a human homologue of previously identified murine Abl-interactor 1 (Abi1) 
[39]. Both Abi1 and Abl contain SH3 and proline-rich sequences. These two proteins 
associate through the SH3 domain of Abi1 and the proline-rich region of Abl [17,39]. 
Overexpression of Abi1 decreased cell proliferation in NIH3T3-based EGFR overexpressors 
[17] while overexpression of the murine Abi1 suppressed v-Abl transforming activity [39]. 
Abi1/Eps8 associate with Sos1 and enable the latter protein to act as a guanine nucleotide 
exchange factor (GEF) of Rac to facilitate membrane ruffling in response to the activation of 
Ras and PI-3 kinase [21,40]. Strikingly, PI3K was also present in this multi-protein complex 
containing Abi1/Eps8/Sos1 to activate Rac [41]. It is noteworthy that alternatively spliced 
Abi1 fused with MLL has been identified in a human acute myeloid leukemia patient, 
suggesting the role of Abi1 in leukemogenesis [42]. 
1.3.4. RN-tre 
RN-tre (Related to the N-terminal of tre) was originally identified by utilizing Eps8 SH3 as a 
probe to fish out its binding protein(s) in a bacterial cDNA expression library generated 
from NIH3T3 cells [16]. RN-tre shares a homology domain (TrH) with tre oncoprotein at its 
N-terminus and contains an extended proline-rich sequence at the C-terminus. The PXXDY 
consensus is present at aa725-aa729 (GeneBank database, accession number D13644; [16]). 
Overexpression of full-length RN-tre in NIH3T3 cells did not cause cell transformation [16]. 
However, NIH3T3 cells transfected with a plasmid encoding RN-tre C-terminal truncated 
mutant (lacking aa463-aa828) exhibited growth advantage in both soft agar and in low 
serum (1%) cultured medium [16]. The TrH domain in RN-tre possesses a Rab5 GTPase-
activating protein (GAP) activity [43]. RN-tre overexpression suppressed EGF 
internalization via its Rab5 GAP activity [43]. Interactions with Grb2 [44] and/or Eps8 [43] 
are required for RN-tre inhibiting EGF receptor endocytosis. The association between RN-
tre and Eps8 inhibits the ability of Eps8 to complex with Abi1 and Sos1 and attenuates EGF-
mediated Rac activation [43].  
1.3.5. Shb 
Shb is an adaptor protein containing amino-terminal proline-rich sequences and a C-terminal 
SH2 domain [45]. Unlike Abi1 and RN-tre, there is no PXXDY consensus found in Shb 
sequences. Shb interacts with Eps8 SH3 domain and phosphorylated PDGF-receptor and FGF 
receptor-1 (via Shb SH2 domain) [14]. Although the role of Eps8-Shb interaction in cancer 
biology was not defined yet, overexpression of Shb reduced Eps8 expression [46] and induced 
apoptosis of NIH3T3 cells cultured in low serum [47]. Markedly, while Shb overexpression 
reduced tumor growth of PC3 prostate cancer cells [48], Shb attenuation sensitized SVR 
endothelial tumor cells to apoptotic agents such as cisplatin and staurosorine [49]. 
1.3.6. IRSp53 
IRSp53 (Insulin/IGF-1 Receptor tyrosine kinase Substrate of 53 kDa; [50]) was also 
designated as brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2) [51,52]. 
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Its interaction with Eps8 was originally observed from a GST-IRSp53 SH3 pull-down 
experiment [22] and confirmed by a yeast two-hybrid screening utilizing N-terminal Eps8 
sequences as a bait to search for Eps8 binding partners [23]. IRSp53 contains an N-terminal 
I-BAR (inverse-Bin-Amphiphysin-Rev) domain, followed by a CRIB, an SH3, a WW-binding 
sequence (WWB), and a PDZ (post synaptic density 95, disc large, zonula occludens-1) 
domain. The I-BAR domain might form dimers and induce membrane curvature depending 
on the shape of I-BAR dimer (reviewed in [53,54]). In addition to the originally identified 53-
kDa protein IRSp53S (designated IRSp53 from now on); three other IRSp53 isoforms 
(designated IRSp58M, IRSp53T, and IRSp53L) were identified in human cells.  In contrast, 
only three murine homologues (i.e. mIRSp53S, mIRSp58M, and mIRSp53T) were detected 
[55]. Interaction between IRSp53 SH3 domain and Eps8 N-terminal proline-rich sequences 
(aa207-aa221) activates Rac and results in cell motility and invasion of cancer cells [22]. 
Interestingly, in addition to the SH3 domain, PPPDY (aa468-aa471; GeneBank accession 
number NP_001138360) within the IRSp53 C-terminal WWB domain also participates in the 
association with Eps8 SH3 [23]. The interplay between Eps8 and IRSp53 is important for Src-
mediated STAT3 activation that leads to cell proliferation in cancer cells [23].   
1.4. Eps8-mediated signal transduction 
Mechanistic studies reveal that serum-induced ERK activation is involved in Eps8-mediated 
transformation since coexpression of dominant negative MEK1 blocks its induced 
oncogenesis. Consistent with the PH domain of Eps8 being critical for its oncogenic 
potential and membrane targeting, PH-truncated Eps8 is unable to trigger ERK activation in 
response to serum. These data corroborate the importance of the PH domain of Eps8 for its 
membrane association, ERK activation and its ability to transform cells [30].  
Src becomes activated when its SH3 and/or SH2 are occupied. Given Eps8 interacts with Src 
SH3 in vitro [13] and the Src SH3-binding region of Eps8 resides in its multiple proline-rich 
containing sequences, Eps8 is thereby speculated to increase Src enzymatic activity. In 
agreement with the mechanism underlying Src activation, Eps8 does elevate Src activity. 
This can be verified by diminished Eps8, which reduces Src activation as reflected by 
decreased Src Pi-Y416, which can be restored by ectopically expressed Eps8 [36]. 
Remarkably, Eps8 also regulates the activity and the expression level of FAK. While 
activation of FAK can be achieved by Src-mediated phosphorylation [56], its elevated 
expression relies on Akt/mTOR/STAT3 Pi-S727 pathway, which also modulates cyclin D1 
expression [36]. 
Expressing small interfering RNA of eps8 in HeLa and SiHa cells impedes G1-phase 
progression. In addition to cyclin D1, attenuated Eps8 also reduces expression of cyclins D3 
and E, elevates accumulation of p53 and p21Waf1/Cip1, and inhibits hyperphosphorylation of 
Rb. Reintroduced siRNA-resistant eps8 into Eps8-attenuated HeLa and SiHa cells reverses 
the described alteration, indicating that the effect of Eps8 on the mentioned cell cycle 
modulators is specific. Eps8 facilitates p53 degradation and decreased levels of Eps8 block 
this process and cause p53 accumulation. Studies of the turnover rate of p53 reveal that Eps8 
 
EPS8, an Adaptor Protein Acts as an Oncoprotein in Human Cancer 93 
attenuation significantly increases the half-life of p53 in HeLa cells from ~12 min to ~40 min 
[37]. It is noteworthy that via accelerated degradation of p53 as well as increased activation 
of Src and Akt, Eps8 enables cervical cancer cells to be resistant to chemotherapeutic agents. 
With a genome-wide screen, matrix metalloproteinase 9 (MMP9) along with the forkhead 
transcription factor FOXM1 and a cohort of its target genes encoding the cell cycle mediators 
and the chemokine ligands (i.e. CXCL5 and CXCL12) are upregulated by Eps8 through a 
PI3K/Akt-dependent mechanism [57]. Through degradation of extracellular matrix 
components as well as processing of cytokine and growth factors, Eps8-elicited MMP9 plays a 
critical role in the migratory and invasive phenotype of squamous cell carcinoma (SCC) [58]. 
It is well established that Eps8 forms a complex with Sos1 and Abi1 to transmit signals to Rac 
from receptor tyrosine kinases [21,26,40] and PI3K [41]. By its N-terminal region, Abi1 is 
recruited to the tips of filopodia and lamellipodia in motile cells [59], and associates to WAVE-
1 [60], the actin regulatory protein, further supporting its importance in actin remodeling. 
Notably, Eps8 also interacts with RN-tre (a specific Rab5 GAP) to modulate Rab5 activity, 
inhibit receptor internalization and prolong receptor signaling at the cell membrane [43]. 
IRSp53 is an adaptor protein that plays an important role in actin cytoskeleton 
reorganization.  By pull-down assays, Eps8 is demonstrated as an IRSp53-binding protein. 
Through its N-terminal proline-rich sequence, Eps8 directly associates with the SH3 domain 
of IRSp53. This Eps8/IRSp53 complex reinforces the formation of a trimolecular Rac-GEF 
complex (i.e. Eps8/Abi1/Sos1) to synergistically activate Rac and contribute to cell motility 
[22]. Through an independent yeast two-hybrid screening, IRSp53 was identified as an Eps8-
interacting protein. In addition, its C-terminal SH3/WWB-containing domain (aa376-aa521) 
was essential and sufficient for Eps8 association [23]. Strikingly, Eps8 modulates IRSp53 
expression in cells transformed with v-Src and attenuation of IRSp53 results in reduced cell 
proliferation in culture and reduced tumor formation in mice, which can be partly rescued 
by ectopically expressed IRSp53. Src drives the formation of Eps8/IRSp53 complex, which 
leads to activation of Akt, ERK, STAT3 and enhancement of cyclin D1. This signaling event 
not only occurs in v-Src transformed cells but also in EGF-stimulated cells. Notably, 
Eps8/IRSp53 is important in both cell proliferation and cell mobility [23]. 
2. Prospective study of Eps8 as an anti-cancer drug targeting protein 
As a signaling intermediate, Eps8 has been demonstrated to be critical in proliferation and 
control of actin dynamics that lead to increased mitogenesis and motility of various tumor 
cells (see below). Now, we will not only summarize the published reports regarding the role 
of Eps8 in human tumors, but also discuss its potential to become a novel tumor marker as 
well as a therapeutic target for cancer treatment. 
2.1. Aberrant overexpression of Eps8 in human cancer 
Eps8 overexpression confers the ability of murine fibroblasts to form foci in culture and to 
grow tumors in mice [30]. Its oncogenic potential invites the speculation that Eps8 might be 
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Its interaction with Eps8 was originally observed from a GST-IRSp53 SH3 pull-down 
experiment [22] and confirmed by a yeast two-hybrid screening utilizing N-terminal Eps8 
sequences as a bait to search for Eps8 binding partners [23]. IRSp53 contains an N-terminal 
I-BAR (inverse-Bin-Amphiphysin-Rev) domain, followed by a CRIB, an SH3, a WW-binding 
sequence (WWB), and a PDZ (post synaptic density 95, disc large, zonula occludens-1) 
domain. The I-BAR domain might form dimers and induce membrane curvature depending 
on the shape of I-BAR dimer (reviewed in [53,54]). In addition to the originally identified 53-
kDa protein IRSp53S (designated IRSp53 from now on); three other IRSp53 isoforms 
(designated IRSp58M, IRSp53T, and IRSp53L) were identified in human cells.  In contrast, 
only three murine homologues (i.e. mIRSp53S, mIRSp58M, and mIRSp53T) were detected 
[55]. Interaction between IRSp53 SH3 domain and Eps8 N-terminal proline-rich sequences 
(aa207-aa221) activates Rac and results in cell motility and invasion of cancer cells [22]. 
Interestingly, in addition to the SH3 domain, PPPDY (aa468-aa471; GeneBank accession 
number NP_001138360) within the IRSp53 C-terminal WWB domain also participates in the 
association with Eps8 SH3 [23]. The interplay between Eps8 and IRSp53 is important for Src-
mediated STAT3 activation that leads to cell proliferation in cancer cells [23].   
1.4. Eps8-mediated signal transduction 
Mechanistic studies reveal that serum-induced ERK activation is involved in Eps8-mediated 
transformation since coexpression of dominant negative MEK1 blocks its induced 
oncogenesis. Consistent with the PH domain of Eps8 being critical for its oncogenic 
potential and membrane targeting, PH-truncated Eps8 is unable to trigger ERK activation in 
response to serum. These data corroborate the importance of the PH domain of Eps8 for its 
membrane association, ERK activation and its ability to transform cells [30].  
Src becomes activated when its SH3 and/or SH2 are occupied. Given Eps8 interacts with Src 
SH3 in vitro [13] and the Src SH3-binding region of Eps8 resides in its multiple proline-rich 
containing sequences, Eps8 is thereby speculated to increase Src enzymatic activity. In 
agreement with the mechanism underlying Src activation, Eps8 does elevate Src activity. 
This can be verified by diminished Eps8, which reduces Src activation as reflected by 
decreased Src Pi-Y416, which can be restored by ectopically expressed Eps8 [36]. 
Remarkably, Eps8 also regulates the activity and the expression level of FAK. While 
activation of FAK can be achieved by Src-mediated phosphorylation [56], its elevated 
expression relies on Akt/mTOR/STAT3 Pi-S727 pathway, which also modulates cyclin D1 
expression [36]. 
Expressing small interfering RNA of eps8 in HeLa and SiHa cells impedes G1-phase 
progression. In addition to cyclin D1, attenuated Eps8 also reduces expression of cyclins D3 
and E, elevates accumulation of p53 and p21Waf1/Cip1, and inhibits hyperphosphorylation of 
Rb. Reintroduced siRNA-resistant eps8 into Eps8-attenuated HeLa and SiHa cells reverses 
the described alteration, indicating that the effect of Eps8 on the mentioned cell cycle 
modulators is specific. Eps8 facilitates p53 degradation and decreased levels of Eps8 block 
this process and cause p53 accumulation. Studies of the turnover rate of p53 reveal that Eps8 
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attenuation significantly increases the half-life of p53 in HeLa cells from ~12 min to ~40 min 
[37]. It is noteworthy that via accelerated degradation of p53 as well as increased activation 
of Src and Akt, Eps8 enables cervical cancer cells to be resistant to chemotherapeutic agents. 
With a genome-wide screen, matrix metalloproteinase 9 (MMP9) along with the forkhead 
transcription factor FOXM1 and a cohort of its target genes encoding the cell cycle mediators 
and the chemokine ligands (i.e. CXCL5 and CXCL12) are upregulated by Eps8 through a 
PI3K/Akt-dependent mechanism [57]. Through degradation of extracellular matrix 
components as well as processing of cytokine and growth factors, Eps8-elicited MMP9 plays a 
critical role in the migratory and invasive phenotype of squamous cell carcinoma (SCC) [58]. 
It is well established that Eps8 forms a complex with Sos1 and Abi1 to transmit signals to Rac 
from receptor tyrosine kinases [21,26,40] and PI3K [41]. By its N-terminal region, Abi1 is 
recruited to the tips of filopodia and lamellipodia in motile cells [59], and associates to WAVE-
1 [60], the actin regulatory protein, further supporting its importance in actin remodeling. 
Notably, Eps8 also interacts with RN-tre (a specific Rab5 GAP) to modulate Rab5 activity, 
inhibit receptor internalization and prolong receptor signaling at the cell membrane [43]. 
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involved and contribute to development of human cancers. Indeed, following is the 
published reports concerning the role of Eps8 in various human tumors. 
2.1.1. Breast cancer 
Accumulated evidence indicates that gene amplification contributes to activation of 
oncogenes, and is often associated with tumor progression, acquired drug resistance and 
poor prognosis [61]. By an integration of serial analysis of gene expression with cDNA array 
comparative genomic hybridization, Yao et al. [62] aimed to identify and characterize 
amplicons and their targets in both in situ and invasive breast carcinomas. Their 
characterization of the 12p13-p12 amplicon identified four putative oncogenes including 
Eps8. Compared with a panel of normal mammary epithelial cells, Eps8 was confirmed to be 
overexpressed in breast tumors with 12p13 amplification by quantitative RT-PCR as well as 
fluorescence in situ hybridization.   
2.1.2. Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive maliganacy and 
characterized by early invasion and metastasis [63]. In pancreatic ductal cells, Eps8 
colocalizes to the tips of F-actin filaments, filopodia, and the leading edge of cells.  Its 
knockdown alters actin-based cytoskeletal structures and cell shape, impairs cell-cell 
junctions and protrusion formation. 
Studies of the expression of Eps8 in cell lines derived from various tumor stages 
demonstrate that the levels of Eps8 are higher in cell lines derived from metastases and 
ascites as compared to those from primary tumors [64]. These results suggest that Eps8 
plays a critical role in the metastatic potential of PDAC.  
2.1.3. Thyroid cancer 
Papillary thyroid carcinoma (PTC) is a common thyroid maligancy whose biological 
behavior varies widely. By studying the expression profiles of eight matched pairs of PTC 
and normal throid tissues, Eps8 was identified as one of the overexpressed genes in PTC 
[65]. Notably, Griffith et al. [66] performed a meta-review of thyroid cancer biomarkers from 
a large number of published studies, identified twelve candidate diagnostic biomarkers, 
including Eps8. Unfortunately, no follow-up study, even at the RNA level, has confirmed 
Eps8 upregulation in thyroid lesions. Thus, inclusion of Eps8 as a diagnostic marker for 
thyroid cancer requires further investigation.  
2.1.4. Oral cancer 
Oral squamous cell carcinoma (OSCC) is a common maligancy. Its local invasion and 
regional lymph node metastases usually cause early death. Using expression microarrays, 
the eps8 gene was identified as being overexpressed in OSCC cell lines compared with 
normal oral keratinocytes. Despite attenuation of Eps8 in VB6, BICR56, and CA1 OSCC cells 
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does not inhibit cell proliferation, but it does impair the cell spreading and migration 
toward fibronectin. Not surprisingly, Eps8 was upregulated in a subset of OSCCs where it 
correlated significantly with lymph node metastasis. Knockdown of Eps8 suppressed V6-, 
and 51-integrin-dependent Rac1 activation and inhibited tumor cell invasion in an 
organotypic model of OSCC [67].  
2.1.5. Ovarian cancer 
Among gynecologic cancers, ovarian cancer has the greatest motality rate due to its 
metastasis [68]. Not relying on the vasculature for metastasis as seen in solid tumors, 
ovarian maligancy is confined within the abdominal cavity and extends to adjacent organs 
and/or disseminate throughout the peritoneal cavity [69]. Lysophosphatidic acid (LPA), a 
growth factor-like phospholipid, retains migration-stimulating potential and is present at 
high levels in ascites of ovarian cancer patients. LPA-mediated cell motility is confirmed to 
play an important role in ovarian cancer metastasis, and the integrity of Sos1/Eps8/Abi1 
tricomplex is essential for LPA-induced Rac activation, cell migration and metastatic 
colonization. Strikingly, only coexpression of the three members of the tricomplex correlates 
with advanced stages and shorter survival of ovarian cancer patients [70]. For ovarian 
cancer metastasis, these findings not only indicate the tricomplex is a reliable marker, but 
also suggest targeting the tricomplex can be developed as a therapeutic approach.  
2.1.6. Colorectal cancer 
Colorectal cancer (CRC) is the most common gastrointestinal cancer and one of the leading 
causes of cancer mortality worldwide. Preferentially increased Eps8 in the advanced stage of 
human CRC specimens is detected. Intriguingly, simultaneous up-regulation of Eps8, Src 
and FAK in CRC is observed and these three proteins are positively correlated as indicated 
by Spearman rank correlation. This is in agreement with Eps8 modulating the expression of 
FAK via mTOR/STAT3 pathway [35].  
2.1.7. Cervical cancer 
Cervical carcinoma evolves slowly from intraepithelial neoplasia to invasive carcinoma and 
is the second most common malignancy among women [68]. Through clinicopathologic 
examination and immunohistochemical staining, an intimate correlation between Eps8 
abundance and the aggressiveness (local lymph node metastasis or parametrium invasion) 
of early-stage cervical cancer is established. Concurrently, Eps8 expression inversely 
correlates with the survival rate of cervical cancer patients [36].  
2.1.8. Esophageal cancer 
A thorough analysis of both esophageal squamous cell carcinoma and esophageal 
adenocarcinoma revealed 4-6 fold increase in expression of Eps8 in esophageal cancers 
compared to adjacent normal tissues. Notably, unlike colon cancer, higher Eps8 expression 
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in tumors as compared to their nearby normal tissue was independent of grade of 
esophageal cancer [72].   
2.1.9. Pituitary tumor 
Comprising some of the most common intracranial neoplasms, pituitary tumors can either 
be detected clinically (i.e. acromegaly and amenorrhea) or become clinically silent such as 
those of the gonadotrope lineage [73]. By DNA microarrays, eps8 is identified as an 
overexpressed transcript (5.9-fold) in pituitary tumors compared with normal controls. Xu et 
al. [74] demonstrated that overexpression of Eps8 in gonadotrope pituitary cells results in 
activation of ERK and Akt, which provide proliferative stimulation and antiapoptotic 
protection respectively. Remarkably, the above mentioned signaling components are 
upregulated in human pituitary tumor tissues suggesting a functional significance of Eps8 
in human pituitary tumorigenesis. 
2.2. The potential of Eps8 attenuation in cancer treatment  
Accumulated evidence revealed the significance of Eps8 in tumor development and 
metastasis. According to the elucidated mechanisms underlying Eps8-mediated 
transformation, suppressed expression of Eps8 as well as disruption of the Eps8-containing 
signaling complex become two promising strategies to inhibit tumorigenesis. 
2.2.1. Suppressing expression of Eps8 
Considering Eps8 is an oncoprotein whose overexpression is closely linked to tumor 
formation, suppressing its expression might provide a means to treat and eradicate tumors. 
Strategies published to decrease Eps8 expression are described below. 
2.2.1.1. Histone deacetylase inhibitors  
Epigenetic modulation of gene expression is implicated in cancer development. Emerging 
evidences indicate the acetylation status of histones controls the acess of transcription 
factors to DNA and influences gene expression. Histone acetylation and deacetylation are 
mediated by histone acetyl transferases (HATs) and histone deacetylases (HDACs) 
respectively. HDAC inhibitors are well documented to promote differentiation, growth 
arrest and apoptosis of cancer cells with minimal effects on normal tissues. Notably, HDAC 
inhibitors not only decompact histone/DNA complex, but also influence acetylation status 
and function of nonhistone proteins [75]. A number of HDAC inhibitors have entered 
preclinical and early clinical studies. Although these compounds were chosen for their 
ability to inhibit histone deacetylation, they still had widely varying potency and HDAC 
isoenzyme specificity as well as different effects on acetylation of nonhistone proteins. To 
date, the prominent targets of HDAC inhibitors include HDACs, p21WAF1/CIP1, p53, death 
receptor proteins (i.e. TNF-, Fas and TRAIL receptors), HIF-1, and VEGFR [75].  
Trichostatin A (TSA), an antifungal agent, is a HDAC inhibitor. The reversal of v-Src-
mediated transformation by TSA is attributable to its suppression of Eps8 expression. RT-
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PCR and Northern analyses reveal the significant decrease of eps8 transcripts in TSA-treated 
v-Src-expressing cells relative to control cells [31]. Similar reduction of Eps8 is also obtained 
when butyrate, another well known HDAC inhibitor is applied (unpublished result). These 
data indicate Eps8 can be added to the growing list of HDAC inhibitor targets and its 
downregulation contributes to the antineoplastic effects of HDAC inhibitors.   
2.2.1.2. Mithramycin 
Mithramycin (MIT, also known as mithracin, aureolic acid and plicamycin), a polyketide 
produced by various soil bacteria of the genus streptomyces, is an inhibitor that blocks the 
binding of the Sp-family transcription factors to the GC box [76]. To date, expression of 
several proto-oncoproteins such as Met, Myb, Myc, Ras and Src can be suppressed by MIT. 
Interestingly, in several cancer cell lines, MIT also reduces the protein and mRNA levels of 
Eps8 in dose- and time-dependent manners [77]. Considering the mechanistic action exerted 
by MIT, the promoter composition and the transcriptional regulation of eps8 gene warrant 
further investigation.  
2.2.1.3. Small interference RNA or short hairpin RNA methodology 
Expressing either small interference RNA (siRNA) [31,36,37] or short hairpin RNA (shRNA) 
of eps8 [58] in tumor cells efficiently inhibits the expression of Eps8. Decreased levels of Eps8 
alters the behavior of cancer cells such as (1) suppressed v-Src-mediated transformation in 
fibroblasts [31], (2) reduced colonocyte proliferation and motility in colon cancer cells [36], 
(3) retarded cell cycle and decreased chemoresistance in cervical cancer cells [37], (4) 
impaired tumorigenicity of HNSCC cells in xenograft assays [58]. Hence, using siRNA (or 
shRNA) methodology to suppress Eps8 expression in tumor cells might block their 
progression, invasion and increase their chemosensitivity to anti-cancer drugs. 
2.2.2. Disruption of the formation of Eps8-containing complexes 
Eps8 exerts its effects through the formation of various complexes. The well-studied ones 
are Sos1/Eps8/Abi1 and Eps8/IRSp53. Formation of both complexes results in Rac activation 
and promotes cell proliferation and cell motility. 
2.2.2.1. Disruption of Sos1/Eps8/Abi1 complex formation 
Sos1/Eps8/Abi1 tricomplex is well established to mediate Rac activation and whose integrity 
is required for LPA-stimulated cell motility and metastatic colonization in ovarian cancer 
cells. Given coexpression of Sos1, Eps8 and Abi1, but not any one alone, correlates with 
advanced stages as well as shorter survival of ovarian cancer patients [70], silencing any 
member of Sos1/Eps8/Abi1 tricomplex and/or targeting this tricomplex can be developed as 
a therapeutic approach for tumor metastasis.     
2.2.2.2. Disruption of Eps8/IRSp53 complex formation  
Eps8/IRSp53 complex, occurs at the leading edge of motile cells, augments Sos1/Eps8/Abi1 
trimolecular complex formation, and synergistically activates Rac. Inhibiting its formation 
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reduces the mobility and invasiveness of fibrosarcoma cells [22]. Strikingly, elevated activity of 
Akt, ERK, STAT3, and augmented expression of cyclin D1 are also dictated by Eps8/IRSp53 
that can be reduced by SU6656, an inhibitor of Src family kinases [23]. Of note, through 
activation of Src, EGF induces the formation of Eps8/IRSp53 and activation of STAT3 in HeLa 
cells [23]. Since the association between Eps8 and IRSp53 is Src-dependent and might be a 
physiological event in relaying EGF signaling, strategies that interrupt the interaction between 
Eps8 and IRSp53 can be developed and applied for cancer treatment. Specifically designed 
peptides, naturally occurring or artificially synthesized chemicals that block the association 
between Eps8 and IRSp53 might fulfill the purpose and become novel cancer therapeutics. 
3. Concluding remarks 
Considering a spectrum of proteins bind to Eps8 and play important roles in cell proliferation 
and migration (Figure 2), Eps8 upregulation is thus expected to cause human carcinogenesis. 
Indeed, aberrant overexpression of Eps8 is closely linked to many types of human cancer. 
Although Eps8-mediated signal transduction is gradually being resolved, several important 
questions still remain unanswered. For instance, tyrosyl phosphorylation of Eps8 mediated by 
either Src or EGFR is not addressed yet. Where are these tyrosine residues located? How does 
their phosphorylation contribute to abnormal cell proliferation and motility in cancer cells? In 
addition, Eps8 possesses a nuclear localization signal (Figure 1). However, to date there are no 
reports regarding the role of nuclear Eps8 and how the nuclear localization of Eps8 is 
regulated? Tremendous work needs to be done before these questions get answers. 
 
Figure 2. The signals transmitted by Eps8. Active EGFR and Src phosphorylate Eps8 and induce Eps8-
IRSp53 interaction that facilitates Src-mediated STAT3 Pi-Y705 and dimerization, resulting in the 
increased transcription of Cyclin D1 and FAK and in cell cycle progression. By binding to RN-tre, Eps8 
reduces Rab5 activity and hinders EGFR endocytosis. In addition to its actin-capping activity, Eps8 
interacts with proteins listed in the square box, activates Rac, promotes membrane actin polymerization, 
and increases motility. Nu: nucleus. 
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IRSp53 interaction that facilitates Src-mediated STAT3 Pi-Y705 and dimerization, resulting in the 
increased transcription of Cyclin D1 and FAK and in cell cycle progression. By binding to RN-tre, Eps8 
reduces Rab5 activity and hinders EGFR endocytosis. In addition to its actin-capping activity, Eps8 
interacts with proteins listed in the square box, activates Rac, promotes membrane actin polymerization, 
and increases motility. Nu: nucleus. 
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1. Introduction 
1.1. Investigations connected with a 65 kDa tumor associated protein 
1.1.1. Purification and characterization of a 65 kDa tumor associated protein 
Tumorigenesis is a multistep process during which appearance of tumor-specific antigens 
can occur. A wide variety of transformed rodent cells secrete transformation-related 
proteins. In 1992, a tumor-associated phosphoprotein with molecular weight (MW) of about 
65 kDa (p65) was isolated from cell culture medium containing rat transplantable 
hepatocellular carcinoma 1682C cell line and purified to homogeneity [1].  For purification, 
in the first step ammonium-sulfate precipitation and high-performance liquid 
chromatography on molecular-sieving and phenyl hydrophobic interaction columns were 
used. Next, the protein was concentrated in a Rotofor isoelectrofocusing cell and finally 
separated by isoelectrofocusing followed by SDS-polyacrylamide gel electrophoresis. 
Purification fold after the Rotofor concentration step was about 11 000. This protein had a pI 
of 5.8 in isoelectrofocusing gels and in SDS-PAGE migrated as a single band. The tumor 
origin of this 65 kDa protein was confirmed by in vivo labeling of hepatocellular carcinoma 
cells in culture with [32P]orthophosphate or [35S]methionine followed by 
immunoprecipitation of the p65 from cell culture medium, SDS-PAGE and 
autoradiography. Thin-layer chromatography (TLC) showed that the p65 molecule contains 
phosphotyrosine, phosphothreonine, and phosphoserine. The carbohydrate content of the 
purified p65 protein was confirmed by Western blot analysis with the use of biotinylated 
lectins. Positive reaction with concanavalin A, wheat-germ agglutinin, and Ricinus communis 
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Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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agglutinin I was observed, which suggested the presence of D-mannose or N-acetyl-D-
glucosamine, D-galactose and N-acetylglucosamine respectively [1].   
In our further purification procedure of P65 protein from tissue culture of human breast 
carcinoma MCF-7 cells the extensive rotofor concentration step was successfully replaced 
with TCA precipitation. Having in hand purified p65 rat / P65 human, a comparison of both 
proteins isolated from different sources was performed [2]. Analysis of the amino acid 
compositions revealed a high degree of relatedness between the human and rat proteins. 
Also, N-terminal amino acid sequences of p65/P65 proteins were identical for the first 9 
residues and no homology with other proteins was indicated. Amino acid sequence 
established for the N-terminal end of the p65 molecule was as follow: DPENVVRADT. 
Furthermore, peptide maps of the rat and human p65/P65 were generated by cyanogen 
bromide (CNBr) treatment. The cleavage of p65/P65 with CNBr resulted in four major 
peptides identifiable by silver staining of the Tricine SDS-PAGE prepared according to 
Schagger and Von Jagow 1987 [3]. The peptide patterns for p65/P65 were identical. The 
peptides have molecular weights of about 51, 39, 30, 19 kDa. Identical cleavage maps were 
obtained for rat and mouse p65. N-terminal sequence analysis of four peptides generated by 
CNBr treatment, resulted in short amino-acids residues 1-6, 1-10, 1-14 and 1-10, respectively, 
were almost identical, therefore the most probable sequences were established and their 
sequences were as follows: 51 kDa – TGPPWT, 39 kDa – FSLQLNSRGG, 30 kDa – 
REKVRLSSARQRLR and 19 kDa - TTHNRNPKKW. High degree of homology between 
human and rat proteins resulted in cross-reaction of both antigens with antibodies raised in 
rabbits against p65 isolated from the rat cell line THC 1682C. Similar cross reactivity to 
polyclonal anti-rat p65 antibodies was observed for p65 from mice bearing chemically 
induced papillomas. On the basis of collected data it was suggested the p65 is highly 
conserved in different species [4]. 
1.2. P65 Protein in experimental models of carcinogenesis    
Polyclonal antibodies raised against p65 antigen isolated from cell culture medium of 
transplantable hepatocellular carcinoma (THC 1682C) have been employed to monitor the 
carcinogenic process in multistage rodent models of liver, skin and mammary gland 
carcinogenesis. In the first experimental model female Sprague-Dawley rats  were initiated 
by the single dose of 10 mg/kg body weight of N-diethylnitrosamine (DEN) in physiological 
saline by gastric intubation. Twenty four hours later a 2/3 of liver was removed by surgery 
(partial hepatectomy). Six weeks after DEN administration a part of the animals were 
sacrificed at one -week intervals and their livers were used for immunohistochemical 
analysis and their blood was analyzed for the presence of p65 by ELISA (Enzyme Linked 
Immunosorbent Assasy). In the liver the detectable number of p65 positive minifoci were 
observed one week after promotion by partial hepatectomy (PH). The number of p65 
positive hepatocytes increased steadily during the first three weeks after DEN/PH. Positive 
p65 immunoreaction was observed in the nuclei of the hepatocytes, more precisely, within 
the nuclear envelopes and also in the cytoplasm. Also, three weeks after DEN/PH the p65 
rapidly accumulated in the blood plasma, reached a plateau by the 3rd week and then 
FJ194940.1 Gene and Its Protein Product ACJ04040.1 – 
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markedly dropped by the 6th week, probably due to immune clearance. Later it increased 
again in parallel with the growth of p65 positive foci [4].   
The second model was based on seven week old male SENCAR mice. Skin tumors were 
induced on the back by a single dose of 10 mmol of 7,12-dimethylbenz[a]antracene (DMBA) 
and repetitive application of 1 g of 12-0-tetradecanoylphorbol-13-acetate (TPA, 
carcinogenesis promoter) twice a week for 20 weeks on the shaved dorsal skin. Blood 
samples were randomly obtained from four mice at monthly intervals to detect p65 antigen 
by the use of ELISA. The p65 was detected in this system as early as 4 weeks after the 1st 
TPA application, with slow increases in its activity for up to 24 weeks [4].  
The third model was also based on chemically {N-methyl-N-nitrosourea (NMU)}-induced 
mammary adenocarcinoma in rats. The presence of p65 in urine and serum of rats bearing 
N-methyl-N-nitrosourea-induced mammary gland adenocarcinomas were analyzed by 
ELISA developed on the basis of polyclonal antibodies raised against rat p65 antigen. The 
correlation coefficient between tumor burden and p65 concentration in urine and serum was 
0.65 and 0.77, respectively. The average levels of p65 in normal urine and normal serum 
were 37 + 32 and 48 + 38 ng/ml, respectively. In the case of urine obtained from rats bearing 
mammary adenocarcinoma, the mean p65 level was 119.0 + 35.9 ng/ml and its serum level 
was 225.4 + 67.5 ng/ml. Sensitivity, specificity and predictive value for serum and urine 
marker elevation were 78.5, 70.0 and 78.5% respectively. Concentrated urinary proteins were 
phosphorylated in vitro and separated by IEF or SDS-PAGE. IEF analysis of phosphorylated 
proteins followed by autoradiography barely showed any radioactive bands in the urine of 
control rats but three major radioactive bands with pI of 5.8, 5.5 and 5.0 in the urine of 
adenocarcinomas-bearing animals were observed. The strongest of these bands 
corresponded to pI ~ 5.8 in IEF was further analyzed by SDS-PAGE and showed a MW of 65 
kDa. Two lighter bands corresponded to pI 5.5 and 5.0 and MW of 50 and 41 kDa apparently 
representing degradation products of the p65. The 65 kDa protein with a pI of 5.8 identified 
in the urine of tumor-bearing rats bound to an antiphosphotyrosine monoclonal and an anti-
p65 polyclonal antibody as determined by Western blot analysis [5]. 
Also in vivo phosphorylation of urinary proteins was performed by i.p. injection of 
[32P]orotophosphate into control- and mammary adenocarcinoma-bearing animals, which 
was followed by immunoprecipitation and subsequent separation of the in vivo-labeled 
urinary proteins by SDS-PAGE. No radioactive bands were observed in the case of 
immunoprecipitation of control urinary proteins with the preimmune or anti-p65 IgG, as 
well as in experimental urinary proteins treated with preimmune serum. By using anti-p65 
antibodies for immunoprecipitation of in vivo phosphorylated urinary proteins we were able 
to detect the p65 antigen only in urine of rats bearing adenocarcinomas [5]. 
1.3. Anti-p65 antibodies as a tool in cancer detection 
Described data strongly suggest that p65 is highly conserved in various species and this 
phenomenon could explain why human, rat, and mouse p65 antigens cross-reacted with 
polyclonal antibodies raised in rabbits against p65 isolated from the rat cell line THC 1682C. 
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On the basis of such antibodies the ELISA procedure was developed in order to analyze the 
presence of p65 in blood plasma, serum and urine of rats bearing adenocarcinoma [5]. The 
ELISA was also tested on a limited panel of cancer patients’ sera as well as sera from non-
cancer patients. It was proven that serum samples obtained from patients with advanced 
leukemia and lung adenocarcinoma contain significantly higher levels of P65 antigen than 
those present in control serum  [4]. Anti-p65 rabbit polyclonal antibodies were also useful in 
immunohistochemical studies on p65 detection in either frozen or paraffin-embedded liver 
sections taken from experimental animals [4].  
Having in hand purified p65/P65 antigens from rat transplantable hepatocellular carcinoma 
THC 1682C cell line and the human breast carcinoma MCF-7 cell line the possibility to 
produce monoclonal antibodies (MABs) against human and rat antigen was opened [6]. A 
few hybridomas secreting monoclonal antibodies against p65/P65 protein were established. 
MAbs expanded in culture medium were isolated with the use of affinity chromatography 
on Protein A-Sepharose, and their subclass  was determined as IgG1 by isotyping using 
immunodiffusion assay on 1.5% agarose gel containing goat anti-mouse subclasses of IgG 
and IgM. A rapid and sensitive sandwich type ELISA, with the use of purified MAbs was 
established to measure markedly elevated amounts of p65/P65 in sera obtained from tumor-
bearing animals and from cancer patients. The average level of p65 in normal rat sera was 38 
ng/ml (SD 13 ng/ml), and in sera from rats bearing mammary adenocarcinomas, the average 
value was 1005 + 140 ng/ml, ranging from 200 to 3400 ng/ml. In control human sera, the 
mean P65 level was 34 + 35 ng/ml, while sera of patients with a variety of cancers had a 10-
fold higher average P65 value of 344 + 57 ng/ml, ranging from 50 to 2230 ng/ml. More than 
80% of tested sera from adenocarcinoma-bearing rats as well as from cancer patients had 
p65/P65 levels elevated. Overall the assay had a sensitivity of 80.9% and specificity of 85%. 
Different categories of cancer such as breast, ovary and endometrium, head and neck, lung 
and leukemia had increased P65 levels: 83.5%, 95.0%, 81.2%, 55.5% and 88.9%, respectively 
[6]. The purified IgG1 MAbs with high titers and strong anti-P65 specificities were also 
suitable for visualization of the P65 antigen expression in tumor tissue sections [6]. Human 
P65 antigen has been isolated from culture medium of the breast cancer cell line (MCF-7). 
That is why detailed analysis of sera as well as paraffin slides from breast cancer patients 
was performed [7]. ELISA showed that 90.2% of cancer patients’ sera were positive for P65. 
The average level of P65 was 446.5 ±243.8 ng/ml and the range was from 135.2 to 958.9 
ng/ml. The average P65 level in control sera was 37 + 29.5 ng/ml. Furthermore, in the group 
of patients with benign breast disease P65 levels were slightly elevated above the mean, 
with the average P65 value of 74.0 + 41.2 ng/ml. It was also noticed that serum P65 level 
correlated with the pathological state of the disease. Elevation of P65 was not obvious in 
patients with pathological stages 0 and 1, but in stages IIA, IIB, IIIB and IV showed a 
marked increase above the cut-off point 2+SD (96ng/ml). In case of immunohistochemical 
analysis with the use of monoclonal antibodies against P65 80% of analyzed tissue slides 
were positive showing nucleocytoplasmic reaction [7].   
Preliminary screening study based on P65 level determination in sera taken from patients 
with different categories of cancer showed increased P65 levels in the case of leukemias 
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(88.9%) [6]. It was the reason of P65 examination in patients with lymphocytic and 
granulocytic leukemia [8]. Using the anti-P65 monoclonal antibodies (MB2 and MF11) in a 
double-antibody sandwich ELISA the expression of the protein in sera of healthy controls, in 
patients with benign, non-neoplastic disease as well as in sera of patients with leukemia in 
different stages of development were established. The upper limit of normal P65 
concentration was 115 U/ml (mean plus two standard deviations above the mean in the 
control group) [8]. The level of P65 was above normal in 95% of acute lymphocytic leukemia 
(ALL), 83% of acute myeloblastic leukemia (AML), 37% of chronic lymphocytic leukemia 
(CLL), and 30% of chronic myelogenous leukemia (CML). Monoclonal antibody was also 
used for immunocytochemical staining of isolated lymphocytes from normal peripheral 
blood and from blood of leukemic patients. The P65 positivity was 83% in CLL, 100% in 
ALL and 75% in AML patients  [8]. Distribution of P65 in noncancer and cancer human sera 
samples base on already published results: [6-8] are presented in Table 1. 
 
Diagnosis Average concentration 
of P65 (ng/ml)          








ALL – acute 
lymphoblastic leukemia
570.6 + 86.0 95 
AML – acute myelocytic 
leukemia 
429,5 + 71.3 83 
CLL – chronic 
lymphocytic leukemia 
252.2 +80.6 37 
CML – chronic 
myelocytic leukemia 
196.3 + 87.6 30 
Normal  (n=80) 34.8 + 34 0 
Benign (n=61) 124 + 149.4 8 
   
Breast cancer (n=132) 466.5 + 243.8 90.2 
Benign (n=68) 74.0 = 41.2 20 
Normal (n=112) 37.4 +29.5 10.8 
 
Ovary/Endometrium 232 + 74 95 
Head /Neck 328 + 121 81.2 
Lung 328 +158 55.5 
Table 1. The medium concentrations of P65 (ng/ml) in sera from normal donors and from patients with 
benign diseases and different malignant cancers as well as leukemias 
1.4. P65-like protein 
The presence of a protein antigenically related to P65 (p65-like) was also shown in fetal 
serum [9]. Isoelectrofocusing followed by polyacrylamide gel electrophoresis in the presence 
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On the basis of such antibodies the ELISA procedure was developed in order to analyze the 
presence of p65 in blood plasma, serum and urine of rats bearing adenocarcinoma [5]. The 
ELISA was also tested on a limited panel of cancer patients’ sera as well as sera from non-
cancer patients. It was proven that serum samples obtained from patients with advanced 
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those present in control serum  [4]. Anti-p65 rabbit polyclonal antibodies were also useful in 
immunohistochemical studies on p65 detection in either frozen or paraffin-embedded liver 
sections taken from experimental animals [4].  
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MAbs expanded in culture medium were isolated with the use of affinity chromatography 
on Protein A-Sepharose, and their subclass  was determined as IgG1 by isotyping using 
immunodiffusion assay on 1.5% agarose gel containing goat anti-mouse subclasses of IgG 
and IgM. A rapid and sensitive sandwich type ELISA, with the use of purified MAbs was 
established to measure markedly elevated amounts of p65/P65 in sera obtained from tumor-
bearing animals and from cancer patients. The average level of p65 in normal rat sera was 38 
ng/ml (SD 13 ng/ml), and in sera from rats bearing mammary adenocarcinomas, the average 
value was 1005 + 140 ng/ml, ranging from 200 to 3400 ng/ml. In control human sera, the 
mean P65 level was 34 + 35 ng/ml, while sera of patients with a variety of cancers had a 10-
fold higher average P65 value of 344 + 57 ng/ml, ranging from 50 to 2230 ng/ml. More than 
80% of tested sera from adenocarcinoma-bearing rats as well as from cancer patients had 
p65/P65 levels elevated. Overall the assay had a sensitivity of 80.9% and specificity of 85%. 
Different categories of cancer such as breast, ovary and endometrium, head and neck, lung 
and leukemia had increased P65 levels: 83.5%, 95.0%, 81.2%, 55.5% and 88.9%, respectively 
[6]. The purified IgG1 MAbs with high titers and strong anti-P65 specificities were also 
suitable for visualization of the P65 antigen expression in tumor tissue sections [6]. Human 
P65 antigen has been isolated from culture medium of the breast cancer cell line (MCF-7). 
That is why detailed analysis of sera as well as paraffin slides from breast cancer patients 
was performed [7]. ELISA showed that 90.2% of cancer patients’ sera were positive for P65. 
The average level of P65 was 446.5 ±243.8 ng/ml and the range was from 135.2 to 958.9 
ng/ml. The average P65 level in control sera was 37 + 29.5 ng/ml. Furthermore, in the group 
of patients with benign breast disease P65 levels were slightly elevated above the mean, 
with the average P65 value of 74.0 + 41.2 ng/ml. It was also noticed that serum P65 level 
correlated with the pathological state of the disease. Elevation of P65 was not obvious in 
patients with pathological stages 0 and 1, but in stages IIA, IIB, IIIB and IV showed a 
marked increase above the cut-off point 2+SD (96ng/ml). In case of immunohistochemical 
analysis with the use of monoclonal antibodies against P65 80% of analyzed tissue slides 
were positive showing nucleocytoplasmic reaction [7].   
Preliminary screening study based on P65 level determination in sera taken from patients 
with different categories of cancer showed increased P65 levels in the case of leukemias 
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(88.9%) [6]. It was the reason of P65 examination in patients with lymphocytic and 
granulocytic leukemia [8]. Using the anti-P65 monoclonal antibodies (MB2 and MF11) in a 
double-antibody sandwich ELISA the expression of the protein in sera of healthy controls, in 
patients with benign, non-neoplastic disease as well as in sera of patients with leukemia in 
different stages of development were established. The upper limit of normal P65 
concentration was 115 U/ml (mean plus two standard deviations above the mean in the 
control group) [8]. The level of P65 was above normal in 95% of acute lymphocytic leukemia 
(ALL), 83% of acute myeloblastic leukemia (AML), 37% of chronic lymphocytic leukemia 
(CLL), and 30% of chronic myelogenous leukemia (CML). Monoclonal antibody was also 
used for immunocytochemical staining of isolated lymphocytes from normal peripheral 
blood and from blood of leukemic patients. The P65 positivity was 83% in CLL, 100% in 
ALL and 75% in AML patients  [8]. Distribution of P65 in noncancer and cancer human sera 
samples base on already published results: [6-8] are presented in Table 1. 
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Table 1. The medium concentrations of P65 (ng/ml) in sera from normal donors and from patients with 
benign diseases and different malignant cancers as well as leukemias 
1.4. P65-like protein 
The presence of a protein antigenically related to P65 (p65-like) was also shown in fetal 
serum [9]. Isoelectrofocusing followed by polyacrylamide gel electrophoresis in the presence 
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of SDS was used for its isolation. Fractionated serum proteins after transfer onto 
nitrocellulose sheets were further analyzed by Western blot technique with the use of anti-
P65 monoclonal antibody. Such analysis revealed that P65 protein has four isoforms. The 
isoforms, after isolation from polyacrylamide gels were used together for polyclonal 
antibody production [9]. Additional analysis of fetal serum fractions separated by 
electrophoresis on cellulose acetate membrane followed by immunostaining with anti-P65 
monoclonal antibody revealed that the p65-like protein had a similar location to one of -
globulin [9].  
1.5. Anti-p65-like protein antibodies as a tool in cancer detection 
Polyclonal antibody raised in rabbits against p65-like protein was tested by 
immunohistochemistry technique in breast cancer patients (frozen sections) and compared 
with that of anti-human-P65 monoclonal antibodies [10]. Comparison of the percentage of 
tumor cells showing positive immunoreaction with mono- and polyclonal antibodies 
showed a weak reactivity in significantly higher percentage of investigated cases 27% for 
MAb and 7% for PAb. On the other hand, medium and strong reactions were observed in a 
larger amount of cases after probing of the tumor tissue with a polyclonal antibody – 91% in 
comparison to 73% stained by a monoclonal antibody. In all cases positive for P65, 
immunohistochemical reaction was observed in the cytoplasm and in the area surrounding 
the nuclei [10]. 
Further comparative studies connected with clinical evaluation of the usefulness of 
polyclonal and monoclonal antibodies raised against P65/p65 protein were done by 
immunohistochemistry on paraffin-embedded tissue slides from breast cancer patients [11]. 
More than one hundred cases including infiltrating ductal breast carcinomas, fibrocystic 
disease and fibroadenoma were assessed immunohistochemically using monoclonal 
antibodies against human P65 antigen, and polyclonal antibodies against p65-like protein 
present in fetal serum. There were no evident differences in P65 detection between 
polyclonal and monoclonal antibodies, but monoclonal antibody causes more specific 
immunohistochemical reactions. Fibrocystic disease with large epithelioplasia that had 
precancerous status, gave a positive response when anti-P65 antibodies were utilized. This 
observation correlated with our previous data showing unique properties of anti-p65 
antibodies of staining premalignant foci in the early stages of chemical carcinogenesis. In the 
most cases of breast cancer, a positive immunoreaction occurred with poly- and monoclonal 
anti-p65/P65 antibodies in the cytoplasm and/or nuclei.  
The p65-like protein was also analyzed in B-chronic lymphocytic leukemia (CLL) cells as 
well as in normal lymphocytes, followed by their separation to nuclear, mitochondrial, and 
microsomal fractions by differential centrifugation. The cellular fraction of CLL and normal 
lymphocytes were separated by SDS-PAGE electrophoresis followed by Western blot 
analysis with the use of anti-p65 like polyclonal antibody [12]. P65 antigen was recognized 
as a predominant polypeptide in the leukemic nuclear fraction. No cross reactivity was 
observed with normal lymphocyte nuclear proteins in the region of 65 kDa [12]. 
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To get a better idea about the role of the P65 protein in cancer formation and growth a more 
advanced study was undertaken on paraffin-embedded infiltrating ductal breast cancer 
tissue slides [13]. It was noticed that the percentage of positive cells with cytoplasmic 
expression of P65 was significantly higher in histologically more differentiated cancers 
(grade I and II according to Bloom & Richardson) than in grade III. The percentage of 
immunopositive nuclei grew with the advance of the disease and was the highest in poorly-
differentiated (grade III) tumors. The tumors with P65 cytoplasmic reaction were mainly 
small (T1, T2), without lymph nodes (N0) and distant (M0) metastases. The straight 
dependence existed between P65 nucleic reaction and tumor size, metastases to lymph 
nodes and distant metastases. The obtained results suggested that transfer of P65 protein 
from cytoplasm to nuclei of the breast cancer cells is connected with more clinically 
advanced stages and worse prognosis for patients [13].  
1.6. P65 and selected factors employed in clinical diagnosis and prognosis in 
breast cancer 
Steroid hormone receptors (estrogen and progesterone), proliferating cell nuclear antigen 
(PCNA), Ki67, epidermal growth factor receptor (EGFR), oncogene c-ErbB2, tumor 
suppressor gene P53, anti-apoptotic gene Bcl-2 are among factors often used in clinical 
diagnosis and monitoring breast cancer, among other types of cancer. A computer search of 
Protein Sequence Database (PSD) revealed that the N-terminal peptide of human and rat 
P65/p65, which have been sequenced for the first 10 residues, is unique. Analysis of the 
amino-acid sequences of several internal peptides, generated by CNBr treatment, as 
described above, showed 100% identity in 6 amino-acids to c-erbA upstream of the DNA-
binding domain, and 87.5% of identity in 10 amino-acids to human prostate specific antigen 
among other proteins [2]. On the basis of partial amino acid sequence analysis it could be 
suggested that P65/p65 is like the thyroid hormone receptor (THRA) or c-erbA1 and belongs 
to a family of nuclear receptors for various hydrophobic ligands such as steroids, vitamin D, 
retinoic acid and thyroid hormones. These hormones are composed of several domains 
important in hormone binding, DNA-binding dimerization and activation of transcription. 
It was shown that P65/p65 is located in nuclei of malignant cells of different cancers and this 
observation may support such hypothesis. It is well known that cytoplasmic receptors bind 
hormone and rapidly translocate it to the nucleus. This fact may explain immunostaining 
showing the presence of p65/P65 not only in nuclei, but also in the cytoplasm in breast 
cancer tissues. The presence of P65 in the cytoplasm as well as in nuclei of cancer cell may 
also suggest that P65 may function as a transcriptional factor. 
Taking into consideration above mentioned data P65 expression was investigated in 
paraffin-embedded tissue slides from infiltrating ductal breast cancer specimens by 
immunohistochemistry using monoclonal antibodies recognizing human P65 antigen and 
polyclonal antibodies recognizing p65-like protein present in fetal serum in parallel with 
estrogen and progesterone receptors, which are very important prognostic factors in 
mammary gland tumors [14]. The P65/p65 expression was correlated with estrogen receptor 
(ER) and progesterone receptor (PR) levels. Statistically significant correlation was found 
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of SDS was used for its isolation. Fractionated serum proteins after transfer onto 
nitrocellulose sheets were further analyzed by Western blot technique with the use of anti-
P65 monoclonal antibody. Such analysis revealed that P65 protein has four isoforms. The 
isoforms, after isolation from polyacrylamide gels were used together for polyclonal 
antibody production [9]. Additional analysis of fetal serum fractions separated by 
electrophoresis on cellulose acetate membrane followed by immunostaining with anti-P65 
monoclonal antibody revealed that the p65-like protein had a similar location to one of -
globulin [9].  
1.5. Anti-p65-like protein antibodies as a tool in cancer detection 
Polyclonal antibody raised in rabbits against p65-like protein was tested by 
immunohistochemistry technique in breast cancer patients (frozen sections) and compared 
with that of anti-human-P65 monoclonal antibodies [10]. Comparison of the percentage of 
tumor cells showing positive immunoreaction with mono- and polyclonal antibodies 
showed a weak reactivity in significantly higher percentage of investigated cases 27% for 
MAb and 7% for PAb. On the other hand, medium and strong reactions were observed in a 
larger amount of cases after probing of the tumor tissue with a polyclonal antibody – 91% in 
comparison to 73% stained by a monoclonal antibody. In all cases positive for P65, 
immunohistochemical reaction was observed in the cytoplasm and in the area surrounding 
the nuclei [10]. 
Further comparative studies connected with clinical evaluation of the usefulness of 
polyclonal and monoclonal antibodies raised against P65/p65 protein were done by 
immunohistochemistry on paraffin-embedded tissue slides from breast cancer patients [11]. 
More than one hundred cases including infiltrating ductal breast carcinomas, fibrocystic 
disease and fibroadenoma were assessed immunohistochemically using monoclonal 
antibodies against human P65 antigen, and polyclonal antibodies against p65-like protein 
present in fetal serum. There were no evident differences in P65 detection between 
polyclonal and monoclonal antibodies, but monoclonal antibody causes more specific 
immunohistochemical reactions. Fibrocystic disease with large epithelioplasia that had 
precancerous status, gave a positive response when anti-P65 antibodies were utilized. This 
observation correlated with our previous data showing unique properties of anti-p65 
antibodies of staining premalignant foci in the early stages of chemical carcinogenesis. In the 
most cases of breast cancer, a positive immunoreaction occurred with poly- and monoclonal 
anti-p65/P65 antibodies in the cytoplasm and/or nuclei.  
The p65-like protein was also analyzed in B-chronic lymphocytic leukemia (CLL) cells as 
well as in normal lymphocytes, followed by their separation to nuclear, mitochondrial, and 
microsomal fractions by differential centrifugation. The cellular fraction of CLL and normal 
lymphocytes were separated by SDS-PAGE electrophoresis followed by Western blot 
analysis with the use of anti-p65 like polyclonal antibody [12]. P65 antigen was recognized 
as a predominant polypeptide in the leukemic nuclear fraction. No cross reactivity was 
observed with normal lymphocyte nuclear proteins in the region of 65 kDa [12]. 
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To get a better idea about the role of the P65 protein in cancer formation and growth a more 
advanced study was undertaken on paraffin-embedded infiltrating ductal breast cancer 
tissue slides [13]. It was noticed that the percentage of positive cells with cytoplasmic 
expression of P65 was significantly higher in histologically more differentiated cancers 
(grade I and II according to Bloom & Richardson) than in grade III. The percentage of 
immunopositive nuclei grew with the advance of the disease and was the highest in poorly-
differentiated (grade III) tumors. The tumors with P65 cytoplasmic reaction were mainly 
small (T1, T2), without lymph nodes (N0) and distant (M0) metastases. The straight 
dependence existed between P65 nucleic reaction and tumor size, metastases to lymph 
nodes and distant metastases. The obtained results suggested that transfer of P65 protein 
from cytoplasm to nuclei of the breast cancer cells is connected with more clinically 
advanced stages and worse prognosis for patients [13].  
1.6. P65 and selected factors employed in clinical diagnosis and prognosis in 
breast cancer 
Steroid hormone receptors (estrogen and progesterone), proliferating cell nuclear antigen 
(PCNA), Ki67, epidermal growth factor receptor (EGFR), oncogene c-ErbB2, tumor 
suppressor gene P53, anti-apoptotic gene Bcl-2 are among factors often used in clinical 
diagnosis and monitoring breast cancer, among other types of cancer. A computer search of 
Protein Sequence Database (PSD) revealed that the N-terminal peptide of human and rat 
P65/p65, which have been sequenced for the first 10 residues, is unique. Analysis of the 
amino-acid sequences of several internal peptides, generated by CNBr treatment, as 
described above, showed 100% identity in 6 amino-acids to c-erbA upstream of the DNA-
binding domain, and 87.5% of identity in 10 amino-acids to human prostate specific antigen 
among other proteins [2]. On the basis of partial amino acid sequence analysis it could be 
suggested that P65/p65 is like the thyroid hormone receptor (THRA) or c-erbA1 and belongs 
to a family of nuclear receptors for various hydrophobic ligands such as steroids, vitamin D, 
retinoic acid and thyroid hormones. These hormones are composed of several domains 
important in hormone binding, DNA-binding dimerization and activation of transcription. 
It was shown that P65/p65 is located in nuclei of malignant cells of different cancers and this 
observation may support such hypothesis. It is well known that cytoplasmic receptors bind 
hormone and rapidly translocate it to the nucleus. This fact may explain immunostaining 
showing the presence of p65/P65 not only in nuclei, but also in the cytoplasm in breast 
cancer tissues. The presence of P65 in the cytoplasm as well as in nuclei of cancer cell may 
also suggest that P65 may function as a transcriptional factor. 
Taking into consideration above mentioned data P65 expression was investigated in 
paraffin-embedded tissue slides from infiltrating ductal breast cancer specimens by 
immunohistochemistry using monoclonal antibodies recognizing human P65 antigen and 
polyclonal antibodies recognizing p65-like protein present in fetal serum in parallel with 
estrogen and progesterone receptors, which are very important prognostic factors in 
mammary gland tumors [14]. The P65/p65 expression was correlated with estrogen receptor 
(ER) and progesterone receptor (PR) levels. Statistically significant correlation was found 
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between ER or PR level and P65/p65 cytoplasmic reaction and inverse correlation with 
nucleic localization of P65/p65 protein [13,14]. It should be underlined that patients with 
high levels of ER and PR are more sensitive to antiestrogen therapy. Usually a high ER level 
is accompanied by a high PR level. When only one type of receptor is present, the 
percentage of patients sensitive to such therapy significantly decreases.  
PCNA and Ki67 belong to prognostic factors for clinical evaluation of breast cancer; 
especially their proliferating indexes (PI-PCNA, PI-Ki67) are very useful prognostic factors. 
A strong correlation between PI-PCNA and PI-Ki67 was established in our studies in the 
group of patients suffering from infiltrating ductal breast carcinoma. High PI-PCNA was 
accompanied by loss of steroid receptors (ER/PR) and low level of P65/p65 antigen. Those 
data confirmed that appearance of P65 protein is connected to carcinogenic or tumorigenic 
processes and that this factor is not induced by cellular proliferation associated with non-
neoplastic diseases [15]. It was also established that there is no correlation between P65 and 
c-ErbB2, EGFR or P53 expression. In low differentiated tumors (grade III) high P53 index 
and high EGFR and c-ErbB2 expression was connected with low P65 expression [16].  
2. Studies of P65/p65 gene expression at the mRNA level 
2.1. Development of PCR studies of P65/p65 gene expression in different cancers 
and comparison with prognostic factors  
Having in hand short N-terminal amino acid sequence for whole P65/p65 molecule as well 
as for four peptides generated by CNBr treatment, the most probable nucleotide sequences 
were generated. To establish RT-PCR conditions, a forward primer was designed on the 
basis of N-terminal domain of whole P65 molecule and reverse primers designed on the 
basis of its four internal peptides. As a source of RNA for RT-PCR method optimization 
human promyelocytic leukemic cell line (HL-60), which secretes P65 antigen was chosen. 
The best primers and the best condition for the PCR were established in preliminary 
experiments. The best results were achieved for primers based on N-terminal sequence of 
whole P65 molecule and N-terminal sequence established for 51 kDa peptide. The size of the 
product of PCR reaction was about 150 bp long [17]. 
On the basis of this technique P65 gene expression was analyzed in various types of 
leukemia: acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL) and 
chronic lymphocytic leukemia (CLL). No relationship between the expression of P65 gene 
and clinical stage of leukemia was observed. The highest frequency of P65 gene expression 
was found in the group of patients with CLL (average 66%). This percentage was lower in 
patients with acute leukemia and took out 42% in ALL and 46% in AML [17]. When P65 
gene expression was analyzed in limited groups of ALL and AML patients, where both 
peripheral blood and bone marrow were collected, the percentage of P65 positivity 
increased to 83 and 75, respectively. Predominant presence of P65 gene transcript in bone 
marrow cells may be explained by the hypothesis that investigated gene is expressed 
preferentially in some type of white blood cells, which do not pass through the bone 
marrow-blood barrier [17].  
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P65 gene expression was also investigated in the cases of follicular thyroid cancer and follicular 
adenomas and in the contrary to our earlier studies this gene was not observed in any of the 
analyzed follicular cancers but it was observed in 65% of follicular adenoma cases [18].   
P65 gene expression was also analyzed in frozen tissue slides taken from patients diagnosed 
as ductal and lobular breast cancer, classified as G3, and in a limited panel of proliferative 
breast disease cases [19]. It was shown that P65 gene expression is connected with small 
tumor size and with absence of metastases to regional lymph nodes. In contrast to P65, c-
ErbB2 expression was observed in patients with large tumors and with metastases to 
regional lymph nodes. Thus, an inverse relationship was found between these two genes 
(P65 and c-ErbB2). Notably, the P65 gene expression occurred in the group of proliferating 
breast disease cases, which were correlated with higher risk of breast cancer. In contrast, 
lack of P65 was evident in cases classified as fibroadenomas [19].  
Because of the biological similarity between breast and prostate adenocarcinomas and some 
evidence suggested that the P65 gene may be a novel member of the superfamily of genes 
that encode nuclear receptors for hydrophobic ligands, P65 gene expression was also 
evaluated in prostate cancer. Similarly to the investigated breast cancer cases, the expression 
of P65 was observed in a significant percentage of well- and moderately-differentiated 
tumors [20]. P65 gene expression was also compared to expression of other factors 
connected with prostate cancer like well-known oncogene c-ErbB2 (poor prognostic factor) 
and prostate specific gene DD3, highly overexpressed in prostate cancer tissue. In all 
investigated stages of disease straight dependence between P65 and DD3 gene expression 
and opposite dependence between P65 and c-ErbB2 expression were observed [20]. P65 gene 
expression was also observed in some cases diagnosed as benign prostatic hyperplasia 
(BPH) (Balcerczak et al., unpublished data), which may suggest that its appearance may 
follow transition from benign to adenocarcinoma state. It is already well documented that 
H. pylori causes critical alterations in gastric mucin structure. Long-term bacterial infection is 
associated with development of gastritis and peptic ulcer and is presumed to be a risk factor 
for gastric cancer development. The presence of H. pylori infection was determined by 
urease test. Additionally, we had been looking for the presence of P65 gene transcript in the 
group of gastric cancers and adjacent normal gastric mucosa. There was no correlation 
between P65 gene expression and H. pylori infection, which suggests that H. pylori is not 
involved in the process of P65 gene activation. In the case of gastric cancers P65 gene 
expression was connected with poor prognosis for the patients because its expression was 
detectable in cases with lymph nodes and distant metastases [21]. Taking into consideration 
that H. pylori has been suggested to be a tumor-promoter in gastric carcinogenesis, our 
earlier results confirmed such hypothesis because anti-P65 antibodies detected only 
preneoplastic foci that were tumor-promoter independent [4]. 
2.2. Qualitative and quantitative analysis of P65 gene expression in colorectal 
cancer - comparison with bad prognostic factors   
When we analyzed gastric cancer cases, it was first time the positive dependence between 
P65 gene expression and poor prognosis for the patients was observed. That is why our 
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between ER or PR level and P65/p65 cytoplasmic reaction and inverse correlation with 
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high levels of ER and PR are more sensitive to antiestrogen therapy. Usually a high ER level 
is accompanied by a high PR level. When only one type of receptor is present, the 
percentage of patients sensitive to such therapy significantly decreases.  
PCNA and Ki67 belong to prognostic factors for clinical evaluation of breast cancer; 
especially their proliferating indexes (PI-PCNA, PI-Ki67) are very useful prognostic factors. 
A strong correlation between PI-PCNA and PI-Ki67 was established in our studies in the 
group of patients suffering from infiltrating ductal breast carcinoma. High PI-PCNA was 
accompanied by loss of steroid receptors (ER/PR) and low level of P65/p65 antigen. Those 
data confirmed that appearance of P65 protein is connected to carcinogenic or tumorigenic 
processes and that this factor is not induced by cellular proliferation associated with non-
neoplastic diseases [15]. It was also established that there is no correlation between P65 and 
c-ErbB2, EGFR or P53 expression. In low differentiated tumors (grade III) high P53 index 
and high EGFR and c-ErbB2 expression was connected with low P65 expression [16].  
2. Studies of P65/p65 gene expression at the mRNA level 
2.1. Development of PCR studies of P65/p65 gene expression in different cancers 
and comparison with prognostic factors  
Having in hand short N-terminal amino acid sequence for whole P65/p65 molecule as well 
as for four peptides generated by CNBr treatment, the most probable nucleotide sequences 
were generated. To establish RT-PCR conditions, a forward primer was designed on the 
basis of N-terminal domain of whole P65 molecule and reverse primers designed on the 
basis of its four internal peptides. As a source of RNA for RT-PCR method optimization 
human promyelocytic leukemic cell line (HL-60), which secretes P65 antigen was chosen. 
The best primers and the best condition for the PCR were established in preliminary 
experiments. The best results were achieved for primers based on N-terminal sequence of 
whole P65 molecule and N-terminal sequence established for 51 kDa peptide. The size of the 
product of PCR reaction was about 150 bp long [17]. 
On the basis of this technique P65 gene expression was analyzed in various types of 
leukemia: acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL) and 
chronic lymphocytic leukemia (CLL). No relationship between the expression of P65 gene 
and clinical stage of leukemia was observed. The highest frequency of P65 gene expression 
was found in the group of patients with CLL (average 66%). This percentage was lower in 
patients with acute leukemia and took out 42% in ALL and 46% in AML [17]. When P65 
gene expression was analyzed in limited groups of ALL and AML patients, where both 
peripheral blood and bone marrow were collected, the percentage of P65 positivity 
increased to 83 and 75, respectively. Predominant presence of P65 gene transcript in bone 
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FJ194940.1 Gene and Its Protein Product ACJ04040.1 – 
 Potential Tumor Marker – From Protein to cDNA and Chromosomal Localization 113 
P65 gene expression was also investigated in the cases of follicular thyroid cancer and follicular 
adenomas and in the contrary to our earlier studies this gene was not observed in any of the 
analyzed follicular cancers but it was observed in 65% of follicular adenoma cases [18].   
P65 gene expression was also analyzed in frozen tissue slides taken from patients diagnosed 
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further work was focused on colorectal cancer. Patients with colorectal cancer have the 
highest mortality among those with cancer. We examined 109 couples of colorectal cancer 
tissue and adjacent, healthy colorectal mucosa from the same patients and a few samples of 
colorectal mucosa from patients without colorectal neoplastic disease. For 19 of them the 
P65 expression was observed both in cancer tissue and in adjacent colorectal mucosa. In 58 
remaining pairs P65 gene expression was not detected. None of a few cases of healthy 
mucosa revealed the expression of P65 gene. Analysis was performed by qualitative 
technique based on reverse transcription followed by PCR [22] and quantitative analysis by 
real-time PCR based on fluorescence dye SYBR Green [23]. P65 gene expression was 
detected in nearly 50% (n=51) of investigated colorectal cancer cases. There was no 
statistically significant correlation between age, gender and expression of the P65 gene. The 
investigated group consisted of 37 cases of rectal and 72 cases of colon cancers. P65 gene 
expression levels determined by quantitative analysis were statistically lower in cancers 
originating in the rectum as compared to those originating in the colon (p=0.0099, Mann-
Whitney U test). The analyzed carcinomas were histologically classified as tubular and 
mucinous adenocarcinomas. There was no statistical correlation between histological type of 
tumor and P65 gene expression. There was no statistically significant dependence between 
P65 gene expression and histological grade. P65 gene expression was compared with several 
clinicopathological parameters (TNM classification) such as depth of tumor invasion (T), 
lymph node metastases (N), and distant metastases (M). Expression of P65 was also 
correlated with vessel invasion and the presence of lymphocytes in tumor tissue. P65 gene 
expression was higher in more advanced tumors (T3 and T4, deep wall penetration), while 
in the T1-T2 group lower levels were recorded. There was statistical dependence between the 
expression of P65 and the depth of tumor penetration. Another parameter analyzed was the 
expression of P65 gene in cases with (N1-N2) and without (N0) lymph-node metastasis. This 
analysis also revealed significant statistical correlation between them and, in cases classified as 
N0, the P65 expression level was lower than in the N1-N2 cases. Statistically significant 
correlation was also found between P65 gene expression and distant metastases. In carcinomas 
with distant metastases (M1) the levels of P65 were two times higher than in the group of 
cancers without distant metastases (M0). The cases without lymphocytes in tumor tissue 
showed higher levels of P65 then those with the presence of lymphocytes. Furthermore, in the 
group of tumors without vessel invasion, P65 gene expression was lower than in tumors with 
the vessel invasion, but these differences were not statistically significant [22, 23]. 
2.3. Influence of anticancer drugs on P65/p65 expression  
In our further studies, we aimed to get information about the possible stimulation of 
apoptosis and P65 expression by different compounds in HL-60 cells. For this reason, we 
have tested the expression of different genes connected with apoptosis like Bcl-2, c-Myc, ICE, 
P53 and Bax as well as P65 expression after treatment of human acute promyelocytic 
leukemia cell line HL-60 by carboplatin alone and in combination with cytoprotective agent 
amifostine. Bcl-2, c-Myc, ICE and P53 gene expression was estimated semi-quantitatively 
using a human apoptosis set 1 detection kit (hAPO1-MPCR) based on multiplex PCR 
reaction. Bax and P65 gene expression was also estimated semi-quantitatively with the use 
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of multiplex PCR method where cDNA was generated from total RNA isolated from HL-60 
cells with the use of reverse transcriptase. Expression of the investigated genes was 
determined by normalization to the expression of reference (housekeeping) GAPDH or -
actin genes. HL-60 cells exposed to carboplatin alone showed about 120-fold increase in 
caspase 3 activity. Combination of carboplatin with amifostine induced the enzyme activity 
up to 280 times. The level of Bcl-2 gene expression was diminished, whereas Bax gene 
showed tendency to grow in HL-60 cells treated with carboplatin in combination with 
amifostine as compared to the cells treated with carboplatin only. Protein product of Bcl-2 
has been shown to block apoptosis in experimental systems and also genetic evidence has 
indicated that Bcl-2 suppresses apoptosis. It is known that Bax expression is usually 
connected with induction of programmed cell death. Similarly, to the Bax gene, an 
increasing tendency was also noticed for the P65, but its biological role in this process is still 
unknown [24].  
In the same model (HL-60 cells in culture), the influence of amifostine alone and in 
combination with doxorubicin, cytarabine, or etoposite on Bcl-2, Bax, and P65 genes 
expression was investigated. It was shown that amifostine potentiated cytotoxic action of 
doxorubicin but not cytarabine and etoposide. HL-60 cells treated with doxorubicin alone 
showed about 35-fold increase in caspase 3 activity. The enzyme activity was stimulated by 
combination of doxorubicin with amifostin up to 94 times. Semi-quantitative reverse 
transcriptase-polymerase chain reaction showed a decrease in Bcl-2 and an increase in Bax 
and P65 expression in HL-60 cells treated with doxorubicin in combination with amifostine 
when compared with the cells treated only with doxorubicin [25]. 
Expression of the p65 gene was also analyzed in experimental colon cancer under the 
influence of 5-fluorouracil (5-FU) given alone and in combination with hormonal 
modulation. It was found that in the control group (mice bearing colon 38 cancer without 
treatment) the expression of p65 gene was present in 57% of investigated samples. In the 
groups treated with tamoxifen (TAM) or lanreotide (LAN) p65 expression was detected in 
87.5% and 83.3% of analyzed cases, respectively. Both these substances increased apoptotic 
index in colon 38 cancer as determined by TUNEL method, and a tumor mass. After 
combined treatment with TAM and LAN a percentage of p65 positive cases in the cancer 
group was similar to that of the control group and equal to approximately 60%. This 
treatment did not increase proapoptotic effects of these drugs used individually. In the 
group treated with 5-FU and LAN p65 gene expression was also close to the control value 
(about 66%). Similarly in this group the combined treatment with these two drugs did not 
cause any favorable effect on apoptosis. In the group treated with 5-FU alone the expression 
of p65 was present in about 80% of samples and increased apoptotic index was observed. In 
the group treated with a combination of 5-FU and TAM, all analyzed cases exhibited p65 
gene expression [26]. 
On the basis of these studies, we can conclude that different types of in vitro treatment of 
HL-60 cells, as well as mice bearing colon 38 cancer treated in vivo, which leads to apoptosis, 
is connected with stimulation of p65/P65 gene expression. 
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2.4. Cloning, sequencing and chromosomal localization of P65 gene  
Our next goal was to clone and sequence human P65 cDNA and analyze its expression in 
malignant tissues. The 5'-RACE and 3'-RACE with previously designed primers [17] were 
carried out to obtain the 5' and 3' missing portions of the cDNA, respectively. Amplification 
product of about 900 bp was obtained in 5’-RACE only and cloned in pCR 2.1. Fourteen 
clones were obtained and gene inserts in seven of them sequenced. The complete cDNA of 
the human P65 gene was compiled by overlapping the sequences of cloned 5'-RACE PCR 
products. The human P65 transcript consisting of 921 bp was deposited in GenBank Acc No 
FJ194940.1. and, from that time, the P65 name was replaced by FJ194940.1. [27] 
BLAT (BLAST-Like Alignment Tool) located the cloned cDNA sequence on human 
chromosome 1. The cloned sequence spans 2150 bp genomic DNA and consists of five 
exons. The sequence of intron 1 and intron 4 does not match human genomic sequence. The 
best matches for intron 1 covered only 37% of sequence in length. Better results were 
obtained in the BLAT search against the Human Endogenous Retrovirus Database HERVd 
[28]. Intron 1 sequence was similar to rv_001141. This is a complete typical provirus 
(soloLTR) with TSD belonging to family HERVL66. Provirus rv_001141 is located on 
chromosome 1. The most probable explanation is that an integration of additional copy of 
rv_001141 took place. Part of intron 4 sequence shows similarity (52% coverage, 83% 
identity) to the second intron of MLLT3 (NW_001839149).  
Integration of an additional copy of rv_001141 changed transcription in this chromosome 
region. In normal human tissues, this chromosome region (224789942 – 224797092) 
corresponds to an uncharacterized transcript (GenBank Acc No AK055856) and three EST: 
DA627076, DA625438, and DA627327. All of them were found in kidney [27]. 
Chromosomal localization of cDNA of the human FJ194940.1. gene was experimentally 
determined with the use of CHORI-17 (Hydatidiform Mole) Homo sapiens BAC Library 
from BACPAC Resource Center (http://bacpac.chori.org) and was shown to be located on 
chromosome 1: 224792167-224794166. On the basis of established sequence 40 bp long 
synthetic probe for FJ194940.1. was designed to target a conserved sequence ~900 bp 
upstream of exon 1. Hybridizations with a 32P-labeled probe were performed with high-
density colony filters containing clones from chromosome 1 segments. The library was 
hybridized using radioactive probes. Clones from probe-positive well positions were 
recovered from freezer archives and grown in liquid culture (Balcerczak, Mirowski 
unpublished data). 
2.5. Possible splice variants for FJ194940.1 gene transcript 
To confirm the exon-intron structure of FJ194940.1 gene generated by the bioinformatics 
program, eight pairs of primers were designed (Table 2). Four of these primers 
corresponded to the interior sequences of potential exons. They were denoted as II, III, IV 
and V. The other corresponded respectively to 3’ end and 5’ end of adjacent exons. They 
were denoted as I/II, II/III, III/IV and IV/V [29]. 
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Exon Primer sequence Expected 
amplicon 
length 
 Forward primer Reverse primer  






II/III TGTGAAACAAGCAGTGCAAC GCTTGTTGGTCAGCCTTCTG 155 
III TTTTCCATGTTGATGCTCA CGCCTGAGTCTGCAGTAAT 101 
III/IV TGCTCATGCATCTCTGCTTT TTTGAAATGGGAGCCACTGT 218 
IV CAGTGGCTCCCATTTCAAAG TCAAACAGGTGATCGTTCCA 
 
189 
IV/V CAGCTGGCCTAATCGAAAGA TCCAGCATTTCAGCAAGAGA 155 
V CTCTCTTGCTGAAATGCTGG GGCCCAGGCTTTAAACTATA 94 
Table 2. Primer sequence specific for potential exons and exon junctions of FJ194940.1 gene and 
expected product size 
The preliminary study has indicated that FJ194940.1. gene transcript probably has different 
splice variants. The mRNA expression of FJ194940.1 was determined in various types of 
cancers (breast n =25, colon n=30, thyroid n=25, and acute and chronic leukemias n=50) by 
semi-quantitative RT-PCR. Amplification conditions were established by gradient PCR. 
Messenger RNAs for exon III as well as for junction of III/IV and IV/V were found in all 
investigated samples. PCR product with primers set for exon V was observed in all types of 
cancers, but it occurred irregularly. Also irregularly, but only in some types of cancer (breast 
cancer, colon cancer and acute leukemia) products appeared from exon II and IV and 
junction of II/III. Additionally, it was proven that there is no statistically significant 
correlation between the presence of exon V and clinical stage and/or cancer grade. 
2.6. Detailed investigation of FJ194940.1 gene alternative splicing in colon cancer 
A detailed analysis of 102 colon cancer cases was conducted to confirm an initial observation 
that pre-mRNA of FJ194940.1. gene has undergone alternative splicing. Using the method 
developed earlier and the above mentioned sets of primers, a total of 18 forms of mRNA 
FJ194940.1 splice variants were identified. They have appeared with differential prevalence. 
Those isoforms arise from different combinations of 4 interior parts of exons (II, III, IV, V) 
and 4 different exon-exon junctions (created by 3’ and 5’ ends of particular, adjacent exons 
I/II, II/III, III/IV and IV/V). The full-length transcript, which was defined as exons I-V and all 
exon-exon junctions, was seen as the most prevalent in colon cancer samples, being 
identified in 40 of 102 (39.2%) cases. On the other hand, taking all detected variants (rest of 
the 17 types of isoforms) into account, they were found in 62 of 102 (60.8%) of patients. Some 
variants were not observed more frequently than full-length transcripts [29]. 
The variants of FJ194940.1 gene are characterized by the lack at least one, as well as the lack 
of two, three or four investigated elements simultaneously in this gene transcript. 
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correlation between the presence of exon V and clinical stage and/or cancer grade. 
2.6. Detailed investigation of FJ194940.1 gene alternative splicing in colon cancer 
A detailed analysis of 102 colon cancer cases was conducted to confirm an initial observation 
that pre-mRNA of FJ194940.1. gene has undergone alternative splicing. Using the method 
developed earlier and the above mentioned sets of primers, a total of 18 forms of mRNA 
FJ194940.1 splice variants were identified. They have appeared with differential prevalence. 
Those isoforms arise from different combinations of 4 interior parts of exons (II, III, IV, V) 
and 4 different exon-exon junctions (created by 3’ and 5’ ends of particular, adjacent exons 
I/II, II/III, III/IV and IV/V). The full-length transcript, which was defined as exons I-V and all 
exon-exon junctions, was seen as the most prevalent in colon cancer samples, being 
identified in 40 of 102 (39.2%) cases. On the other hand, taking all detected variants (rest of 
the 17 types of isoforms) into account, they were found in 62 of 102 (60.8%) of patients. Some 
variants were not observed more frequently than full-length transcripts [29]. 
The variants of FJ194940.1 gene are characterized by the lack at least one, as well as the lack 
of two, three or four investigated elements simultaneously in this gene transcript. 
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 5 of the 18 FJ194940.1 isoforms represented the lack of only one investigated 
component. Those types of isoforms were detected in 33 of the 102 colon cancer cases 
(32.4%). The most frequent single omitted element was the junction of II/III exons 
(16.7%), whereas the most infrequently isolated omitted element was the junction of 
III/IV as well as IV/V exons (1.9% and 1.9% respectively).  
 Two elements were missing in 6 out of 18 FJ194940.1 isoforms. Those types of isoforms 
were detected in 18 of the 102 colon cancer cases (17.6%). All but 2 of these variants had 
omissions of interior sequence of exon with the deleted region of exon-exon junction, 
i.e. a) II and II/III, b) III and III/IV, c) IV, IV/V, d) II/III, III. 
 Three elements were missing in 4/18 FJ194940.1 isoforms. Those types of isoforms were 
detected in 7 of the 102 colon cancer cases (6.9%).  
 Four elements were missing in 2/18 FJ194940.1 isoforms. Those types of isoforms were 
detected in 4 of the 102 colon cancer cases (3.9%). One of these isoforms was missing the 
entire exon IV. 
To sum up the results mentioned above, the splice variant with one element deleted is the 
most prevalent isoform of FJ194940.1. The most frequently omitted element of FJ194940.1 
gene transcript was the junction of II/III exons (36/102, 35.3%). This junction of exons was 
missing less frequently than in combination with other elements of FJ194940.1 cDNA. The 
most infrequently skipped element was the junction of IV/V exons (5.9%). This was 
incidental to the lack of an interior sequence in exon IV. All samples contained amplification 
products for the junction of I/II exons and exon V. All possible splice variants of FJ194940.1 
gene are presented on Figure 1 and number of cases with the presence and absence of 
analyzed splice variants are presented in Table 3.  
Additionally, to assess applicability of FJ194940.1 splice variants elements as prognostic 
factors in colon cancer, their expression with established prognostic features and survival 
time of patients suffering from this disease were also compared. Statistical analysis was 
carried out with reference to whole FJ194940.1 transcript and to particular exons and exon-
exon junctions, but no significant correlations were found. The whole transcript was divided 
into two parts A and B. The part A consists of exons II and III as well as I/II, II/III exon-exon 
junctions, while part B is composed of exons IV, V, III/IV, and IV/V exon-exon junctions. 
Part A contains the most frequently skipped element of the examined transcript, while part 
B contains its longest component.  
No associations were found between gender, familial history and expression of both 
examined parts of FJ194940.1 gene transcript. Expressions of both parts A and B were not 
connected with tumor localization. There was not a statistically significant association 
between part A and B of FJ194940.1 gene expression and histological type of tumor. There 
was link between part B of FJ194940.1 gene transcript expression and tumor grading. 
Expression of part B is connected with well (G1) and moderately (G2) differentiated cases. 
Expression of both parts of investigated gene transcript and some clinical staging features, 
including depth of tumor invasion, lymph nodes metastases, distant metastases, and stage, 
according to pTNM classification, were compared. No statistically significant associations 
were noted between mentioned parameters and expression of part A as well as part B of 
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FJ194940.1 gene transcript. The expression levels of analyzed parts of FJ19940.1 gene 
transcript were also compared to the presence of lymphocytes in tumor and vascular 
invasion. Venous invasion was significantly related to presence of all elements in part A of 
the FJ194940.1 gene transcript (p=0.0477). There was no statistical significance connection 
between the presence of lymphocytes in tumor and expression of part A or B of FJ194940.1 
gene transcript. There was no statistically significant difference in survival time comparing 
patient with presence and absence of whole transcript in spite of the visible tendency for 
shorter survival of those without at least one element in whole transcript (p=0.0690).  
 
Figure 1. 18 possible splice variants of FJ194940.1 gene in colorectal cancer cases (n=102). From the left - 
the number of cases where splice variants were detected. Amplified exons II, III, IV and V and their 
junctions I/II, II/III, III/IV, IV/V.  
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 Number of cases with the presence of 
investigated amplicon 
Number of cases with the absence of 
investigated amplicon 
I/II 102 (100,0%) 0 (0,0%) 
II 84 (82,4%) 18 (17,6%) 
II/III 66 (64,7%) 36 (35,3%) 
III 90 (88,2%) 12 (11,8%) 
III/IV 86 (84,3%) 16 (15,7%) 
IV 84 (82,4%) 18 (17,6%) 
IV/V 96 (94,1%) 6 (5,9%) 
V 102 (100,0%) 0 (0,0%) 
Table 3. The expression frequency of investigated exons and their junctions in investigated transcript of 
FJ194940 gene.  
2.7. From cDNA to amino acid sequence 
ORF (Open Reading Frame) Finder found several open reading frames on cDNA, which 
could code protein(s). Sequences of generated peptides were compared by BLAST with 
sequences of proteins available in GenBank and SwissProt databases. The best results were 
obtained for ORF number 2 in reading frame 2 on the direct strand extending from base 374 
to base 790 (Balcerczak and Mirowski unpublished data). 
The peptide amino acids sequences were found to be significantly similar to the integrase 
core domain in the Conserved Domain Database, and to the human protein EAW69787 
referred as similar to Pro-Pol-dUTPase polyprotein, RNaseH, dUTPase, integrase, protease 
and reverse transcriptase (LOC768966) in the GenBank database. The deduced peptide has a 
molecular weight of 15.74 kDa and is probably one of possible FJ194940.1. gene protein 
products. This hypothesis is in agreement with results that confirmed alternative splicing of 
the investigated gene. It is also possible that the TAA stop codon at the 790 position is 
skipped and protein synthesis further continued.  
2.8. Anti-peptide antibodies 
The deduced protein (15.74 kDa) is substantially smaller than P65. For experimental 
evidence of this protein sequence potential antigenic region(s) were searched for future 
experimental analysis. The EMBOSS (European Molecular Biology Open Software Suite) 
ANTIGENIC program, Kolaskar and Tongaonkar and Peptide Select Program were used. 
Sequences predicted as antigenic by all the software were used for induction of antibody 
production. Three peptides (IC14, CL14 and CR14) were chosen for further experiments. 
Peptides were modified by adding cysteine to the C-terminus or N-terminus and conjugated 
with KLH. Obtained antibodies were used in Western-blotting analysis of two cell lines: 
promyelocytic HL-60 and lymphoblastic NALM-6. Positive results were obtained for 
antibodies IC14 and CR 14 and, in Western blot analysis, two immunoactive bands were 
detected. The first one had a molecular weight of about 65 kDa and the second about 15 kDa 
(Mirowski, Balcerczak unpublished data).   
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2.9. Possible mechanism of transcription in human neoplasm 
Sequence of FJ194940.1 fragment determined in this study had the length of 921 bp. An 
insertion of an additional copy of HERV provirus rv_001141 probably occurs during the 
carcinogenic process, which changes transcription of chromosome 1 224792176 - 222794166 
region. In normal human tissues this chromosome region encodes transcript AK055856 
expressed in kidney. Integration of rv_001141 leads to alteration of transcription [27].  
It is already well known that the retrovirus family is an etiological agent of human cancer, 
mainly leukemia and lymphomas. The presence of endogenous retroviruses (HERV) 
sequences in the human genome is well documented. In contrast to the normal tissues, 
HERV sequences are transcriptionally-active in embryonic cells, such as placenta and 
theratocarcinoma [30] as well as in tumor cells [31]. Several factors regulate HERV 
expression. In tumor cells, HERV expression can be stimulated by INF- [32], TNF-, IL-1 
and IL-1 [33]. Other factors, which can stimulate their transcription, are steroid hormones, 
including glucocorticoids. HERV-K10 (in breast cancer cells) belongs to the family of 
sequences that are activated in placenta by steroids. On the other hand, HERV-E expression 
is hindered during therapy with the use of steroids [34]. Another group of factors, which can 
influence activity of endogenous retroviruses, are products of exogenous viruses e.g., 
Epstein-Barr, which upregulate transcription of env gene of HERV-K18, which is located in 
the intron of the CD48 gene [30]. Endogenous retroviruses have influence on genomic DNA 
organization and deregulate genes expression, creating additional transcription initiation 
sites, incorrect splicing, inserting stop codons or or polyadenylation signal [30,32,35]. As a 
consequence of interruption of gene function, many diseases can develop e.g., cancer, if 
HERV insertion is present in a proto-oncogene or suppressor gene or their vicinity. Such 
situation is observed in rats with N-methyl–N nitrosurea induced mammary gland 
carcinoma, where defective sequence of HERV in c-H-ras gene intron leads this gene to 
overexpression [36]. In our previous study P65 antigen was found in the serum and urine of 
rats with N-methyl-N-nitrosourea-induced mammary adenocarcinomas [5].    
3. Conclusion  
FJ194940.1 and its protein product seem to be a potential new molecular marker, which may 
be used for monitoring of oncological patients, especially with colon cancer. Its 
chromosomal localization and exon-intron structure was predicted by BLAT, confirmed by 
RT-PCR and also with the use of CHORI-17 (Hydatidiform Mole) Homo sapiens BAC 
Library from BACPAC Resource Center analysis. The best matches in cloned sequence of 
FJ194940.1 gene were found for the Human Endogenous Retrovirus Database HERVd, 
especially with the family of HERVL66. RT-PCR analysis with sets of primers designed for 
different exons and junctions of exons, showed alternative splicing of mRNA FJ194940.1 in 
different tumors. It leads to production of different FJ194940.1 isoforms that are expressed 
with differential prevalence in colon cancer cases. Established nucleotide sequence of 
FJ194940.1 gene opens the possibility for further studies with the use of labeled probes or 
polyclonal / monoclonal antibodies raised against recombinant proteins and such 
investigations are in progress.   
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1. Introduction 
Oxygen is essential for the survival of all living beings. A balanced oxygen environment is 
required since both lower and higher than the required oxygen levels can be detrimental to 
the cells (Figure 1). The oxygen state of a tissue results from the relative contributions of 
oxygen consumption and delivery. Different organs in the body exist under different 
oxygen environments, depending on the location and function of the cells in an organ. Most 
healthy organs reside in 3-6% oxygen [1] while conditions lower than 3% oxygen are 
described as hypoxia. Cells also survive in hypoxic environments during normal 
development [2]. However, hypoxia is mostly detrimental to the cells by disrupting the 
oxygen homeostasis. 
Cancer cells are capable of surviving under hypoxic conditions by inducing the expression 
of metabolic enzymes required for anaerobic metabolism. To fulfill their oxygen and 
nutritional requirements, cancer cells can also induce the formation of blood vessels by a 
process called angiogenesis. A transcription factor called hypoxia inducible factor-1 (HIF-1) 
is responsible for induction of specific gene expression by binding to hypoxic response 
elements (HRE) present in the promoters of these target genes, which are essential for cells 
to survive under a low oxygen environment, as reviewed recently in [3]. When hypoxic 
tumor cells are reoxygenated due to angiogenesis, oxidative stress may occur. However, 
angiogenesis in tumors is aberrant due to sparse arteriolar supply [4], low vascular density 
[5], and inefficient orientation of microvessels [6]. This creates a scenario where cancer cells 
are in flux, where they cycle between hypoxia and the reoxygenated state. There are two 
dominant timescales that contribute to the cycling kinetics. One is of a faster frequency with 
a few cycles per hour and primarily arises from fluctuations in red blood cell flux [7]. The 
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slower timescale varies from hours to days and is due to vascular remodeling [8]. This 
makes angiogenesis irregular with respect to both space and time, thereby leading to an 
unstable cancer environment that oscillates between low and high oxygen conditions. This 
cycling phenomenon is termed intermittent hypoxia or cycling hypoxia [9]. The involvement 
of reoxygenation phases in intermittent hypoxia suggests the possibility that redox 
enzymes, such as thioredoxin, may be upregulated in addition to the hypoxic enzymes.  
 
Figure 1. Oxygen homeostasis. Low cellular oxygen results in hypoxic stress causing cells to upregulate 
pathways involved in increasing the oxygen supply. On the other hand, higher oxygen levels result in 
oxidative stress and many antioxidants are induced in response, in order to reduce the available oxygen 
and prevent subsequent cellular damage.  
2. The thioredoxin system 
Cellular oxygen status is a key regulator of several important biological functions. To 
maintain the oxygen homeostasis, cells utilize antioxidant systems. An important 
antioxidant system that is present in all species and is conserved through evolution is the 
thioredoxin system. It comprises thioredoxin and thioredoxin reductase and catalyses 
oxidoreductase reactions through a dithiol-disulfide exchange mechanism [10]. Thioredoxin 
is a small 12kDa protein containing an active site motif of Cys-Gly-Pro-Cys. Reduced 
thioredoxin catalyses the reduction of disulphide bonds in other oxidised proteins and in 
the process itself becomes oxidised such that a disulphide bond forms between the two 
cysteine residues in its active site. Thioredoxin is then restored to a reduced state by 
thioredoxin reductase with the use of NADPH [10]. 
2.1. Subcellular localisation and functions of thioredoxin 
Thioredoxin is found in the cytoplasm, in the nucleus and also in the extracellular 
environment and it has distinct functions in each location (Figure 2). The key function of the 
thioredoxin system is to maintain the redox balance of cells by either directly scavenging 
highly unstable and reactive molecules known as reactive oxygen species (ROS) [11] or by 
regulating the activity of several other important enzymes, such as peroxiredoxins [12] and 
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methionine sulfoxide reductase (MSR) [13] that also maintain the cellular oxygen balance. 
Peroxiredoxins are a family of small (22-27 kDa) peroxidases comprised of 6 isoforms. They 
use their -SH groups as reducing equivalents and act to reduce peroxides such as H2O2, 
organic hydroperoxides and peroxynitrite [12]. The oxidised form of peroxiredoxins can 
then be recycled back to their active reduced form through the action of an electron donor, 
which for peroxiredoxins 1-5 is thioredoxin. The MSR family consists of MSRA and MSRB 
antioxidant proteins and provides an indirect defense against ROS. Methionine residues in 
several proteins become oxidised by ROS to Met-S-O and Met-R-O, epimers of methionine 
sulfoxide (Met-O). This can render the proteins non-functional. MSRA and MSRB can 
restore the functionality of proteins by reducing the Met-S-O and Met-R-O bound proteins 
respectively [14]. During this process the MSR proteins become oxidised, but are reduced to 
their active form by thioredoxin. Thioredoxin also directly interacts with the apoptotic 
pathway by binding to apoptosis signal-regulating kinase-1 (ASK-1), a member of the 
MAPKKK family. The reduced form of thioredoxin binds to ASK-1 but in the presence of 
ROS, thioredoxin becomes oxidised and dissociates. This allows the free ASK-1 to promote 
apoptosis [15]. 
 
Figure 2. Localisation of thioredoxin with some of its functions and regulatory pathways. 
In the nucleus, thioredoxin is responsible for regulating the activity of several transcription 
factors. Nuclear factor-κB (NF-κB) is a transcription factor involved in the regulation of 
apoptosis and is activated in response to ROS [16]. Under normal conditions, NF-κB is 
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inhibited by I-κβ, which keeps NF-κB sequestered in the cytosol. In response to oxidative 
stress, I-κβ is degraded and releases NF-κβ, which is translocated to the nucleus. In the 
nucleus, thioredoxin directly reduces Cys62 in the p50 subunit of NF-κB, which allows NF-
κB to bind to the specific recognition sequence in the promoter of its target genes, such as 
those involved in cell survival, to induce their expression [16]. Thus, thioredoxin contributes 
to the upregulation of anti-apoptotic proteins. Thioredoxin can also regulate transcription 
factors via indirect mechanisms through redox factor-1 (Ref-1), which is an intermediate 
protein that reduces several other transcription factors to enhance their binding to the 
promoters of their target genes [17]. Activator protein-1 (AP-1) is a heterodimeric complex 
of Fos and Jun proteins that binds to the DNA regulatory element known as the AP-1 
binding site [18]. AP-1 mediates growth of cells in response to external stimuli. Thioredoxin 
acts on Ref-1, which in turn activates AP-1 by reducing the highly conserved cysteine 
residues in the DNA-binding domains of Fos (Cys154) and Jun (Cys272) [17]. Therefore, 
thioredoxin is also involved in cell growth. Furthermore, under hypoxic conditions, 
thioredoxin activates HIF-1 through Ref-1. 
Thioredoxin is also secreted by a variety of normal and neoplastic cells through an as yet 
unknown pathway [19]. Secreted thioredoxin has been implicated in immune responses [20, 
21] and in cell survival mechanisms [22, 23]. Extracellular thioredoxin has been suggested to 
have chemotactic activity and to act as chemo-attractant for neutrophils, monocytes and T-
cells [24]. Extracellular thioredoxin has also been associated with cancer cell metastasis [25] 
and the promotion of a matrix metalloproteinase-9 (MMP-9) dependent invasive phenotype 
in malignant breast cancer cells [26]. 
2.2. The thioredoxin system and cancer 
High levels of thioredoxin have been observed in many cancer cells and tumors in response 
to the elevated levels of oxidative stress these cells are considered to experience. High levels 
of both thioredoxin and thioredoxin reductase have been observed in the most metastatic 
tumors [27]. Using prostate cancer cell lines, Chaiswing and colleagues showed that the 
more invasive cell line displayed a more reduced cellular state [28]. In addition, when two 
human lung carcinoma cell lines expressing either high or low thioredoxin levels were 
injected into immuno-deficient mice, the high thioredoxin expressing cell lines resulted in 
more aggressive tumors being formed [29]. These studies suggest that thioredoxin plays a 
critical role in promoting tumor progression. 
While the specific roles that thioredoxin has in cancer metastasis are yet to be fully 
identified, it is known to have a role in regulating MMP function. MMPs are involved with 
extracellular matrix (ECM) degradation, an important aspect of metastasis [30]. MMP 
activity is regulated by tissue inhibitor of matrix metalloproteinases (TIMPs) [31]. In normal 
cells, MMP levels are maintained by TIMPs and ECM degradation is inhibited. In tumor 
cells, the MMP/TIMP balance is disturbed, leading to ECM degradation and subsequent 
tumor invasion. Addition of extracellular thioredoxin was shown to preferentially inhibit 
TIMPs, leading to an increase in overall MMP activity and thus, stimulating neuroblastoma 
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cell invasion [25]. Recently, it was shown that over-expression of thioredoxin in MDA-MB-
231 breast cancer cells stimulated MMP-9 expression by upregulating NF-κB, Sp1 and AP-1 
activity and enhancing binding of these transcription factors to the MMP-9 gene promoter. 
Transfection of a construct expressing a dominant negative redox inactive thioredoxin 
protein inhibited MMP-9 promoter activity and subsequent NF-κB, SP1 and AP-1 binding 
[26]. 
2.3. Induction of the thioredoxin system by oxidative stress 
The induction of thioredoxin expression during oxidative stress in both normal and cancer 
cells has been well documented and occurs primarily through an antioxidant response 
element (ARE) in the thioredoxin gene promoter. ARE elements are short cis-acting 
elements found in the promoter regions of many genes encoding antioxidant enzymes and 
they regulate gene expression during oxidative stress [32]. A redox-sensitive transcription 
factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a critical role in mediating the 
antioxidant gene expression via the ARE element [33]. Nrf2 is ubiquitously expressed in 
most tissues and is continuously degraded in the cytosol under normal oxygen conditions 
via its inhibitor “kelch-like erythroid cell-derived protein-1” (Keap1) [34]. Keap1 contains 
several cysteine residues that act as redox sensors. Upon changes in the cellular oxygen 
environment, these cysteine residues are oxidised [35]. As a result, Keap1 undergoes a 
conformational change and releases Nrf2, which is translocated into the nucleus [32]. In the 
nucleus, Nrf2 forms a heterodimer with small maf proteins and binds to the ARE of the 
target antioxidant genes [36], including thioredoxin [37] and thioredoxin reductase [38] 
(Figure 3). 
 
Figure 3. Antioxidant gene expression via the ARE/Nrf2 pathway. 
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cell invasion [25]. Recently, it was shown that over-expression of thioredoxin in MDA-MB-
231 breast cancer cells stimulated MMP-9 expression by upregulating NF-κB, Sp1 and AP-1 
activity and enhancing binding of these transcription factors to the MMP-9 gene promoter. 
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[26]. 
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conformational change and releases Nrf2, which is translocated into the nucleus [32]. In the 
nucleus, Nrf2 forms a heterodimer with small maf proteins and binds to the ARE of the 
target antioxidant genes [36], including thioredoxin [37] and thioredoxin reductase [38] 
(Figure 3). 
 
Figure 3. Antioxidant gene expression via the ARE/Nrf2 pathway. 
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3. The HIF-1 signaling pathway 
Hypoxia-inducible factor-1 (HIF-1) is an important transcription factor that regulates the 
expression of several vital genes in response to oxygen deficient conditions [3]. These 
include genes encoding metabolic enzymes to allow growth under hypoxia and proteins 
that assist hypoxic tissues to re-establish oxygen supply. Of particular relevance to tumors, 
HIF-1 induces the expression of vascular endothelial growth factor (VEGF), which is 
required for angiogenesis. HIF-1 transcription factor is a complex of two subunits: aryl 
hydrocarbon receptor nuclear translocator (ARNT), also known as HIF-1β, which is 
constitutively expressed in all cells, and HIF-α, which is stabilised under hypoxia. Normally, 
HIF-α is synthesized and continuously degraded in the cytosol, but in response to a low 
oxygen environment it starts accumulating rapidly [39]. HIF-α is then translocated into the 
nucleus, where it dimerises with HIF-1β to form the HIF-1 complex, which then binds to the 
hypoxia responsive element (HRE) in the promoters of target genes to activate their 
expression [3] (Figure 4). 
 
Figure 4. Regulation of the HIF-1 signaling pathway and the expression of its target genes. 
3.1. HIF-1 proteins and hypoxic regulation 
Both HIF-1 subunits belong to the basic helix-loop-helix (bHLH)/Per-ARNT-Sim (PAS) 
family of transcription factors. The bHLH domain aids in DNA-binding while the PAS 
domain mediates protein-protein interaction. Both domains also act as an interface for 
dimerisation of the α and β subunits [40]. There are three identified HIF-α subunits [3] and 
one β subunit, which is alternatively spliced [41]. HIF-1α is the most characterised form and 
will be discussed in this chapter. HIF-1α and HIF-2α have structurally similar DNA binding 
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and dimerisation domains, but they differ in their transactivation domains. This may 
explain why a genome wide screen detected both HIF-1α and HIF-2α bound to the same 
HRE consensus sites, but without initiating the same transcriptional response [42]. 
Moreover, HIF-2α is only expressed in certain tissues [43], while HIF-1α is ubiquitously 
expressed. Overall their biological actions in response to hypoxia are distinct, as reviewed 
by Loboda and colleagues [44]. For example, HIF-1α, but not HIF-2α regulates the 
transcription of genes encoding enzymes involved in glycolysis [45], while HIF-2α has been 
associated with adaptation to high altitude exposure [46]. Furthermore, Bracken and co-
workers showed in PC12 rat cells that HIF-1α required a shorter duration (4h) under 
hypoxia to be stabilized, whereas a longer hypoxic exposure (16h) was required for HIF-2α 
stabilization. However, this difference was cell-line specific [47]. In human colon cancer, 
advanced tumors displayed strong HIF-1α staining and weak HIF-2α staining, while in early 
stage tumors, strong HIF-2α and weak HIF-1α staining was observed. This implies that HIF-
1α and HIF-2α have different roles in colon cancer [48]. In contrast, HIF-3α has inhibitory 
function since it lacks the transactivation domain, but binds to HIF-1α and prevents it from 
activating transcription. Therefore, HIF-3α is also called ‘inhibitory PAS domain’ (IPAS) and 
arises as an alternatively spliced product of the HIF-1α gene [49]. 
There are two transactivation domains in HIF-1α: the amino-terminal transactivation 
domain (NAD) and the carboxy-terminal transactivation domain (CAD) [50, 51]. These 
domains are involved in the transcriptional activation of HIF-1α under hypoxia. The NAD 
overlaps the oxygen-dependent degradation domain (ODD), linking the transcriptional 
activity of HIF-1 with the stabilisation of the protein [50]. On the other hand, the 
transcriptional activity of the CAD is associated with the binding of transcriptional co-
activators, including CREB-binding protein (CBP)/p300 [52]. The recruitment of the co-
activators is redox-regulated and requires Ref-1, which reduces the cysteine residue at 
position 800 of HIF-1α within the CAD region [53]. The co-activators are then able to bind 
HIF-1 and subsequently initiate transcription. It should be noted that Ref-1 is an 
intermediate protein that is regulated by thioredoxin. 
3.2. Regulation of HIF-1 under normoxia 
Although the HIF-1α proteins are activated in response to hypoxia, they do not sense the 
changes in the oxygen environment themselves. Sensors to such changes have been 
identified as oxygen-dependent hydroxylases. The hydroxylases responsible for modifying 
HIF-1α are the ‘prolyl hydroxylase domain-containing proteins’ (PHDs) and an asparaginyl 
hydroxylase called ‘Factor Inhibiting HIF-1’ (FIH-1) [54]. These hydroxylases continuously 
modify HIF-1α in presence of oxygen. When there is a negative change in oxygen 
availability, PHDs and FIH-1 can no longer hydroxylate HIF-1α, which is stabilised and 
translocated to the nucleus [55] (Figure 5). 
Under higher oxygen conditions, PHDs modify distinct proline residues (Pro 402 and Pro 
564) in the ODD domain of HIF-1α [56], leading to the recruitment of von Hippel-Lindau 
(VHL) proteins [57] and subsequent degradation of HIF-1α [58]. The PHD family has three 
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and dimerisation domains, but they differ in their transactivation domains. This may 
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associated with adaptation to high altitude exposure [46]. Furthermore, Bracken and co-
workers showed in PC12 rat cells that HIF-1α required a shorter duration (4h) under 
hypoxia to be stabilized, whereas a longer hypoxic exposure (16h) was required for HIF-2α 
stabilization. However, this difference was cell-line specific [47]. In human colon cancer, 
advanced tumors displayed strong HIF-1α staining and weak HIF-2α staining, while in early 
stage tumors, strong HIF-2α and weak HIF-1α staining was observed. This implies that HIF-
1α and HIF-2α have different roles in colon cancer [48]. In contrast, HIF-3α has inhibitory 
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activity of HIF-1 with the stabilisation of the protein [50]. On the other hand, the 
transcriptional activity of the CAD is associated with the binding of transcriptional co-
activators, including CREB-binding protein (CBP)/p300 [52]. The recruitment of the co-
activators is redox-regulated and requires Ref-1, which reduces the cysteine residue at 
position 800 of HIF-1α within the CAD region [53]. The co-activators are then able to bind 
HIF-1 and subsequently initiate transcription. It should be noted that Ref-1 is an 
intermediate protein that is regulated by thioredoxin. 
3.2. Regulation of HIF-1 under normoxia 
Although the HIF-1α proteins are activated in response to hypoxia, they do not sense the 
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identified as oxygen-dependent hydroxylases. The hydroxylases responsible for modifying 
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Under higher oxygen conditions, PHDs modify distinct proline residues (Pro 402 and Pro 
564) in the ODD domain of HIF-1α [56], leading to the recruitment of von Hippel-Lindau 
(VHL) proteins [57] and subsequent degradation of HIF-1α [58]. The PHD family has three 
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members: PHD1, PHD2 and PHD3, with PHD2 being the most abundant and highly active 
towards HIF-1α [59]. PHDs require only a short stretch of HIF-1α amino acids (as short as 20 
residues) for the selective recognition of proline hydroxylation sites and subsequent VHL-
binding. These sites reside within an LXXLAP motif, which is highly conserved between the 
HIF-α isoforms as well as across species [58]. The hydroxylation enables the VHL protein to 
bind HIF-1α, which initiates degradation via the ubiquitination pathway [58, 60]. VHL-
deficient cells have the HIF-1α subunit constitutively stabilised and thus, HIF-1 is constantly 
activated in these cells [57]. 
 
Figure 5. Regulation of HIF-1α during normoxia and hypoxia. 
An additional hydroxylation event in the CAD domain ensures that any HIF-1α that escapes 
degradation is rendered inactive. This process involves the hydroxylation of an asparagine 
residue instead of a proline and suppresses the recruitment of CBP/p300 co-activators [54]. 
This asparaginyl hydroxylase is the FIH-1, and uses both HIF-1α and HIF-2α as substrates. 
In HIF-1α, FIH-1 hydroxylates an asparagine residue at position 803. FIH-1 is an Fe(II)-
dependent enzyme and plays the role of a second oxygen sensor within the hypoxic 
response pathway [61]. 
Thus, under normoxia, prolyl and asparaginyl hydroxylases prevent the activation of HIF-
1α by acting on the NAD and CAD domains respectively. However, when oxygen levels 
decrease, these hydroxylases become inactive, HIF-1α proteins are stabilised and 
translocated to the nucleus where they dimerise with HIF-1β. The reduction of a key 
cysteine residue in the CAD by Ref-1, through the action of thioredoxin, results in the 
recruitment of transcriptional co-activators and subsequent expression of the target genes. 
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3.3. Regulation of the HIF-1 system by ROS 
While HIF-1 is stabilised and active under conditions of low oxygen, paradoxically ROS can 
also stabilise HIF-1. Under normoxia, the addition of H2O2 caused HIF-1α stabilisation and 
enhanced expression from HRE-reporter constructs [62]. In addition, Hep3B 0 cells, which 
do not have mitochondrial electron transport function, can exhibit HRE-luciferase reporter 
activity under normoxia upon addition of H2O2 [62]. The molecular basis for ROS stabilising 
HIF-1 was shown by exposing murine breast tumor cells to nitric oxide (NO). Addition of 
NO caused nitrosylation of a specific cysteine residue in the ODD domain of HIF-1α under 
normoxia. The VHL protein was therefore unable to bind to HIF-1α, thereby preventing its 
degradation [63]. This represents a control mechanism that bypasses the function of the 
PHD enzymes under normoxia, since the nitrosylation did not prevent or change the level of 
proline hydroxylation detected in the NAD domain. 
ROS is also believed to play a role in the HIF-1 signaling pathway during hypoxia. Cells 
with non-functional mitochondria, and therefore, reduced ROS levels, were unable to 
stabilise HIF-1α in response to hypoxia [62, 64]. When H2O2 was inhibited by catalase over-
expression in human 293 cells under hypoxia, there was reduced HRE-luciferase reporter 
activity, suggesting lower HIF-1α activity, which was restored by the addition of H2O2 [62]. 
These observations suggest that the presence of H2O2 in the cytosol is necessary for HIF-1α 
stabilisation under hypoxia. One possible role of ROS may be to inhibit the PHD enzymes. 
Addition of 10 µM H2O2 showed more than 50% inhibition of PHD enzyme function in vitro 
but did not increase HIF-1α transcriptional activity in Hep3B cells [65]. This is implies that 
HIF-1α activation by ROS can occur through multiple pathways including both stabilisation 
and recruitment of co-activators.   
While ROS appears to exert some regulatory function on HIF-1, there is still debate as to 
whether ROS levels are increased [62, 66, 67] or decreased [68-70] during hypoxia. 
Contradictory results may occur due to differences in cell type, mode of generating hypoxia, 
oxygen levels and assays used to measure ROS. Work from our laboratory demonstrated 
that MDA-MB-231 breast cancer cells grown under hypoxia have reduced ROS levels [68]. 
However, we found that how the cells were processed was extremely important. If cells 
were processed under normoxic conditions following the hypoxic growth then increased 
ROS levels were observed. When cells were maintained under hypoxia throughout the 
processing steps, then a decrease was evident [68]. This indicates that cells grown in hypoxia 
must be maintained in hypoxia during processing to avoid introduction of an inadvertent 
reoxygenation step (however brief), thus, mimicking the intermittent hypoxia observed in 
tumors. 
3.4. Redox regulation of the HIF-1 system 
The activity of the HIF-1 system is regulated by the thioredoxin redox system, via Ref-1. 
Thioredoxin provides the reducing potential for Ref-1 to reduce a cysteine residue in the 
CAD domain of HIF-1α that enhances the ability of HIF-1 to recruit co-activators [53]. 
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Consequently, cell lines engineered to over-express thioredoxin also displayed increased 
HIF-1α levels, enhanced HIF-1 DNA binding and increased activation of HIF-1 regulated 
gene promoters. This results in increased levels of hypoxia regulated proteins such as VEGF 
[71, 72] and cyclooxygenase-2 (COX-2) [73]. In contrast, when cells were transfected with the 
dominant negative redox inactive thioredoxin protein, VEGF and COX-2 levels were 
decreased. Other small molecule inhibitors of the thioredoxin system, such as quinols, also 
led to down regulation of HIF-1 activity [72] and subsequently to a decrease in VEGF and 
inducible nitric oxide synthase (iNOS) expression in MCF-7 breast cancer cells [74]. 
A recent study showed that thioredoxin reductase levels were decreased during hypoxia 
and as a consequence higher ROS levels were observed [75]. They concluded that hypoxia 
does not increase mitochondrial ROS production, but that lower thioredoxin reductase 
levels are responsible for higher ROS levels. Since HIF-1 is also regulated by ROS, this study 
demonstrated that the thioredoxin redox system could modulate HIF-1 signalling by 
indirectly affecting ROS levels, in addition to the direct interaction described above.  
4. Redox and hypoxic systems: the intermittent hypoxia link 
The tumor environment is in flux between hypoxia and reoxygenation. Hypoxia induces the 
formation of new blood vessels, which are often poorly formed, causing an inconsistent 
oxygen supply [7]. Therefore, cells can experience a cycling between hypoxia and 
reoxygenation. Hypoxic pathways are induced during periods of low oxygen while the 
reoxygenation results in induction of antioxidant proteins, including the redox enzymes. 
Thus, the interplay between the two systems is important to study in tumors. Interestingly, 
the cycling between hypoxia and reoxygenation enhances HIF-1 activity. Many of the 
studies undertaken to assess the role of HIF-1 and redox signaling in cancer are performed 
using cancer cell lines. Therefore, each cancer cell line should be evaluated for its suitability 
as a model system for intermittent hypoxia. 
4.1. Use of an in vitro model system for intermittent hypoxia 
The MDA-MB-231 breast cancer cell line is often used as an in vitro model system for 
metastatic cancer. However, most researchers grow these cells under what is usually 
regarded as normoxia, that is 20% oxygen, despite this not being physiologically relevant. 
We wanted to assess the suitability of this cell line for hypoxic cycling studies. Our first aim 
was to determine the most appropriate level of oxygen to use to ensure a strong hypoxic 
response is generated. We assayed the lactate dehydrogenase (LDH) activity present in 
MDA-MB-231 cells grown in either 1% oxygen or 0.1% oxygen. LDH is a glycolytic enzyme, 
which is upregulated in response to hypoxia through the binding of HIF-1 to an HRE 
element in its gene’s promoter [76]. Cells were cultured in 5% CO2 with either 1% oxygen or 
0.1% oxygen for 24 hours in a hypoxic C-chamber (Biospherix, New York, USA), and then 
lysed within a C-shuttle glovebox (Biospherix) using a buffer comprised of 150 mM NaCl, 50 
mM Tris-HCl pH 8.0, 0.5 % (v/v) Nonidet P-40, 0.5 mM EDTA, 2 mM PMSF, 1 l/ml 
proteinase inhibitor cocktail VI (AG-Scientific, California, USA). Protein estimation was 
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performed using the DC protein assay kit (BioRad, NSW, Australia) and equal amounts of 
cell lysate were used to measure LDH activity. The assay buffer contained 50 mM Tris-HCl 
pH 7.5, 1 mg/ml NADH, 1 mg/ml pyruvate and the LDH activity was measured at 340 nm 
using a Spectromax Plate reader. The results are presented in Figure 6. The data is expressed 
as a change in percentage of LDH activity relative to normoxic treated cells, with normoxia 
represented as 100%. While cells grown at both 1% and 0.1% oxygen levels showed an 
increase in LDH activity, only cells grown in 0.1% oxygen had a statistical significance 
compared to cells grown under normoxia. 
 
Figure 6. Relative LDH activities in MDA-MB-231 cells after 24 hours of 1% O2 or 0.1 % O2 growth. 
Normoxia and 0.1% hypoxia treated cells showed significant difference using a one-way ANOVA 
employing Tukey’s Post-Hoc test, as indicated by * (p < 0.05). Data presented as mean ± SEM from three 
independent experiments conducted in triplicate. 
We then wanted to assess the morphology and viability of the MDA-MB-231 cells grown 
under various oxygen growth conditions. We selected 0.1% oxygen as the hypoxic condition 
to culture these cells in, to ensure a strong hypoxic response. The MDA-MB-231 cells were 
grown under prolonged hypoxia (16 hours) followed by different lengths of reoxygenation 
by transferring cells to 20% oxygen (referred to as normoxia). To assess the effect of cycling 
hypoxia, cells were also subjected to 4 pre-conditioning (PC) cycles (comprising 10 minutes 
hypoxia and 20 minutes reoxygenation) prior to the hypoxic growth phase. These different 
conditions are illustrated in Figure 7. The cycling between hypoxia and normoxia was 
repeated four times within a 2 hour period before cells were transferred into prolonged 
hypoxia for 16 hours. Since 20% oxygen is much higher than 0.1% oxygen switching to 
normoxia results in a reoxygenation step. After cells were grown in 0.1% hypoxia for 16 
hours they were either processed using the hypoxic C-Shuttle glovebox to maintain hypoxic 
conditions or re-oxygenated by being transferred to normoxic conditions for 2, 4 or 6 hours. 
These cells were processed under normoxia. 
To confirm that cells were viable under these oxygen growth conditions, a fluorescence 
activated cell sorting (FACS) based assay was used. Cells were harvested and detached 
using cell dissociation buffer (Life Technologies), washed in phosphate buffered saline (PBS) 
pH 7.4, and then resuspended at a concentration of 1×106 cells/ml containing an appropriate 
dilution of 7-aminoactinomycin D. The cells were then stored on ice until they were 
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using cancer cell lines. Therefore, each cancer cell line should be evaluated for its suitability 
as a model system for intermittent hypoxia. 
4.1. Use of an in vitro model system for intermittent hypoxia 
The MDA-MB-231 breast cancer cell line is often used as an in vitro model system for 
metastatic cancer. However, most researchers grow these cells under what is usually 
regarded as normoxia, that is 20% oxygen, despite this not being physiologically relevant. 
We wanted to assess the suitability of this cell line for hypoxic cycling studies. Our first aim 
was to determine the most appropriate level of oxygen to use to ensure a strong hypoxic 
response is generated. We assayed the lactate dehydrogenase (LDH) activity present in 
MDA-MB-231 cells grown in either 1% oxygen or 0.1% oxygen. LDH is a glycolytic enzyme, 
which is upregulated in response to hypoxia through the binding of HIF-1 to an HRE 
element in its gene’s promoter [76]. Cells were cultured in 5% CO2 with either 1% oxygen or 
0.1% oxygen for 24 hours in a hypoxic C-chamber (Biospherix, New York, USA), and then 
lysed within a C-shuttle glovebox (Biospherix) using a buffer comprised of 150 mM NaCl, 50 
mM Tris-HCl pH 8.0, 0.5 % (v/v) Nonidet P-40, 0.5 mM EDTA, 2 mM PMSF, 1 l/ml 
proteinase inhibitor cocktail VI (AG-Scientific, California, USA). Protein estimation was 
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performed using the DC protein assay kit (BioRad, NSW, Australia) and equal amounts of 
cell lysate were used to measure LDH activity. The assay buffer contained 50 mM Tris-HCl 
pH 7.5, 1 mg/ml NADH, 1 mg/ml pyruvate and the LDH activity was measured at 340 nm 
using a Spectromax Plate reader. The results are presented in Figure 6. The data is expressed 
as a change in percentage of LDH activity relative to normoxic treated cells, with normoxia 
represented as 100%. While cells grown at both 1% and 0.1% oxygen levels showed an 
increase in LDH activity, only cells grown in 0.1% oxygen had a statistical significance 
compared to cells grown under normoxia. 
 
Figure 6. Relative LDH activities in MDA-MB-231 cells after 24 hours of 1% O2 or 0.1 % O2 growth. 
Normoxia and 0.1% hypoxia treated cells showed significant difference using a one-way ANOVA 
employing Tukey’s Post-Hoc test, as indicated by * (p < 0.05). Data presented as mean ± SEM from three 
independent experiments conducted in triplicate. 
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hypoxia, cells were also subjected to 4 pre-conditioning (PC) cycles (comprising 10 minutes 
hypoxia and 20 minutes reoxygenation) prior to the hypoxic growth phase. These different 
conditions are illustrated in Figure 7. The cycling between hypoxia and normoxia was 
repeated four times within a 2 hour period before cells were transferred into prolonged 
hypoxia for 16 hours. Since 20% oxygen is much higher than 0.1% oxygen switching to 
normoxia results in a reoxygenation step. After cells were grown in 0.1% hypoxia for 16 
hours they were either processed using the hypoxic C-Shuttle glovebox to maintain hypoxic 
conditions or re-oxygenated by being transferred to normoxic conditions for 2, 4 or 6 hours. 
These cells were processed under normoxia. 
To confirm that cells were viable under these oxygen growth conditions, a fluorescence 
activated cell sorting (FACS) based assay was used. Cells were harvested and detached 
using cell dissociation buffer (Life Technologies), washed in phosphate buffered saline (PBS) 
pH 7.4, and then resuspended at a concentration of 1×106 cells/ml containing an appropriate 




Figure 7. Oxygen growth conditions used to grow MDA-MB-231 cells. Schematic representation 
outlining the different combinations of hypoxia and reoxygenation and their respective length of 
exposure used to grow MDA-MB-231 cells. Red indicates growth under 20% oxygen. Blue indicates 
growth in 0.1% oxygen. N: normoxia (20% oxygen); R: reoxygenation; H: hypoxia; PC: pre-conditioning.  
 
Figure 8. Viability of MDA-MB-231 cells in response to different oxygen growth conditions. Non-PC 
treated samples and PC treated samples were analysed separately using a one-way ANOVA employing 
Tukey’s Post-Hoc test. A statistical difference was observed compared to normoxia, as indicated by * (P 
< 0.01). A statistical difference was observed for all reoxygenation samples compared to hypoxic cells, as 
indicated by ∆ (p < 0.01). Data is presented as mean ± SEM from at least two independent experiments. 
analysed for viability using the BD FACSAria flow cytometer (BD Biosciences). The results 
are shown in Figure 8. Upon growth in hypoxia cellular viability decreases, while after 
reoxygenation cell viability returns to levels consistent with those of cells grown in 
normoxia. A decrease in cell viability following hypoxic growth has also been observed by 
other researchers using different cell lines [77, 78]. 
The morphology of the cells grown in each oxygen growth condition was assessed by 
microscopy. Cells were also grown in media containing 100μM H2O2 for 30 minutes as a 
control for oxidative stressed cells. After exposing MDA-MB-231 cells to different oxygen 
growth conditions, cell morphology was examined under an Olympus CK30 microscope 
(Olympus Co., Japan) at 100X magnification. Experiments were performed multiple times 
with representative images shown in Figure 9. Cells exposed to 100μM H2O2 for 30 minutes  
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Figure 9. Morphology of MDA-MB-231 cells after different oxygen growth treatments. A): Normoxia 
treated cells, B): 100μM H2O2 treated cells, C): 0.1% hypoxia treated cells, D): PC-H treated cells, E): H/R 
2h treated cells, F): PC-H/R 2h treated cells, G): H/R 4h treated cells, H): PC-H/R 4h treated cells, I): H/R 
6h treated cells, J): PC-H/R 6h treated cells. Images were taken using an Olympus CK30 microscope at 
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(Figure 9B) exhibited altered cell morphology compared to normoxia treated cells (Figure 
9A). These cells appeared to be less elongated and more rounded in shape. The cells 
exposed to hypoxia (Figure 9C) or PC-hypoxia (Figure 9D) showed a similar morphology to 
H2O2 treated cells. When hypoxia or PC-hypoxia treated cells were exposed to a longer 
period of reoxygenation (Figure 9I and J) their morphology becomes very similar to that of 
the normoxia treated cells. This trend suggests that the cells become stressed when exposed 
to hypoxia but recover during the reoxygenation phase. No difference was observed in 
overall morphology between hypoxia (Figure 9C) or PC-hypoxia (Figure 9D) treated cells or 
their respective reoxygenation exposures (Figure 9E, G and I compared to Figure 9F, H and 
J, respectively). 
Since various methodologies are used to generate hypoxia it is important to establish the 
appropriate conditions for each cell line. MDA-MB-231 cells grown at 0.1% oxygen elicited a 
hypoxic response, whereas 1% oxygen did not induce a significant hypoxic response. A 
decrease in cellular viability in response to hypoxia was observed compared to normoxia, 
but returned to normal levels during reoxygenation. Cells also exhibited a more rounded 
morphology during hypoxia, consistent with a stress response. The recovery of the cells 
during reoxygenation suggests that signaling pathways are involved that enable cells to 
adapt to these changing oxygen conditions, with the most likely candidates being the HIF-1 
and redox-dependent pathways. 
4.2. Expression of the HIF-1 system under intermittent hypoxia 
Several studies have implicated an upregulation in levels of the HIF-1 transcription factor 
under intermittent hypoxia. This increase supersedes the HIF-1 levels found in acute 
hypoxia [79, 80]. Yuan and co-workers found this to be Ca+2 dependent [80]. They 
demonstrated the involvement of calcium-calmodium dependent kinase II (CaMK II) under 
intermittent hypoxia. CaMK II phosphorylates p300, a co-activator required for the 
transcriptional activity of HIF-1, thereby increasing the HIF-1 transactivation [80]. In 
contrast, under acute hypoxia, HIF-1 transcriptional activity is increased as a result of a 
decrease in the O2 dependent asparaginyl hydroxylation in the CAD region of HIF-1α, 
assisting in the recruitment of co-activators [54]. 
Intermittent hypoxia has been linked to increased tumor invasion and resistance against 
radiotherapy [81, 82] and to enhanced metastasis in rodent lungs [83]. Liu and colleagues 
demonstrated that intermittent hypoxia treated H446 lung cancer cells had a greater 
metastatic ability and radio-resistance. They found HIF-1α was involved in both processes 
[84]. Intermittent hypoxia exposed endothelial cells also showed enhanced migration and 
exhibited an increased resistance against irradiation as compared to their counterparts 
grown in normoxia or acute hypoxia. This effect was also mediated by HIF-1α since siRNA 
targeting HIF-1α abolished the radiation resistance [82]. Therefore, HIF-1α may be expected 
to have a role in tumor invasion observed under intermittent hypoxia. 
Differences in expression of HIF-1α and HIF-2α under acute and intermittent hypoxia have 
been shown in sleep-disordered breathing. While intermittent hypoxia caused an 
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upregulation in HIF-1α levels, the HIF-2α levels were down-regulated in intermittent 
hypoxia treated rat PC12 cells and also in in vivo rat models. In contrast, acute hypoxia 
upregulated both HIF-1α and HIF-2α [85]. It was proposed that down-regulation of HIF-2α 
contributes to oxidative stress, at least in part via transcriptional down-regulation of a HIF-2 
target gene, an antioxidant called superoxide dismutase (SOD). Intermittent hypoxia also 
increased ROS by decreasing the mitochondrial complex I activity. The increase in ROS 
levels was linked to the upregulated HIF-1α levels under intermittent hypoxia [86]. 
Therefore, the differential regulation of HIF-1α and HIF-2α is believed to cause oxidative 
stress resulting from an imbalance between ROS and antioxidants [85]. Similar mechanisms 
may contribute to higher levels of ROS in cancer cells. However, as antioxidants are proteins 
that scavenge ROS, one may expect that antioxidant levels would be augmented in such a 
scenario. Interestingly, a number of studies implicate an upregulation of antioxidants in 
cancer cells cultured under intermittent hypoxia. 
4.3. Expression of redox enzymes under hypoxia and intermittent hypoxia 
Since intermittent hypoxia involves phases of reoxygenation, it is reasonable to expect that 
redox enzymes would be induced during these reoxygenation phases. The expression of 
thioredoxin during the hypoxic phase has been less clear. In hypoxic regions of tumors, 
thioredoxin expression has been reported as high [87], but intermittent hypoxia may 
contribute to this high expression. In cells cultured in vitro there has been conflicting reports 
regarding thioredoxin expression levels under hypoxia.  
Thioredoxin protein levels were increased in A549 human lung cancer cells during growth 
in 0.05% oxygen [88] and in both human endothelial progenitor cells and human umbilical 
vein endothelial cells cultured in 1% oxygen [78], as assessed by Western blotting. Our work 
[68] showed a visible increase (by Western blotting) in thioredoxin levels in MDA-MB-231 
cells cultured in 0.1% hypoxia, but this increase was not statistically significant. In addition, 
neither thioredoxin nor thioredoxin reductase promoter activity was increased under 
hypoxia [68]. Ref-1 protein levels were also not increased [68] while other studies reported 
that peroxiredoxin protein levels were not increased in A549 cells cultured in hypoxia [89]. 
A recent study showed a decrease in thioredoxin reductase protein levels under hypoxia 
[75]. Previously, it was reported that thioredoxin reductase was increased in human 
endothelial progenitor cells but not in human umbilical vein endothelial cells under hypoxia 
[78]. This conflicting data suggests that as with the variable ROS levels reported under 
hypoxia, expression of the thioredoxin system under hypoxia may depend on the specific 
cell line, oxygen levels or how samples are processed. For example, Jewell and co-workers 
observed that thioredoxin levels in the nucleus were increased after as little as 30 seconds of 
oxygen exposure following hypoxic growth [90]. Thus, in some reported cases, cells may 
have received an inadvertent reoxygenation stimulus during processing of cells after 
hypoxic growth, which was sufficient to induce antioxidant gene expression. 
Since reoxygenation stimulates the production of ROS, one might expect that high levels of 
thioredoxin would be detected in cells reoxygenated after hypoxia. However, this appears 
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9A). These cells appeared to be less elongated and more rounded in shape. The cells 
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appropriate conditions for each cell line. MDA-MB-231 cells grown at 0.1% oxygen elicited a 
hypoxic response, whereas 1% oxygen did not induce a significant hypoxic response. A 
decrease in cellular viability in response to hypoxia was observed compared to normoxia, 
but returned to normal levels during reoxygenation. Cells also exhibited a more rounded 
morphology during hypoxia, consistent with a stress response. The recovery of the cells 
during reoxygenation suggests that signaling pathways are involved that enable cells to 
adapt to these changing oxygen conditions, with the most likely candidates being the HIF-1 
and redox-dependent pathways. 
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Several studies have implicated an upregulation in levels of the HIF-1 transcription factor 
under intermittent hypoxia. This increase supersedes the HIF-1 levels found in acute 
hypoxia [79, 80]. Yuan and co-workers found this to be Ca+2 dependent [80]. They 
demonstrated the involvement of calcium-calmodium dependent kinase II (CaMK II) under 
intermittent hypoxia. CaMK II phosphorylates p300, a co-activator required for the 
transcriptional activity of HIF-1, thereby increasing the HIF-1 transactivation [80]. In 
contrast, under acute hypoxia, HIF-1 transcriptional activity is increased as a result of a 
decrease in the O2 dependent asparaginyl hydroxylation in the CAD region of HIF-1α, 
assisting in the recruitment of co-activators [54]. 
Intermittent hypoxia has been linked to increased tumor invasion and resistance against 
radiotherapy [81, 82] and to enhanced metastasis in rodent lungs [83]. Liu and colleagues 
demonstrated that intermittent hypoxia treated H446 lung cancer cells had a greater 
metastatic ability and radio-resistance. They found HIF-1α was involved in both processes 
[84]. Intermittent hypoxia exposed endothelial cells also showed enhanced migration and 
exhibited an increased resistance against irradiation as compared to their counterparts 
grown in normoxia or acute hypoxia. This effect was also mediated by HIF-1α since siRNA 
targeting HIF-1α abolished the radiation resistance [82]. Therefore, HIF-1α may be expected 
to have a role in tumor invasion observed under intermittent hypoxia. 
Differences in expression of HIF-1α and HIF-2α under acute and intermittent hypoxia have 
been shown in sleep-disordered breathing. While intermittent hypoxia caused an 
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upregulation in HIF-1α levels, the HIF-2α levels were down-regulated in intermittent 
hypoxia treated rat PC12 cells and also in in vivo rat models. In contrast, acute hypoxia 
upregulated both HIF-1α and HIF-2α [85]. It was proposed that down-regulation of HIF-2α 
contributes to oxidative stress, at least in part via transcriptional down-regulation of a HIF-2 
target gene, an antioxidant called superoxide dismutase (SOD). Intermittent hypoxia also 
increased ROS by decreasing the mitochondrial complex I activity. The increase in ROS 
levels was linked to the upregulated HIF-1α levels under intermittent hypoxia [86]. 
Therefore, the differential regulation of HIF-1α and HIF-2α is believed to cause oxidative 
stress resulting from an imbalance between ROS and antioxidants [85]. Similar mechanisms 
may contribute to higher levels of ROS in cancer cells. However, as antioxidants are proteins 
that scavenge ROS, one may expect that antioxidant levels would be augmented in such a 
scenario. Interestingly, a number of studies implicate an upregulation of antioxidants in 
cancer cells cultured under intermittent hypoxia. 
4.3. Expression of redox enzymes under hypoxia and intermittent hypoxia 
Since intermittent hypoxia involves phases of reoxygenation, it is reasonable to expect that 
redox enzymes would be induced during these reoxygenation phases. The expression of 
thioredoxin during the hypoxic phase has been less clear. In hypoxic regions of tumors, 
thioredoxin expression has been reported as high [87], but intermittent hypoxia may 
contribute to this high expression. In cells cultured in vitro there has been conflicting reports 
regarding thioredoxin expression levels under hypoxia.  
Thioredoxin protein levels were increased in A549 human lung cancer cells during growth 
in 0.05% oxygen [88] and in both human endothelial progenitor cells and human umbilical 
vein endothelial cells cultured in 1% oxygen [78], as assessed by Western blotting. Our work 
[68] showed a visible increase (by Western blotting) in thioredoxin levels in MDA-MB-231 
cells cultured in 0.1% hypoxia, but this increase was not statistically significant. In addition, 
neither thioredoxin nor thioredoxin reductase promoter activity was increased under 
hypoxia [68]. Ref-1 protein levels were also not increased [68] while other studies reported 
that peroxiredoxin protein levels were not increased in A549 cells cultured in hypoxia [89]. 
A recent study showed a decrease in thioredoxin reductase protein levels under hypoxia 
[75]. Previously, it was reported that thioredoxin reductase was increased in human 
endothelial progenitor cells but not in human umbilical vein endothelial cells under hypoxia 
[78]. This conflicting data suggests that as with the variable ROS levels reported under 
hypoxia, expression of the thioredoxin system under hypoxia may depend on the specific 
cell line, oxygen levels or how samples are processed. For example, Jewell and co-workers 
observed that thioredoxin levels in the nucleus were increased after as little as 30 seconds of 
oxygen exposure following hypoxic growth [90]. Thus, in some reported cases, cells may 
have received an inadvertent reoxygenation stimulus during processing of cells after 
hypoxic growth, which was sufficient to induce antioxidant gene expression. 
Since reoxygenation stimulates the production of ROS, one might expect that high levels of 
thioredoxin would be detected in cells reoxygenated after hypoxia. However, this appears 
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not to be the case. In our studies [68] MDA-MB-231 cells cultured in 0.1% oxygen followed 
by reoxygenation had increased thioredoxin levels as assessed visually on Western blots, but 
this was statistically non-significant when quantitated by densitometry. In addition, after 6 
hours of reoxygenation, the levels were visually decreasing. This correlates with other 
studies that reported a visible decrease in thioredoxin protein levels in A549 cells grown in 
0.2% oxygen followed by 6 hours or more of reoxygenation [91]. Their work showed that 
thioredoxin was oxidised during the reoxygenation phase [91], probably by the increased 
ROS levels [68]. After 6 hours of reoxygenation, ROS levels start to decrease and it is 
possible that the cells no longer require thioredoxin. No change in Ref-1 was observed 
during reoxygenation [68], but peroxiredoxin 1 expression was increased [89]. 
When conditions mimicking intermittent hypoxia are utilized, the involvement of 
thioredoxin is quite apparent. Malec and co-workers utilized several different schemes to 
grow A549 cells alternating between hypoxia and reoxygenation [92]. While a maximum of 
three 2-hour cycles were used for either hypoxia or reoxygenation, the schemes with the 
greatest number of cycles of hypoxia and reoxygenation resulted in the highest thioredoxin 
levels. Nrf2 was also increased under these conditions and may be responsible for the 
increased thioredoxin expression [92]. Our work [68] used a scheme that mimicked an 
ischemia/reperfusion study performed in the heart [93]. In that study, 4 short cycles of 
ischemia and reperfusion (of 10 and 20 minutes respectively) prior to longer-term growth in 
ischemia and subsequent reperfusion led to very high levels of thioredoxin. These pre-
conditioning conditions also provided the heart protection from damage otherwise caused 
by the longer-term ischemia and reperfusion. We applied these oxygen growth conditions 
(Figure 7) to cancer cells and also detected high levels of thioredoxin in cells pre-conditioned 
with short cycles of hypoxia and reoxygenation followed by a longer exposure to hypoxia 
and reoxygenation [68]. Maximum thioredoxin protein levels were obtained after 4 hours of 
reoxygenation, which was confirmed to be statistically significant. These short cycles may 
also represent what happens in tumors due to red blood cell flux [7] and may provide the 
tumor with protection against subsequent oxidative insult. Without the pre-conditioning 
cycling, thioredoxin levels were not increased by as much during reoxygenation, indicating 
that the cycling may provide an advantage to the cells. Of interest is that Ref-1 levels were 
also higher in MDA-MB-231 cells subjected to the pre-conditioning, but not in cells grown 
without this step [68]. Since Ref-1 and thioredoxin regulate HIF-1 activity, the short pulses 
of hypoxia may be responsible for their induction. We found that the promoter activity of 
both thioredoxin and thioredoxin reductase were dependent on Nrf2 in the reoxygenation 
phase, and that cells cultured with the pre-conditioning cycles did not exhibit higher 
promoter activity [68]. Therefore, the mechanism for inducing higher thioredoxin protein 
levels in cells subjected to cycling may not be at the transcriptional level. 
4.4. The Interaction of redox and hypoxic pathways under intermittent hypoxia 
Cancer cells can reside in conditions of hypoxic as well as oxidative stress. HIF-1 and Nrf2 
are two important transcription factors that play a crucial role in each of these conditions. 
While HIF-1 is important for cell survival under low oxygen conditions, Nrf2 provides 
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cytoprotection against oxidative stress by upregulating antioxidants such as thioredoxin. 
Both HIF-1 and Nrf2 are induced in cells under intermittent hypoxia. This presents a 
possible link between the oxygen- and redox-dependent regulatory pathways. As described 
in 4.2, the increase in HIF-1 levels under intermittent hypoxia supersedes the HIF-1 levels 
observed in acute hypoxia. Similarly, higher thioredoxin levels were observed under 
intermittent hypoxia in comparison to acute hypoxia [68, 92]. Higher levels of other 
antioxidants have also been observed under intermittent hypoxia. For example, Prx1 was 
upregulated in response to hypoxia/reoxygenation, through the action of Nrf2, which binds 
to the ARE in the Prx1 promoter. In cells lacking Nrf2, Prx1 expression was compromised 
[89]. ROS levels are also higher under intermittent hypoxia [68] and are involved in both 
HIF-1 regulation and induction of antioxidant expression through the action of Nrf2. This 
may induce higher thioredoxin levels, which in turn results in the higher HIF-1 levels 
observed under intermittent hypoxia. 
The high levels of both thioredoxin and HIF-1 in cancer cells cultured under intermittent 
hypoxia also have implications for tumor metastasis [79, 92]. Thioredoxin enhances the 
invasive behavior of tumor cells by regulating MMP activity, which is required for ECM 
degradation [25, 26]. HIF-1 over-expression during hypoxia has also been associated with 
ECM degradation by upregulating MMP-2 [94] and MMP-9 gene expression [95]. In a 
separate study, intermittent hypoxia treated A549 and H446 lung cancer cells exhibited 
increased invasion in comparison to normoxic cells. Down-regulation of the HIF-1α gene 
decreased the cellular migration in these cells, thereby linking HIF-1 to cancer cell invasion 
under intermittent hypoxia [84]. Moreover, both thioredoxin and HIF-1 have been linked to 
the development of resistance against anticancer therapeutics [82, 96, 97]. These common 
outcomes suggest an interplay of redox and hypoxic systems under intermittent hypoxia, 
with possible consequences for the design and testing of therapeutics. 
5. Consequences for drug development 
Development of resistance in cancer cells against chemotherapies presents a major setback 
in the prevention and cure of the disease that kills millions of people every year. Many 
chemotherapeutics are based on heavy metals, such as gold and platinum that generate ROS 
in cells, causing damage to DNA, proteins and lipids, and ultimately leading to apoptosis 
[98]. However, cells upregulate their antioxidant defenses in order to scavenge ROS, and as 
a result cancer cells become resistant to these drugs. High levels of thioredoxin and other 
antioxidant proteins in tumors are correlated with resistance to various chemotherapeutic 
agents, including cisplatin [97], docetaxel [96] and tamoxifen [99]. Furthermore, breast 
tumors with high levels of thioredoxin and other antioxidants prior to treatment with 
docetaxel were correlated with a high likelihood of developing resistance during therapy 
[100]. Therefore, anti-cancer therapies could be designed to inhibit the thioredoxin system in 
combination with radiation or chemotherapy. 
Radiation treatment has been shown to cause reoxygenation of hypoxic tumors by 
increasing perfusion. As the better oxygenated cells die due to irradiation, the oxygen 
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not to be the case. In our studies [68] MDA-MB-231 cells cultured in 0.1% oxygen followed 
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that the cycling may provide an advantage to the cells. Of interest is that Ref-1 levels were 
also higher in MDA-MB-231 cells subjected to the pre-conditioning, but not in cells grown 
without this step [68]. Since Ref-1 and thioredoxin regulate HIF-1 activity, the short pulses 
of hypoxia may be responsible for their induction. We found that the promoter activity of 
both thioredoxin and thioredoxin reductase were dependent on Nrf2 in the reoxygenation 
phase, and that cells cultured with the pre-conditioning cycles did not exhibit higher 
promoter activity [68]. Therefore, the mechanism for inducing higher thioredoxin protein 
levels in cells subjected to cycling may not be at the transcriptional level. 
4.4. The Interaction of redox and hypoxic pathways under intermittent hypoxia 
Cancer cells can reside in conditions of hypoxic as well as oxidative stress. HIF-1 and Nrf2 
are two important transcription factors that play a crucial role in each of these conditions. 
While HIF-1 is important for cell survival under low oxygen conditions, Nrf2 provides 
The Interaction Between Redox and Hypoxic Signalling Pathways  
in the Dynamic Oxygen Environment of Cancer Cells 141 
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antioxidants have also been observed under intermittent hypoxia. For example, Prx1 was 
upregulated in response to hypoxia/reoxygenation, through the action of Nrf2, which binds 
to the ARE in the Prx1 promoter. In cells lacking Nrf2, Prx1 expression was compromised 
[89]. ROS levels are also higher under intermittent hypoxia [68] and are involved in both 
HIF-1 regulation and induction of antioxidant expression through the action of Nrf2. This 
may induce higher thioredoxin levels, which in turn results in the higher HIF-1 levels 
observed under intermittent hypoxia. 
The high levels of both thioredoxin and HIF-1 in cancer cells cultured under intermittent 
hypoxia also have implications for tumor metastasis [79, 92]. Thioredoxin enhances the 
invasive behavior of tumor cells by regulating MMP activity, which is required for ECM 
degradation [25, 26]. HIF-1 over-expression during hypoxia has also been associated with 
ECM degradation by upregulating MMP-2 [94] and MMP-9 gene expression [95]. In a 
separate study, intermittent hypoxia treated A549 and H446 lung cancer cells exhibited 
increased invasion in comparison to normoxic cells. Down-regulation of the HIF-1α gene 
decreased the cellular migration in these cells, thereby linking HIF-1 to cancer cell invasion 
under intermittent hypoxia [84]. Moreover, both thioredoxin and HIF-1 have been linked to 
the development of resistance against anticancer therapeutics [82, 96, 97]. These common 
outcomes suggest an interplay of redox and hypoxic systems under intermittent hypoxia, 
with possible consequences for the design and testing of therapeutics. 
5. Consequences for drug development 
Development of resistance in cancer cells against chemotherapies presents a major setback 
in the prevention and cure of the disease that kills millions of people every year. Many 
chemotherapeutics are based on heavy metals, such as gold and platinum that generate ROS 
in cells, causing damage to DNA, proteins and lipids, and ultimately leading to apoptosis 
[98]. However, cells upregulate their antioxidant defenses in order to scavenge ROS, and as 
a result cancer cells become resistant to these drugs. High levels of thioredoxin and other 
antioxidant proteins in tumors are correlated with resistance to various chemotherapeutic 
agents, including cisplatin [97], docetaxel [96] and tamoxifen [99]. Furthermore, breast 
tumors with high levels of thioredoxin and other antioxidants prior to treatment with 
docetaxel were correlated with a high likelihood of developing resistance during therapy 
[100]. Therefore, anti-cancer therapies could be designed to inhibit the thioredoxin system in 
combination with radiation or chemotherapy. 
Radiation treatment has been shown to cause reoxygenation of hypoxic tumors by 
increasing perfusion. As the better oxygenated cells die due to irradiation, the oxygen 
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consumption decreases [101]. This has been linked with accumulation of ROS. Moeller and 
colleagues observed an elevation in levels of HIF-1 regulated proteins after 72 hours of 
radiation exposure [102]. Inhibition of ROS by a SOD mimetic prevented the stabilisation of 
HIF-1α and sensitized the tumor to the damage caused by radiation [103]. In a separate 
study, they observed a delay in tumor growth following radiation when HIF-1 was inhibited 
using an antisense knockdown technique [104]. HIF-1β null tumor lines were also found to 
be sensitive to radiotherapy as they prevent the HIF-1 response [105]. All these studies 
suggest that radiation treatment causes an increase in ROS levels that stabilise HIF-1α and 
leads to the subsequent increase in levels of HIF-1 mediated proteins. 
The formation of stress granules has been observed in hypoxic tumors, which were found to 
disaggregate upon radiation exposure [102]. Stress granules contain mRNA transcripts and 
are formed in cells under stress. To save energy during stress, these transcripts are not 
translated into proteins [106]. Upon reoxygenation of hypoxic cells (during irradiation), the 
HIF-1 regulated transcripts are released and are translated, leading to an increase in VEGF 
and erythropoietin levels. This promotes angiogenesis, cell survival and proliferation, 
ultimately making the cells resistant to radiotherapy [102]. 
Cancer cells are often resistant not only to a single drug but develop cross-resistance against 
a range of drugs. Multidrug resistance (MDR) in cancer cells induces resistance against the 
efficacy of structurally and mechanistically different anticancer drugs, significantly 
decreasing their effectiveness. Higher drug doses in MDR cells not only produce toxic 
effects but also further stimulate the resistance, making tumors hard to treat [107]. MDR 
may arise due to alterations in targets, evasion of apoptosis, alteration in drug-uptake and 
transport of drugs out of cells [108]. The efflux of drugs from cells is mediated by 
transmembrane transporters belonging to the ATP-binding cassette (ABC) protein 
superfamily. These proteins use ATP to transport drugs out of cells [109]. One highly 
studied ABC transporter protein is P-glycoprotein (Pgp) (an MDR1 gene product) that has 
been linked to MDR in cancer cells [110]. High levels of Pgp are found in MDR cells and 
coincide with higher expression of HIF-1 [111-113]. Doublier and co-workers found MCF7 
breast cancer cells grown under hypoxia to be resistant to doxorubicin. This resistance was 
associated with an increased Pgp expression via increased HIF-1 activation since 
transfection with siRNA specific to HIF-1 abolished this increase. They also observed that 
the binding of HIF-1 to the MDR1 gene promoter was higher in hypoxic cells. These cells 
accumulated lower levels of doxorubicin compared to normoxic cells [112]. Therefore, these 
roles of HIF-1 should be assessed during optimization of treatment strategies. 
6. Conclusion 
The oxygenation state of the cells has immense importance in cancer biology and both 
oxygen- and redox-dependent regulatory pathways are crucial for the process of 
carcinogenesis. While HIF-1 is important for tumor cells to adapt to hypoxia, thioredoxin 
protects cells from damage due to high oxygen levels. Since cancer cells have the ability to 
survive under conditions of both hypoxic and oxidative stress, one may expect a cross talk 
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between the oxygen- and redox-dependent systems in tumors. This idea is further 
potentiated by the role of ROS in regulating the HIF-1 activity under both normoxia and 
hypoxia, and in inducing the thioredoxin system under oxidative stress. 
The in vivo tumor environment is dynamic and cycles between low and high oxygen 
conditions. Surprisingly, these conditions are not taken into account while designing 
anticancer drugs. Most anticancer drugs are evaluated under normoxia (20% oxygen), which 
is not physiologically relevant and does not reflect the actual in vivo tumor environment. 
Therefore, drugs tested under normoxic laboratory conditions may not respond similarly in 
the patient’s body. Hence, it is important to evaluate the effectiveness of various 
chemotherapeutics under a wide range of oxygen conditions, particularly under intermittent 
hypoxia. Furthermore, both HIF-1 and thioredoxin levels are higher in cells grown under 
intermittent hypoxia. The higher levels of both these proteins have also been linked to 
enhanced invasion and resistance to treatment in cancer cells (Figure 10). 
Therefore, the pathological implications of an upregulation of these important systems in 
cancer demonstrate the vital need to increase our understanding of the molecular 
mechanisms involved in the hypoxic and reoxygenation conditions encountered by the 
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1. Introduction 
The extracellular matrix (ECM) is composed of fibronectin, collagen, elastic fibers and 
microfibrils with many associated adaptor proteins and proteoglycans. The 
microenvironments of cancer tissues differ from those of normal tissues, and intimately 
communicate with the cancer cell surface. For example, in breast cancer stroma compared 
with a normal breast lobule, 2,338 genes are upregulated and 1,234 genes are downregulated 
in ductal carcinoma in situ, and a further 76 genes are upregulated and 229 genes are 
downregulated in invasive carcinoma [1]. Histologically, smooth muscle actin-positive 
fibroblasts appear in the cancer stroma. Cancer cells and their microenvironments seem to 
influence each other during early carcinogenesis, and the microenvironments appear to play 
important roles in cancer development. The tumor microenvironment is unique in 
containing higher amounts of versican and hyaluronan, and lower amounts of latent 
transforming growth factor β-binding proteins. These stromal changes in hyaluronan-
binding proteins and microfibril-associated molecules may facilitate cancer spreading, and 
targeting of specific components of the cancer stroma could lead to effective anticancer 
therapies. In this chapter, we review the dynamics of ECM proteins such as versican, 
hyaluronan, fibrillin-1 and latent transforming growth factor β-binding proteins in cancer 
tissues. In addition, hyaluronan-binding proteins are discussed.  
2. Versican 
Versican is a type of ECM proteoglycan that was initially identified in cultured human 
fibroblasts, followed by isolation of its chicken homolog, PG-M, from chondrogenic 
condensation areas of developing limb buds [2]. Versican is a macromolecule composed of a 
 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
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specific core protein and covalently linked glycosaminoglycan chains named chondroitin 
sulfate (CS), which are linear, negatively charged polysaccharides comprising repeating 
disaccharides of acetylated hexosamines [2,3]. It is produced by cancer, lymphoma and 
leukemia cells, as well as activated peritumoral fibroblasts. Imunohistochemical staining 
with an anti-versican antibody (clone; 2B1 [4]) showed that versican is accumulated in the 
stroma of cancers such as melanoma, breast cancer and ovarian cancer (Figure 1). Versican 
regulates cell adhesion, proliferation, migration, survival, differentiation and angiogenesis, 
and its expression is increased with higher tumor grade and worse outcome [3].  
 
Figure 1. Anti-versican (2B1) immunohistochemistry of human invasive breast cancer. Versican is 
expressed in cancer stroma (x200). 
Versican can be expressed as one of four splice variants (Figure 2) [5]. The amino- and 
carboxy-terminal globular domains (G1 and G3, respectively) are present in all isoforms, 
which differ in whether they contain two alternatively spliced CS-attachment regions (CS-α 
and CS-β). Specifically, versican V1 contains only the CS-β region, V2 contains only the CS-α 
region, V0 contains both CS regions and V3 contains neither of the CS regions. Each versican 
isoform has different functional roles. The V1 isoform enhances cell proliferation and 
protects NIH3T3 mouse fibroblasts against apoptosis [6]. We investigated the alterations in 
versican isoforms in breast cancer tissues in comparison with matched normal tissues using 
real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [7]. Total RNA was 
isolated using an SV total RNA isolation system (Promega, Madison, WI). First-strand 
cDNA was synthesized from the total RNA using a SuperScript VILO cDNA Synthesis Kit 
(Invitrogen, Carlsbad, CA), and amplified using specific primers for versican V0, V1, V2  
and V3. The housekeeping gene glyceraldhyde-3-phosphate dehydrogenase (GAPDH)  
was amplified as an internal control. The designed primers were as follows:  
V0, 5’-gcacaaaatttcaccctgacatt-3’ and 5’-cttctttagattctgaatctattggatgac-3’; V1, 5’-
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cccagtgtggaggtggtctac-3’ and 5’-ctcaaatcactcattcgacgtt-3’; V2, 5’-
tcagagaaaataagacaggacctgatc-3’, and 5’-catacgtaggaagtttcagtaggataaca-3’; and V3, 5’-
ccctccccctgatagcagat-3’ and 5’-ggcacgggttcattttgc-3’. Real-time quantitative RT-PCR was 
performed using a Thermal Cycler Dice Real Time System (Takara Biochemicals, Shiga, 
Japan). Each PCR mixture contained 12.5 μl of Master Mix (SYBR Premix ExTaqTMII; Takara 
Biochemicals), 0.01 mol/l forward and reverse primers, and 100 ng of first-strand cDNA in 
deionized water. After heating each sample to 95℃ for 10 s, 45 cycles of 95℃ for 5 s and 60
℃ for 30 s were performed. The fluorescence was measured as a function of temperature. 
All samples were run in triplicate, and PCR amplifications of the GAPDH and target genes 
were run in parallel for each sample. The results were analyzed by the Thermal Cycler Dice 
Real Time System TP800 software, version 2.00. To obtain estimates of the mRNA expression 
levels of the target genes by real-time RT-PCR, the GAPDH mRNA expression level was given 
a value of 1.0 and used to normalize the other mRNA expression levels. The cancer and 
normal tissues expressed all four versican isoforms, with the V1 isoform showing the most 
abundant expression in both tissues (0.18±0.14 in cancer tissues and 0.032±0.028 in normal 
tissues) [7]. In the cancer tissues, the mRNA levels of V0 and V1 were increased by about 12-
fold and 6-fold, respectively, compared with the normal tissues. The mRNA levels of V2 and 
V3 were very low in the normal tissues, and did not change in the cancer tissues. The versican 
V1-transfected Swarm rat chondrosarcoma cells show enhanced cell motility and migration, 
and produce tumors with more spindle-shaped cells and more myxomatous stroma in SD rats 
[8]. These findings suggest that versican V1 enhances the invasive capacity and leads to the 
formation of a cell-associated matrix in the cancer tissues. V2 has the opposite functions to V1, 
by inhibiting cell proliferation and lacking any association with apoptotic resistance, whereas 
V3 expression has a dual role in tumor growth and metastasis [9,10].  
 
Figure 2. Schematic representation of human versican isoforms and domains. 
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Globular domains G1 and G3 include a hyaluronan binding portion and epidermis growth 
like repeats, respectively, and they play a crucial role in the function of versican [2,3]. For 
these reasons, G1 and G3 in breast cancer and non-cancerous lesions were compared by dot 
blot analyses [7]. Frozen samples (200 mg) were minced into small pieces using a Tissue 
Grinder System (Biomedical Polymers, Gardener, MA), homogenized in chilled lysis buffer 
comprising 4 M guanidine-HCl and 1 % protease inhibitor cocktail (Sigma, St. Louis, MO), 
and extracted at 4℃ for 48 h. After centrifugation, the supernatants were dialyzed against 50 
mM Tris-HCl (pH 8.0) and 0.15 M NaCl at 4℃ overnight using Slide-A-Lyzer MINI Dialysis 
Units (Pierce, Rockford, IL). The protein contents in the lysates were measured using a 
Micro BCA Protein Assay Reagent Kit (Pierce), and aliquots containing 30 μg of protein 
were immobilized on nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) 
using a PR648 Slot Blot Manifold dot blot apparatus (GE Healthcare). The membranes were 
blocked with 10 % non-fat milk, and incubated with the 6084 antibody recognizing G1 [11] 
or the 2B1 antibody recognizing G3 [4]. In the breast cancer tissues, the staining intensities 
with the 6084 and 2B1 antibodies were increased by about two-fold and four-fold, 
respectively, compared with the non-cancerous tissues [7]. Immunohistochemical staining 
supported these findings.  
The G1 and G3 domains are thought to be related to the proliferation and migration of cells. 
For example, the G1 domain stimulates cell migration and proliferation by destabilizing cell 
adhesion in NIH3T3 cells and astrocytoma cells [12,13]. The G3 domain promotes breast 
cancer cell proliferation, invasion and bone metastasis and enhances cancer apoptosis, by 
upregulating the epidermal growth factor receptor (EGFR)-mediating signaling pathway. 
Activation of phosphorylated extracellular regulated protein kinases (ERKs) is correlated 
with high levels of G3 expression [14]. The G3 domain contains two epidermal growth factor 
(EGF)–like motifs, and the activated EGF-EGFR-ERK pathway plays important roles in cell 
cycle progression and apoptosis.   
Versican is cleaved by proteases, which play important roles in tissue remodeling and 
modulation of cell microenvironments through degradation of the ECM and processing of 
growth factors and adhesion molecules. A disintegrin and metalloproteinase with 
thrombospondin motifs (ADAMTS) proteins, a family of proteases, are composed of the 
following seven domains: signal peptide, prodomain, metalloproteinase domain, disintegrin 
domain, thrombospondin type 1 motif, cysteine-rich domain and spacer region. Versican is 
cleaved by ADAMTS-1 and ADAMTS-4 at Glu441-Ala442, and a 70-kDa neoepitope 
DPEAAE sequence is generated. ADAMTS-1 in breast cancer cells can promote their growth 
and metastasis through local accumulation of versican fragments and angiogenesis [15]. 
This indicates that the concentration of versican is influenced by the cleavage as well as the 
production, and ADAMTS plays a role in the cancer development. 
3. Hyaluronan and receptors for hyaluronan-mediated motility 
Hyaluronan (HA) is a nonsulfated glycosaminoglycan of repeating D-glucuronic acid and 
N-acetyl-D-glucosamine disaccharide units. It is a major constituent of the ECM, and plays 
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an important role in tissue remodeling during development [16,17]. The high concentrations 
of HA in embryonic tissues are correlated with their rates of cell migration and proliferation, 
and HA accumulation induces epithelial-mesenchymal transition, at regions such as the 
future valve sites of the embryonic heart tube. In addition, HA can bind large amounts of 
water, and form viscous gels at relatively low concentrations. HA is synthesized by HA 
synthase (HAS) enzymes at the cytoplasmic face of the plasma membrane, and its secretion 
takes place by extrusion during polymer elongation [18]. HAS enzymes have three different 
isoforms, and HAS-2 and HAS-3 are common in cancer tissues [19]. HAS-2 in breast cancer 
stem-like cells (CSCs) promotes tumor progression in bone by stimulating the interactions of 
CSCs with macrophages and stromal cells [20]. HA plays a critical role in generating a 
favorable microenvironment by promoting the interactions of macrophages and CSCs, and 
HAS-2 may promote cancer cell proliferation.  
HA synthesis is correlated with the level of HAS mRNA, suggesting that transcriptional 
regulation is important [21]. In addition to measuring the HAS mRNA levels, several 
different methods have been utilized for detecting HA. Histologically, the expression of HA 
was evaluated by staining with biotinylated HA-binding protein (5 μg/ml) prepared from 
bovine nasal cartilage. Another method used was HA-dependent pericellular coat assays. 
Cells were cultured in dishes, and the medium was then replaced with phosphate-buffered 
saline containing 1 x 1016 formalin-fixed horse erythrocytes. After 20 min, the dishes were 
observed and areas without erythrocytes were considered to be HA [22]. 
HA is rich in cancer stroma, including that of lung, bladder, prostate, colon and breast 
cancers (Figure 3), and stromal HA accumulation is typical for high-grade and poorly 
differentiated carcinoma [23]. An HA rich matrix supports tumor growth and spreading by 
regulating cell proliferation, and migration or by enhancing tumor angiogenesis in the 
cancer. In breast cancer in transgenic mice, HA overproduction accelerates tumor 
angiogenesis through stromal reactions, most notably in the presence of versican [24]. On 
the other hand, the HAS suppressor, 4-methylumbelliferone (MU), suppresses cell adhesion, 
locomotion, and matrix metalloproteinase (MMP)-9 and N-cadherin expression, and inhibits 
tumor metastasis [25-27]. HA is composed of high and low molecular weight forms that 
have been shown to have opposite functions. High- molecular-weight HA suppresses 
vascularization, and has anti-inflammatory and immunosuppressive functions. Low-
molecular-weight HA, including HA oligosaccharides (less than 50 oligomers (mers)), has 
an angiogenic function, and induces cytokines and chemokines in inflammation and ECM 
degradation [28]. HA changes its biological activities depending on its molecular weight, 
and HA oligosaccharides (12 mers) suppress the growth of breast cancer [29]. MU and HA 
oligosaccharides may be candidates for anticancer therapies.       
HA is present not only in the ECM, but also in the cellular cytoplasm and nucleus. Although 
the mechanism for HA internalization remains controversial, one possibility is that HA is 
transported in a retrograde manner through the Golgi, endoplasmic reticulum and 
cytoplasm. HA accumulation is seen in the cytoplasm of malignant cells, such as colon and 
gastric cancer cells and lymphoma cells. A high level of HA on tumor cells is a strong 
indicator of an unfavorable outcome [30]. The intracellular HA-binding proteins include 
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indicator of an unfavorable outcome [30]. The intracellular HA-binding proteins include 
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CDC37 (p50), receptors for HA-mediated motility (RHAMM), P-32 and intracellular HA-
binding protein (IHABP)-4 [31]. RHAMM was isolated from culture supernatants of chick 
embryonic heart fibroblasts [32], and is present in the cell membrane, centrosomes and 
microtubules. RHAMM is overexpressed in the G2/M phase of cancer cells and in many 
kinds of cancers [33,34]. These observations suggest that HA and RHAMM play important 
intracellular roles in mitosis, maintaining the cell shape, and modulating centrosomes and 
microtubules, which enhance cell proliferation and migration.  
 
Figure 3. Histochemistry with biotinylated hyaluronan binding protein in human invasive breast 
cancer. Hyaluronan is expressed in cancer stroma (x200). 
CDC37 and RHAMM form complexes with heat shock protein (Hsp) 90 and Hsp70, 
respectively [31,33]. The CDC37-Hsp90-HA complex stabilizes protein kinases such as Cdk4, 
p60Src kinase, casein kinase II, MPS1 kinase and Raf-1, and is important for trafficking of 
kinases from the cytoplasm to the nucleus. On the other hand, the complex of Hsp70 (GRP78 
and GRP75) and RHAMM was confirmed by coimmunoprecipitation and glutathione-S-
transferase (GST)-RHAMM fusion protein-binding assays [33]. For the GST-RHAMM fusion 
protein-binding assays, a membrane with transferred proteins from OHK cells (a malignant 
lymphoma cell line) after two-dimensional gel electrophoresis was used. The membrane 
was incubated with 0.05 μg/ml of GST-RHAMM fusion protein containing the central 
domain at room temperature for 1 h. After washing with PBS/Tween-20 at room 
temperature for 1 h, the localization of the RHAMM fusion protein binding was visualized 
using a peroxidase-conjugated anti-GST antibody (Amersham, Uppsala, Sweden) and an 
enhanced chemiluminescence system (Amersham). The membrane was then stripped by 
incubation in 0.05 M sodium phosphate (pH 6.5), 10 mM SDS and 0.1 M β-mercaptoethanol 
at 50℃ for 30 min, followed by a wash with PBS/Tween-20. The stripped membrane was 
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then evaluated for another GST-RHAMM fusion protein (C-terminal domain) or GST. The 
transferred proteins from OHK cells were visualized with Coomassie brilliant blue R-250 
and the spots corresponding to the proteins bound to RHAMM were excised from the 
membrane and submitted for sequencing. GRP78 and GRP75 were identified as RHAMM-
binding proteins [33]. Double immunostaining revealed that GRP78 and GRP75 colocalized 
with RHAMM in the interphase of the cell cycle. The RHAMM-Hsp70 complex may 
stabilize microtubules in the interphase, and the separation of RHAMM and Hsp70 may 
play a role in cell division.  
HA is cleaved into 10 to 15 disaccharide fragments by hyaluronidases (HYALs). In humans, 
four HYALs have been identified, namely HYAL1, HYAL2, HYAL3 and PH20 [35]. In lung 
cancer, wild-type HYAL1 was associated with a poorer prognosis, while the HYAL3-v1 
variant was associated with a better prognosis [36]. Increased HYAL1 expression and 
hyaluronidase activity are associated with an unfavorable prognosis in bladder and 
prostatic cancers [37].  
4. HA-versican-fibrillin-1 complex and HA-verscian complex  
Versican interacts with HA and fibrillin-1 at its N-terminus and C terminus, respectively 
[2,38]. Fibrillin-1 is a major structural component of connective tissue microfibrils, and has 
significant roles in the maintenance of microfibrils and elastic fibers. The HA-versican-
fibrillin-1 complex and its cleavage products exist in the ciliary nonpigmented epithelium 
and the vitreous body [39]. Regarding skin tissues, immunoblotting analyses of skin extracts 
with the 6084 antibody and biotin-conjugated HA revealed that versican was a major HA-
binding component in the dermis [11]. MMP-12 (macrophage metalloelastase) degraded 
versican and abrogated its HA-binding ability. Immunohistochemical analyses revealed that 
the elastic materials in solar elastosis lesions were negative for 6084 antibody, but positive 
for 2B1 antibody, indicating loss of the HA-binding regions in the aggregated elastic fibers. 
In solar elastosis, which is seen in photoaged skin of elderly people, abrogation of the HA- 
binding ability of versican by MMP-12 is observed. On the other hand, assembly of HA-
versican aggregates in the pericellular sheath of cancer cells promotes their motility [40]. 
Similar locations of HA, versican and fibrillin-1 were seen in the ECM of breast cancer 
tissues [7], but their exact functions in cancer were not elucidated.  
5. Latent transforming growth factor β binding proteins 
Latent transforming growth factor β binding protein (LTBPs) are large extracellular 
glycoproteins that are structurally related to fibrillins, and are major regulators of 
transforming growth factor-β (TGF-β) bioavailability and action [41]. TGF-β is a potent 
growth inhibitor in the early stage of carcinogenesis, controlling cellular growth and 
inducing apoptosis. In the advanced stage of carcinogenesis, TGF-β acts as an oncogenic 
factor and induces invasion-associated epithelial-mesenchymal transition. TGF-β is thought 
to enhance tumor growth and invasion through regulation of immune functions and 
angiogenesis, as well as the production of stromal components [42]. TGF-β is secreted as a 
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latent complex containing one of the LTBPs. Latent TGF-β consists of the mature growth 
factor and the TGF-β propeptide, also known as the latency-associated peptide (LAP). The 
LTBPs and TGF-β propeptides have four and three isoforms, respectively. LTBP-1 and 
LTBP-3 bind all three TGF-β LAP isoforms with high affinity, while LTBP-4 shows a weak 
binding capacity only for the TGF-β1 LAP isoform. LTBP-1, LTBP-3 and LTBP-4 regulate 
TGF-β action at multiple levels [41]; (a) they ensure correct folding and efficient secretion; 
(b) they direct temporal and spatial deposition in the extracellular space; and (c) they 
regulate activation. These findings show that LTBPs have multiple roles with regard to TGF-
β action, and the instability of the TGF-β associations with LTBPs yields inflammation and 
tumors. It has been reported that LTBP-1 and LTBP-3 expression is downregulated in 
hepatoma and mesothelioma, respectively, compared with normal tissues [43,44]. In breast 
cancer tissues, LTBP-4 was decreased (Figure 4) [7]. Downregulation of LTBP-3 expression 
in malignant mesothelioma contributes to increased TGF-β signaling activity [44], and 
upregulated TGF-β signaling following LTBP reduction seems to induce carcinoma. TGF-β 
signaling plays a key role in carcinogenesis, and the LTBP downregulation appears to be 
critical to cancer progression. 
 
Figure 4. Anti LTBP-4 immunohistochemistry of human invasive breast cancer. LTBP-4 expression is 
absent (x100). 
6. Conclusion 
Versican, HA and LTBP distributions in the cancer ECM differ from those of normal tissues 
(Figure 5), and the ECM alteration facilitates cancer cell proliferation, migration and 
angiogenesis. In addition, these proteins can interact with each other, and exert a crucial role 
in the cancer progression. For these reasons, a novel cancer therapy that targets an 
individual ECM protein and the complex of these ECM proteins is proposed. One of our 
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future research goals is to elucidate the function of HA-versican-microfibril complex in the 
cancer stroma.  
 
Figure 5. A diagram of the breast cancer tissue. Cancer stroma is rich in hyaluronan and versican, while 
normal tissues have LTBP-4. 
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1. Introduction 
During the process of tumorigenesis, some cells separate themselves from the tumor to 
invade distant tissues. Cellular migration in this process is similar to what occurs during 
embryonic development and wound healing. Unlike these two healthy processes, which 
involve the creation of a structure or the healing of tissue, metastasis results in the formation 
of a cellular mass that, if not eliminated, leads to the death of the organism. The process of 
metastasis includes the invasion of the basal membrane and nearby tissue by tumoral cells 
and the intravasation towards the blood vessels or infiltration of the lymphatic vessels. This 
is followed by the mechanisms of survival of tumor cells in these vessels and their 
extravasation to different tissues of the organism, where they may be able to proliferate. 
This pathogenic process requires a precise coordination of various signaling pathways that 
allows the tumor cells to move across the cell membrane, remodel the matrix, transport 
themselves by circulation [1] and create the appropriate conditions, at a distance, for 
establishing themselves in a different organ (Figure 1). 
Although exploring this complex process of motility and invasion by tumoral cells is 
fundamental for deepening the understanding of metastasis [2], much remains a mystery 
despite the enormous amount of research contributions. Both in vitro and in vivo, the time 
required for analyzing the evolution of this pathogenesis is excessive. Today the best way to 
make functional evaluations of the genetic changes that take place in humans with metastasis 
is with animal models. Although time consuming, a complete follow up can be carried out of 
the entire process, from the moment of the appearance of a primary tumor, to the strategies 
used by cancerous cells to escape from the controls of adhesion, their interaction with 
endothelial cells during their migration, and the establishment of a secondary tumor through 
the preparation of a new microenvironment favorable to tumor growth in the affected organ. 
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1. Introduction 
During the process of tumorigenesis, some cells separate themselves from the tumor to 
invade distant tissues. Cellular migration in this process is similar to what occurs during 
embryonic development and wound healing. Unlike these two healthy processes, which 
involve the creation of a structure or the healing of tissue, metastasis results in the formation 
of a cellular mass that, if not eliminated, leads to the death of the organism. The process of 
metastasis includes the invasion of the basal membrane and nearby tissue by tumoral cells 
and the intravasation towards the blood vessels or infiltration of the lymphatic vessels. This 
is followed by the mechanisms of survival of tumor cells in these vessels and their 
extravasation to different tissues of the organism, where they may be able to proliferate. 
This pathogenic process requires a precise coordination of various signaling pathways that 
allows the tumor cells to move across the cell membrane, remodel the matrix, transport 
themselves by circulation [1] and create the appropriate conditions, at a distance, for 
establishing themselves in a different organ (Figure 1). 
Although exploring this complex process of motility and invasion by tumoral cells is 
fundamental for deepening the understanding of metastasis [2], much remains a mystery 
despite the enormous amount of research contributions. Both in vitro and in vivo, the time 
required for analyzing the evolution of this pathogenesis is excessive. Today the best way to 
make functional evaluations of the genetic changes that take place in humans with metastasis 
is with animal models. Although time consuming, a complete follow up can be carried out of 
the entire process, from the moment of the appearance of a primary tumor, to the strategies 
used by cancerous cells to escape from the controls of adhesion, their interaction with 
endothelial cells during their migration, and the establishment of a secondary tumor through 
the preparation of a new microenvironment favorable to tumor growth in the affected organ. 
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Figure 1. Separation of tumoral cells from a primary tumor and its migration to reach a blood or 
lymphatic vessel for dissemination to a secondary site is a very complex process that includes changes 
in the expression of multiple genes, which are genes involved in cell adhesion, survival, 
chemoattraction, growth factors, miRNAs. In the figure you can see some of the genes involved 
throughout this process. 
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2. Primary tumor migration 
The majority of deaths from cancer are due to metastasis. Nevertheless, in any given 
moment only a small proportion of tumoral cells acquire the capacity of invasion and 
dissemination [3]. This capacity is favored by the activation of signaling pathways that 
trigger the metastatic cascade, which results from the continuous exposure to the 
development of the primary tumor, to growth factors, to angiogenesis and to accumulated 
genetic changes [4]. Since the probability that tumoral cells that travel to new sites give rise 
to a tumor is very small [5], the process of tumorigenesis is actually quite lengthy. Yachida 
et al [6], after analyzing autopsies of victims of metastatic pancreatic cancer, proposed a 
quantitative model of tumor development and metastasis. They consider that at least a 
decade must pass between the occurrence of the initial mutation and the birth of the parent 
cancerous cell that eventually results in a tumor. Another five years or more are required for 
the acquisition of a metastatic capacity. After this latter event, the process takes place very 
quickly, with the life expectancy of two years for the affected patient. Hence, the challenge is 
to detect a tumor after the onset of the parent cancerous cell but before metastasis.  
Some years ago, Engel et al [7] found that the period from the onset of metastasis to the 
diagnosis of breast cancer was approximately 6 years. For the purpose of establishing such a 
diagnosis, two types of tumoral cells can be detected: those circulating in the blood and 
those disseminated in lymphatic nodes and bone marrow. Such tumor cells can persist for 
years, awaiting the adequate conditions in some organ to be able to establish themselves in a 
secondary tumor. In the event of the existence of both types of tumor cells in a patient, the 
likelihood of tumor development is quite high [8].  
There are two proposed models for explaining metastasis. Firstly, there is the model of 
linear progression, which considers that tumoral cells pass through multiple successive 
rounds of mutations, resulting in the selection of the most apt for proliferation in a relatively 
autonomous manner, followed by the transport of these clones to a new site. Secondly, the 
model of parallel progression holds that tumor cells separate themselves from the primary 
tumor before the acquisition of the malignant phenotype, and that these cells then undergo 
a somatic progression and metastatic growth at a distant site [9, 10].  
Detailed analysis of diverse data, including that from animal and computational models, 
suggests that dissemination is not a lengthy process, at least in breast cancer, prostate cancer 
or cancer of the esophagus [11,12]. Thus at least for these cancers, the model of parallel 
progression is best supported to explain metastasis from the primary tumor. Through the 
use of comparative genomic hybridization, Baudis [13] analyzed 5918 malignant epithelial 
neoplasias and observed typical imbalances: whereas there were recurrent findings of 
increases in 8q2, 20q, 1q, 3q, 5p, 7q and 17q, similar patterns of losses were seen in 3p, 4q, 
13q, 17p and 18q, among others. These genetic similarities between primary and metastatic 
tumors tend to indicate a convergent evolution more than the result of selection starting 
from a clone [5]. Nowadays it is well known that tumoral cells abandon the primary tumor 
before cancer is diagnosed. The possibility that these cells develop a tumor in a distinct 




Figure 1. Separation of tumoral cells from a primary tumor and its migration to reach a blood or 
lymphatic vessel for dissemination to a secondary site is a very complex process that includes changes 
in the expression of multiple genes, which are genes involved in cell adhesion, survival, 
chemoattraction, growth factors, miRNAs. In the figure you can see some of the genes involved 
throughout this process. 
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2. Primary tumor migration 
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cancerous cell that eventually results in a tumor. Another five years or more are required for 
the acquisition of a metastatic capacity. After this latter event, the process takes place very 
quickly, with the life expectancy of two years for the affected patient. Hence, the challenge is 
to detect a tumor after the onset of the parent cancerous cell but before metastasis.  
Some years ago, Engel et al [7] found that the period from the onset of metastasis to the 
diagnosis of breast cancer was approximately 6 years. For the purpose of establishing such a 
diagnosis, two types of tumoral cells can be detected: those circulating in the blood and 
those disseminated in lymphatic nodes and bone marrow. Such tumor cells can persist for 
years, awaiting the adequate conditions in some organ to be able to establish themselves in a 
secondary tumor. In the event of the existence of both types of tumor cells in a patient, the 
likelihood of tumor development is quite high [8].  
There are two proposed models for explaining metastasis. Firstly, there is the model of 
linear progression, which considers that tumoral cells pass through multiple successive 
rounds of mutations, resulting in the selection of the most apt for proliferation in a relatively 
autonomous manner, followed by the transport of these clones to a new site. Secondly, the 
model of parallel progression holds that tumor cells separate themselves from the primary 
tumor before the acquisition of the malignant phenotype, and that these cells then undergo 
a somatic progression and metastatic growth at a distant site [9, 10].  
Detailed analysis of diverse data, including that from animal and computational models, 
suggests that dissemination is not a lengthy process, at least in breast cancer, prostate cancer 
or cancer of the esophagus [11,12]. Thus at least for these cancers, the model of parallel 
progression is best supported to explain metastasis from the primary tumor. Through the 
use of comparative genomic hybridization, Baudis [13] analyzed 5918 malignant epithelial 
neoplasias and observed typical imbalances: whereas there were recurrent findings of 
increases in 8q2, 20q, 1q, 3q, 5p, 7q and 17q, similar patterns of losses were seen in 3p, 4q, 
13q, 17p and 18q, among others. These genetic similarities between primary and metastatic 
tumors tend to indicate a convergent evolution more than the result of selection starting 
from a clone [5]. Nowadays it is well known that tumoral cells abandon the primary tumor 
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organ depends largely on the characteristics of the primary tumor. 
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2.1. Cell invasion 
Tumor cells must acquire certain characteristics for cell migration to occur, such as polarity 
and disassociation from their point of origin. Afterwards, these cells must undergo cycles of 
extension and contraction, and at the same time they adhere to and are released from the 
substrate [14] to move from one site to another. During this process their form is radically 
modified. 
The ability of cells to migrate, studied since 1863 after the discovery by Virchow, allowed 
them to carry out various processes including embryogenesis, angiogenesis and wound 
healing to immune response [15], Cell migration can be divided into stages according to the 
changes observed in the morphology of the cell: polarization, protrusion, adhesion, 
translocation of the cell body, and retraction of the rear portion. The physiology of cell 
migration is diverse, depending on the type of cell involved [16]. For instance, fibroblasts 
and melanocytes generally migrate mesenchymally, as individual cells that are highly 
adhesive and require proteolytic remodeling of the matrix [17,18.]. These cells form 
specialized protrusions of the membrane, among which are lamellipodia, which are actin 
projections of the cytoskeleton formed in the extreme front part of the mobile cell, and 
invadopodia (invasive pseudopods), which are proteolytically active protrusions of the 
plasmatic membrane that are responsible for the focal degradation of the components of the 
extracellular matrix (ECM). The latter type, characteristic of highly invasive tumor cells, 
contains sites of matrix metalloproteinases (MMPs) [19]. Wolf et al [20] observed that tumor 
cells do not always require MMPs, since they can escape through openings in the ECM by 
means of a great contractile force. Also among specialized protrusions of the membrane of 
metastatic fibroblasts and melanocytes are philopodia and podosomes. The former 
protrusions are in the shape of thin bundles of actin, and are in charge of probing the 
environment in search of signals [21]. The latter are functionally the same as invadopodia, 
forming in macrophages and osteoclasts associated with a tumor, and aiding in the process 
of invasion. The capacity of malignant cells to migrate in a directional manner is due to the 
presence of receptors on their surface that allows them to follow the gradient of chemokines 
[22]. Among the most common type of chemokines are CXCR4 and CCR7, which have been 
found in diverse types of cancer and are attracted by CXCL12 and CCL21, respectively [23].  
2.2. Mechanisms of invasion 
Yilmaz et al [24] suggest classifying the invasion by cancerous cells as individual or 
collective. The use of one or another type of mobility depends on the type of malignant 
tumor and the surrounding tissue, defined by distinct patterns in the activity of extracellular 
proteases, matrix-cell adhesion mediated by integrins, cell-cell adhesion mediated by 
cadherins, cellular polarity and cytoskeletal arrangements [25]. Epithelial cells, which are 
the most common source of diverse cancers, can exhibit multiple phenotypes of migration. 
They commonly have a stationary behavior and form layers of cells interconnected with 
strong bonds. They are capable of moving individually, as a layer, or as a tubular structure. 
The latter type of structure is found during embryonic development [26]. Among epithelial 
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tumoral cells, all these three types can be found for any particular tissue, suggesting that 
these pathogenic cells have the capacity to change from individual to collective migration, 
according to the environment that they face.  
2.3. Individual cell migration 
The movement of cells inside of living organisms is highly complex and strictly coordinated. 
For instance, hematopoietic cells exhibit a highly individualized ameboid movement, with 
little adhesion and without causing remodeling of the matrix. Tumor cells are capable of 
taking advantage of the strategies of healthy cells, moving in the same individual manner 
for example as a leukocyte or fibroblast. Individual migration of cells can have some 
variants: ameboid or mesenchymal [27, 28], solitary or in single file. When cells are 
transported to a new location, their form is modified. They often, but not always, adopt a 
bottle form. The constriction of their apexes can have two functions: (i) the cells can 
transport much of their intracellular content and begin the movement out of the epithelium, 
and (ii) they can reduce the amount of non-adhesive apex membrane, since by passing 
through the epithelial layer to arrive to the new location the apical point breaks. 
Additionally, this form allows for passage through the epithelium layer with a reduced 
space left behind. The apical constriction is driven by contractions based on actinomiosine, 
while the apical membrane is reduced by endocytosis. The cells must carry out a process of 
de-epithelialization, which means that they lose an essential property of epithelial cells— 
contact with neighboring cells.  
Apart from the eventual loss of the adherence of the apical point, the adjoining surfaces 
forming the bottle neck are also broken up [29]. Due to employment of intravital 
multiphoton imaging, it has been possible to observe tumor cells in movement, and 
therefore to see breast cancer cells utilizing ameboid movement to transport themselves 
rapidly (4µm/min) [30]. During transport these cells acquire a polarized phenotype, 
bearing Ca2+ in front of and behind the cell, which allows for the retraction of the rear portion 
[31]. This process of retraction is supported by the contraction of miosine II and by the disassembly of 
focal adhesion at the rear of the cell, due to the breakage mediated by calpain of the proteins 
of focal bonds, including integrins, talin, vinculin and focal adhesion kinase (FAK) [32]. Focal 
adhesion is composed of a structural point and adhesion signaling between the ECM and 
the cytoskeleton. The velocity of the formation and disassembly of the focal adhesions is 
what determines the efficiency of cellular migration [33]. In tumor cells the loss of E-cadherin 
facilitates the formation of focal adhesion and better communication with the ECM. The 
small STPases (Rho, Rac, CDC42) are among the key molecules for initiating remodeling of 
the cytoskeleton. The remodeling of actin is mediated by actin-related proteins (such as 
ARP2/3) [34]. The other type of individual migration, mesenchymal migration, can be used 
by cells that undergo a transition from the epithelial to mesenchymal cell type, the latter of 
which is present in 10-40% of carcinomas [35]. This type of migration requires proteolysis of 
ECM proteins so that the cells can move through the matrix-filled spaces of the tumor [19].  
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tumoral cells, all these three types can be found for any particular tissue, suggesting that 
these pathogenic cells have the capacity to change from individual to collective migration, 
according to the environment that they face.  
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little adhesion and without causing remodeling of the matrix. Tumor cells are capable of 
taking advantage of the strategies of healthy cells, moving in the same individual manner 
for example as a leukocyte or fibroblast. Individual migration of cells can have some 
variants: ameboid or mesenchymal [27, 28], solitary or in single file. When cells are 
transported to a new location, their form is modified. They often, but not always, adopt a 
bottle form. The constriction of their apexes can have two functions: (i) the cells can 
transport much of their intracellular content and begin the movement out of the epithelium, 
and (ii) they can reduce the amount of non-adhesive apex membrane, since by passing 
through the epithelial layer to arrive to the new location the apical point breaks. 
Additionally, this form allows for passage through the epithelium layer with a reduced 
space left behind. The apical constriction is driven by contractions based on actinomiosine, 
while the apical membrane is reduced by endocytosis. The cells must carry out a process of 
de-epithelialization, which means that they lose an essential property of epithelial cells— 
contact with neighboring cells.  
Apart from the eventual loss of the adherence of the apical point, the adjoining surfaces 
forming the bottle neck are also broken up [29]. Due to employment of intravital 
multiphoton imaging, it has been possible to observe tumor cells in movement, and 
therefore to see breast cancer cells utilizing ameboid movement to transport themselves 
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bearing Ca2+ in front of and behind the cell, which allows for the retraction of the rear portion 
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focal adhesion at the rear of the cell, due to the breakage mediated by calpain of the proteins 
of focal bonds, including integrins, talin, vinculin and focal adhesion kinase (FAK) [32]. Focal 
adhesion is composed of a structural point and adhesion signaling between the ECM and 
the cytoskeleton. The velocity of the formation and disassembly of the focal adhesions is 
what determines the efficiency of cellular migration [33]. In tumor cells the loss of E-cadherin 
facilitates the formation of focal adhesion and better communication with the ECM. The 
small STPases (Rho, Rac, CDC42) are among the key molecules for initiating remodeling of 
the cytoskeleton. The remodeling of actin is mediated by actin-related proteins (such as 
ARP2/3) [34]. The other type of individual migration, mesenchymal migration, can be used 
by cells that undergo a transition from the epithelial to mesenchymal cell type, the latter of 
which is present in 10-40% of carcinomas [35]. This type of migration requires proteolysis of 
ECM proteins so that the cells can move through the matrix-filled spaces of the tumor [19].  
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2.4. Collective cell invasion 
Targeted multicellular migration can be of two types: (i) collective cellular migration, in 
which the cells undergoing transport maintain close contact with one another, and (ii) 
streaming, in which these cells are not always in direct contact [22, 23]. This latter type is 
carried out by cells during the stage of gastrulation in embryonic development and in 
wound healing. Collective cell migration, where the cells are bonded together in layers, is 
more common than individual migration under normal physiological conditions [36]. The 
best understood collective cell migration is that of wound healing. Neurons and smooth 
muscle cells also move collectively, as a cohesive group and in a coordinated and integrated 
manner. The cells involved in this movement retain much of their epithelial characteristics, 
such as the cell to cell adhesion, averting the need for an epithelial-mesenchymal transition 
that leads to a modification of cellular shape [37]. In all types of collective migration, the 
foremost cells of the migratory group actively participate in chemotaxis and degradation of 
the matrix in order to make way for passage. These leading cells are linked to the cells 
behind them, dragging them through the remodeled matrix [36].  
In tumor cell collective migration, the leading cell can be a tumor cell with proteolytic 
activity or a stromal cell of the tumoral microenvironment [38]. Among the most relevant 
proteins for collective cell migration are the 1 and 3 integrins grouped in the ruffling 
edges of the cell group in movement. These proteins are responsible for providing the 
adhesion and dynamic strength necessary for transporting the cell group. The leading cells 
have the greatest proteolytic capacity in relation to the ECM, and it is their production of the 
metalloproteinases MT1-MMP and MMP-2 that enable proteolysis, as these proteins cut 
collagen fibers and form a pathway for collective migration and expansion of the migratory 
group [39, 40]. In squamous carcinomas of the larynx, lungs, esophagus, cervix and skin, 
among other tissues, collective invasion has been associated with the presence of 
podoplanin and CDC42 proteins [41-43].  
3. The epithelial to mesenchymal transition (EMT) 
Regarding the acquisition of mobility, a fundamental process in the transformation to a 
malignant cell, the best understood phenomenon is the epithelial-mesenchymal transition. 
The epithelial layer is formed by cells with apical-basal polarity that maintain the laminar 
structure intact through various types of adhesion, thus forming the barrier necessary for 
the good functioning of the epithelial layers. This barrier, known as the apical joint complex, 
is formed and maintained by cell to cell contact at the cell surfaces that surround the apical-
lateral dominion. This complex includes the adhesive joints (AJ), which promote the 
integrity of the tissue by maintaining a strong bond between the cells [44] and have 
cadherins as their principal component [45]. The resulting tight joints (TJ) form a physical 
barrier to the movement of ions, macromolecules, immune cells and pathogens between the 
epithelial cells [46] and desmosomes. The AJ as well as the TJ are closely related with the 
actin cytoskeleton and are functionally regulated by filaments of the circumference of 
actomyosin [47]. Their dynamic interaction is important during the morphogenesis of 
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epithelial tissues in embryonic development, in tissue repair [48], and in the maintenance of 
an effective epithelial barrier in an adult [49].  
During early embryonic development, there is a process of essential differentiation resulting 
in the establishment of the germinal layers in the epithelial-mesenchymal transition (EMT) 
[29]. The EMT, discovered by Frank Lillie in 1908, is an important mechanism for the 
reorganization of the germinal layers [50]. This process, whose essential characteristics are 
the interruption of intercellular contacts and the acquisition of a fibroblast-type conjugated 
morphology, converts well-organized epithelial cells into isolated cells with a mesenchymal 
morphology that are capable of transporting themselves [51] to become established in new 
tissues, thus allowing for inductive interactions during embryogenesis. Currently, it is 
thought that three subtypes of EMT exist: EMT type 1 is related to embryonic development, 
EMT type 2 to wound healing, and EMT type 3 to tumor cells [52]. As Thiery [53] points out, 
it took a long time for EMT to be recognized as a mechanism of tumor progression due to 
the difficulty of detecting the process in patients. Today, it is known that tumor cells utilize 
the EMT as a key element in the invasive process, a phenomenon very similar to embryonic 
EMT. There are diverse pathways in common between embryonic and tumoral EMT, 
including the stimulation by TGF-β that induces phosphorylation of β-catenin, which in 
turn activates transcription factors such as Snail [54], as well as diverse growth factors and 
proteins. This is accompanied by a loss of diverse epithelial proteins such as E-Cadherin,  
and -catenins, Claudin, ocludin and citokeratins, and at the same time an overexpression of 
mesenchymal proteins such as vimentin, fibronectin, metalloproteinases, actin and integrins 
v and 1 [55, 56]. E-cadherin is a key protein because it facilitates the adhesion of epithelial 
cells and desmosomes [57], which in turn prevents cellular mobility and metastatic 
dissemination.  
The cadherin switch is essential to increase mobility, but is not always necessary for the 
morphological changes that accompany the EMT [58]. The expression of cadherins can be 
inactivated by somatic mutations, hypermethylation and desacetylation of histones or 
transcriptional repression. Some researchers have considered that the expression of N-
cadherin is more important for metastasis than that of E-cadherin [59], based on the fact that 
the former is a mesenchymal protein marker found overexpressed in cells with the EMT. 
Camand et al [60] found that a decrease in the N-cadherin levels, through regulation of focal 
adhesion formation, promotes a more rapid migration in healthy and tumoral glia cells. In 
the latter cells, this contributes to the invasive capacity of astrocyte tumors.  
Integrins, a determining factor in the process of cellular adhesion, can also induce EMT. 
Recently, Gupta et al [61] proposed that integrin 91 is implicated in EMT by accelerating 
lung tumor cell migration, mediated by scr, in a TGF-independent manner. To date, a wide 
variety of proteins and factors have been discovered that regulate EMT. Indeed, it is thought 
that hundreds of genes significantly modify their expression during EMT [52]. One example 
is Twist, a potent inducer of EMT that was originally identified as an inducer of the 
mesoderm in Drosophila [62]. Its expression in epithelial cells causes the loss of cell to cell 
adhesion mediated by E-cadherin, which leads to cell decomposition. It also activates BMI1 
polycomb proteins, which induce stem-like properties and thus annul the p53- and Rb-
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dependent pathways that would otherwise allow the cells to enter in premature senescence 
induced by oncogenes. Twist also suppresses the production of let-7i, which in turn allows 
cells to acquire mobility in the last stage of EMT [63, 64]. The overexpression and activation 
of the signaling pathways of HER-2/Neu and TGF activate EMT in tumoral cells of breast 
cancer.  
EMT is also regulated by alternative splicing, such as that of ENAH, a regulating protein of 
the cytoskeleton of actin. The transcript present in epithelial cells contains a small exon 11a, 
which is absent in mesenchymal cell lines and during the EMT [65]. RBFOX2 is a splicing 
factor which together with ESRP1 and ESRP2, proteins for binding with RNA that are 
specific to the epithelium, promote splicing of transcripts that are important in EMT [66]. 
The loss of ESRPs in epithelial cells induces morphological changes similar to EMT [67]. On 
the other hand, Shapiro et al [68] found a partial induction of the splicing program in 
mesenchymal cells by means of the ectopic expression of ESRP1 or by elimination of 
RBFOX2 in immortalized epithelial mammary cells. Mesenchymal isoform IIIc of FGFR2, 
isoform 3 of catenin p120, and isoform CD44s of CD44 are all expressed in mesenchymal 
cells and in tumoral cells with the EMT, as reviewed in [69]. 
Just as the process of EMT resembles that observed during embryonic development, it 
seems that both pathways are regulated by an intricate interaction of transcriptional and 
post-transcriptional programs, as was discovered by observing that the ribonucleoprotein, 
heterogeneous nuclear E1 (hnRNP E1) is a selective transductional regulator of transcripts of 
EMT induced by TGFβ. Due to its capacity to bind to RNA, hnRNP E1 adheres to 3'-UTR 
BAT structural elements present in the transcripts of mRNA necessary for EMT, and upon 
doing so silences these elements. This silencing, mediated by hnRNP E1, occurs during the 
stage of elongation when hnRNP E1 impedes the release of the elongation factor eukaryote 1 
A1 (eEF1A1) of the ribosomal site A. The phosphorylation of hnRNP by Akt2, mediated by 
TGFβ, restores the transduction of white transcripts of EMT. The attenuation of the 
expression of hnRNP E1 in non-invasive breast cancer cell lines induces not only EMT but 
also metastasis [70,71]. Furthermore, the steroid hormones such as androgens have also been 
observed to be implicated in the maintenance of cellular characteristics, evidenced by the 
fact that Sun et al [72] found that the absence of androgens in prostate tumors is associated 
with a worse prognosis and acquisition of cell characteristics typical of mesenchymal or 
stem cells.  
With triple negative breast cancer (ER-, PR- HET2-), there is an overexpression of N-cadherin 
and EMT, leading to a worse prognosis. Regulation by miRNAs is not an exception in EMT, 
particularly the miRNAs of the miR-200 (miR-200a, miR-200b, miR-200c, miR-141 and miR-
429) and miR-205 family. These miRNAs participate in the regulation of EMT induced by 
TGF by mediating the production of ZEB1 and ZEB2 [73,74]. Recently miR-29b was added 
to the list of miRNAs that regulate EMT, due to the fact that an increase in miR-29b in PC3 
prostate cancer cells inhibits the capacity of these tumoral cells to invade and colonize [75]. 
In addition to TGF, other growth factors such as EGF, HGF, PDGF, FGF2, TNF and IGF 
can induce EMT by activating the expression of transcriptional repressors of E-cadherin or 
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by activating the transduction signaling pathways, such as MAPK, PI3K, Wnt/-catenin, NF-
B and Notch [69 and references there].  
3.1. EMT reversion 
After tumoral cells are disseminated, they must reactivate their epithelial properties by 
means of the reversion of the process of EMT, known as the mesenchymal-epithelial 
transition (MET). In the metastatic process, just as EMT is essential for the initial 
transformation of cells from being part of the epithelial tissue to being released from 
intercellular connectedness and ready for transport, MET is critical for the later stages of 
metastasis. Possibly this latter change is triggered by the local environment after 
extravasation towards the parenchyma of the invaded organs [76]. Although EMT has been 
extensively studied, there is much yet to be discovered about the molecular mechanisms 
that regulate MET. One of the keys to the process of MET is the re-expression of E-cadherin, 
which enables tumor cells to interact with the tissue of the recently colonized organ [77]. 
Leontovich et al [78] demonstrated that the constitutive activation of Raf-1 induces the 
overexpression of HER-2/Neu, leading in turn to the development of metastasis in 
xenografts of MCF7 ER+ cells. This metastasis was linked to the activation of the MET 
pathway, and curiously it was characterized by a reduction in the expression of genes 
implicated in EMT, such as TGFB2, TWIST and FOXC1. On the other hand, Phino et al [79] 
found that the levels of glycosylation of E-cadherin regulated by Mgat3/GnT-III were 
diminished in EMT, and that they were recovered when the cells once again acquired an 
epithelial phenotype. Other genes identified in MET are WT1, BMB7, WNT4 and the protein 
formina IV of the cytoskeleton [53 and references there]. Diverse miRNAs have been found 
to be deregulated in tumors, particularly metastamir, which is implicated in metastasis [80]. 
Wang & Wang [81] summarized the types of metastamir that are deregulated in breast 
cancer cells: miR-9, -10b, -21, -29a, -31, -103/107, -126, -335, -210, and -373. All of these are 
involved in migration, aggressiveness and the worst prognoses. An increase in the levels of 
miR-200 induces MET by reducing motility and aggressiveness [82]. Likewise, the 
expression of miR124 modifies the morphology and capacity of metastasis of MDA-MB-231 
cells, as well as by decreasing the levels of vimentina, a mesenchymal marker [83]. The 
regulation of diverse transcription factors, receptors for growth factors (including FGFR2b, 
FGFR2c, EGFR and HER2), and the activation of Akt are other elements in the reversion of 
MET.  
3.2. Collective to ameboid transition and the mesenchymal to ameboid transition 
Through the process of metastasis, cells can undergo changes in the way in which they 
transport themselves. In explants of melanoma, it has been observed that the inhibition of 
the integrin 1 provokes the separation of groups of cells, which thus become individual 
ameboid cells. These cells acquire the capacity to migrate, independently of proteases and/or 
integrins, similar to that observed in ameboid movement. Hence, the transition from 
collective invasion to ameboid movement of individual cells is an interchangeable and 
bidirectional process that depends on environmental factors, making evident the great 
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dependent pathways that would otherwise allow the cells to enter in premature senescence 
induced by oncogenes. Twist also suppresses the production of let-7i, which in turn allows 
cells to acquire mobility in the last stage of EMT [63, 64]. The overexpression and activation 
of the signaling pathways of HER-2/Neu and TGF activate EMT in tumoral cells of breast 
cancer.  
EMT is also regulated by alternative splicing, such as that of ENAH, a regulating protein of 
the cytoskeleton of actin. The transcript present in epithelial cells contains a small exon 11a, 
which is absent in mesenchymal cell lines and during the EMT [65]. RBFOX2 is a splicing 
factor which together with ESRP1 and ESRP2, proteins for binding with RNA that are 
specific to the epithelium, promote splicing of transcripts that are important in EMT [66]. 
The loss of ESRPs in epithelial cells induces morphological changes similar to EMT [67]. On 
the other hand, Shapiro et al [68] found a partial induction of the splicing program in 
mesenchymal cells by means of the ectopic expression of ESRP1 or by elimination of 
RBFOX2 in immortalized epithelial mammary cells. Mesenchymal isoform IIIc of FGFR2, 
isoform 3 of catenin p120, and isoform CD44s of CD44 are all expressed in mesenchymal 
cells and in tumoral cells with the EMT, as reviewed in [69]. 
Just as the process of EMT resembles that observed during embryonic development, it 
seems that both pathways are regulated by an intricate interaction of transcriptional and 
post-transcriptional programs, as was discovered by observing that the ribonucleoprotein, 
heterogeneous nuclear E1 (hnRNP E1) is a selective transductional regulator of transcripts of 
EMT induced by TGFβ. Due to its capacity to bind to RNA, hnRNP E1 adheres to 3'-UTR 
BAT structural elements present in the transcripts of mRNA necessary for EMT, and upon 
doing so silences these elements. This silencing, mediated by hnRNP E1, occurs during the 
stage of elongation when hnRNP E1 impedes the release of the elongation factor eukaryote 1 
A1 (eEF1A1) of the ribosomal site A. The phosphorylation of hnRNP by Akt2, mediated by 
TGFβ, restores the transduction of white transcripts of EMT. The attenuation of the 
expression of hnRNP E1 in non-invasive breast cancer cell lines induces not only EMT but 
also metastasis [70,71]. Furthermore, the steroid hormones such as androgens have also been 
observed to be implicated in the maintenance of cellular characteristics, evidenced by the 
fact that Sun et al [72] found that the absence of androgens in prostate tumors is associated 
with a worse prognosis and acquisition of cell characteristics typical of mesenchymal or 
stem cells.  
With triple negative breast cancer (ER-, PR- HET2-), there is an overexpression of N-cadherin 
and EMT, leading to a worse prognosis. Regulation by miRNAs is not an exception in EMT, 
particularly the miRNAs of the miR-200 (miR-200a, miR-200b, miR-200c, miR-141 and miR-
429) and miR-205 family. These miRNAs participate in the regulation of EMT induced by 
TGF by mediating the production of ZEB1 and ZEB2 [73,74]. Recently miR-29b was added 
to the list of miRNAs that regulate EMT, due to the fact that an increase in miR-29b in PC3 
prostate cancer cells inhibits the capacity of these tumoral cells to invade and colonize [75]. 
In addition to TGF, other growth factors such as EGF, HGF, PDGF, FGF2, TNF and IGF 
can induce EMT by activating the expression of transcriptional repressors of E-cadherin or 
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by activating the transduction signaling pathways, such as MAPK, PI3K, Wnt/-catenin, NF-
B and Notch [69 and references there].  
3.1. EMT reversion 
After tumoral cells are disseminated, they must reactivate their epithelial properties by 
means of the reversion of the process of EMT, known as the mesenchymal-epithelial 
transition (MET). In the metastatic process, just as EMT is essential for the initial 
transformation of cells from being part of the epithelial tissue to being released from 
intercellular connectedness and ready for transport, MET is critical for the later stages of 
metastasis. Possibly this latter change is triggered by the local environment after 
extravasation towards the parenchyma of the invaded organs [76]. Although EMT has been 
extensively studied, there is much yet to be discovered about the molecular mechanisms 
that regulate MET. One of the keys to the process of MET is the re-expression of E-cadherin, 
which enables tumor cells to interact with the tissue of the recently colonized organ [77]. 
Leontovich et al [78] demonstrated that the constitutive activation of Raf-1 induces the 
overexpression of HER-2/Neu, leading in turn to the development of metastasis in 
xenografts of MCF7 ER+ cells. This metastasis was linked to the activation of the MET 
pathway, and curiously it was characterized by a reduction in the expression of genes 
implicated in EMT, such as TGFB2, TWIST and FOXC1. On the other hand, Phino et al [79] 
found that the levels of glycosylation of E-cadherin regulated by Mgat3/GnT-III were 
diminished in EMT, and that they were recovered when the cells once again acquired an 
epithelial phenotype. Other genes identified in MET are WT1, BMB7, WNT4 and the protein 
formina IV of the cytoskeleton [53 and references there]. Diverse miRNAs have been found 
to be deregulated in tumors, particularly metastamir, which is implicated in metastasis [80]. 
Wang & Wang [81] summarized the types of metastamir that are deregulated in breast 
cancer cells: miR-9, -10b, -21, -29a, -31, -103/107, -126, -335, -210, and -373. All of these are 
involved in migration, aggressiveness and the worst prognoses. An increase in the levels of 
miR-200 induces MET by reducing motility and aggressiveness [82]. Likewise, the 
expression of miR124 modifies the morphology and capacity of metastasis of MDA-MB-231 
cells, as well as by decreasing the levels of vimentina, a mesenchymal marker [83]. The 
regulation of diverse transcription factors, receptors for growth factors (including FGFR2b, 
FGFR2c, EGFR and HER2), and the activation of Akt are other elements in the reversion of 
MET.  
3.2. Collective to ameboid transition and the mesenchymal to ameboid transition 
Through the process of metastasis, cells can undergo changes in the way in which they 
transport themselves. In explants of melanoma, it has been observed that the inhibition of 
the integrin 1 provokes the separation of groups of cells, which thus become individual 
ameboid cells. These cells acquire the capacity to migrate, independently of proteases and/or 
integrins, similar to that observed in ameboid movement. Hence, the transition from 
collective invasion to ameboid movement of individual cells is an interchangeable and 
bidirectional process that depends on environmental factors, making evident the great 
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plasticity that tumoral cells can have [84]. The mesenchymal-ameboid transition can serve as 
a compensatory mechanism of migration after the inhibition of pericellular proteolysis. This 
transition provokes a change from a cellular form similar to a fibroblast to a round or 
elliptical shape, and at the same time spurs a change in the cytoskeletal organization as well 
as the distribution of integrins [85]. 
4. The tumor microenvironment 
During the process of migration, cancerous cells pass through different microenvironments, 
including the stroma, the endothelium of blood vessels, the lymphatic vessels and the tissue 
of the organ where the secondary tumor forms [86]. In each of these sites, the 
microenvironment exerts a strict control over the behavior of tumor cells [87]. 
Cells can cross the basal membrane (BM) during embryonic development and immune 
vigilance, either as part of the embryonic process or more routine morphological processes 
such as leukocyte activity [88]. The BM is a dense layer of the extracellular matrix that is 
highly reticular and rich in laminina, collagen type IV, perlecan, nidogen-1 and nidogen-2. 
Its structural function is to delimit epithelial and endothelial tissue, and to give polarity to 
cells [89, 90]. After the loss of intercellular adhesion, cells acquire a mobile phenotype and 
produce metalloproteinases that allow them to digest the BM. Hence, the BM is the first 
barrier that tumor cells must cross [2]. As a tumor invades an organ, there is a dynamic 
interaction between invasive cells, the invaded tissue and the BM that separate the two. 
Although it has not been easy to study this process in vitro, the transmigration of leukocytes 
has proved to be a very useful model, allowing for the identification of regions of the 
perivascular BM that have less resistance to invasion. These regions contain reduced levels 
of laminin and collagen IV [91]. It is not yet clear how carcinoma cells initiate the invasive 
process after abandoning the primary tumor, but there is evidence that points to the 
participation of invadopodium in the proteolysis of vascular BM.  
4.1. Interactions with the extracellular matrix 
A critical component of the cellular microenvironment is the extracellular matrix (ECM), a 
biopolymer complex that provides healthy and tumor cells with biophysical and 
biochemical signals that influence their function and survival [92]. Cells are capable of 
sensing and responding to changes in the conformation of the ECM through a process of 
mutual feedback that involves cellular contractile mechanisms. Each cell type responds to 
the rigidity that is characteristic of its host [93]. Integrins are crucial participants in the 
communication of cells with the ECM, because they act as a conduit between extracellular 
ligands and the cytoskeleton. Therefore they have the capacity of responding to the rigidity 
of the external substrate through a counter-response exerted by the actomiosin network. 
They act as mechanosensors that undergo conformational changes in response to 
mechanical forces, resulting in increased adhesion between the cells and the ECM, the 
formation of focal adhesions, and the dispersion of the cells [94]. The extracellular signals 
mediated by integrins are transduced internally through focal adhesion components [95]. 
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Tumor cells have the capability of ignoring the conformational changes that take place in the 
ECM, and this capability is associated with the activation of integrin 1 and the 
phosphorylation of FAK in a manner dependent on fibronectin and the overexpression of 
αvβ3 [96]. Lysyl oxidase (LOX), a copper-dependent amine oxidase that catalyzes the 
crosslinking of collagen, elastin and fibrin in the ECM, can modulate metastasis by 
facilitating extravasation or by conditioning the metastatic niche, the latter done by 
increasing the rigidity of the ECM and fibrillar collagen [97]. As can be seen, although the 
ECM is considered a barrier for the dissemination of tumor cells, its remodeling by tumor 
cells actually converts it into a promoter of the same process. The release of proteins from 
the ECM by tumor MMPs can create a promigratory stimulus, in part by increasing the 
rigidity of the tissue, which in turn augments the motility of tumor cells [98].  
4.2. The cancer-associated fibroblast and the tumor associated macrophages and 
immune cells 
Diverse signals emanating from tumor cells allow them to recruit and activate host cells, 
particularly monocytes, fibroblasts and mesenchymal stem cells, all of which are abundant 
in the microenvironment of a tumor. Among these cell types, fibroblasts are the most 
abundant and important in the interaction with the tumor. The carcinoma associated 
fibroblasts (CAFs) are miofibroblasts with contractile properties and a staining capacity for 
alpha-smooth muscle actin (-SMA). Several studies have reported that they can potentiate 
tumorigenesis by expressing proteins that favor migration or by altering the stromal 
environment in a way that facilitates colonization. Brentnall et al [99] point out that the 
overexpression of paladin by the activation of k-ras can transform normal fibroblasts into 
miofibroblasts in 5 days. As a result, the expression of paladin alters the morphology and 
behavior of cells, leading to an increased cellular migration, the degradation of the ECM by 
the formation of invadopodia, and the creation of tunnels through which cancerous cells can 
transport themselves. Malanchi et al [100] found that to facilitate the process of colonization, 
infiltrating tumor cells need to induce the expression of stromal periostina (POSTN) in the 
target organ for a secondary tumor. POSTN is a component of the ECM that is expressed by 
fibroblasts, both in healthy tissue as well as in the stroma of a primary tumor. Møller et al 
[101] reported that fibulin 5, whose expression is downregulated by factors released by 
fibroblasts in tumors, is capable of suppressing metastatic colonization of the lungs and liver 
by inhibiting the production of metalloproteinase 9 and by reducing the invasive behavior 
of fibroblasts. Hence, tumor cells avoid the expression of this protein.  
Epithelial cells produce multiple factors that recruit various cells able to facilitate the 
infiltration of tumors, including tumor-associated macrophages (TAMs), tumor-associated 
neutrophils (TANs), lymphocytes, mesenchymal stem cells, endothelial cells and the 
aforementioned CAFs. In the case of macrophages, experimental evidence exists supporting 
the idea that they can differentiate into pro-inflammatory macrophages (M1) or anti-
inflammatory macrophages (M2), depending on the stimulus [102,103]. TAMs are similar to 
M2 macrophages, promoting tumor progression by their incapacity to induce T cells, their 
increased expression of manose and scavenger receptors, as well as their release of pro-
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plasticity that tumoral cells can have [84]. The mesenchymal-ameboid transition can serve as 
a compensatory mechanism of migration after the inhibition of pericellular proteolysis. This 
transition provokes a change from a cellular form similar to a fibroblast to a round or 
elliptical shape, and at the same time spurs a change in the cytoskeletal organization as well 
as the distribution of integrins [85]. 
4. The tumor microenvironment 
During the process of migration, cancerous cells pass through different microenvironments, 
including the stroma, the endothelium of blood vessels, the lymphatic vessels and the tissue 
of the organ where the secondary tumor forms [86]. In each of these sites, the 
microenvironment exerts a strict control over the behavior of tumor cells [87]. 
Cells can cross the basal membrane (BM) during embryonic development and immune 
vigilance, either as part of the embryonic process or more routine morphological processes 
such as leukocyte activity [88]. The BM is a dense layer of the extracellular matrix that is 
highly reticular and rich in laminina, collagen type IV, perlecan, nidogen-1 and nidogen-2. 
Its structural function is to delimit epithelial and endothelial tissue, and to give polarity to 
cells [89, 90]. After the loss of intercellular adhesion, cells acquire a mobile phenotype and 
produce metalloproteinases that allow them to digest the BM. Hence, the BM is the first 
barrier that tumor cells must cross [2]. As a tumor invades an organ, there is a dynamic 
interaction between invasive cells, the invaded tissue and the BM that separate the two. 
Although it has not been easy to study this process in vitro, the transmigration of leukocytes 
has proved to be a very useful model, allowing for the identification of regions of the 
perivascular BM that have less resistance to invasion. These regions contain reduced levels 
of laminin and collagen IV [91]. It is not yet clear how carcinoma cells initiate the invasive 
process after abandoning the primary tumor, but there is evidence that points to the 
participation of invadopodium in the proteolysis of vascular BM.  
4.1. Interactions with the extracellular matrix 
A critical component of the cellular microenvironment is the extracellular matrix (ECM), a 
biopolymer complex that provides healthy and tumor cells with biophysical and 
biochemical signals that influence their function and survival [92]. Cells are capable of 
sensing and responding to changes in the conformation of the ECM through a process of 
mutual feedback that involves cellular contractile mechanisms. Each cell type responds to 
the rigidity that is characteristic of its host [93]. Integrins are crucial participants in the 
communication of cells with the ECM, because they act as a conduit between extracellular 
ligands and the cytoskeleton. Therefore they have the capacity of responding to the rigidity 
of the external substrate through a counter-response exerted by the actomiosin network. 
They act as mechanosensors that undergo conformational changes in response to 
mechanical forces, resulting in increased adhesion between the cells and the ECM, the 
formation of focal adhesions, and the dispersion of the cells [94]. The extracellular signals 
mediated by integrins are transduced internally through focal adhesion components [95]. 
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Tumor cells have the capability of ignoring the conformational changes that take place in the 
ECM, and this capability is associated with the activation of integrin 1 and the 
phosphorylation of FAK in a manner dependent on fibronectin and the overexpression of 
αvβ3 [96]. Lysyl oxidase (LOX), a copper-dependent amine oxidase that catalyzes the 
crosslinking of collagen, elastin and fibrin in the ECM, can modulate metastasis by 
facilitating extravasation or by conditioning the metastatic niche, the latter done by 
increasing the rigidity of the ECM and fibrillar collagen [97]. As can be seen, although the 
ECM is considered a barrier for the dissemination of tumor cells, its remodeling by tumor 
cells actually converts it into a promoter of the same process. The release of proteins from 
the ECM by tumor MMPs can create a promigratory stimulus, in part by increasing the 
rigidity of the tissue, which in turn augments the motility of tumor cells [98].  
4.2. The cancer-associated fibroblast and the tumor associated macrophages and 
immune cells 
Diverse signals emanating from tumor cells allow them to recruit and activate host cells, 
particularly monocytes, fibroblasts and mesenchymal stem cells, all of which are abundant 
in the microenvironment of a tumor. Among these cell types, fibroblasts are the most 
abundant and important in the interaction with the tumor. The carcinoma associated 
fibroblasts (CAFs) are miofibroblasts with contractile properties and a staining capacity for 
alpha-smooth muscle actin (-SMA). Several studies have reported that they can potentiate 
tumorigenesis by expressing proteins that favor migration or by altering the stromal 
environment in a way that facilitates colonization. Brentnall et al [99] point out that the 
overexpression of paladin by the activation of k-ras can transform normal fibroblasts into 
miofibroblasts in 5 days. As a result, the expression of paladin alters the morphology and 
behavior of cells, leading to an increased cellular migration, the degradation of the ECM by 
the formation of invadopodia, and the creation of tunnels through which cancerous cells can 
transport themselves. Malanchi et al [100] found that to facilitate the process of colonization, 
infiltrating tumor cells need to induce the expression of stromal periostina (POSTN) in the 
target organ for a secondary tumor. POSTN is a component of the ECM that is expressed by 
fibroblasts, both in healthy tissue as well as in the stroma of a primary tumor. Møller et al 
[101] reported that fibulin 5, whose expression is downregulated by factors released by 
fibroblasts in tumors, is capable of suppressing metastatic colonization of the lungs and liver 
by inhibiting the production of metalloproteinase 9 and by reducing the invasive behavior 
of fibroblasts. Hence, tumor cells avoid the expression of this protein.  
Epithelial cells produce multiple factors that recruit various cells able to facilitate the 
infiltration of tumors, including tumor-associated macrophages (TAMs), tumor-associated 
neutrophils (TANs), lymphocytes, mesenchymal stem cells, endothelial cells and the 
aforementioned CAFs. In the case of macrophages, experimental evidence exists supporting 
the idea that they can differentiate into pro-inflammatory macrophages (M1) or anti-
inflammatory macrophages (M2), depending on the stimulus [102,103]. TAMs are similar to 
M2 macrophages, promoting tumor progression by their incapacity to induce T cells, their 
increased expression of manose and scavenger receptors, as well as their release of pro-
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tumorigenic factors (e.g., TGF-1, IL-10 and MMPs) and pro-angiogenic factors [104]. As 
they generally accumulate in hypoxic zones, the pro-angiogenic program of TAMs is 
triggered, resulting in the secretion of VEGF, IL-1b, TNF-a, angiogenin and semaphorin 4D. 
By secreting urokinasetype plasminogen activator (uPA) and its receptor, uPAR, TAMs can 
participate in the degradation of the ECM [105]. 
The non-neoplasic cells present in the stroma of the tumor produce a series of chemokines 
and growth factors that form a complex network of communication within the tumoral 
microenvironment. One factor produced by the CAFs is CXCL12, which promotes the 
migration of tumor cells towards blood vessels [106]. TAMs co-migrate with tumor cells in a 
paracrine-dependent manner. They produce EGF, which increases the migration of breast 
cancer cells that express EGFRs. In response, these tumor cells secrete CSF1, thereby 
attracting the TAMs that express CSF1Rs [107]. Campbell et al [108] found that the TAMS 
positive to CD68 and PCNA are associated with a worse prognosis for breast cancer 
patients.  
Macrophages are capable of regulating other stromal cells and of exerting influence through 
them. For instance, the loss of signaling by TGF- in mammary fibroblasts produces an 
increase in the secretion of CCL2, which in turn results in a progression of 4T1 tumors, 
either through direct action on cancerous cells or through the recruitment of macrophages 
[109]. The infiltration of lymphocytes is associated with metastasis and an increased 
expression of the activator of the NF-κB (RANK) receptor and of its ligand (RANKL). In 
particular, T regulatory cells (Treg) infiltrated in a breast cancer tumor stimulate metastasis 
in breast cancer through the signaling by RANKL-RANK to IKK-, causing the suppression 
of the inhibitor of the antimetastatic serine proteinase and maspin, and favoring the survival 
of circulating tumor cells [110]. It is possible that CAFs express CCL5, thus attracting Treg 
cells that express CCR1 and produce RANKL. Treg cells secrete IL-4 and IL-13, which in this 
case would result in the activation of TAMs and consequently the promotion metastasis in 
RANK-positive tumors [111]. Neutrophils, on the other hand, participate in the preparation 
of the tumoral microenvironment. They produce enzymes that remodel the ECM, and also 
produce ROS, which in turn activates NF-B and in this way allows tumor cells to attenuate 
their apoptotic response and increase their mutation rate [112]. 
5. Survival of tumoral cells and modulation of cell survival 
The metastatic process has various rate-limiting steps, and consequently only a minority of 
tumor cells is able to reach distant sites [86]. It has been suggested that approximately 0.01% 
of circulating tumor cells can manage to produce a metastasis [113]. Talin 1 is one of the 
proteins whose altered expression allows for the survival of tumor cells. It can recruit focal 
adhesion proteins ILK, FAK and Src through its interaction with integrin , resulting in the 
promotion of the survival, invasion and angiogenesis of tumor cells. Its overexpression 
allows prostate cancer tumor cells to activate survival signals and resist death by anoikis 
[114]. In this sense, the PI3K/Akt and Wnt/-catenin signaling pathways, along with 
mutations in p53 and other genes, play an important role in the avoidance of death by 
metastatic cells.  
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The adhesion of tumor cells to the ECM is not sufficient for inducing a survival signal. The 
changes in the cytoskeleton associated with adhesion signaling are critical for tumor cell 
survival. Halder & Johnson [115] indicate that the newly established Hippo suppressor 
pathway (which regulates the size of organs by maintaining a balance between proliferation 
and apoptosis in physiological conditions) might be involved in tumor proliferation. The 
Hippo pathway phosphorylates and inhibits the transcriptional coactivator Yes-associated 
protein (YAP), a key oncogene for the regulation of the size of organs. This inactivation is 
triggered by the reorganization of the cytoskeleton. Once the cell has separated, the Hippo 
kinases Lats 1/2 are activated, causing the inhibition of YAP, and therefore resulting in 
anoikis. It has been found that with metastatic prostate cancer, the levels of expression of 
Lats 1/2 are significantly downregulated [116], whereas, Lamar et al [117] demonstrated that 
increased YAP activity promotes metastasis and tumor growth at both the primary site and 
the metastatic site. 
5.1. Integrins in cell survival and apoptosis (anoikis) 
A loss of balance between cell division and cell death is common in cancer, due to a decrease 
in apoptotic cell death that leads to the progression of a tumor. There are various ways by 
which a malignant tumor cell averts or resists apoptosis.  
The distinctive morphological characteristic of apoptosis is the condensation of chromatin 
and the posterior fragmentation of the nucleus, accompanied by a reduction of cell volume, 
a retraction of pseudopods, and the formation of vacuoles, all leading to a loss of integrity of 
the cell membrane [110]. The biochemical changes that occur during apoptosis are: (i) the 
activation of caspases, (ii) the rupture of DNA and proteins, and (iii) changes in the 
membrane related to its recognition by phagocytes [111].  
Tumor cells can avert apoptosis by altering the balance of pro-and anti-apoptotic proteins, 
decreasing the function of caspases, and altering the signaling of receptors related to cell 
death [112]. A cancerous cell in an ectopic site, whether near a primary tumor or in route to 
a secondary organ, can employ various mechanisms to avert the process of apoptosis known 
as anoikis [113]. Through anoikis, a healthy cell in an inappropriate location activates its 
programmed death by separating itself from its neighbors and its microenvironment, and 
thus is eliminated. Anoikis is therefore a barrier against the formation and survival of 
potentially oncogenic clones. Only non-adherent cells, such as leukocytes and mature 
hematopoietic cells, are protected from anoikis [114].  
The principal effector mechanisms of anoikis are autophagy and apoptosis [115]. A critical 
step in the series of changes through which a tumor cell passes to avoid apoptosis is a 
change in the expression of integrins, which are a family of receptors that receive signals 
from the ECM. This change is based on genetic and epigenetic alterations that can only 
occur in the microenvironment of a tumor [116], allowing tumor cells to ignore signals by 
the ECM and act as if they were in the appropriate microenvironment. Besides this extrinsic 
pathway, tumor cells can also avoid apoptosis by damaging the mitochondria, an intrinsic 
pathway allowing these cells to hyperactivate mechanisms of survival and proliferation 
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tumorigenic factors (e.g., TGF-1, IL-10 and MMPs) and pro-angiogenic factors [104]. As 
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thus is eliminated. Anoikis is therefore a barrier against the formation and survival of 
potentially oncogenic clones. Only non-adherent cells, such as leukocytes and mature 
hematopoietic cells, are protected from anoikis [114].  
The principal effector mechanisms of anoikis are autophagy and apoptosis [115]. A critical 
step in the series of changes through which a tumor cell passes to avoid apoptosis is a 
change in the expression of integrins, which are a family of receptors that receive signals 
from the ECM. This change is based on genetic and epigenetic alterations that can only 
occur in the microenvironment of a tumor [116], allowing tumor cells to ignore signals by 
the ECM and act as if they were in the appropriate microenvironment. Besides this extrinsic 
pathway, tumor cells can also avoid apoptosis by damaging the mitochondria, an intrinsic 
pathway allowing these cells to hyperactivate mechanisms of survival and proliferation 
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[117]. Another important factor in anoikis is the integrity of the cytoskeleton [118], since 
many pro-apoptotic proteins, including BIM and BMF, co-locate with the cytoskeleton. 
In vertebrates, integrins are a family of receptors composed of 18 subunits  and 8 subunits 
, whose combination gives rise to 24 types of these receptors [119]. Changes in the integrins 
that act as receptors for the ECM are essential for the avoidance of anoikis. The normal 
functioning of these receptors not only provides a physical bond with the ECM, but also 
establishes a platform that depends on signals from adhesion molecules, including adaptor 
proteins and kinases [120, 121]. For instance, the integrins α1β1, α2β1, α3β1, α5β1, α6β1, 
α6β4 and αvβ3 have a profound impact on cell survival [122]. 
A particularly important structure in this sense is hemidesmosome, in which there are 
complexes of integrin-talin-paxilin-actin that receive signals from the ECM and transduce 
these signals through various proteins such as focal adhesion kinase (FAK) in order to avoid 
anoikis. FAK, the kinase linked to the integrin ILK, tyrosine kinase Src, PI3K, the 
extracellular signal-related kinase (ERK) and the adaptor protein Shc are key to the 
transduction of signals mediated by integrins for protection against anoikis [123]. The FAK 
binds to the cytoplasmic tails of the integrins and is autophosphorylated at the Y397 residue 
in order to transmit a survival signal [124]. After the adhesion of integrins with the 
appropriate proteins of the ECM, FAK and ILK recruit and activate PI3K/Akt, ERK and the 
Jun kinase (JNK) pathway [125].  
The separation of these cells, which move towards the vascular lymphatic space, as well as 
their implantation in a site with an unknown ECM can cause the separation of the  and  
subunits of the heterodimeric receptors of integrin, which in turn leads to the deactivation of 
FAK, of the family of tyrosine kinases Src, and of ILK. Whereas this attenuates pro-survival 
pathways, including the mitogen-activated protein kinase/ERK, Akt/phosphatase, tensin 
homologue (PTEN), and the nuclear factor B (NF-B) [126], it at the same time stimulates 
other mechanisms of survival. The latter mechanisms include the activation of PKB/Akt, 
which can inhibit anoikis at multiple levels. This inhibition takes place by the inactivation of 
caspase 9, by a scavenging process that is dependent on the phosphorylation of the pro-
apoptotic Bad protein by the 14-3-3 protein, by the activation of NF-B, and by the inhibition 
of transcription factors Fork-head [127-130].  
It has been seen that the response to anoikis can be recovered by silencing FAK with siRNAs 
in pancreatic cancer cells [131]. Recently it was found that the inhibition of the proteins of 
the subfamily of Rho and the expression of Akt in the B16F10 cell line inactivates the FAK 
pathway and induces anoikis in resistant cells [132]. Whereas healthy epithelial cells express 
the receptor for collagen α2β1 and receptors for laminin α3β1 and α6β1, hyperproliferative 
cells overexpress integrins αvβ5 and αvβ6 and squamous carcinoma cells overexpress αvβ6. 
The latter integrin is required for the adhesion of melanoma cells to dermic collagen and for 
survival in the environment of the new tissue [133-137]. Goldstein et al [138] found that the 
substitution of valine by glutamic acid at aminoacid 600 of B-RAF (B-RAFV600E), which is 
found in 66% of melanomas, is an event that leads to resistance to anoikis by continuous 
activation of MEK/ERK and the inhibition of BIM, a pro-apoptotic protein. Whereas in a 
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healthy cell BIM levels are increased upon its separation from its tissue as a mechanism to 
activate its programmed death, this does not occur in tumor cells. Although the 
overexpression of integrin αvβ3 is associated with an increase in invasiveness, it has also 
been implicated in the induction of anoikis, which suggests that it has a dual role in 
tumorigenesis [139, 140].  
ANGPTL4, a regulator of the metabolism of lipids, leads to the activation of Rac1 and FAK 
by binding to integrins β1 and β5. This phenomenon protects against anoikis through the 
activation of Src, Akt/PKB and ERK. Hence, the binding of ANGPTL4 with integrins is 
capable of deceiving the mechanism of programmed death by generating a false impression 
of anchorage [141]. The phosphorylation of ERK2 by FAK, though, leads to the 
phosphorylation of BIM, marking the latter for ubiquitination and degradation. Another 
critical protein for resisting anoikis is the 5 integrin, which as shown by Shen et al [142], 
has its expression in gastric cancer regulated by the S100A4 protein. S100A4 permits the 
survival of tumor cells and favors the overexpression of the 5 integrin.  
By interacting with integrins, the microenvironment modulates their function in an 
important way. Marchan et al [143] found that β3 expressed in pancreatic cancer cells has 
important effects, including the promotion of migration in single-layer cell cultures, the 
induction of anoikis in vitro, and the suppression of tumor growth in vivo. At the same time 
that tumor cells avoid programmed death by anoikis, they acquire a mesenchymal 
phenotype that allows them to begin migration.  
6. Transendothelial or lymphatic migration and extravasation 
Tumor cells must go in and out of blood vessels by crossing endothelial layers as part of the 
metastatic process, and in order to do this they undergo dramatic changes in their shape, 
driven by a reorganization of their cytoskeleton. The most difficult part of these changes in 
malignant cells, which adopt elastic and viscous properties for this purpose, is the 
deformation of the nucleus in interphase, because it is 10 times more rigid than the 
cytoplasm [144].  
Intravasation is the principal route for the dissemination of tumor cells coming from 
carcinomas. Once inside of a blood vessel, the survival of tumor cells is affected by various 
factors, including hemodynamic forces, immunological stress, and collisions with blood 
cells. Consequently, only a very small number of tumor cells manage to leave blood vessels 
[145]. The majority of tumor cells that enter the bloodstream are detained in the 
microvasculature of the first organ they pass through [146].  
It has been demonstrated that in breast cancer tumors, intravasation depends on the 
paracrine loop between tumor cells and TAMs [100]. In one clinical study of patients with 
breast cancer, the half-life of tumor cells in the bloodstream was from 1 to 2.4 h [147]. Png et 
al [148] pointed out that endothelial cells play an important initial role in metastasis by 
providing signals that promote this process. These researchers identified molecules such as 
secretory IGFBP2, the transference protein PITPNC1, and the kinase MERK as necessary for 
mediating the recruitment of metastatic endothelial cells.  
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Brown & Ruoslahti [149] suggested that there are molecules that favor the capture of tumor 
cells in blood vessels. In the case of breast cancer cells, the expression of metadherin favors 
homing in the pulmonary vasculature. In the majority of tumors of epithelial origin, the first 
sign of metastasis is found in regional lymphatic nodes. Once inside the lymphatic vessels, 
tumor cells can produce local or regional metastasis, or can enter in a quiescent state, whose 
duration depends in great part on the immune system. Immune vigilance can induce 
quiescence in individual cells by detaining the cell cycle through signals mediated by 
cytokines [150, 151]. It is estimated that 80% of metastasis of solid tumors, such as in breast 
cancer and melanoma, are disseminated through the lymphatic system [151].  
In the bloodstream a tumor cell can be detained or can succeed in passing through the wall 
of a blood vessel. If the tumor cell has a diameter greater than that of a given blood vessel, 
mechanical or occlusive detainment will occur. This mechanism of detention has been 
observed in mouse models of brain cancer metastasis [152]. On the other hand, if the tumor 
cell has a diameter less than that of the blood vessel, it must bond to the wall of this channel 
in order to be able to leave the bloodstream. There is evidence that tumor cells are associated 
with platelets, which can mask and protect these cells from being located by natural killer 
cells [153]. Platelets can also facilitate the accumulation of VEGF at the bond between a 
tumor cell and the endothelium tissue, favoring vascular hyperpermeability and 
consequently extravasation [154].  
7. Colonization 
During the progression of cancer, the colonization of distant organs by circulating tumor 
cells marks the difference between a possibly curable tumor and a systemic and generally 
incurable disease [155]. After an analysis of breast cancer tumors, Paget [156] concluded that 
the local microenvironment of some organs must be favorable for the dissemination of 
tumor cells or their progenitors. On the one hand, the microenvironment of the target organ 
is a determinant for the survival of tumor cells, and on the other hand the accumulation of 
these malignant cells in a given organ can create an adequate stromal microenvironment to 
allow metastasis [157].  
In the preparation of an adequate niche, the primary tumor secretes VEGFA to mobilize 
progenitor hematopoietic cells from bone marrow (HPCs) toward the bloodstream, and 
from there to the site of metastasis. The same process occurs with fibronectin, 
metalloproteinases and growth factors, all of which can be synthesized by the primary 
tumor and released to the bloodstream, later to accumulate in the target organ. In this way, 
these molecules prepare a premetastatic microenvironment, to which the HPCs arrive and 
continue this process of adaptation for the purpose of their own survival.  
Tumor cells and macrophages are recruited towards the premetastatic niche due to the 
chemokines synthesized by cells associated with cancer [158]. It has been shown that 
chemokines are chemotactic molecules important for colonization of a given organ [159, 
160]. Wendel et al [161], by utilizing intravital observation techniques, were able to 
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demonstrate that the receptor of chemokine CXCR4 plays an important role in the 
extravasation of breast cancer tumor cells towards their target organs.  
The anatomy of some organs provides a barrier to metastasis. In the case of the lungs, 
endothelial capillaries are surrounded by a basal membrane [162]. In the blood-brain barrier, 
capillaries have tight junctions and astrocyte foot processes [163]. Capillaries in bone 
marrow and the liver, on the other hand, are fenestrated, making them susceptible to 
invasion [162].  
Another important factor in the ability of a tumor to invade a distant organ is the type of 
primary tumor. Breast cancer tumors positive for estrogen receptors, as well as ocular 
prostate cancer tumors and melanoma tumors, can give metastatic signals decades after 
elimination of the primary tumor [7, 164-166]. This is due to the fact that tumor cells are 
disseminated from the primary tumor various years before detection of the primary tumor. 
Adenocarcinoma of pancreatic and lung cancer have malignant cells that rapidly acquire the 
capacity to infiltrate and colonize without requiring a process of quiescence to generate a 
macrometastasis [167, 168]. Furthermore, tumor cells in general can adopt two distinct states 
of quiescence while awaiting a favorable microenvironment. They can exist as individual 
cells (cellular quiescence) or as small indolent groups (tumor mass quiescence), in either 
case maintaining a balance between proliferation and death during the period of latency 
[169].  
7.1. Most frequent organs for metastasis 
Although no organ is totally protected from the development of metastasis, this process 
tends to take place more frequently in certain regions of the body, including the lymphatic 
nodes (lymphatic metastasis), lungs, liver, bone marrow, brain (haematogenic metastasis), 
peritoneum and pleura [145]. Each type of cancer is more prone to certain organs. When it 
occurs, metastasis exists in at least 2 organs, with an average of 5.6 metastases per patient.  
With breast cancer, metastasis generally is a slow process that occurs in the lymph nodes, 
lungs, bone marrow, liver or brain. Only in 6-18% of breast cancer patients does metastasis 
takes place in the gastrointestinal tract, with the stomach and small intestine being the most 
frequent hosts. On the other hand, colorectal cancer rarely metastasizes to bone marrow 
[170]. Adrenal glands are the preferred site for metastasis of lung cancer tumors with small 
cells [171]. In North and South America, lung and breast cancer are the first and second 
source of metastasis to the brain. Generally the earliest metastasis takes place with lung 
cancer [172], with 80% of such events occurring in the cerebellar hemispheres [173]. 
However, the most frequent metastasis to the cerebellar hemispheres occurs in breast cancer 
patients [174]. This frequency can be explained in part by the production of osteoclast-
activating factors, such as the parathyroid hormone related protein (PTHrP), IL-1, IL-6, IL-11 
and GM-CSF by breast cancer tumor cells [175]. These osteoclasts release growth factors 
derived from bones, such as TGF- and IGF-1 [176]. Contrarily, the metastasis of tumor cells 
from prostate cancer to bone marrow generally stimulates the formation of bone, regulated 
by the production of osteoblast-activating factors such as endothelin-1, BMPs and PDGF. In 
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cells (cellular quiescence) or as small indolent groups (tumor mass quiescence), in either 
case maintaining a balance between proliferation and death during the period of latency 
[169].  
7.1. Most frequent organs for metastasis 
Although no organ is totally protected from the development of metastasis, this process 
tends to take place more frequently in certain regions of the body, including the lymphatic 
nodes (lymphatic metastasis), lungs, liver, bone marrow, brain (haematogenic metastasis), 
peritoneum and pleura [145]. Each type of cancer is more prone to certain organs. When it 
occurs, metastasis exists in at least 2 organs, with an average of 5.6 metastases per patient.  
With breast cancer, metastasis generally is a slow process that occurs in the lymph nodes, 
lungs, bone marrow, liver or brain. Only in 6-18% of breast cancer patients does metastasis 
takes place in the gastrointestinal tract, with the stomach and small intestine being the most 
frequent hosts. On the other hand, colorectal cancer rarely metastasizes to bone marrow 
[170]. Adrenal glands are the preferred site for metastasis of lung cancer tumors with small 
cells [171]. In North and South America, lung and breast cancer are the first and second 
source of metastasis to the brain. Generally the earliest metastasis takes place with lung 
cancer [172], with 80% of such events occurring in the cerebellar hemispheres [173]. 
However, the most frequent metastasis to the cerebellar hemispheres occurs in breast cancer 
patients [174]. This frequency can be explained in part by the production of osteoclast-
activating factors, such as the parathyroid hormone related protein (PTHrP), IL-1, IL-6, IL-11 
and GM-CSF by breast cancer tumor cells [175]. These osteoclasts release growth factors 
derived from bones, such as TGF- and IGF-1 [176]. Contrarily, the metastasis of tumor cells 
from prostate cancer to bone marrow generally stimulates the formation of bone, regulated 
by the production of osteoblast-activating factors such as endothelin-1, BMPs and PDGF. In 
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this way, the activated osteoblasts can maintain the proliferation and survival of the tumor 
cells [177].  
Cyclooxygenase COX 2, EGFR, the ligand HBEGF and 2,6-sialyltransferase ST6GALNAC5 
are mediators of the passage of cancerous cells through the blood-brain barrier. 
Nevertheless, only ST6GALNAC5 mediates metastasis of breast cancer tumor cells to the 
brain, facilitating the both the passage through the blood-brain barrier and the adhesion of 
these cells to brain endothelial cells [178]. A recent study [179] reported that the greatest 
number of metastasis to the brain occur in breast cancer patients of African origin. The least 
frequent teratogenic metastases are found in the kidneys, gonads, spleen, subcutaneous fat 
and especially in the walls of the gastrointestinal tract, uterus, heart and skeletal muscle 
[180]. 
The gradients of chemokines can explain the tropism of some types of cancer. It has been 
suggested that in organs with high levels of chemokine expression, these latter molecules 
can attract metastatic tumor cells that express the corresponding receptor. This model has 
been demonstrated in the metastasis of breast and prostate cancer tumors to bone marrow 
due to the presence of CXCR4-CXCL12. With solid and hematopoietic tumors, chemokines 
CCL21 and CCL19 are present in metastasis to lymphatic nodules with the corresponding 
receptor CCR7 [18].  
8. Conclusion 
The capacity of tumor cells to be transported to organs distant from the primary tumor is 
driven by two types of factors: the complex interactions between tumor cells and their 
surroundings, and the changes in such cells that allow them to adapt to their environment. 
Among the latter factors is the hallmark of tumor cells: their capacity to avoid apoptosis. At 
the onset of the metastatic process, the epithelial-mesenchymal transition is critical for a 
tumor cell to escape the controls of adhesion and be released for transport from the primary 
tumor. It must then be able to move across the cell membrane, remodel the extracellular 
matrix, transport itself by circulation, and establish itself in a distant organ. The 
mesenchymal-epithelial transition is critical for this last stage in which the tumor cell 
survives in a new organ. Although very few tumor cells are able to achieve this task, 
metastasis unfortunately is a common occurrence with cancer patients due to the continuous 
exposure to the development of the primary tumor, to growth factors, to angiogenesis and 
to accumulated genetic changes. The great complexity of the regulatory network that is 
implicated in the susceptibility of an organ to metastasis, as well as the capacity of tumor 
cells to dodge the immune response and influence the microenvironment of a given organ to 
make it favorable to metastasis, makes the study of metastasis for the purpose of drug 
design for cancer treatment a titanic task. The advantage is that there are now thousands of 
researchers and hundreds of thousands of reports in the field of metastasis. Furthermore, 
metastasis is a lengthy process, often taking a decade. Hence, the challenge is to detect a 
tumor after the onset of the parent cancerous cell but before metastasis. 
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1. Introduction 
Prostate cancer (PCA) is the most commonly diagnosed cancer affecting men in many 
countries and it has been estimated that there would be 33, 000 deaths due to PCA in the 
United States in 2011 alone [1]. The standard chemotherapy for metastatic castration-
resistant prostate cancer (CRPC) is the taxane anticancer drug docetaxel in combination with 
the steroid prednisone. In the past two years, autologous immunotherapy sipuleucel-T 
(Provenge), the new taxane drug cabazitaxel (Jevtana) and a P450 C17 inhibitor drug 
abiraterone acetate (Zytiga) were also approved by the US FDA (Food and Drug 
Administration) [2]. Unfortunately, those drugs can only offer limited survival benefit but 
have significant side effects that negatively affect the quality of life of the patients.  
In contrast to chemotherapy, cancer chemoprevention uses naturally occurring or synthetic 
chemicals to block, delay or reverse carcinogenesis, progression and metastasis and is 
increasingly being recognized as essential for winning the war on PCA. Animal models are 
essential for development of effective chemoprevention. Currently, the mouse models used 
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lesions/cancers develop ‘‘naturally’’ in situ in the genetically engineered hosts and can be 
followed over a long time course [4]. 
2. TRAMP model represents at least two lineages of prostate 
carcinogenesis 
The transgenic adenocarcinoma of mouse prostate (TRAMP) model was originally 
developed by Dr. Greenberg in 1995 [5]. It belongs to the first generation of models based on 
SV40 viral oncogenes [3]. In this TRAMP model, the rat probasin promoter (-426 to 28 bp) 
drives the expression of SV40 large T-antigen (T-Ag) and small t-antigen in the prostate. T-
Ag abrogates P53 and Rb tumor suppressor proteins by direct binding. Simultaneously, 
small t-antigen interacts with protein phosphatase 2A [6] to regulate activity of the mitogen 
activated protein kinase activation pathway and the AP-1 transcription factor activity [7]. T-
Ag and small t-antigen act spontaneously to propel the genesis of prostate epithelial lesions 
and malignant carcinomas and metastases. The TRAMP model is by far the most widely 
used PCA transgenic model for chemoprevention studies because of its simplicity in 
breeding compared to next generations of transgenic models based on deletions, insertions 
or mutations of mouse genes to mimic their changes in human PCA.  
For more than one decade since its inception, the TRAMP model has been believed to 
represent a single lineage of epithelial lesion progression with well-defined kinetics and 
molecular marker alterations. The progression was thought to start from low and high grade 
PIN, to well-differentiated (WD) and moderately-differentiated (MD) adenocarcinoma in the 
dorsolateral prostate lobes (DLP) and finally by stoichastic phenotypic conversion, to poorly 
differentiated adenocarcinomas (PD-Ca) with lymph node and other distant metastases [8]. 
Many subsequent publications interpreted the histology results and molecular 
characterizations using such a paradigm. 
However, several recent studies have suggested that the poorly-differentiated neuro-
endocrine (NE)-like carcinomas (NECa) [9, 10] belonged to a distinct lineage from the 
epithelial lesions, which included low and high grade PIN, WD to MD 
“adenocarcinomas” of the original classification by Dr. Greenburg [8]. Those epithelial 
lesions were recently termed “atypical hyperplasias of T-Ag” (AHT) to distinguish from 
the human prostate cancer pathogenesis because they did not invade adjacent tissues [9]. 
In addition, the incidence of the NECa was found to be profoundly affected by the genetic 
background of the host mice [9]. In the C57BL/6 background, the lifetime incidence of 
NECa was estimated to be about 20% whereas in the FVB background, 87% NECa 
incidence was recorded by as early as 16 weeks of age and reached 100% by 20 weeks of 
age [9]. Furthermore, these NECa mostly arose in the ventral prostate (VP) lobes instead 
of the DLP in both strains [9, 10]. Tissue reconstitution experiments carried out by 
Chiaverotti et al indicated that NECa did not arise from the trans-differentiation of pre-
existing AHT [9]. Tang et al reported that stress induced by anti-cancer treatments 
(castration and/or docetaxol) increased the incidence of NECa in TRAMP mice ((C57BL/6 
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x FVB) F1) [11]. However, the conclusion might be questionable since no mouse in the 
control group had NECa by the time of death, although they all developed 
adenocarcinoma in their prostates. 
These findings significantly challenged the classical notion of single-lineage disease 
progression in the TRAMP DLP [8, 12]. Since the TRAMP model has been increasingly used 
for prostate cancer chemoprevention studies, it is very critical to further characterize the 
lobe-specificity of lesion lineages and NECa incidence in the prostate to consolidate the 
advantages of this model and minimize its limitations for both etiological and 
chemoprevention studies. To experimentally approach this, our group estimated the 
incidence of NECa based on 90 TRAMP mice in the C57BL/6 background spanning the age 
range of 16-50 weeks from several study cohorts [13-15]. We also characterized the 
histological features of different lineages of carcinogenesis in this model using archived 
tissue blocks from those studies [13-15]. In addition, by using state-of-the-art proteomics, we 
sought insights on mechanisms underlying carcinogenesis of different lineages and possible 
targets of chemopreventive reagents [15-17]. Here, we review our results as well as from 
other researchers’ work to provide an objective analysis of the utility of this preclinical 
model for cancer chemoprevention studies. 
3. Histological characteristics of prostate carcinogenesis in TRAMP 
model 
In our studies, the female heterozygous C57BL/TGN TRAMP mice (line PB Tag 8247NG) 
were purchased from The Jackson Laboratory (Bar Harbor, ME), and were cross-bred with 
non-transgenic C57BL/6 males [13-15]. H&E and immuno-histological (IHC) staining were 
routinely performed in our lab and the results are summarized in Table 1 [15]. Figure 1a 
shows the H&E staining of representative morphological features of DLP and VP with 
micro-NECa in TRAMP mice [15]. As can be seen in Figure 1b-1e, the AR-expressing 
glandular prostate epithelial lesions, which are now termed atypical hyperplasias of T-Ag 
(AHT), express nuclear T-Ag, epithelial membrane-staining of E-cadherin and are negative 
for synaptophysin (SYP), which is a neuroendocrine cell marker [15]. Staining of Ki67 
(Figure1f), a proliferative index protein, showed a descending order of NE-Ca >> DLP AHT 
> VP epithelium. In the prostate from wild-type mice, single layer luminal epithelial cells 
were stained positive for nuclear AR, membrane E-cadherin with rare Ki-67 positive 
proliferating cells, while negative for T-Ag and SYP (Figure 2) [13-15]. In contrast, poorly-
differentiated prostate carcinomas (PD) as classified by Greenberg [5] had distinct 
morphological features compared to AHT described above, regardless of the microscopic 
size found within the VP lobe (Figure 1, right panels) or those weighing over many grams 
[15]. Those lesions/tumors expressed strong T-Ag and SYP (except negative in trapped 
glandular epithelial islands), and were negative for AR and E-cadherin (except positive in 
the trapped glandular epithelial islands) [15].  
We analyzed all tumors and prostates in our cohorts with the above panel of biomarkers. 
The incidence of macroscopic tumors (>1 gram) in TRAMP mice of 16-18, 22-24 and 26 
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weeks of age (WOA) were 10%, 20% and 30%, respectively. They were all poorly 
differentiated NECa expressing SYP [13, 15]. In another study, 31 C57BL/6 TRAMP mice in 
the control group (no chemo-preventive agents administrated) were followed up to 50 
WOA. Ten large tumors traceable to the prostate were found (32.3%) and they were all SYP 
positive poorly differentiated NECa [13]. Overall, we observed that there was a trend for 
increasing detection of visible macroscopic NECa in TRAMP mice and the life-time NECa 
incidence rate was 1 out of 3 TRAMP mice from our experiments. This value was slightly 
higher than that reported by Chiaverotti (20%) [9]. The possible reason might be a smaller 
number of and younger C57BL/6 TRAMP mice used in their study [9].  
We attempted to identify the anatomical origin of the NECa. Out of 18 NECa’s in a cohort of 
90 C57BL/6 TRAMP mice of 22 to 24 WOA, 12 were traceable to the VP (66.7%), two tiny 
tumors were traced to DLP (11.1%), whereas 1 large tumor was found in the anterior 
prostate (AP) (5.6%). The other three tumors were not traceable to any lobe location due to 
their overwhelming large sizes. These data were consistent with two recent studies showing 
a preponderance of SYP positive NECa arising from VP in the TRAMP mice of both C57BL/6 
and FVB backgrounds [9, 10]. In contrast, the weight of macroscopic tumor-free VP lobes 
was only slightly increased in TRAMP mice compared to their wild type littermates at 24 
WOA (Table 2 [15]), whereas the DLP lobes underwent significant expansion (more than 
doubled) in the TRAMP mice in one study where these lobes were compared side by side 
[14, 15].  
The Greenberg group had reported the prevalence of seminal vesicles (SV) problems such 
as papillary fibroadenoma in the TRAMP mice with C57BL/6 background shortly after the 
strain was established [12, 18]. Later on, several publications also described the 
histogenesis and pathology of SV neoplasms in the TRAMP mice [19, 20]. In one long-
term survival experiment carried out by our group [13], 54.8% (17 out of 31) TRAMP mice 
in the control group developed tumors in their SV and SV tumor loads became 
significantly increased beyond 30 WOA [13, 15]. Tani et al reported that most of the 
tumors contained phyllode lesions, which were typically composed of single layer 
epithelial linings that were negative for T-Ag, but positive for E-cadherin and AR staining 
and stromal cells that were neoplastic. These stromal cells frequently exhibited mitotic 
figures (BrdU incorporation) and SV40-TAg protein expression in the nuclei and were 
positive for desmin immuno-histological staining [19]. Since they did not observe 
conclusive evidence of malignancy such as invasion or metastasis, they recommended 
diagnosis of the SV tumors as epithelial–stromal tumors. The descriptions matched 
phyllodes-tumors in the C57B/6 TRAMP mice reported by Hsu et al [18]. However, in our 
long term studies, tumors/lesions were found in pelvic lymph nodes, liver, lung or kidney 
of mice without significantly increased prostate size but much enlarged SV in very rare 
cases (<5%), suggesting metastatic lesions from the SV tumors [13, 15]. Tables 1&2 
summarize the expression of biomarkers (by immunohisto staining) and tumor incidence 
in different lineages of carcinogenesis in TRAMP mice [15]. 
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Protein Biomarker Wild type TRAMP TRAMP TRAMP Seminal vesicle 
 
Prostrate AHT* NECa/Metastasis 
Epithelial-stromal 
tumors/Metastasis 
T-Antigen - +++ +++ + 
Androgen Receptor ++ +++ - + 
Synaptophysin - - +++ - 
E-cadherin +++ +++ - -/+ 
Ki-67 (MIB-1) <1% ++ +++ ++ 
*AHT-atypical hyperplasia of T-antigen of glandular epithelia 
 
Table 1. Summary of Immunohistochemical Marker Expression in Prostate lesions and metastases in 






Prostate lobes Dorsolateral Lobe uncertain* Ventral Anterior 
Synaptophysin(+) NE 
carcinoma 2/18 3/18 12/18 1/18 
#   (%) 11.10% 16.70% 66.70% 5.60% 
Average tumor weight 0.09 4.98 1.65 1.1 
(Weight range), g (0.07, 0.11) (3.44, 4.38, 7.11) (0.02- 4.84) 
TRAMP lobe weight at 24 
weeks, mg 79.2+3.7 (n =17)
** 
 
15.3+1.1 (n=17) ** 
 
Wild type lobe weight at 
24 weeks, mg 31.7+2.9 (n=8)
 ** 
 
12.5+1.7 (n=8) ** 
 
t-test p<0.001 p>0.05 
*These 3 big tumors are hard to distinguish the exact originating sites. 
**Presented as mean+SEM. t-test analysis between the TRAMP and wild type mice. 
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Figure 1. Immunohistochemical profiling of key protein markers in dorsal lateral (DLP) and ventral 
prostate (VP) with a microscopic neuroendocrine carcinoma (NECa) from a TRAMP B6 mouse. Serial 
sections were stained for hematoxylin and eosin (HE, a), androgen receptor (AR, b), SV40-T antigen (T-
Ag, c), E-cadherin (d), synaptophysin (e) or Ki67 (Mib1) proliferation-associated protein (f). 
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Figure 2. IHC staining patterns of wild type and TRAMP prostate for T-antigen (T-ag, nuclear), Ki67 
proliferative antigen (nuclear), E-cadherin (E-Cad, cell membrane), and androgen receptor (AR, nuclear) 
and Synaptophysin (Syp, arrows point to representative positive NE-cells, cytosolic and cell membrane) 
[15]. 
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4. Molecular changes in prostate carcinogenesis in TRAMP model 
Classical methods detecting the steady levels of mRNAs and proteins, as well as “omics” 
approaches such as microarray, antibody array and two-dimension electrophoresis based 
proteomics have been used to study the molecular changes associated with TRAMP 
carcinogenesis using prostate or serum as starting materials. The Greenberg group reported 
increased expression of basic fibroblast growth factor (FGF2) in the prostates (whole 
prostate) of TRAMP mice ([C57BL/6 X FVB] F1) [21]. They found that the expression of the 
25-kDa isoform of FGF2 was 2-fold higher in PIN and WD and MD tumors than in normal 
DLP and VP; the expression of the 22-kDa isoform of FGF2 was not elevated in PIN lesions, 
but was observed to be increased in WD, MD, PD and androgen-independent tumors. 
Interestingly, the 18-kDa isoform of FGF2 was only expressed in the samples representing 
PD and androgen-independent disease. These observations implicated specific changes in 
the FGF axis with the initiation and progression of PCA. The important role of FGF2 in PCA 
progression was further investigated in an in vivo study [22]. In that study, TRAMP mice 
(C57BL/6 background) were crossed with FGF2 knockout (FGF2-/-, SV129 background) mice, 
and tumor progression in TRAMP mice that were either hemi- or homozygous for 
inactivation of the FGF2 allele was compared with wild-type TRAMP mice. They found that 
even inactivation of one FGF2 allele resulted in increased survival, less PD phenotype in 
primary tumors and a decrease in metastasis [22].  Later on, Agarwal’s group reported that 
the chemopreventive effect of dietary silibinin against TRAMP carcinogenesis (C57BL/6 
background) was accompanied with a decreased plasma FGF2 level [23]. The observation 
further suggested FGF2 as a target for chemoprevention of PCA. Similarly, the roles of 
ERKs, EGFR, NF-κB, clusterin, cyclins, insulin-like growth factor-I (IGF-I), DNMTs and 
other molecular pathways in the TRAMP carcinogenesis have also been reported by 
different groups [24-30]. 
Considering extracellular proteolysis as an important biochemical event in the invasion and 
metastasis of PCA, Bok et al studied the expression of matrix metalloproteases (MMP) and 
other related proteins in TRAMP mice (C57BL6/FVB mix) using gelatin zymography [31]. In 
their study, distinct lobes of the prostate (ventral, lateral, dorsal and anterior), seminal 
vesicles, as well as lymph nodes (LN) with metastases were isolated by micro-dissection if 
possible. They found increased expression of mainly pro-MMP 9 and pro-MMP2 in early 
TRAMP tumors, but substantial elevation of activated MMP9 and MMP2 only in late 
TRAMP tumors. In addition, they found a progressive increase in the activities of cysteine, 
serine and certain membrane-bound proteases (cathepsin B, MT-SP1, MT1-MMP) from 
normal to advanced prostate tumors. Interestingly, a gradual decrease in urokinase 
plasminogen activator (uPA) expression with tumor progression was also observed. Overall, 
the study suggested proteases as potential targets for the therapy and secondary prevention 
of PCA. Ruddat et al profiled the proteome of TRAMP ([C57BL/6TRAMPx-FVB] F1) prostate 
by 2-D electrophoresis followed by peptide identification by MALDI-TOF [32]. In their 
study, the WD dorsal prostate (from mice approximately 14 WOA) was compared with 
normal dorsal prostate tissue. The prostates from mice approximately 25 WOA with PD CA 




Figure 2. IHC staining patterns of wild type and TRAMP prostate for T-antigen (T-ag, nuclear), Ki67 
proliferative antigen (nuclear), E-cadherin (E-Cad, cell membrane), and androgen receptor (AR, nuclear) 
and Synaptophysin (Syp, arrows point to representative positive NE-cells, cytosolic and cell membrane) 
[15]. 
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4. Molecular changes in prostate carcinogenesis in TRAMP model 
Classical methods detecting the steady levels of mRNAs and proteins, as well as “omics” 
approaches such as microarray, antibody array and two-dimension electrophoresis based 
proteomics have been used to study the molecular changes associated with TRAMP 
carcinogenesis using prostate or serum as starting materials. The Greenberg group reported 
increased expression of basic fibroblast growth factor (FGF2) in the prostates (whole 
prostate) of TRAMP mice ([C57BL/6 X FVB] F1) [21]. They found that the expression of the 
25-kDa isoform of FGF2 was 2-fold higher in PIN and WD and MD tumors than in normal 
DLP and VP; the expression of the 22-kDa isoform of FGF2 was not elevated in PIN lesions, 
but was observed to be increased in WD, MD, PD and androgen-independent tumors. 
Interestingly, the 18-kDa isoform of FGF2 was only expressed in the samples representing 
PD and androgen-independent disease. These observations implicated specific changes in 
the FGF axis with the initiation and progression of PCA. The important role of FGF2 in PCA 
progression was further investigated in an in vivo study [22]. In that study, TRAMP mice 
(C57BL/6 background) were crossed with FGF2 knockout (FGF2-/-, SV129 background) mice, 
and tumor progression in TRAMP mice that were either hemi- or homozygous for 
inactivation of the FGF2 allele was compared with wild-type TRAMP mice. They found that 
even inactivation of one FGF2 allele resulted in increased survival, less PD phenotype in 
primary tumors and a decrease in metastasis [22].  Later on, Agarwal’s group reported that 
the chemopreventive effect of dietary silibinin against TRAMP carcinogenesis (C57BL/6 
background) was accompanied with a decreased plasma FGF2 level [23]. The observation 
further suggested FGF2 as a target for chemoprevention of PCA. Similarly, the roles of 
ERKs, EGFR, NF-κB, clusterin, cyclins, insulin-like growth factor-I (IGF-I), DNMTs and 
other molecular pathways in the TRAMP carcinogenesis have also been reported by 
different groups [24-30]. 
Considering extracellular proteolysis as an important biochemical event in the invasion and 
metastasis of PCA, Bok et al studied the expression of matrix metalloproteases (MMP) and 
other related proteins in TRAMP mice (C57BL6/FVB mix) using gelatin zymography [31]. In 
their study, distinct lobes of the prostate (ventral, lateral, dorsal and anterior), seminal 
vesicles, as well as lymph nodes (LN) with metastases were isolated by micro-dissection if 
possible. They found increased expression of mainly pro-MMP 9 and pro-MMP2 in early 
TRAMP tumors, but substantial elevation of activated MMP9 and MMP2 only in late 
TRAMP tumors. In addition, they found a progressive increase in the activities of cysteine, 
serine and certain membrane-bound proteases (cathepsin B, MT-SP1, MT1-MMP) from 
normal to advanced prostate tumors. Interestingly, a gradual decrease in urokinase 
plasminogen activator (uPA) expression with tumor progression was also observed. Overall, 
the study suggested proteases as potential targets for the therapy and secondary prevention 
of PCA. Ruddat et al profiled the proteome of TRAMP ([C57BL/6TRAMPx-FVB] F1) prostate 
by 2-D electrophoresis followed by peptide identification by MALDI-TOF [32]. In their 
study, the WD dorsal prostate (from mice approximately 14 WOA) was compared with 
normal dorsal prostate tissue. The prostates from mice approximately 25 WOA with PD CA 
were not further dissected since it is not practical to differentiate the lobes in an advanced 
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stage. The data revealed that there were few significant changes in the protein abundances 
in the WD dorsal prostates compared to wild-type dorsal prostates, with the exception of 
increases in proliferating cell nuclear antigen (PCNA) and beta tubulin, two proteins 
implicated in cell proliferation, and a more than 2-fold increase in an anti-apoptotic protein 
Hsp60. In contrast, there were substantial changes in protein abundance in the PD tumors 
compared to wild-type dorsal prostates. While some of those changes could be related to the 
disappearance of stromal tissue such as decreased expression of myosin light chain alkali, 
desmin and tropomyosin beta 2, the most notable was the overall decrease in calcium 
homeostasis proteins such as calreticulin and Hsp70 (10-fold decrease) and creatine kinase 
bb (40-fold decrease) in the cancerous tissue. The expression patterns of desmin, Hsp70 and 
calreticulin were further confirmed by Western blot. Although some of their results have 
been cross-validated by us (e.g. down-regulation of calreticulin and tropomyosin beta 2, to 
be discussed later) [16, 17], many of these changes could be due to the differences between 
the cells in the two different carcinogenesis lineages rather than the purported changes due 
to progression of diseases of the Greenberg paradigm. 
Using Affymetrix GeneChip Mouse Genome 430 2.0 micorarrays, Haram et al profiled the 
mRNAs from eight TRAMP (C57BL/6 background, 30±4 WOA)) tumors and DLP or VP of 
nine wild-type mice [33]. Statistical analysis indicated that 3,870 transcripts such as cyclin 
A2, cyclin B1, cyclin B2, cyclin E1, cyclin E2, cyclin F, Forkhead box M1, Aurora Kinase A 
and B were up-regulated in TRAMP tumors and 2,945 transcripts such as cyclin D2 and 
probasin were down-regulated in TRAMP tumors. Real-time RT-PCR confirmed the 
expression of the 11 genes mentioned above. In each real-time PCR experiment, three to four 
normal samples (typically one dorsolateral and three ventral) and four tumors (the same 
four tumor samples in every experiment) were used. Moreover, cross-referencing 
differentially expressed TRAMP genes to public human prostate array datasets revealed 66 
genes with concordant expression in mouse and human PCA. Among the 66 genes, Sox4 
and Tubb2a, which were reported to be up-regulated in primary PCA compared to normal 
prostates, were further validated by real-time RT-PCR. In addition to providing information 
regarding the mechanisms of TRAMP carcinogenesis, the concordance analysis between 
TRAMP and human PCA associated genes also supported the utility of the model. In 
another study, Morgenbesser et al studied the dynamic changes of mRNA profiles in 
TRAMP ([C57BL/6 TRAMP x FVB] F1) mice, especially the genes involved in the acquisition 
of androgen-independent and metastatic tumor growth, using both microarray and SAGE 
approaches [34]. The following cohorts were used in their study: C18 (prostates from wild-
type mice at 18 WOA); C24 (prostates from wild-type mice at 24 WOA); T12 and T18 were 
prostates from TRAMP mice at 12 and 18 WOA representing PIN and MD stages of disease, 
respectively; T24 were PD, androgen-dependent (AD) primary tumors from TRAMP mice at 
24 WOA whereas T(12)24 were PD, androgen-independent (AI) primary tumors from 24-
week-old TRAMP mice that were castrated at 12 WOA. In their paper, differentially 
expressed genes between AD tumors and normal prostates, AI tumors and normal 
prostates, as well as AD and AI tumors were presented. The dynamic changes of ten 
transcripts (e.g. tissue inhibitor of metalloproteinase 4, GATA-binding protein 2, ER-resident 
protein ERdj5, paralemmin, MYC-associated zinc finger protein) over the progress of 
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TRAMP carcinogenesis were further validated by real-time RT-PCR. Their analyses 
uncovered many transcripts that had not previously been implicated in PCA progression, 
especially in the transition from androgen-dependent to androgen-independent status. 
Again, these studies were conducted under the Greenberg paradigm of single lineage 
disease progression. Many of these changes could be due to the differences between the cells 
in the two different carcinogenesis lineages rather than the purported changes due to 
progression of the disease.  
Therefore, it will be prudent to carefully read the descriptions of the tissue samples used in 
the published papers. For example, many older publications prepared lysate from the whole 
prostate whereas very few focused on particular lobes [24, 31, 32]. Recently, researchers 
started to carefully look into the molecular pathways involved in two lineages of 
carcinogenesis (different prostate lobes, mainly DLP and VP) in TRAMP mice after the 
lineage differences of the prostate carcinogenesis had been recognized [9, 13]. For instance, 
Slack-Davis et al studied the requirement for focal adhesion kinase (FAK) signaling in cancer 
progression in TRAMP mice with C57BL/6 background [35]. They found that loss of FAK or 
its inhibition with PF-562271 (small molecular inhibitor for FAK) did not alter the 
progression to AHT. However, continued FAK expression (and activity) is essential for the 
androgen-independent formation of NECa.  
Our group [15] dissected prostate lobes and visible tumors separately in most of our 
experiments in order to assess the lobe-specific biochemical changes. Using these dissected 
lobes/tumors as starting materials, we studied the expression of classical biomarkers by 
immuno-blot. The expression patterns of proliferative cell nuclear antigen (PCNA) (Figure 
3a) confirmed the Ki67 staining patterns by IHC staining described above [15]. Consistent 
with the lack of proliferation of normal prostate epithelium, PCNA was non-detectable in 
the DLP and VP in the wild type mice at 16-18 WOA, whereas significantly higher levels of 
PCNA were detected in the DLP and VP and NECa of TRAMP mice. Since the Ki67 
proliferation index in the VP epithelium appeared to be lower than in TRAMP DLP as 
evidenced by IHC (Figure 1f), the higher level of PCNA in TRAMP VP (Figure 3b) than in 
DLP might be due to the presence of micro NECa foci in the TRAMP VP lobes (NECa has 
much higher Ki67 index, Figure 1f) [15]. We also confirmed the contrasting patterns of AR, 
SYP and E-cadherin expression patterns in the DLP AHT vs. NECa. Although the expression 
of AR and E-cadherin were increased in both DLP and VP in TRAMP mice at 16-18 WOA, 
there were more AR and E-cadherin in VP than in DLP of littermate wild type mice (Figure 
3b) [15]. These patterns are in agreement with that published by the Greenberg group [8, 12] 
and others [9]. In addition, we found that the level of cleaved PARP (endogenous substrate 
for caspase 3) was higher in the NECa than in the DLPs of TRAMP and wild type mice 
(Figure 3a). The STAT3 level in TRAMP DLP was higher than in the wild type DLP and the 
NECa. However, there might be an isoform of STAT3 with higher molecular weight in the 
NECa, indicated by a mobility-retarded band (Figure 3a, arrow) [15]. Our observation was 
consistent with phosphorylative modification and activation of STAT3 in NECa, as reported 
by Aziz et al [36]. The changes of these biomarkers further support molecular differences 
between NECa and DLP AHT.  
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TRAMP carcinogenesis were further validated by real-time RT-PCR. Their analyses 
uncovered many transcripts that had not previously been implicated in PCA progression, 
especially in the transition from androgen-dependent to androgen-independent status. 
Again, these studies were conducted under the Greenberg paradigm of single lineage 
disease progression. Many of these changes could be due to the differences between the cells 
in the two different carcinogenesis lineages rather than the purported changes due to 
progression of the disease.  
Therefore, it will be prudent to carefully read the descriptions of the tissue samples used in 
the published papers. For example, many older publications prepared lysate from the whole 
prostate whereas very few focused on particular lobes [24, 31, 32]. Recently, researchers 
started to carefully look into the molecular pathways involved in two lineages of 
carcinogenesis (different prostate lobes, mainly DLP and VP) in TRAMP mice after the 
lineage differences of the prostate carcinogenesis had been recognized [9, 13]. For instance, 
Slack-Davis et al studied the requirement for focal adhesion kinase (FAK) signaling in cancer 
progression in TRAMP mice with C57BL/6 background [35]. They found that loss of FAK or 
its inhibition with PF-562271 (small molecular inhibitor for FAK) did not alter the 
progression to AHT. However, continued FAK expression (and activity) is essential for the 
androgen-independent formation of NECa.  
Our group [15] dissected prostate lobes and visible tumors separately in most of our 
experiments in order to assess the lobe-specific biochemical changes. Using these dissected 
lobes/tumors as starting materials, we studied the expression of classical biomarkers by 
immuno-blot. The expression patterns of proliferative cell nuclear antigen (PCNA) (Figure 
3a) confirmed the Ki67 staining patterns by IHC staining described above [15]. Consistent 
with the lack of proliferation of normal prostate epithelium, PCNA was non-detectable in 
the DLP and VP in the wild type mice at 16-18 WOA, whereas significantly higher levels of 
PCNA were detected in the DLP and VP and NECa of TRAMP mice. Since the Ki67 
proliferation index in the VP epithelium appeared to be lower than in TRAMP DLP as 
evidenced by IHC (Figure 1f), the higher level of PCNA in TRAMP VP (Figure 3b) than in 
DLP might be due to the presence of micro NECa foci in the TRAMP VP lobes (NECa has 
much higher Ki67 index, Figure 1f) [15]. We also confirmed the contrasting patterns of AR, 
SYP and E-cadherin expression patterns in the DLP AHT vs. NECa. Although the expression 
of AR and E-cadherin were increased in both DLP and VP in TRAMP mice at 16-18 WOA, 
there were more AR and E-cadherin in VP than in DLP of littermate wild type mice (Figure 
3b) [15]. These patterns are in agreement with that published by the Greenberg group [8, 12] 
and others [9]. In addition, we found that the level of cleaved PARP (endogenous substrate 
for caspase 3) was higher in the NECa than in the DLPs of TRAMP and wild type mice 
(Figure 3a). The STAT3 level in TRAMP DLP was higher than in the wild type DLP and the 
NECa. However, there might be an isoform of STAT3 with higher molecular weight in the 
NECa, indicated by a mobility-retarded band (Figure 3a, arrow) [15]. Our observation was 
consistent with phosphorylative modification and activation of STAT3 in NECa, as reported 
by Aziz et al [36]. The changes of these biomarkers further support molecular differences 




Figure 3. Western blot analyses of protein biomarkers in (A) wild type mouse prostate and in TRAMP 
DLP (DLP) and in NE-Carcinomas (NECa); in (B) DLP and VP of wild type and TRAMP mice at 16-18 
WOA. AR, androgen receptor; PCNA, proliferating cell nuclear antigen; PARP, polyADPribose 
polymerase; STAT3, signal transduction and activator of transcription-3. Arrow marks mobility 
retarded STAT3 that is likely phosphorylated [15]. 
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To provide more information on potential molecular correlates of the differences in DLP and 
VP for epithelial lesions and NE-carcinogenesis, we compared the expression level of 
proteins in respective lobes of wild type vs. TRAMP mice of 18 WOA by the iTRAQ 
proteomic approach, as we recently reported [16, 17]. We employed two-dimensional liquid 
chromatography coupled with tandem mass spectrometry (2D-LC-MS/MS) with iTRAQ 
labeling, which enables the concurrent identification and quantification of proteins through 
peptides generated upon tryptic digestion. The principle and advantages of the platform 
have been described in our previous publications [16, 17, 37]. In total, we identified 1068 
proteins expressed in the DLP and VP of TRAMP mice and wild type mice. Among them, 
483 and 748 proteins were identified at FDRs of 1% and 5% respectively. We found that the 
expression levels of 84 proteins were different between DLP and VP in wild-type mice [17]. 
For example, heat shock protein 5/glucose-regulated protein78 (GRP78), transglutaminase 4 
(TGM4), experimental autoimmune prostatitis antigen 2 (EAPA2), probasin, beta-
tropomyosin, calponin-1, as well as high mobility group box 1 & 2 were preferentially 
expressed in DLP, whereas there were higher levels of prostatic spermine-binding protein 
(SBP), serine peptidase inhibitor Kazal type 3 (SPINK3), polymeric immunoglobulin 
receptor (PIGR), solute carrier family 12 member 2, epidermal growth factor (EGF) and 
clusterin in the VP lobe. The expression pattern of GRP78 and clusterin were validated by 
immuno-blots [17]. The mRNA abundances of prostatic proteins in each lobe of mice or rats 
have been investigated by Fujimoto et al and Berquin et al using PCR and microarray, 
respectively [38-40]. Our results not only agreed with theirs but also extended to more lobe 
specific proteins. Importantly, we found that different sets of proteins were involved in lobe 
specific carcinogenesis in TRAMP mice. The expression levels of 118 proteins were 
significantly altered in DLP and/or VP during TRAMP carcinogenesis. 55 and 36 proteins 
were uniquely changed in DLP or VP respectively and only 27 proteins were found to be 
significantly modulated in both lobes during TRAMP carcinogenesis [17]. The majority (24 
out of 27 proteins) shared the same trend, albeit the extent of change was not exactly the 
same. Shared changes in DLP and VP might indicate possible common molecular events 
associated with carcinogenesis such as elevated proliferation (e.g. up-regulation of 
HMGB1&2 and nuclear proteins such as histone(s)), oxidative stress (e.g. decreased 
antioxidant enzyme PRDX6) and disruption of stroma (e.g. down-regulation of SMMHC 
(myosin-11) and calponin-1) [17]. The three proteins, namely clusterin, polymeric 
immunoglobulin receptor and aldose reductase, which were differentially expressed in DLP 
versus VP, were more likely related to lobe-specific mechanisms of carcinogenesis. 
Interestingly, although some of prostatic proteins had been reported to be regulated by 
androgen signaling [38], EAPA2 and calreticulin were down-regulated in DLP whereas zinc-
alpha-2-glycoprotein was only down-regulated in VP during carcinogenesis. These 
observations suggested that AR signaling could play different roles in carcinogenesis of 
different lobes of TRAMP mice.  
To shed light on the key expression signatures or “master switches” that may not be 
virtually identified due to technical limitation, we analyzed the lists of differentially 
expressed proteins in each lobe by IPA software for pathway connections based on gene 
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peptides generated upon tryptic digestion. The principle and advantages of the platform 
have been described in our previous publications [16, 17, 37]. In total, we identified 1068 
proteins expressed in the DLP and VP of TRAMP mice and wild type mice. Among them, 
483 and 748 proteins were identified at FDRs of 1% and 5% respectively. We found that the 
expression levels of 84 proteins were different between DLP and VP in wild-type mice [17]. 
For example, heat shock protein 5/glucose-regulated protein78 (GRP78), transglutaminase 4 
(TGM4), experimental autoimmune prostatitis antigen 2 (EAPA2), probasin, beta-
tropomyosin, calponin-1, as well as high mobility group box 1 & 2 were preferentially 
expressed in DLP, whereas there were higher levels of prostatic spermine-binding protein 
(SBP), serine peptidase inhibitor Kazal type 3 (SPINK3), polymeric immunoglobulin 
receptor (PIGR), solute carrier family 12 member 2, epidermal growth factor (EGF) and 
clusterin in the VP lobe. The expression pattern of GRP78 and clusterin were validated by 
immuno-blots [17]. The mRNA abundances of prostatic proteins in each lobe of mice or rats 
have been investigated by Fujimoto et al and Berquin et al using PCR and microarray, 
respectively [38-40]. Our results not only agreed with theirs but also extended to more lobe 
specific proteins. Importantly, we found that different sets of proteins were involved in lobe 
specific carcinogenesis in TRAMP mice. The expression levels of 118 proteins were 
significantly altered in DLP and/or VP during TRAMP carcinogenesis. 55 and 36 proteins 
were uniquely changed in DLP or VP respectively and only 27 proteins were found to be 
significantly modulated in both lobes during TRAMP carcinogenesis [17]. The majority (24 
out of 27 proteins) shared the same trend, albeit the extent of change was not exactly the 
same. Shared changes in DLP and VP might indicate possible common molecular events 
associated with carcinogenesis such as elevated proliferation (e.g. up-regulation of 
HMGB1&2 and nuclear proteins such as histone(s)), oxidative stress (e.g. decreased 
antioxidant enzyme PRDX6) and disruption of stroma (e.g. down-regulation of SMMHC 
(myosin-11) and calponin-1) [17]. The three proteins, namely clusterin, polymeric 
immunoglobulin receptor and aldose reductase, which were differentially expressed in DLP 
versus VP, were more likely related to lobe-specific mechanisms of carcinogenesis. 
Interestingly, although some of prostatic proteins had been reported to be regulated by 
androgen signaling [38], EAPA2 and calreticulin were down-regulated in DLP whereas zinc-
alpha-2-glycoprotein was only down-regulated in VP during carcinogenesis. These 
observations suggested that AR signaling could play different roles in carcinogenesis of 
different lobes of TRAMP mice.  
To shed light on the key expression signatures or “master switches” that may not be 
virtually identified due to technical limitation, we analyzed the lists of differentially 
expressed proteins in each lobe by IPA software for pathway connections based on gene 
ontogeny and functionality [17]. Proteins with altered expression in DLP during 
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carcinogenesis were preferentially clustered into Immunological Disease/Cancer/Antigen 
Presentation and Post-Translational Modification/Protein Folding/Cancer networks. 14-3-3 
zeta/delta (YWHAZ, up-regulated only in DLP), NF-κB, epidermal growth factor (EGF, up-
regulated only in DLP), ERK1/2, PKCs were identified as distinct inferred network nodes for 
those networks. On the other hand, proteins with altered expression in VP were mapped to 
Connective Tissue Disorders/Developmental Disorder/Genetic Disorder and Cancer/Cell 
Cycle/Cellular Development pathways with ERK1/2 and FGF2 identified as distinct network 
nodes in the two networks. We further used immunoblot to study the expression pattern of 
FGF2 proteins, which were not identified by LC-MS/MS but unraveled by IPA analysis as 
important proteins in the TRAMP carcinogenesis of the VP lobe. The data indicated that 
different isoforms of FGF2 were expressed in each lobe and FGF2 was only up-regulated in 
the VP lobe of TRAMP mice [17]. To our knowledge, we are the first to systematically 
compare the different protein profile changes between DLP and VP lobes during TRAMP 
carcinogenesis. Our results further support the concept that the C57BL/6 TRAMP mouse 
represents two lineages of prostate carcinogenesis in DLP and VP lobes. Further efforts to 
narrow down possible target proteins and investigation on the functional significance of 
those proteins will not only help understand the mechanisms of TRAMP carcinogenesis, but 
also facilitate the understanding and use of TRAMP model in the field of prostate cancer 
chemoprevention. 
5. Effects of chemopreventive agents on prostate carcinogenesis in 
TRAMP model and possible mechanisms 
Because the breeding strategy of TRAMP mice is straightforward, TRAMP mice have been 
widely used in evaluating potential preventive modalities by many groups in the past 
decade. Besides the effect of androgen deprivation therapy (ADT) on the progression of 
PCA by surgical castration of TRAMP mice [41, 42], the effects of many agents with chemo-
preventive potential including green tea [26, 43],  NSAIDs [44, 45], flutamide [46],  retinoic 
acid [47],  vitamin E analog [48], genistein [24, 49], epigallocatechin-3-gallate (EGCG) [50],  
silibinin [23, 51], dietary restriction [52] and immunotherapy [53, 54], have been studied 
using this model. While most of the publications reported anti-cancer effects of their test 
compounds, El Touny et al showed that feeding TRAMP mice (TRAMP-FVB) with a diet 
containing 0.25% genistein from 12 to 20 WOA induced an aggressive progression of PCA, 
as evidenced by a 16% increase in the number of WD and PD prostates, coinciding with a 
70% incidence of pelvic lymph node metastases as opposed to 0% in the control group [49].  
The recognition of different lineages of carcinogenesis in the TRAMP prostate has 
important implications on the interpretation of chemoprevention data. Due to the distinct 
characteristics of AHT in DLP and NECa in VP, their sensitivity to different chemo-
preventive agents might not be the same. Knowledge of lineage-specific effects of each 
agent will be essential for selecting additional models to confirm the efficacy and to 
ultimately benefit clinical translation studies. In addition, it can provide valuable insights 
into mechanism studies for molecular pathway(s) and targets specific to the particular 
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lineage of carcinogenesis. Using this paradigm, our group evaluated the chemopreventive 
efficacy of next-generation selenium compounds methylseleninic acid (MSeA) and 
methylselenocysteine (MSeC) in TRAMP mice with C57BL/6 background [13]. In a short-
term experiment, TRAMP mice of 8 WOA were given an oral dose of MSeA or MSeC at 3 
mg Se/kg daily and were euthanized at either 18 or 26 WOA. By 18 WOA, the 
genitourinary tract and DLP weights for both treatment groups were lower than for the 
control (p< 0.01). At 26 weeks, 4 of 10 control mice had genitourinary weight >2 g whereas 
only 1 of 10 in each of the treatmente groups did. The efficacy was accompanied by 
delayed lesion progression, increased apoptosis, and decreased proliferation without 
appreciable changes of T-antigen expression in the DLP. In another experiment, giving 
MSeA to TRAMP mice from 10 or 16 WOA increased their survival to 50 weeks of age and 
delayed the death due to SYP-positive NECa, SYP-negative prostate lesions and seminal 
vesicle hypertrophy [13]. Interestingly, although MSeA and MSeC were considered as 
precursors of methylselenol, the proteins they modulated in the DLP of TRAMP mice 
were quite different as indicated by proteomic profiling. The data suggest that MSeA and 
MSeC should be developed as separate agents rather than as equal precursors of 
methylselenol [16]. Very recently, our group also demonstrated that oral administration of 
the alcoholic extract of Angelica gigas (AGN), a traditional Korean herb, had strong 
inhibitory effect on two lineages of carcinogenesis in TRAMP mice, especially the NECa 
[55, 56]. In contrast to the examples of MSeA, MSeC and AGN described above, we also 
published a lack of efficacy of a novel sulindac derivative sulindac sulfide amide (SSA) 
against NECa, whereas it exerted a significant protection against the DLP epithelial 
lesions [14]. Consistent with the fact that NECa originated from VP independently of AR, 
suppressing AR signaling in DLP was one of the important mechanisms underlying the 
chemopreventive effect of SSA, both in vivo and in vitro [14]. Similar to our strategy, 
Harper et al gave TRAMP mice (C57BL/6) water containing 0.06% EGCG starting at 5 
WOA and dissected DLP and VP carefully when mice were euthanized at 12 WOA [50]. 
They found that EGCG significantly reduced the incidence of HG-PIN (Grade 3) from 
100% to 17% in the VP of TRAMP mice but did not have a protective effect in DLP. At 28 
WOA, it was difficult to dissect DLP and VP separately and EGCG did not have any 
inhibitory effect against TRAMP carcinogenesis in general. 
As mentioned above, the life-time NECa incidence has been estimated to be approximately 
30% in TRAMP mice with C57BL/6 background. Rest of the mice will be free of NECa and 
may therefore model the epithelial lineage lesions that are more relevant to the human 
prostate epithelial adeno-carcinogenesis, since the majority of human PCA are 
adenocarcinomas.   
On the other hand, NECa occurs in nearly 100% of the TRAMP mice in the FVB background 
and the DLP undergoes more epithelial lesion growth than does the VP [9, 12]. This might 
have contributed to the assumption that a single lineage of carcinogenesis progressed from 
DLP epithelial lesions to poorly differentiated Ca (i.e., NECa) by the Greenberg group. 
Based on the current information, the C57BL/6 background will be a preferred choice over 
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carcinogenesis were preferentially clustered into Immunological Disease/Cancer/Antigen 
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the FVB background for chemoprevention studies since the former allows a clear separation 
of estimation of the impact of the test agents on both lineages of lesions in the prostate, 
provided that the studies are terminated before SV tumors in the C57BL/6 TRAMP mice 
become a serious complication to survival.  
Since many studies had followed the Greenberg paradigm for interpretation of their 
results, it will be prudent to carefully look into the genetic background of TRAMP mice, 
the manner with which prostate/tumors were collected and the end point(s) chosen to 
evaluate the efficacy. Some of the studies as shown below could be questionable in term 
of the conclusions.   In the study by Adhami et al [43], TRAMP mice (C57BL/6 
background) were given water containing 0.1% green tea polyphenols (GTP) starting at 
ages representing different stage of the disease: 6 WOA (normal prostate), 12 WOA (PIN), 
18 WOA (WD) and 28 WOA (MD). Follow-up monitoring showed that the earlier the 
treatment started, the greater was tumor-free survival extended. The mean genitourinary 
weights showed the same trends. IGF-I and its downstream targets including 
phosphatidylinositol 3-kinase and pAkt were significantly inhibited only when GTP 
treatment was initiated no later than 18WOA. In another study, TRAMP mice (C57BL/6 
background) starting at 4, 12, 20, and 30 WOA were fed with control or 1% silibinin 
supplemented diet for 8 to 15 weeks [51]. In general, silibinin feeding inhibited neoplastic 
progression of the prostate in TRAMP mice at various stages. For the most part, the tumor 
stage at onset time of treatment determined the mechanisms for silibinin’s efficacy. 
Silibinin treatment during the early stages of prostate tumor development in TRAMP 
mice inhibited the progression at PIN stage via anti-proliferation. When the mice were 
burdened with higher stage lesions, silibinin significantly delayed the progression of the 
disease via both anti-proliferative and anti-angiogenesis mechanisms. Anti-angiogenesis, 
along with inhibition of epithelial-mesenchymal transition (EMT) via decreasing the 
expression of MMPs, snail-1, and fibronectin, as well as increasing E-cadherin expression 
levels might also contribute to the anti-metastatic effect of silibinin. Studies aiming to 
define the “stage-specific” efficacy and mechanisms of chemoprevention are very crucial 
for the identification of in vivo targets mediating the chemopreventive effect of 
corresponding agents. In addition, the information will be very important to select the 
right indications for clinical trials. 
6. The concept of cancer stem cells in TRAMP model  
The concept of cancer stem cells (CSC) or tumor-initiating cells assumes that cancers are 
mainly sustained by a small pool of neoplastic cells, which are responsible for cancer 
initiation and/or progression. Although currently no single protein is widely accepted as a 
definitive stem cell marker in the prostate, investigations using in vitro and in vivo models, 
especially tissue recombination strategies, reveal a multifaceted nature of stem cells for 
prostate cancer and highlight the importance of targeting cancer stem cells in the therapy 
and prevention of prostate cancer [57-59]. The role of “cancer stem cells” in TRAMP 
carcinogenesis has received some attention. Chiaverotti et al observed an increased 
frequency of neuroendocrine precursor lesions in TRAMP mice with FVB background as 
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early as 4 WOA [9]. Some of these lesions exhibited properties of bi-potential stem cells as 
evidenced by co-expressing the transcriptional factors Foxa1 and Foxa2, and markers of 
epithelium (E-cadherin) and neuroendocrine (SYP). In their proposed  model of two 
lineages of carcinogenesis [9], a pluripotent stem cell of the normal prostate is 
transformed by SV40 Tag expression and starts to proliferate. Initially these proliferative 
foci maintain a transitional epithelial/NE phenotype co-expressing E-cadherin, SYP, as 
well as Foxa1 and Foxa2. These bipotential cells continue to proliferate, undergo full NE 
differentiation with loss of E-cadherin and then progress to an overt NECa. On the other 
hand, luminal cells of the normal prostate proliferate and form focal areas of hyperplasia 
after transformed by SV40 Tag expression. These foci expand to the entire glandular 
lumen and end up with AHT but do not invade the surrounding stroma and do not 
metastasize. 
Huss et al reported the expression and function of a breast cancer resistance protein 
(BCRP/ABCG2) in putative prostate stem cells and prostate tumor stem cells in several 
models including TRAMP mice (C57BL/6 TRAMP X FVB F1) [60]. BCRP is a member of the 
ATP-binding cassette (ABC) transporter family and expressed consistently by adult stem 
cell populations that possess pluripotentiality and long-term repopulation capability. IHC 
staining indicated that the BCRP+ putative tumor stem cells were localized to foci of AR- 
cells in glands of VP, where the greatest number of NECa would arise after castration. The 
AR- foci that contained the BCRP+ cells were preexisting and not induced by androgen 
deprivation since the frequency of BCRP+ cells was similar in intact (2.0%) and castrated 
(1.8%) TRAMP mice (between 1 and 14 days post-castration). In TRAMP mice, BCRP+/AR- 
cells behaved as label-retaining cells, a stem cell characteristic. The role of BCRP+ putative 
tumor stem cells as the nidus of NECa was further supported by the fact that NECa 
harvested from castrated TRAMP mice contained large focal areas of proliferating, 
BCRP+/AR-/SYP+ cells. BCRP-mediated efflux of androgen might be one of the mechanisms 
for maintenance of the prostate stem cell phenotype since it might be associated with their 
insensitivity to androgen-mediated differentiation and androgen deprivation–induced 
apoptotic cell death. 
ADT was reported to result in a state of androgen independence with more malignant 
behavior in TRAMP mice [41]. Whether certain types of “cancer stem cells” were activated 
during or after castration awaits further investigation. Recently, Tang et al studied the 
effect of surgical castration on the expression of stem cell markers in the prostates of 
TRAMP mice [61]. They castrated TRAMP mice (genetic background not specified) at 12 
WOA and dissected the DLP lobes at two time-points: 10 weeks (Cas-10; n=12) and 20 
weeks (Cas-20; n=9) after castration. They found that stem cell markers Sca-1 (stem cell 
antigen-1), CD133 and c-Kit (CD117) were overexpressed in the luminal cells of the Cas-10 
group, but not in the Cas-20 group. Immuno-blots showed that the expression of bcl-2 and 
GRP78 were significantly higher in the DLP from the Cas-10 compared to that from the 
Cas-20 group. Using anti-Sca-1 antibody conjugated magnetic beads, they estimated the 
abundance of Sca-1 positive cells in the cell suspension prepared by digesting the DLP 
lobes with collagenase/hyaluronidase/DNase I. They found that the abundance of Sca-1 
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the FVB background for chemoprevention studies since the former allows a clear separation 
of estimation of the impact of the test agents on both lineages of lesions in the prostate, 
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weights showed the same trends. IGF-I and its downstream targets including 
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early as 4 WOA [9]. Some of these lesions exhibited properties of bi-potential stem cells as 
evidenced by co-expressing the transcriptional factors Foxa1 and Foxa2, and markers of 
epithelium (E-cadherin) and neuroendocrine (SYP). In their proposed  model of two 
lineages of carcinogenesis [9], a pluripotent stem cell of the normal prostate is 
transformed by SV40 Tag expression and starts to proliferate. Initially these proliferative 
foci maintain a transitional epithelial/NE phenotype co-expressing E-cadherin, SYP, as 
well as Foxa1 and Foxa2. These bipotential cells continue to proliferate, undergo full NE 
differentiation with loss of E-cadherin and then progress to an overt NECa. On the other 
hand, luminal cells of the normal prostate proliferate and form focal areas of hyperplasia 
after transformed by SV40 Tag expression. These foci expand to the entire glandular 
lumen and end up with AHT but do not invade the surrounding stroma and do not 
metastasize. 
Huss et al reported the expression and function of a breast cancer resistance protein 
(BCRP/ABCG2) in putative prostate stem cells and prostate tumor stem cells in several 
models including TRAMP mice (C57BL/6 TRAMP X FVB F1) [60]. BCRP is a member of the 
ATP-binding cassette (ABC) transporter family and expressed consistently by adult stem 
cell populations that possess pluripotentiality and long-term repopulation capability. IHC 
staining indicated that the BCRP+ putative tumor stem cells were localized to foci of AR- 
cells in glands of VP, where the greatest number of NECa would arise after castration. The 
AR- foci that contained the BCRP+ cells were preexisting and not induced by androgen 
deprivation since the frequency of BCRP+ cells was similar in intact (2.0%) and castrated 
(1.8%) TRAMP mice (between 1 and 14 days post-castration). In TRAMP mice, BCRP+/AR- 
cells behaved as label-retaining cells, a stem cell characteristic. The role of BCRP+ putative 
tumor stem cells as the nidus of NECa was further supported by the fact that NECa 
harvested from castrated TRAMP mice contained large focal areas of proliferating, 
BCRP+/AR-/SYP+ cells. BCRP-mediated efflux of androgen might be one of the mechanisms 
for maintenance of the prostate stem cell phenotype since it might be associated with their 
insensitivity to androgen-mediated differentiation and androgen deprivation–induced 
apoptotic cell death. 
ADT was reported to result in a state of androgen independence with more malignant 
behavior in TRAMP mice [41]. Whether certain types of “cancer stem cells” were activated 
during or after castration awaits further investigation. Recently, Tang et al studied the 
effect of surgical castration on the expression of stem cell markers in the prostates of 
TRAMP mice [61]. They castrated TRAMP mice (genetic background not specified) at 12 
WOA and dissected the DLP lobes at two time-points: 10 weeks (Cas-10; n=12) and 20 
weeks (Cas-20; n=9) after castration. They found that stem cell markers Sca-1 (stem cell 
antigen-1), CD133 and c-Kit (CD117) were overexpressed in the luminal cells of the Cas-10 
group, but not in the Cas-20 group. Immuno-blots showed that the expression of bcl-2 and 
GRP78 were significantly higher in the DLP from the Cas-10 compared to that from the 
Cas-20 group. Using anti-Sca-1 antibody conjugated magnetic beads, they estimated the 
abundance of Sca-1 positive cells in the cell suspension prepared by digesting the DLP 
lobes with collagenase/hyaluronidase/DNase I. They found that the abundance of Sca-1 
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cells was more than 3 times higher in the TRAMP Cas-10 group than in wild-type mice at 
12WOA. However, it was dramatically lower in the TRAMP Cas-20 group, which was 
consistent with the IHC data. Although their work described the dynamic expression of 
certain stem cell markers during TRAMP carcinogenesis in DLP, the information is too 
preliminary to draw any conclusion on the effect of castration on “cancer stem cells” in 
TRAMP mice.  
In one recently published paper [15], our group compared different treatment regimens 
with MSeA on TRAMP mice (C57BL/6) to investigate whether MSeA could irreversibly 
inhibit early events in TRAMP carcinogenesis (e.g. activation of “cancer stem cells”). MSeA 
exposure to TRAMP mice (C57BL/6) from 5 to 15 WOA was sufficient to elicit protective 
effects against the two lineages of carcinogenesis to the same extent as continuous MSeA 
exposure from 5 to 23 WOA [15]. Similar findings in a chemically-induced mammary 
carcinogenesis model was reported by Ip et al [62], in which selenium-enriched garlic given 
for 1-month duration right after a single carcinogen exposure was as effective as when it 
was provided throughout the 6-month post-initiation period of the study. Those data 
suggested a possibility that MSeA treatment during the initiation stage of carcinogenesis 
permanently inactivated early critical initiated (“cancer stem”) cells in both lineages. The 
potential mechanisms of inactivation of “cancer stem cells” by MSeA might be apoptosis, 
which is consistent with the pro-apoptotic effect of MSeA and MSeC in TRAMP DLP 
reported previously [13], or another lasting epigenetic modification.  
7. Conclusion  
The paradigm of distinct lineages of carcinogenesis in the TRAMP model and our data with 
MSeA, a sulindac derivative compound and AGN extract shed new light on the utility of 
this preclinical model for chemoprevention studies in spite of much concern regarding of 
the NE nature of the resultant carcinomas and metastasis. Future data collection and 
analyses should incorporate this new knowledge for efficacy assessment and for molecular 
target validations, avoiding ‘‘apple versus orange’’ comparisons. 
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1. Introduction 
Studies on urinary bladder cancer have underpinned that the urolith is one of the key 
factors in the carcinogenesis process when rodents are treated with thymine, melamine [1] 
and uracil [2-5], all of which induce intrarenal crystal deposition/calculus formation. 
Fukushima et al. [2] and Cohen et al. [6-8] have investigated in detail about factors 
implicated in the urolith formation as well as the role of calculi in urinary bladder 
carcinogenesis. The crystal or calculus acts as a subsequent sustained proliferative stimulus 
ultimately leading to tumors. However, rodent bladder tumors cannot be directly 
extrapolated for humans. In fact, there is a suggestion of a weak association concerning 
calculi in humans as a potential risk factor for bladder cancer [9]. A major difference 
between rodent and human bladders, which potentially affects the carcinogenic hazard from 
calculi, is related to the horizontal versus vertical status. Rodents, because of their horizontal 
stature, have a bladder that can retain calculi in the bladder for long periods of time, 
without completely obstructing the urinary flow.  
Xanthine oxidoreductase catalyzes the last two reactions of purine catabolism: the 
hydroxylation of hypoxanthine to xanthine and of xanthine to uric acid. Xanthine 
oxidoreductase inhibitors such as allopurinol and febuxostat are used as therapeutic agents 
against gout and hyperuricemia. They induce decreases in circulating uric acid and 
concomitant increases in blood xanthine, followed by intrarenal xanthine deposition leading 
to nephropathy in rodents. The xanthine crystals or calculi mediated by xanthine 
oxidoreductase inhibitors may repeatedly stimulate the epithelium of the renal pelvis and/or 
urinary bladder leading to proliferative lesions. Indeed, it has been described that 
carcinomas of the urinary bladder occurred in the carcinogenicity study of febuxostat [10]. 
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However, the pathomechanism of urinary bladder carcinogenesis due to xanthine deposits 
remains undetermined. With the above background, the mechanism of urinary bladder 
carcinogenesis induced by FYX-051 [11-13], 4-(5-pyridin-4-yl-1H-[1, 2, 4]triazol-3-
yl)pyridine-2-carbonitrile, a xanthine oxidoreductase inhibitor, in rats, has been 
investigated.  
Thus far, we have performed studies of FYX-051-induced nephropathy in rats [14-17]. In this 
chapter, first, general aspects concerning calculi formation and its bladder carcinogenesis are 
described. Second, the characteristics of FYX-051-induced nephropathy are described with 
respect to both identification of renal deposits precipitated after FYX-051 administration and 
marked species difference in nephropathy. Next, our aim was to prevent xanthine deposition 
after FYX-051 administration in rats by simultaneous treatment with citrate, and have 
established the experimental model. Using the model, a mechanistic study by simultaneous 
treatment with citrate for 52 weeks was performed. Based on the results of the 52-week study, 
finally, the extrapolation of carcinogenesis in rats for humans is discussed.  
2. Formation of calculi and its effects on bladder  
Solid materials can be generated in the urine by administration of a variety of chemicals, 
which lead to the formation of calculi [18]. Urinary calculi in rats and/or mice can be 
produced via variety of mechanisms as described by Cohen et al. [6]. The calculi can arise 
from the administered chemical itself such as melamine [19, 20], or from one of its 
metabolites such as diethylene glycol leading to calcium oxalate [21], or from an 
endogenous substance that results from the administration of the chemicals such as glycine 
leading to orotic acid [22]. Disorders of intermediate metabolism can also result in similar 
effects in the kidney and lower urinary tracts, such as the formation of urate calculi 
following surgical portacaval shunt in rats [23].  
A major consequence of a calculus in the bladder lumen is abrasion of the mucosa surface, 
resulting in erosion and ulceration. These cause an acute inflammatory reaction, but are 
always accompanied by marked regenerative hyperplasia. Urothelial cell number is markedly 
increased secondary to not only simple hyperplasia but papillary and nodular hyperplasia, 
frequently a diffuse papillomatosis. In addition, the rate of proliferation is also increased 10-
100 times. This results in 1000-10000 times increase in the number of cell divisions compared 
with normally quiescent adult urothelium. Although the formation of proliferative lesions 
produced by these foreign materials are reversible as evidenced by an example of uracil [24], 
stimulation of the urothelium for a long period leads to papilloma followed by carcinoma. 
3. Factors affecting calculus formation 
Of particular importance to factors that affect the formation of calculi in the urine are 
species, strain and sex [7, 25-27]. Rats and mice are the most commonly used species in 
carcinogen bioassays and in most mechanistic studies with animal models. Of major 
importance for comparison to humans are the extremely high levels of protein, osmolality, 
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and concentrations of various salts in the urine of rats and mice. There are marked variations 
in urinary composition and in response to treatment between rats and mice. Calculi tend to 
more readily form in rats than in mice [25, 28]. The proliferative response seems to be greater 
in rats than in mice, partly because of the reaction; primarily papillomatous response in rats, 
whereas there is a nodular response involving small number of cells in mice [4, 24]. As to the 
sex difference, male rodents are frequently affected to a greater extent than females. Several 
factors including potential hormonal effects and total amounts of specific types of urinary 
proteins have been suggested for this difference [25, 27, 29, 30, 31].  
The major factor, however, related to calculus formation is the dose of the chemicals 
administrated [32, 33]. An adequate amount of the chemical is needed to be administered to 
generate a sufficiently high concentration in the urine to lead to precipitation and calculus 
formation. The dose effect is the greatest fundamental factor in extrapolating the results in 
rodents to potential carcinogenic hazards in humans. Other factors that strictly affect the 
formation of calculi are physical, chemical and physiological properties. Urinary pH is a 
particularly fundamental factor [7, 25-27]. Effects of urinary pH have been identified for a 
variety of chemicals, based on its effects on the solubility of various salts, for example, urate 
or xanthine being greater at increased pH, while calcium phosphate crystals are formed 
more readily by the same condition.                                                                                               
4. Nephropathy and identification of renal deposits precipitated after 
FYX-051 administration 
In the long-term toxicity study of FYX-051 in rats, nephropathy with intrarenal deposits was 
observed. HPLC and LC-MS/MS analyses of intrarenal deposits in rats treated with FYX-051 
have proven that the entity was xanthine [14]. The pathomechanism of nephropathy could 
be speculated as follows. Treatment with FYX-051 induced high blood xanthine levels due to 
its pharmacological activity, and consequently, renal xanthine deposition occurred mainly 
during the process of urine-condensation from distal tubules to collecting ducts. When the 
amount of deposited xanthine exceeds the capacity of the kidney to excrete foreign 
materials, renal tubules and collecting ducts (particularly remarkable in distal tubules) are 
occluded by these deposits, leading to secondary interstitial nephritis. 
5. Species difference in nephropathy induced by FYX-051 
Thirteen-week toxicity study of FYX-051 in rats and dogs demonstrated that the no observed 
adverse effect level (NOAEL) was estimated to be 0.3 and 10 mg/kg/day, respectively. On 
the other hand, no changes were seen even at 300 mg/kg/day in the case of 52-week 
treatment of monkeys (Table 1). It was shown that rats are very susceptible to FYX-051-
induced intrarenal xanthine deposition and subsequent nephropathy. The mechanism of 
marked species difference on nephropathy was investigated. As a result, three factors were 
found to be involved in the species difference. First, urinary excretion of purine metabolites 
in terms of body weight as an index of the rate of purine metabolism, which is the key factor 
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of species difference, was thirty-fold higher in rats than in monkeys (Table 2). As the second 
factor, urinary xanthine solubility was two- and six-fold higher in dogs and monkeys, 
respectively, than in rats (Table 3). The fact was mainly mediated by the higher urinary pH 
of the former two species than the latter, because urinary xanthine solubility is dependent 
on urinary pH. Third, exposure level of FYX-051 was five-fold higher in rats than in other 
species (Table 4). The species difference of FYX-051-induced nephropathy seems to be 
caused by the combined effects of the above three factors. 
 
 NOAEL (mg/kg/day) 
Rats Dogs Monkeys 
13-week 0.3 10 > 100 
26-week 0.2 NT NT 
52-week NT NT > 300 
Changes observed in rats and dogs after repeated oral treatment with FYX-051 were nephropathy. NT: Not tested. 
Table 1. No observed adverse effect level (NOAEL) of FYX-051 in repeated toxicity studies using rats, 
dogs and monkeys  
 
Species (A) Body 
weight (kg) 
(B) Urinary 






Rats 0.209 ± 0.023 400.7 ± 58.9 1934.7 ± 385.0 31.2 
Dogs 9.8 ± 0.7 3929.2 ± 790.3 402.8 ± 74.0 6.5 
Monkeys 4.51 ± 0.18 280.4 ± 123.5 62.0 ± 26.0 1.0 
Humans 64.1 ± 7.5 3364.3 ± 419.3 52.8 ± 7.0 0.9 
Data were cited from the references [15, 16]. 





Rats       
6.7 
Dogs      
7.8 
Monkeys      
9.0 
Humans   
5.5 
Urinary xanthinesolubility at 37°C ca. 150 ca. 350 ca. 950 ca. 130 
Data were cited from the references [15, 16]. 
Table 3. Estimated urinary xanthine solubility in the control urine in each species 
 
 Rats      
3 mg/kg 
Dogs      
10 mg/kg 
Monkeys    
10 mg/kg 
Humans    
3 mg/kg 
AUC0-t (μg･h/ml) 13.9 8.81 9.89 2.82 
Ratio (to monkeys) 4.7 0.9 1.0 1.0 
The ratio to monkey’s level was calculated based on AUC of FYX-051 at 10 mg/kg estimated from those at 3 mg/kg.  
Data were cited from the references [15, 16]. 
Table 4. Exposure levels of FYX-051 in each species 
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6. Establishment of simultaneous treatment model with citrate for 
preventing nephropathy 
In the carcinogenicity testing in which FYX-051 was orally given to rats for 2 years, 
transitional cell papilloma and carcinoma were seen in the urinary bladder of male rats, 
along with the xanthine calculus in the cavity at doses of 1 and 3 mg/kg. Urinary bladder 
tumors occurred confined to the apex, the site that easily receives physical stimulation. No 
bladder tumors occurred in animals that died at less than 16 months. 
In order to clarify the mechanism of urinary bladder carcinogenesis observed, we tried to 
prevent the xanthine deposition in the urinary tract by using co-treatment with citrate. 
Citrate is a urine-alkalizing agent and its treatment with large amount of water causes an 
elevation of urinary pH and an increase in urine volume, which are attributable to rapid 
increase in xanthine solubility in urine. Citrate appears to act as an inhibitor of the 
experimental urolithiasis formation in the urine [34]. Due to its chelating effect, citrate in the 
urine may be expected to inhibit the formation of calcium-containing precipitates. The 
experimental conditions suitable for the 52-week simultaneous treatment with FYX-051 and 
citrate in rats were determined.  
Some sodium salts, such as saccharate and ascorbate, at high doses, can lead to the formation 
of calcium phosphate-containing precipitate [35]. In the present study, citrate was used as a 
mixture of its tri-sodium salt, tri-potassium salt, and free acid in a ratio of 2:2:1, calculated as 
anhydrous at molar base, leading to the reduced amount of sodium salt treated. 
6.1. Study on the duration of effects by citrate 
Duration of effects by citrate was examined as shown in Figure 1a. Male F344 rats received a 
single oral dosing of FYX-051 alone at a dose of 30 mg/kg (Group 1) or FYX-051 + 2,000 mg/kg 
citrate (Group 2) orally at a dosing volume of 10 ml/kg. Urine just after urination was collected 
during 1.5 - 2 h, 3.5 - 4 h, 5.5 - 6 h, and 7.5 - 8 h after oral administration of FYX-051. Insoluble 
xanthine concentration in each urine sample was determined as the difference of xanthine 
concentration between whole urine and filtered urine through a 0.45 m pore size filter.  
Simultaneous treatment with citrate remarkably increased urinary citrate concentrations at 
3.5 - 4 h (Figure 2a). In both groups, xanthine was dissolved in urine at 1.5 - 2 h after 
administration, since the insoluble xanthine concentration was nearly zero (Figure 2b). At 
3.5 - 4 h, deposition of xanthine was observed in Group 1. Simultaneous treatment with 
citrate significantly prevented the xanthine deposition. Thereafter, the effects of citrate 
disappeared; no significant difference was observed between the two groups at 5.5 - 6 h and 
7.5 - 8 h after administration. The results indicate a preventative effect of citrate on xanthine 
deposition in urine but also a lack of its durability. 
6.2. Seven-day simultaneous treatment study with citrate 
Because of the lack of durability of citrate effects, it was suggested that at least daily twice 
treatments of citrate are needed to prevent xanthine deposition. We carried out a 7-day 
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of species difference, was thirty-fold higher in rats than in monkeys (Table 2). As the second 
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simultaneous treatment study by two daily treatments to F344 rats, that is, FYX-051 (6 
mg/kg) and citrate (2000 mg/kg) followed by citrate alone treatment under the conditions of 
selected dosing intervals, the second dose of citrate, and dosing volume. In order to 
establish the experimental conditions suitable for the 52-week mechanistic study, in which 
burdens to both animals and technicians should be reduced, the daily first treatment of 
citrate was done as the mixture with FYX-051, and we tried to reduce the second dose of 







Figure 1. Experimental design (Studies a, b and c) and results (Study b) of the simultaneous treatment 
study with FYX-051 and citrate for the determination of experimental conditions suitable for the 52-
week study. Vehicle of FYX-051 is 0.5% CMC-Na. *: P<0.05, **: P<0.01 vs. FYX-051 alone group (group 2 or 
group 11, by Fisher’s exact probability test). Results of ‘Study a’ are shown in Figure 2. Results of ‘Study c’ 
are shown in Figures 3, 4 and Table 5. Figure is modified from reference [17]. 
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Figure 2. Changes in urinary citrate concentration (a) and insoluble xanthine concentration in urine (b) 
in rats receiving the single oral treatment of 30 mg/kg FYX-051 (Group 1, open circles) or 30 mg/kg FYX-
051 + 2,000 mg/kg citrate (Group 2, closed circles). Each value represents the mean ± SD of 5 animals. *: 
P<0.05, **: p<0.01, significant difference was observed between the two groups by Student's t test. Figure 
is from reference [17]. 
Relative kidney weights and blood urea nitrogen (BUN) level significantly increased in the 
FYX-051 group (Group 2) compared to the controls (Group 1). Autopsy revealed yellowish-
white granular deposits on the cut surface of the kidney or in the urinary bladder in all rats 
of Group 2. In groups treated with citrate, increased kidney weights and BUN were 
prevented almost completely (data not shown). Treatment of citrate, 2,000 and 2,000 mg/kg 
at an interval of 3 h with dosing volume of 15 ml/kg (Group 3) remarkably reduced granular 
deposits on the cut surface of the kidney and in the urinary bladder, although the deposition 
still remained in the renal pelvis in 1 out of 8 rats (Figure 1b). When the interval of citrate 
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establish the experimental conditions suitable for the 52-week mechanistic study, in which 
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treatments was 5 h (Group 9), granular deposits were seen in the renal pelvis in 2 out of 7 
rats. In case of 4 h (Group 6), however, no granular deposition in the renal pelvis was 
observed. Neither a reduction of citrate dose from 2,000 to 1,500 mg/kg (Group 7) nor 
decreased dosing volume from 15 to 10 ml/kg (Group 8) revealed apparent effects on the 
incidence of crystal deposition. Similarly, the dose of citrate and dosing volume failed to 
affect the granular deposition when the dosing interval was 3 h (Groups 4 and 5 vs. Group 
3) or 5 h (Groups 12 and 13 vs. Group 9). 
The present results indicate that the dosing interval of citrate has a great significance, and is 
optimal at 4 h, but not at 3 or 5 h, because this treatment completely inhibited intrarenal 
xanthine deposition. A decrease in dose of citrate for the second treatment or the dosing 
volume was well tolerated for prevention of granular deposits in the renal pelvis.  
7. Effects of simultaneous treatment model with citrate on nephropathy 
and bladder carcinogenesis in rats 
7.1. Four-week simultaneous treatment study with citrate 
A 4-week study under the established conditions was carried out as shown in Figure 1c. 
The male F344 rats were divided into 4 groups of 8 animals each. In the simultaneous 
treatment group with citrate, first, animals received 3 mg/kg FYX-051 and 2000 mg/kg 
citrate, and 4 h later 1500 mg/kg citrate alone at a volume of 10 ml/kg, based on a 7-day 
study.  
In the treatment group with FYX-051 alone (Group 3), laboratory investigations revealed 
chylous urine, granular deposits (xanthine crystals) in urinary sediments, and trends of 
increased serum creatinine compared with the control group (Group 1) (Table 5). 
Pathological examinations revealed increased relative kidney weights and gross renal 
findings such as focal pale changes, focal rough surface, scar, and white patch. 
Histopathologically, these were characterized by basophilia and dilatation of renal tubules, 
cell debris in tubular lumen, crystalline materials in the cortex, medulla, and papilla, 
calculus, fibrosis, and transitional cell hyperplasia (Figure 3a). In addition, calculus and 
transitional cell hyperplasia were also present in the urinary bladder in one instance each 
(Figure 4a, Table 5).  
Citrate treatment alone (Group 2) and simultaneous treatment with FYX-051 (Group 4) 
apparently increased urinary pH compared with Groups 1 and 3 (Table 5). In Group 4, no 
noticeable changes were seen in the kidneys nor were alterations seen in the urinary bladder 
(Figures 3b, 4b). The serum creatinine level in the Group 4 was equivalent to the Group 1, 
with attaining a significant decrease compared with the Group 3. Additionally, treatment 
with citrate exhibited no remarkable effect on the exposure levels of FYX-051. These 
observations showed that FYX-051-induced nephropathy could be markedly depressed by 
simultaneous treatment with 3,500 mg/kg of citrate, leading to the disappearance of 
transitional cell hyperplasia in the urinary bladder. 
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Figure 3. Photomicrographs of the kidney (cortex to outer medulla) from a male F344 rat treated orally 
with (a) 3 mg/kg FYX-051 (Group 3) or (b) 3 mg/kg FYX-051 + 3,500 mg/kg citrate (Group 4) for 4 weeks. 
Note (a) mild interstitial nephritis and (b) normal histology; magnification 100×, HE staining. 
 
Figure 4. Photomicrographs of the urinary bladder from a male F344 rat treated orally with (a) 3 mg/kg 
FYX-051 (Group 3) or (b) 3 mg/kg FYX-051 + 3,500 mg/kg citrate (Group 4) for 4 weeks. Note (a) mild 
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Figure 4. Photomicrographs of the urinary bladder from a male F344 rat treated orally with (a) 3 mg/kg 
FYX-051 (Group 3) or (b) 3 mg/kg FYX-051 + 3,500 mg/kg citrate (Group 4) for 4 weeks. Note (a) mild 
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No. of animals 8 8 8 8 
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Serum creatinine (mg/dl) 0.22 ± 0.02 0.22 ± 0.03 0.26 ± 0.05  0.21 ± 0.02* 
BUN (mg/dl) 20.4 ± 0.7 23.3 ± 2.3 22.5 ± 4.4 22.1 ± 1.4 
Relative kidney weight (%) 0.717 ± 0.028 0.777 ± 0.016†† 0.778 ± 0.070† 0.765 ± 0.022 
Autopsy 
-Kidney 
 pale, focal 
 rough surface, focal 
 scarred 
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  No. of animals                           
  AUC0-24h (g･h/ml) 
   
6 
5.51 ± 0.75 
 
 5 
5.03 ± 0.48 
Data were expressed as the mean ± SD.     a Regeneration     bDiagnosis     cNo histopathological changes 
*Significant difference compared with Group 3 (P<0.05, by Aspin-Welch’s t test). 
†Significant difference compared with Group 1 (P<0.05, by Aspin-Welch’s t test). 
††Significant difference compared with Group 1 (P<0.01, by Student’s t test). Table is from reference [17]. 
Table 5. Data of urinalysis, blood chemistry, relative kidney weights, histopathology of urinary organs 
and toxicokinetics in male rats receiving FYX-051 alone or simultaneous treatment with citrate 
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7.2. Mechanistic study by simultaneous treatment with citrate for 52 weeks 
The male F344 rats were divided into 4 groups of 17 males each. Treatment of FYX-051 and 
citrate was done in a same manner as 4 week study. As shown in Table 6, in the FYX-051 
alone treatment group, the following findings were observed: a significant decrease in 
urinary osmolality, crystals in sediments, hematuria, significant increases of serum BUN 
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15.9 ± 1.3 
0.27 ± 0.03 
 
22.6 ± 1.7  
0.24 ± 0.02  
      
42.0 ± 12.8 ** 
0.72 ± 0.19 ** 
 
21.7 ± 2.7 ## 
0.24 ± 0.02 ## 
Kidney weight 
Absolute (g)  
Relative (g%) 
 
2.27 ± 0.14 
0.602 ± 0.028 
 
2.32 ± 0.09 
0.732 ± 0.027 
 
2.00 ± 0.15 ** 
0.616 ± 0.049 
 
2.38 ± 0.14 ## 
0.737 ± 0.027 ## 
Gross pathology – – Kidney: atrophy (13),  
 calculus (4), rough  
 surface (5), white  
 patch (6)  
Urinary bladder: 
 calculus (16) 
– 
Histopathology  – – Kidney: interstitial  
 nephritis (17), simple 
 hyperplasia of  
 transitional cell (17) 
Urinary bladder:  
 simple hyperplasia (4)
 and papillary  
 hyperplasia (1) of  
 transitional cell  
– 
–: No remarkable change 
*, ** Significant difference was observed in FYX-051 alone group when compared with the vehicle control group (p < 
0.05. 0.01, by Student's t-test). 
#, ## Significant difference was observed in the simultaneous treatment group with citrate when compare with FYX-051 
alone group (p < 0.05, 0.01, by Student's  t-test).  
Table 6. Data for urinalysis, blood chemistry, kidney weight, gross pathology, and histopathology in 
rats receiving simultaneous treatment with FYX-051 and citrate for 52 weeks 
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surface, interstitial nephritis, simple hyperplasia of transitional cells. In the urinary bladder, 
calculus, simple and papillary hyperplasia of transitional cells was observed in 16, 4 and 
1/17 males in the FYX-051 alone group, respectively. Oyasu [36] has postulated that 
commonly, distinction between papillary hyperplasia and papilloma of transitional cells is 
difficult. Accordingly, papillary hyperplasia observed in this 52-week mechanistic study 
could be regarded as precancerous lesions for bladder carcinogenesis. Neither xanthine 
crystals nor lesions in any of the kidney and urinary bladder samples were observed in the 
simultaneous treatment group with citrate. 
Thus, simple and papillary hyperplasia of transitional cells followed by papilloma and 
carcinoma in the urinary bladder in rats occurring after the long-term treatment of FYX-051 
were secondary changes caused by xanthine crystals being deposited in the kidney, and no 
other causes could be implicated in these changes. Proposed histogenesis of urinary bladder 
carcinogenesis obtained in this study is shown in Figure 5. 
 
Figure 5. Proposed histogenesis of urinary bladder carcinogenesis induced by xanthine oxidoreductase 
inhibitors in rats 
8. Extrapolation of carcinogenesis in rats for humans 
The extrapolation of the results in rats into humans can be considered as follows. A marked 
species difference between rats and monkeys in FYX-051-induced nephropathy was 
suggested to be mediated by the combined effects of three factors; the rate of purine 
metabolism, urinary xanthine solubility and exposure level of FYX-051 as described above. 
A comparison of these factors relevant to species difference between monkeys and humans 
demonstrated that urinary xanthine solubility in the former was seven-fold higher than in 
the latter, without any differences in the remaining two factors. It should be emphasized 
that in the clinical trial of FYX-051, in which adequate hypouricemic effect was obtained, 
neither xanthine crystals in urine nor serious side effects have been reported, although 


























Mechanism of Urinary Bladder Carcinogenesis Induced by a Xanthine Oxidoreductase Inhibitor, in Rats 233 
guanine phosphoribosyltransferase is congenitally absent [37]. Further, small crystals or 
calculi can be excreted from the bladder in humans in contrast to rodents, as described in 
the introduction section. The outcomes of genotoxicity studies were negative, revealing that 
FYX-051 is a non-genotoxic compound (unpublished data). Thus, urinary bladder 
carcinogenesis, which would be mediated by xanthine deposition in rats after long-term 
treatment with FYX-051 cannot be extrapolated for humans due to extremely low occurrence 
of xanthine deposition in humans.   
9. Conclusion 
It is generally accepted that crystal or calculus in the urinary bladder of rats would 
ultimately cause carcinoma by acting as a proliferative stimulus. However, no direct 
evidence of calculus-mediated carcinogenesis was obtained in the treatment of xanthine 
oxidoreductase inhibitors. In this chapter, the pathomechanism of bladder carcinogenesis in 
rats induced by a xanthine oxidoreductase inhibitor has been clearly shown by 
disappearance of precancerous lesions in the case of prevention of xanthine deposition. This 
work will throw a light on the future studies of urinary bladder carcinogenesis in animals, 
since it was demonstrated that modifying experimental design that affects calculus 
formation produced great differences in the results of studies by long-term treatment. 
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formation produced great differences in the results of studies by long-term treatment. 
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1. Introduction 
1.1. Chemopreventive agents 
Chemoprevention is a promising and relatively new approach to cancer prevention that has 
precedence in cardiology, in which cholesterol lowering antihypertensive, and antiplatelet 
agents are administered to prevent coronary heart disease in high-risk individuals [1]. 
Chemoprevention can be defined as “the use of natural or synthetic chemical compounds to 
reverse, suppress or to prevent one or more of the biological events leading to the 
development of invasive cancer”  
A chemopreventive strategy could potentially either prevent further DNA damage that 
might enhance carcinogenesis or suppress the appearance of the cancer phenotype [2]. 
Chemopreventive agents inhibit or reverse cellular events associated with tumor initiation, 
promotion, and/or progression. The mechanism of chemoprotective activities might 
correlate and balance between phase I + phase II enzymes levels, and influence cellular 
macromolecules, transporters, release of carcinogens, or DNA adducts and DNA repair [3].  
More than 1000 potential chemopreventive agents have been identified in dietary sources, 
and many are being tested in vitro and in vivo systems with a variety of cancer types. 
Identification and testing of a successful chemopreventive agent is a long process, requiring 
in vitro studies, animal efficacy and toxicity studies, and eventually lengthy human clinical 
trials [4].  
1.2. Mechanisms of action of chemopreventive agents 
Broadly defined on the basis of their mechanisms of action, chemopreventive agents can be 
grouped into two general classes: blocking agents and suppressing agents. Blocking agents 
(e.g., flavonoids, oltipraz, indoles, and isothiocyanates) prevent carcinogenic compounds 
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from reaching or reacting with critical target sites by preventing the metabolic activation of 
carcinogens or tumor promoters via enhancing detoxification systems and by trapping 
reactive carcinogens [5]. Suppressing agents (e.g., vitamin D and related compounds, 
nonsteroidal anti-inflammatory drugs [NSAIDS], vitamin A and retinoids, DFMO (2-
difluoromethylornithine), monoterpenes and calcium) prevent the evolution of the 
neoplastic process in cells that would otherwise become malignant. Mechanisms of action 
for suppressing agents are not well understood. Some produce differentiation, some 
counteract the consequences of genotoxic events such as oncogene activation, some inhibit 
cell proliferation, and some have undefined mechanisms [5].  
An ideal chemopreventive agent should have 1. Little or no toxic effects 2. High efficacy 
against multiple sites 3. Capability of oral administration 4. a known mechanism of action 5. 
Human acceptance [6]. A chemopreventive program identifies and accesses specific chemical 
substances, many naturally occurring in foods, with the potential to prevent cancer initiation 
and to either slow or reverse the progression of premalignant lesions to invasive cancer. 
1.3. Types of chemopreventive agents: 
Promising chemopreventive agents being investigated include micronutrients (e.g. vitamin 
A, C and E, β-carotene, molybdenum, and calcium), phytochemicals (e.g. indoles, 
polyphenols, isothiocyanates, flavonoids, monoterpenes, and organosulfides), and 
synthetics (e.g. vitamin A derivatives, piroxicam, tamoxifen, 2-difluoromethylornithine 
[DFMO] and oltipraz). More than 40 promising agents and agent combinations are being 
evaluated clinically as chemopreventive drugs for major cancer targets [7].  
1.3.1. Synthetic chemopreventive agents (Non-Steroidal-anti-inflammatory drugs): 
Several studies have reported a 40-50% decrease in the relative risk of colorectal cancer in 
persons who are continuous users of aspirin or other non steroidal anti-inflammatory drugs 
(NSAIDS) [8], suggesting that these drugs can serve as effective cancer chemopreventive 
agents. Hixson et al., [9] showed that the synthesis of prostaglandins is limited by 
cyclooxygenase. NSAIDS reversibly interrupted prostaglandin synthesis by inhibiting 
cyclooxygenase. NSAIDS can prevent tumor formation by their actions on prostaglandins, 
which can have an immune modulating effect. High levels of prostaglandin E2 can suppress 
the immune system, which keeps malignant cells in check. 
Other mechanisms that can explain the antiproliferative antitumor effects of NSAIDS 
include: interference with membrane-associated processes, such as G-protein signal 
transduction and transmembrane calcium influx, and inhibition of other enzymes, such as 
phospho-diesterase, folate-dependant enzymes, and cyclic adenosine-5`-monophosphatase-
dependent protein kinase, as well as enhancement of immunologic responses and cellular 
apoptosis [10].  
At a macroscopic level, NSAIDS prevent incident neoplasia (adenomas and carcinomas), 
and suppress the growth of carcinomas. Therefore, NSAIDS are effective when given 
 
Cancer Chemoprevention by Dietary Polyphenols 241 
“early” (proceeding adenoma-formation), as well as “late” (following the emergence of 
adenomas) [11].  An alternative explanation for the efficacy of NSAIDS in the prevention of 
colorectal cancer is their ability to scavenge reactive oxygen species [12]. 
1.3.2. Naturally-occurring chemopreventive agents: 
Frequent consumption of fruits and vegetables has been associated with lower incidence of 
cancers at different organ sites. Several factors can contribute to this association, first, the 
nutrients in fruits and vegetables, notably vitamin C, vitamin E, folic acid, provitamin A, 
selenium and zinc, are essential for normal cellular functions, a deficiency in these nutrients 
can enhance the susceptibility of an individual to cancer, second, some nutrients, such as 
vitamin C, vitamin E, selenium and β-carotene, at levels above nutritional needs, can display 
inhibitory activities against carcinogenesis. A third factor is that non-nutritive constituents, 
such as polyphenols, organosulfur compounds, and indoles have anticarcinogen activities. 
Finally, fruits and vegetables contribute fibers and bulkiness to the diet. Persons who 
consume large amounts of fruits and vegetables can eat smaller amounts of meat and other 
animal products that can contribute to higher cancer incidence in the western countries. 
Supplementation with these antioxidant nutrients apparently produces a protective effect 
against cancer. 
Comprehensive reviews of case-control and prospective cohort studies found that the 
relationship between high vegetable and fruit intake and reduced cancer risk appears to be 
strongest for cancers of the alimentary and respiratory tracts (cancers of the colon, 
esophagus, oral cavity and lung) and weakest for hormone related cancers (cancers of the 
breast, ovary, cervix, endometrium and prostate) [13-15]. Reduced cancer risk has been 
linked primarily to consumption of raw vegetables and fresh fruits (citrus, carrots, green leaf 
vegetables, cruciferous vegetables, soy products, and whole grain wheat products) [13-15].  
The beneficial effect of vegetables, fruits and whole grains can be due to either individual or 
combined effects of their constituents, including, fiber, micronutrients and phytochemicals.  
2. Dietary polyphenols and cancer chemoprevention 
Polyphenols constitute one of the largest and ubiquitous groups of phytochemicals. One of 
the primary functions of these plant-derived polyphenols is to protect plants from 
photosynthetic stress, reactive oxygen species, and consumption by herbivores. Polyphenols 
are also an essential part of the human diet, with flavonoids and phenolic acids being the 
most common ones in food. Not surprisingly, there is a growing realization that lower 
incidence of cancer in certain populations can probably be due to consumption of certain 
nutrients, and especially polyphenol rich diets. Consequently, a systematic dissection of the 
chemopreventive potential of polyphenolic compounds in the recent years has clearly 
supported their health benefits, including anti-cancer properties. Given the challenges of 
cancer therapy, ‘chemoprevention’-which uses pharmacological or natural agents to 
impede, arrest or reverse carcinogenesis at its earliest stages’ remains the most practical and 
promising approach for the management of cancer patients [16]. 
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esophagus, oral cavity and lung) and weakest for hormone related cancers (cancers of the 
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2. Dietary polyphenols and cancer chemoprevention 
Polyphenols constitute one of the largest and ubiquitous groups of phytochemicals. One of 
the primary functions of these plant-derived polyphenols is to protect plants from 
photosynthetic stress, reactive oxygen species, and consumption by herbivores. Polyphenols 
are also an essential part of the human diet, with flavonoids and phenolic acids being the 
most common ones in food. Not surprisingly, there is a growing realization that lower 
incidence of cancer in certain populations can probably be due to consumption of certain 
nutrients, and especially polyphenol rich diets. Consequently, a systematic dissection of the 
chemopreventive potential of polyphenolic compounds in the recent years has clearly 
supported their health benefits, including anti-cancer properties. Given the challenges of 
cancer therapy, ‘chemoprevention’-which uses pharmacological or natural agents to 
impede, arrest or reverse carcinogenesis at its earliest stages’ remains the most practical and 
promising approach for the management of cancer patients [16]. 
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Till date, A substantial number of studies in cultured cells, animal models and human 
clinical trials have illustrated a protective role of dietary polyphenols against different types 
of cancers [17–20]. Polyphenols are present in fruits, vegetables, and other dietary 
botanicals. Some estimates suggest that more than 8000 different dietary polyphenols exist, 
and these can be divided into ten different general classes based on their chemical structure 
[21]. Phenolic acids, flavonoids, stilbenes and lignans are the most abundantly occurring 
polyphenols that are also an integral part of everyday nutrition in populations worldwide. 
Some of the common examples of the most studied and promising cancer chemopreventive 
polyphenols include EGCG (from green tea), curcumin (from curry) and resveratrol (from 
grapes and berries). Significant gains have been made in understanding the molecular 
mechanisms underpinning the chemopreventive effects of polyphenols, and consequently, a 
wide range of mechanisms and gene targets have been identified for individual compounds. 
Various mechanistic explanations for their chemopreventive efficacy include their ability to 
interrupt or reverse the carcinogenesis process by acting on intracellular signaling network 
molecules involved in the initiation and/or promotion of cancer, or their potential to arrest 
or reverse the promotion stage of cancer [22; 23]. Polyphenolic compounds can also trigger 
apoptosis in cancer cells through the modulation of a number of key elements in cellular 
signal transduction pathways linked to apoptosis (caspases, bcl-2 genes) [17; 22; 23]. Several 
elegant reviews have described in detail specific genetic and signaling mechanisms that are 
targeted by different polyphenols, and this is beyond the scope of this review article [24–26]. 
However, recent research has suggested that some of the chemopreventive potential of 
dietary polyphenols can in part be due to their ability to modulate epigenetic alterations in 
cancer cells. This is of interest; as epigenetic modifications occur early and are potentially 
reversible, making dietary polyphenol-induced chemoprevention of various human cancers 
an attractive possibility from a clinical standpoint. However, the mechanism of how 
flavonoids do regulate and effect various epigenetic modifications in cancer cells is a topic 
that is still in its infancy. Nevertheless, increasing number of reports has repeatedly shown 
the promise of epigenetic prevention and possibly therapy by dietary polyphenols.  
2.1. Tea   
Tea (Camellia sinensis), next to water, is the most popular beverage consumed by over two 
thirds of the world’s population. The Chinese used tea as a medical drink as early as 3000 
BC, and by the end of the sixth century as a beverage. Tea essentially signifies two or three 
leaves and the terminal apical buds of the shrubs C. sinensis, Camellis asamica and other 
southern varieties. The cultivation area of the tea has gradually expanded in the world, 
especially in tropical countries, and the total cultivation area has expanded to 2,300,000 ha 
with a total amount of production of 2,600,000 t [27]. 
An estimated 2.5 million metric tons of dried tea are manufactured annually. Of this amount 
about 20% is green tea, mainly consumed in Asian countries where tea is a major beverage. 
About 78% is black tea mainly consumed in the western nations and some Asian countries 
and about 2% is oolong tea mainly produced and consumed in South Eastern China. 
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2.1.1. Chemistry and mechanism of action of tea polyphenols: 
Manufacture of black tea takes place by crushing the leaves causing polyphenol oxidase-
dependent oxidative polymerization that leads to the formation of theaflavins, thearubigins 
and other oligomers in a process known as fermentation. Theaflavins (about 1% - 2% of the 
total dry matter of black tea) including theaflavin, theaflavin-3-O-gallate, theaflavin-3/-O-
gallate and theaflavin-3-3/-O-digallate, possess benzotropolone rings with dihydroxy or 
trihydroxy substitution systems which give the characteristic color and taste of black tea. 
About 10 - 20% of the dry weight of black tea is due to thearubigens, which are even more 
extensively oxidized and polymerized, have a wide range of molecular weights and are less 
well characterized.  
Oolong tea, a partially fermented tea, contains monomeric catechins, theaflavins and 
thearubigins. Some characteristic components, such as epigallocatechin esters, theasinensins, 
dimeric catechins and dimeric proanthocyanidins are also found in oolong tea. 
Commercial green tea is made by steaming or drying fresh tea leaves at elevated 
temperature. Its chemical composition is similar to that of fresh tea leaves. Green tea 
contains polyphenols that include flavanols, flavandiols, flavonoids and phenolic acids. 
These compounds can account for up to 30% of the dry weight. Most of the green tea 
polyphenols are flavonols commonly known as catechin. Some major green tea catechins are 
epigallocatechin-3-gallate (EGCG), (-) - epigallocatechin (EGC), epicatechin-3-gallate (ECG), 
- (-) -epicatechin (EC), (+) -gallocatechin and (+)-catechin (Figure 1). Caffeine, theobromine 
and theophylline the principal alkaloids account for about 4% of the dry weight. 
 
Figure 1. Components of green tea 
It has been stated that a cup (200 ml) of green tea contains about 142 mg EGCG, 65 mg EGC, 
17 mg EcC and 76 mg caffeine. The most important chemicals present in tea, which are of 
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considerable pharmacological significance, are the polyphenols and caffeine [28].  
Polyphenols are present to the extent of 30-35% in the dry tea leaf and determine the quality 
of the beverage. The amount of polyphenols depends on the genetic make up of tea and 
environmental factors such as climate, light, rainfall, temperature, nutrient availability and 
leaf age [27].  
Because the mechanisms of antimutagenesis and anticarcinogenesis by tea polyphenols vary 
for different cancers and for the same cancer in different population, tea consumption can 
affect carcinogenesis only in selected situations. Many laboratory studies have demonstrated 
inhibitory effects of tea preparation and tea polyphenols against tumor formation and 
growth. This inhibitory effect is believed to be mainly due to the antioxidative and possible 
antiproliferative effects of polyphenolic compounds in green and black tea. These 
polyphenolics can also inhibit carcinogenesis by blocking the endogenous formation of N-
nitroso compounds, suppressing the activation of carcinogen and trapping of genotoxic 
agents. Yang and Wang [28] showed that tea polyphenols also have high complexation 
affinity to metals, alkaloids and biologic macromolecules such as lipids, carbohydrates, 
proteins and nucleic acids.  
Work of Kuroda and Hara [27] illustrates that the polyphenols in tea have a strong radical 
scavenging and reducing activity. They capture and detoxify radicals of various promoters 
of carcinogenesis and radicals produced in the process of exposure to radiation and light. 
Since tea polyphenols inactivate enzyme and virus activity, they could be effective against 
carcinogenesis caused by some viruses. Tea polyphenols exert their inhibitory actions via 
various mechanisms at different stages of mutagenesis, carcinogenesis, invasion and 
metastasis of tumor cells; they act extracellularly as desmutagens and intracellularly as bio-
antimutagens. Tea polyphenols modulate metabolism, block, suppress, or affect DNA 
replication and repair effects. 
2.1.2. The health effects of green tea 
Green tea has been extensively studied in people, animals, and laboratory experiments. 
Results from these studies suggest that green tea can be useful for the several health 
conditions. 
It has been found that green tea consumption is significantly associated with a lower risk of 
mortality due to stroke [29] and pneumonia [30] and imparts a lower risk of cognitive 
impairment [31], depression [32], and psychological distress [33]. These results have been 
confirmed by other researchers [34–37]. In addition, other epidemiologic studies have 
indicated that green tea consumption is associated with a lower risk of osteoporosis [38, 39], 
and randomized placebo-controlled trials have indicated that green tea is effective in 
lowering cardiovascular risk factors [40, 41]. Because all of the above conditions are major 
causes of functional disability [42–44], it is expected that green tea consumption would 
contribute to disability prevention. Green tea consumption is associated with a lower risk of 
developing functional disability. 
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Atherosclerosis 
Population-based clinical studies indicate that the antioxidant properties of green tea can 
help prevent atherosclerosis, particularly coronary artery disease. (Population-based studies 
mean studies that follow large groups of people over time or studies that are comparing 
groups of people living in different cultures or with different dietary habits.) Researchers 
are not sure why green tea reduces the risk of heart disease by lowering cholesterol and 
triglyceride levels. Studies show that black tea has similar beneficial effects. In fact, 
researchers estimate that the rate of heart attack decreases by 11% with consumption of 3 
cups of tea per day [45].  
High cholesterol and cardiovascular Disease 
Research shows that green tea lowers total cholesterol and raises HDL ("good") cholesterol 
in both animals and people. One population-based clinical study found that men who drink 
green tea are more likely to have lower total cholesterol than those who do not drink green 
tea. Results from one animal study suggest that polyphenols in green tea can block the 
intestinal absorption of cholesterol and promote its excretion from the body. In another 
small study of male smokers, researchers found that green tea significantly reduced blood 
levels of harmful LDL cholesterol. 
Substantial evidence from in vitro and animal studies indicates that green tea (GT) 
preparations inhibit cardiovascular disease (CVD) processes [46-49]. In a previous 
observational study, it has been shown that GT consumption was associated with a 
significantly lower risk of mortality due to CVD among middle-aged adults [50]. The study 
also indicated that GT consumption was associated with reduced mortality from cerebral 
infarction but not with mortality from cerebral hemorrhage. These associations were 
consistent with those reported in another observational study [51]. 
Obesity 
Obesity and its related metabolic abnormalities, including insulin resistance, alterations in 
the insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) axis, and the state of chronic 
inflammation, increase the risk of colorectal cancer (CRC) and hepatocellular carcinoma 
(HCC). However, these findings also indicate that the metabolic disorders caused by obesity 
might be effective targets to prevent the development of CRC and HCC in obese 
individuals. Green tea catechins (GTCs) possess anticancer and chemopreventive properties 
against cancer in various organs, including the colorectal and liver. GTCs have also been 
known to exert anti-obesity, antidiabetic, and anti-inflammatory effects, indicating that 
GTCs might be useful for the prevention of obesity-associated colorectal and liver 
carcinogenesis. Further, branched-chain amino acids (BCAA), which improve protein 
malnutrition and prevent progressive hepatic failure in patients with chronic liver diseases, 
might be also effective for the suppression of obesity-related carcinogenesis because oral 
supplementation with BCAA reduces the risk of HCC in obese cirrhotic patients. BCAA 
shows these beneficial effects because they can improve insulin resistance. Here, we review 
the detailed relationship between metabolic abnormalities and the development of CRC and 
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HCC. We also review evidence, especially that based on our basic and clinical research 
using GTCs and BCAA, which indicates that targeting metabolic abnormalities by either 
pharmaceutical or nutritional intervention can be an effective strategy to prevent the 
development of CRC and HCC in obese individuals [52]. 
Diabetes 
Several studies have reported a protective effect for tea consumption on incident diabetes, 
and the results of a recent meta-analysis indicated that drinking more than 3–4 cups of tea 
(black, green or oolong) per day decreases the risk of Diabetes Mellitus by 20% [53]. Despite 
very high intake of black tea, no significant association for black tea consumption was 
observed, but an inverse correlation was found between green tea drinking and diabetes 
prevalence. Several animal and human studies have shown an antidiabetic effect for green 
tea polyphenols, specifically epigallocatechin gallate (EGCG) [54-57]. EGCG induces its 
antidiabetic effects mostly through reduced hepatic glucose production and enhanced 
pancreatic function [56]. Green tea has been shown to improve glucose tolerance and has 
been suggested as a prophylactic agent against diabetes [55]. 
Weight loss 
Clinical studies suggest that green tea extract can boost metabolism and help burn fat. One 
study confirmed that the combination of green tea and caffeine improved weight loss and 
maintenance in overweight and moderately obese individuals. Some researchers speculate 
that substances in green tea known as polyphenols, specifically the catechins, are 
responsible for the herb's fat-burning effect. 
Cancer  
Many studies suggest an inverse relationship between green tea intake and the risk of a 
variety of cancers, although other studies have found no association. Clinical trials have 
been small and heterogenous with contradictory results. Dietary, environmental, and 
population differences can account for these inconsistencies [58]. 
Several population-based clinical studies have shown that both green and black teas help 
protect against cancer. For example, cancer rates tend to be low in countries such as Japan 
where people regularly consume green tea. However, it is not possible to determine from 
these population-based studies whether green tea actually prevents cancer in people. 
Emerging clinical studies suggest that the polyphenols in tea, especially green tea, can play 
an important role in the prevention of cancer [59].  
Bladder Cancer. Only a few clinical studies have examined the relationship between bladder 
cancer and tea consumption. In one study that compared people with and without bladder 
cancer, researchers found that women who drank black tea and powdered green tea were 
less likely to develop bladder cancer. A follow-up clinical study by the same group of 
researchers revealed that bladder cancer patients (particularly men) who drank green tea 
had a substantially better 5-year survival rate than those who did not. Other study has 
demonstrated the anti-oxidant properties of green tea extract (GTE) against human bladder 
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uroepithelial cells. The data demonstrate that under in vitro conditions, green tea extract can 
afford both normal and tumorigenic human bladder urothelial cells protection (i.e., prevent 
apoptosis) to various degrees after chemical insult with H2O2 [60]. 
Breast Cancer. Although tea has been extensively investigated in in vitro and in vivo studies, 
few epidemiologic studies have evaluated the relationship between green tea and breast 
cancer risk. The results from these studies are inconsistent [61-63]. In general, the cohort 
studies, all based in Japan, report no significant association [61] and the case-control studies 
[62, 63], based on Asian-American or Chinese populations, all report an inverse relationship 
between green tea and breast cancer risk [62]. Previous studies have not evaluated the 
relationship between green tea consumption and pre- and postmenopausal breast cancer. 
The most recent meta-analysis included 7 (2 cohort, 1 nested case–control and 4 case–
control) epidemiological studies of green tea and breast cancer that were published as of 
December 2008 [64]. An inverse association between green tea and breast cancer risk was 
reported from case–control data, while no association was observed from cohort data [64]. 
The nested case–control study reported no association [65], so even if it had been included 
as a cohort study in the pooled analyses, the overall finding would have remained the same. 
In summary, green tea could exert beneficial effects on breast carcinogenesis through 
inhibition of estrogen’s pro-carcinogenic activity either alone by itself or in combination 
with other estrogen-inhibiting factors. Black tea does not appear to have protective effects 
on breast cancer incidence, and can increase risk of hormone-dependent tumors. Future 
research is needed to elucidate the interactive role of tea catechins and other dietary cancer-
inhibitory compounds in mammary carcinogenesis in humans. 
Ovarian Cancer. In a clinical study conducted on ovarian cancer patients in China, 
researchers found that women who drank at least one cup of green tea per day survived 
longer with the disease than those who did not drink green tea. In fact, those who drank 
green tea lived the longest. Other studies found no beneficial effects [66, 67]. In view of the 
variations in rates of breast cancer and tea-drinking practices, one case–control study was 
conducted in Southeast China to evaluate the association between breast cancer and tea 
consumption measured by type, duration, frequency and quantity of tea and the interactions 
between tea consumption and other lifestyle factors. 
Esophageal Cancer. In the Indian studies [68-70], some results indicated that tea (presumably 
black tea) consumption could be responsible for the development of esophageal cancer. The 
authors indicated that this result could be due to drinking hot tea, which was shown to 
occur a couple of decades before in a Chinese cohort. The other possibility could be that 
Indians drink their black tea with milk, which was shown before to counteract positive 
effects of tea.  
The higher content of tea catechins present in green tea than in black tea can explain the 
more consistent inverse association between tea and esophageal cancer risk in studies 
conducted in China and Japan than in European and American countries. The putative 
protective effect of tea consumption, if any, on esophageal cancer development could be 
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responsible for the herb's fat-burning effect. 
Cancer  
Many studies suggest an inverse relationship between green tea intake and the risk of a 
variety of cancers, although other studies have found no association. Clinical trials have 
been small and heterogenous with contradictory results. Dietary, environmental, and 
population differences can account for these inconsistencies [58]. 
Several population-based clinical studies have shown that both green and black teas help 
protect against cancer. For example, cancer rates tend to be low in countries such as Japan 
where people regularly consume green tea. However, it is not possible to determine from 
these population-based studies whether green tea actually prevents cancer in people. 
Emerging clinical studies suggest that the polyphenols in tea, especially green tea, can play 
an important role in the prevention of cancer [59].  
Bladder Cancer. Only a few clinical studies have examined the relationship between bladder 
cancer and tea consumption. In one study that compared people with and without bladder 
cancer, researchers found that women who drank black tea and powdered green tea were 
less likely to develop bladder cancer. A follow-up clinical study by the same group of 
researchers revealed that bladder cancer patients (particularly men) who drank green tea 
had a substantially better 5-year survival rate than those who did not. Other study has 
demonstrated the anti-oxidant properties of green tea extract (GTE) against human bladder 
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uroepithelial cells. The data demonstrate that under in vitro conditions, green tea extract can 
afford both normal and tumorigenic human bladder urothelial cells protection (i.e., prevent 
apoptosis) to various degrees after chemical insult with H2O2 [60]. 
Breast Cancer. Although tea has been extensively investigated in in vitro and in vivo studies, 
few epidemiologic studies have evaluated the relationship between green tea and breast 
cancer risk. The results from these studies are inconsistent [61-63]. In general, the cohort 
studies, all based in Japan, report no significant association [61] and the case-control studies 
[62, 63], based on Asian-American or Chinese populations, all report an inverse relationship 
between green tea and breast cancer risk [62]. Previous studies have not evaluated the 
relationship between green tea consumption and pre- and postmenopausal breast cancer. 
The most recent meta-analysis included 7 (2 cohort, 1 nested case–control and 4 case–
control) epidemiological studies of green tea and breast cancer that were published as of 
December 2008 [64]. An inverse association between green tea and breast cancer risk was 
reported from case–control data, while no association was observed from cohort data [64]. 
The nested case–control study reported no association [65], so even if it had been included 
as a cohort study in the pooled analyses, the overall finding would have remained the same. 
In summary, green tea could exert beneficial effects on breast carcinogenesis through 
inhibition of estrogen’s pro-carcinogenic activity either alone by itself or in combination 
with other estrogen-inhibiting factors. Black tea does not appear to have protective effects 
on breast cancer incidence, and can increase risk of hormone-dependent tumors. Future 
research is needed to elucidate the interactive role of tea catechins and other dietary cancer-
inhibitory compounds in mammary carcinogenesis in humans. 
Ovarian Cancer. In a clinical study conducted on ovarian cancer patients in China, 
researchers found that women who drank at least one cup of green tea per day survived 
longer with the disease than those who did not drink green tea. In fact, those who drank 
green tea lived the longest. Other studies found no beneficial effects [66, 67]. In view of the 
variations in rates of breast cancer and tea-drinking practices, one case–control study was 
conducted in Southeast China to evaluate the association between breast cancer and tea 
consumption measured by type, duration, frequency and quantity of tea and the interactions 
between tea consumption and other lifestyle factors. 
Esophageal Cancer. In the Indian studies [68-70], some results indicated that tea (presumably 
black tea) consumption could be responsible for the development of esophageal cancer. The 
authors indicated that this result could be due to drinking hot tea, which was shown to 
occur a couple of decades before in a Chinese cohort. The other possibility could be that 
Indians drink their black tea with milk, which was shown before to counteract positive 
effects of tea.  
The higher content of tea catechins present in green tea than in black tea can explain the 
more consistent inverse association between tea and esophageal cancer risk in studies 
conducted in China and Japan than in European and American countries. The putative 
protective effect of tea consumption, if any, on esophageal cancer development could be 
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confounded and/or overshadowed by the thermal effect of tea beverages, if consumed at 
high temperature, as well as cigarette smoking or alcohol intake. Future prospective cohort 
studies are required to collect detailed information on tea temperature and histories of 
tobacco and alcohol use that can then be adjusted for when evaluating the protective effect 
of tea on esophageal cancer. 
Prostate Cancer. Among all cancers, prostate cancer is an ideal candidate disease for 
chemoprevention because it is typically diagnosed in men ages >50 years and has a high 
latency period [71, 72]. Therefore, even a slight delay in the progression of this disease by 
chemopreventive intervention could result in a substantial reduction in the incidence of the 
disease and, more importantly, improve the quality of life of the patients [71, 72]. Evidences 
collected from geographic, epidemiologic, and migration studies suggest that frequent 
consumption of green tea is associated with lower frequencies of prostate cancer in Asian 
populations in general compared with those in western societies [73-77]. Laboratory and 
preclinical animal studies also indicate a protective role of green tea against prostate cancer 
[78-82]. 
In summary, observational studies do not provide strong evidence for a protective effect of 
green tea or black tea intake against the development of prostate cancer. There is some 
suggestive evidence that green tea intake can reduce the risk of advanced prostate cancer. 
The phase II clinical trials have provided encouraging evidence in the development of green 
tea catechins as a chemopreventive agent against prostate carcinogenesis.  
Skin Cancer. There has been considerable interest in the use of naturally occurring plant 
products, including polyphenols, for the prevention of UV-induced skin photodamage 
primarily including the risk of skin cancer. Polyphenols, specifically dietary, possessing 
anti-inflammatory, immunomodulatory and anti-oxidant properties are among the most 
promising group of compounds that can be exploited as ideal chemopreventive agents for a 
variety of skin disorders in general and skin cancer in particular. In this respect, 
chemoprevention offers a realistic strategy for controlling the risk of cancers. Furthermore, a 
chemopreventive approach appears to have practical implications in reducing skin cancer 
risk because, unlike the carcinogenic environmental factors that are difficult to control, 
individuals can modify their dietary habits and lifestyle in combination with a careful use of 
skin care products to prevent the photodamaging effects in the skin. Studies from our 
laboratory have shown the efficacy of naturally occurring polyphenols, such as green tea 
polyphenols (GTPs), silymarin from milk thistle and proanthocyanidins from grape seeds 
(GSPs), against UV radiation-induced inflammation, oxidative stress, DNA damage and 
suppression of immune responses [83]. 
Stomach cancer. Recently, Myung et al. conducted a meta-analysis investigating the 
quantitative association between the consumption of green tea and the risk of stomach 
cancer in humans [84]. The analysis included 13 (5 cohort and 8 case–control) studies, all 
conducted in Japanese or Chinese populations. An inverse association was seen in case–
control studies only, but not in cohort studies. However, in a recent pooled analysis of 6 
cohort studies that included more than 218,000 Japanese men and women aged 40 years or 
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older and more than 3500 incident stomach cancer cases found a statistically significant, 
inverse association between green tea consumption and stomach cancer risk in women, but 
not in men [85]. Compared with those drinking <1 cup/day, women with the consumption 
of ≥5 cups/day green tea had an approximately 20% decreased risk of stomach cancer. This 
protective effect was primarily seen among female nonsmokers [85]. 
In the study by Kinlen et al., the positive association between black tea consumption and 
stomach cancer death could be, at least partly, due to the effects of smoking and social class 
[86]. Whereas in the cohort analysis by Khan et al. that included approximately 3100 
Japanese men and women, black tea consumption was associated with a statistically 
significantly increased risk of stomach cancer for women [87]. Given the small sample size 
and low intake of black tea in a population that usually consumed green tea, this positive 
association could be a chance finding. 
Both case–control and cohort studies demonstrated an inverse association between green tea 
consumption and risk of stomach cancer. The protection can be stronger for women than 
men since the former are less likely to smoke cigarettes or drink alcoholic beverages. There 
is lack of evidence in support of a protective role of black tea consumption against the 
development of stomach cancer. 
Cervical Cancer. Cancer of the cervix is the third most common malignancy worldwide in 
women, and the most common gynecologic cancer in the developing world. In developed 
countries, prevention of cervical cancer achieved by the widespread and systematic use of 
cervical cytologic screening, has contributed to the successful decrease in the incidence of 
invasive cervical carcinomas. In the developing world, cervical cancer remains a common 
malignancy impacting the lives of women during their period of highest productivity. 
Especially in low-resource settings, an inexpensive dietary chemo-preventive intervention 
would be an attractive adjunct to existing cervical cancer prevention programs It is well-
known that the regular consumption of fruits and vegetables is highly associated with the 
reduced epidemiologic risk of different types of cancer [88-91] and green tea consumption is 
associated with lowering certain cancer incidences including cervical cancer [92]. 
Lung Cancer. Numerous epidemiological studies examined the association between green tea 
or black tea consumption and risk of lung cancer. A systematic review was conducted to 
evaluate the association between the consumption of green tea or black tea and lung cancer 
risk among 19 studies (13 case–control, 6 prospective cohort) that were published prior to 
September 2007 [93]. Among the 8 studies examining green tea and lung cancer risk, 3 
reported a significantly lower risk while one reported a significantly increased risk of lung 
cancer with high green tea consumption. The remaining 4 studies reported no association 
[93]. More recently, Tang et al. conducted a similar meta-analysis for green tea or black tea 
consumption with lung cancer risk [94]. This analysis included 22 studies published from 
1966 to November 2008 and 12 of them also were included in the analysis by Arts [93]. 
Twelve studies examined the association between green tea and lung cancer risk. A 
statistically significant 18% decreased risk of lung cancer was associated with every 2 
cups/day of green tea consumption. This inverse green tea-lung cancer association was 
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confounded and/or overshadowed by the thermal effect of tea beverages, if consumed at 
high temperature, as well as cigarette smoking or alcohol intake. Future prospective cohort 
studies are required to collect detailed information on tea temperature and histories of 
tobacco and alcohol use that can then be adjusted for when evaluating the protective effect 
of tea on esophageal cancer. 
Prostate Cancer. Among all cancers, prostate cancer is an ideal candidate disease for 
chemoprevention because it is typically diagnosed in men ages >50 years and has a high 
latency period [71, 72]. Therefore, even a slight delay in the progression of this disease by 
chemopreventive intervention could result in a substantial reduction in the incidence of the 
disease and, more importantly, improve the quality of life of the patients [71, 72]. Evidences 
collected from geographic, epidemiologic, and migration studies suggest that frequent 
consumption of green tea is associated with lower frequencies of prostate cancer in Asian 
populations in general compared with those in western societies [73-77]. Laboratory and 
preclinical animal studies also indicate a protective role of green tea against prostate cancer 
[78-82]. 
In summary, observational studies do not provide strong evidence for a protective effect of 
green tea or black tea intake against the development of prostate cancer. There is some 
suggestive evidence that green tea intake can reduce the risk of advanced prostate cancer. 
The phase II clinical trials have provided encouraging evidence in the development of green 
tea catechins as a chemopreventive agent against prostate carcinogenesis.  
Skin Cancer. There has been considerable interest in the use of naturally occurring plant 
products, including polyphenols, for the prevention of UV-induced skin photodamage 
primarily including the risk of skin cancer. Polyphenols, specifically dietary, possessing 
anti-inflammatory, immunomodulatory and anti-oxidant properties are among the most 
promising group of compounds that can be exploited as ideal chemopreventive agents for a 
variety of skin disorders in general and skin cancer in particular. In this respect, 
chemoprevention offers a realistic strategy for controlling the risk of cancers. Furthermore, a 
chemopreventive approach appears to have practical implications in reducing skin cancer 
risk because, unlike the carcinogenic environmental factors that are difficult to control, 
individuals can modify their dietary habits and lifestyle in combination with a careful use of 
skin care products to prevent the photodamaging effects in the skin. Studies from our 
laboratory have shown the efficacy of naturally occurring polyphenols, such as green tea 
polyphenols (GTPs), silymarin from milk thistle and proanthocyanidins from grape seeds 
(GSPs), against UV radiation-induced inflammation, oxidative stress, DNA damage and 
suppression of immune responses [83]. 
Stomach cancer. Recently, Myung et al. conducted a meta-analysis investigating the 
quantitative association between the consumption of green tea and the risk of stomach 
cancer in humans [84]. The analysis included 13 (5 cohort and 8 case–control) studies, all 
conducted in Japanese or Chinese populations. An inverse association was seen in case–
control studies only, but not in cohort studies. However, in a recent pooled analysis of 6 
cohort studies that included more than 218,000 Japanese men and women aged 40 years or 
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older and more than 3500 incident stomach cancer cases found a statistically significant, 
inverse association between green tea consumption and stomach cancer risk in women, but 
not in men [85]. Compared with those drinking <1 cup/day, women with the consumption 
of ≥5 cups/day green tea had an approximately 20% decreased risk of stomach cancer. This 
protective effect was primarily seen among female nonsmokers [85]. 
In the study by Kinlen et al., the positive association between black tea consumption and 
stomach cancer death could be, at least partly, due to the effects of smoking and social class 
[86]. Whereas in the cohort analysis by Khan et al. that included approximately 3100 
Japanese men and women, black tea consumption was associated with a statistically 
significantly increased risk of stomach cancer for women [87]. Given the small sample size 
and low intake of black tea in a population that usually consumed green tea, this positive 
association could be a chance finding. 
Both case–control and cohort studies demonstrated an inverse association between green tea 
consumption and risk of stomach cancer. The protection can be stronger for women than 
men since the former are less likely to smoke cigarettes or drink alcoholic beverages. There 
is lack of evidence in support of a protective role of black tea consumption against the 
development of stomach cancer. 
Cervical Cancer. Cancer of the cervix is the third most common malignancy worldwide in 
women, and the most common gynecologic cancer in the developing world. In developed 
countries, prevention of cervical cancer achieved by the widespread and systematic use of 
cervical cytologic screening, has contributed to the successful decrease in the incidence of 
invasive cervical carcinomas. In the developing world, cervical cancer remains a common 
malignancy impacting the lives of women during their period of highest productivity. 
Especially in low-resource settings, an inexpensive dietary chemo-preventive intervention 
would be an attractive adjunct to existing cervical cancer prevention programs It is well-
known that the regular consumption of fruits and vegetables is highly associated with the 
reduced epidemiologic risk of different types of cancer [88-91] and green tea consumption is 
associated with lowering certain cancer incidences including cervical cancer [92]. 
Lung Cancer. Numerous epidemiological studies examined the association between green tea 
or black tea consumption and risk of lung cancer. A systematic review was conducted to 
evaluate the association between the consumption of green tea or black tea and lung cancer 
risk among 19 studies (13 case–control, 6 prospective cohort) that were published prior to 
September 2007 [93]. Among the 8 studies examining green tea and lung cancer risk, 3 
reported a significantly lower risk while one reported a significantly increased risk of lung 
cancer with high green tea consumption. The remaining 4 studies reported no association 
[93]. More recently, Tang et al. conducted a similar meta-analysis for green tea or black tea 
consumption with lung cancer risk [94]. This analysis included 22 studies published from 
1966 to November 2008 and 12 of them also were included in the analysis by Arts [93]. 
Twelve studies examined the association between green tea and lung cancer risk. A 
statistically significant 18% decreased risk of lung cancer was associated with every 2 
cups/day of green tea consumption. This inverse green tea-lung cancer association was 
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slightly stronger for prospective cohort studies than retrospective case–control studies. The 
protective effect of green tea consumption on lung cancer risk was confined to nonsmokers 
[94]. 
In the same review by Arts [93], 11 of the 19 studies included examined the association 
between black tea consumption and lung cancer risk. Among them, two reported a 
statistically significantly reduced risk while one reported an increased risk for lung cancer 
associated with black tea intake. The remaining 8 studies reported a null association [93]. In 
a more recent meta-analysis by Tang et al., no statistically significant association was 
observed between black tea consumption and lung cancer risk based on 14 studies included 
[94]. Not included in the meta-analyses was a case–control study in Los Angeles, CA with 
558 cases and 837 controls. The results showed that high consumption of dietary 
epicatechin, mainly from black tea, was associated with significantly reduced risk of lung 
cancer, especially among smokers [95]. 
One potential mechanism for the chemopreventive effect of tea on carcinogenesis is the 
strong antioxidant effect of tea polyphenols. Hakim et al. conducted a phase II randomized 
controlled tea intervention trial to evaluate the efficacy of regular green tea drinking in 
reducing DNA damage as measured by urinary 8-hydroxydeoxyguanosine among heavy 
smokers [96]. After consuming 4 cups/day of decaffeinated green tea for 4 months, smokers 
showed a statistically significant 31% decrease in urinary 8-hydroxydeoxyguanosine 
compared with the baseline value. In the same study, no change in urinary 8-
hydroxydeoxyguanosine was seen among smokers assigned to the black tea group [96]. 
These findings support that tea catechins, with highest levels in green tea, exert their 
antioxidative role in reducing the formation of 8-hydroxydeoxyguanosine. However, a lack 
of inverse association between green tea consumption and lung cancer risk in smokers 
suggest that the antioxidation mechanism plays a limited role in reducing the risk of lung 
cancer development. Furthermore, the protective effect of tea consumption on lung cancer 
development for nonsmokers, especially among women, indicates an alternative cancer-
preventive mechanism of tea that is not driven by antioxidation. Additional experimental 
studies that utilize animal models to elucidate the cancer-preventive mechanisms of tea 
catechins on lung carcinogenesis are needed. 
Pancreatic Cancer. Similar to other gastrointestinal organs, epidemiological studies have 
provided mixed results on the association between tea consumption and risk of pancreatic 
cancer. There are a limited number of studies that examined the association between green 
tea consumption and pancreatic cancer. From an early hospital-based case–control study in 
Japan (124 cases and 124 matched controls), no association was observed for pancreatic 
cancer risk with green tea drinking [97]. In contrast, analyses from a population based case–
control study conducted in Shanghai, China (451 cases and 1552 controls) demonstrated a 
statistically significant inverse association with increased green tea consumption and 
pancreatic cancer risk [98]. A prospective cohort study in Japan involved more than 100,000 
Japanese adults with up to 11 years of follow-up and 233 incidents of pancreatic cancer cases 
did not find an association between green tea intake and pancreatic cancer risk [99]. In 
another prospective cohort study with up to 13 years of follow-up and 292 incident 
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pancreatic cancer cases in Japan, Lin et al. reported a higher percentage of dying from 
pancreatic cancer for subjects who consumed ≥7 cups/day of green tea compared with those 
<1 cup/day [100]. 
Available epidemiological data are insufficient to conclude that either green tea or black tea 
can protect against the development of pancreatic cancer. Given the short survival and rapid 
progression of pancreatic cancer, the low participation rates of pancreatic cancer patients in 
retrospective case–control studies or the use of proxy respondents in interview for collection 
of information on tea consumption and other risk factors could bias the results of case–
control studies. Prospective cohort studies offer methodological advantages over case–
control studies. Additional data from well-designed and well-executed prospective cohort 
studies are required before any conclusion on the protective effect of green tea and/or black 
tea against the development of pancreatic cancer can be reached.  
Oral cavity and pharynx Although numerous epidemiological studies examined the 
association between dietary factors and risk of oral and pharyngeal cancers [101], there are 
limited data on the effect of tea consumption on these malignancies. Combining a series of 
case–control studies in Italy with a total of 119 patients with cancer of the oral cavity and 
6147 hospital controls, La Vecchia et al. reported a reduced, but statistically non-significant, 
risk of oral cancer with black tea consumption [102]. Using a similar approach, Tavani et al. 
combined datasets of two hospital-based case–control studies conducted in Italy and 
Switzerland, respectively, and reported no association between black tea consumption and 
oral cancer risk [103]. Recently, Ren et al. examined the association between black tea 
consumption and the risk of developing oral and pharyngeal cancers in the National 
Institutes of Health (NIH)-American Association of Retired Persons (AARP) Diet and Health 
Study [104]. 
The NIH-AARP cohort study enrolled 481,563 AARP members aged 51–71 years who 
resided in eight states of the United States in 1995–1996. After up to 8 years of follow-up, 392 
study participants developed oral cancer and 178 developed pharyngeal cancer. The study 
demonstrated a statistically significant positive relationship between consumption of hot tea 
and risk of pharyngeal cancer. There was a suggestive positive relationship between hot tea 
intake and risk of oral cancer [104]. Consumption of iced tea was not associated with risk of 
oral or pharyngeal cancer. 
There was one prospective cohort study that examined the association between green tea 
consumption and risk of oral cancer in the Japan Collaborative Cohort Study. The cohort 
consisted of 50,221 Japanese men and women aged 40–79 years at baseline and identified 37 
incident oral cancer cases after 10.3 years of follow-up. The inverse association was slightly 
stronger for women than for men [105]. The inverse relation did not reach statistical 
significance due to the relatively small number of cancer cases included in the analysis. 
A randomized, placebo-controlled, phase II clinical trial was conducted to examine the effect 
of green tea extract on the oral mucosa leukoplakia, a well established precancerous lesion 
of oral cancer [106]. Fifty-nine patients were randomly assigned to either the treatment 
group, who were given 3 g/day of a mixed green tea product composed of dried water 
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slightly stronger for prospective cohort studies than retrospective case–control studies. The 
protective effect of green tea consumption on lung cancer risk was confined to nonsmokers 
[94]. 
In the same review by Arts [93], 11 of the 19 studies included examined the association 
between black tea consumption and lung cancer risk. Among them, two reported a 
statistically significantly reduced risk while one reported an increased risk for lung cancer 
associated with black tea intake. The remaining 8 studies reported a null association [93]. In 
a more recent meta-analysis by Tang et al., no statistically significant association was 
observed between black tea consumption and lung cancer risk based on 14 studies included 
[94]. Not included in the meta-analyses was a case–control study in Los Angeles, CA with 
558 cases and 837 controls. The results showed that high consumption of dietary 
epicatechin, mainly from black tea, was associated with significantly reduced risk of lung 
cancer, especially among smokers [95]. 
One potential mechanism for the chemopreventive effect of tea on carcinogenesis is the 
strong antioxidant effect of tea polyphenols. Hakim et al. conducted a phase II randomized 
controlled tea intervention trial to evaluate the efficacy of regular green tea drinking in 
reducing DNA damage as measured by urinary 8-hydroxydeoxyguanosine among heavy 
smokers [96]. After consuming 4 cups/day of decaffeinated green tea for 4 months, smokers 
showed a statistically significant 31% decrease in urinary 8-hydroxydeoxyguanosine 
compared with the baseline value. In the same study, no change in urinary 8-
hydroxydeoxyguanosine was seen among smokers assigned to the black tea group [96]. 
These findings support that tea catechins, with highest levels in green tea, exert their 
antioxidative role in reducing the formation of 8-hydroxydeoxyguanosine. However, a lack 
of inverse association between green tea consumption and lung cancer risk in smokers 
suggest that the antioxidation mechanism plays a limited role in reducing the risk of lung 
cancer development. Furthermore, the protective effect of tea consumption on lung cancer 
development for nonsmokers, especially among women, indicates an alternative cancer-
preventive mechanism of tea that is not driven by antioxidation. Additional experimental 
studies that utilize animal models to elucidate the cancer-preventive mechanisms of tea 
catechins on lung carcinogenesis are needed. 
Pancreatic Cancer. Similar to other gastrointestinal organs, epidemiological studies have 
provided mixed results on the association between tea consumption and risk of pancreatic 
cancer. There are a limited number of studies that examined the association between green 
tea consumption and pancreatic cancer. From an early hospital-based case–control study in 
Japan (124 cases and 124 matched controls), no association was observed for pancreatic 
cancer risk with green tea drinking [97]. In contrast, analyses from a population based case–
control study conducted in Shanghai, China (451 cases and 1552 controls) demonstrated a 
statistically significant inverse association with increased green tea consumption and 
pancreatic cancer risk [98]. A prospective cohort study in Japan involved more than 100,000 
Japanese adults with up to 11 years of follow-up and 233 incidents of pancreatic cancer cases 
did not find an association between green tea intake and pancreatic cancer risk [99]. In 
another prospective cohort study with up to 13 years of follow-up and 292 incident 
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pancreatic cancer cases in Japan, Lin et al. reported a higher percentage of dying from 
pancreatic cancer for subjects who consumed ≥7 cups/day of green tea compared with those 
<1 cup/day [100]. 
Available epidemiological data are insufficient to conclude that either green tea or black tea 
can protect against the development of pancreatic cancer. Given the short survival and rapid 
progression of pancreatic cancer, the low participation rates of pancreatic cancer patients in 
retrospective case–control studies or the use of proxy respondents in interview for collection 
of information on tea consumption and other risk factors could bias the results of case–
control studies. Prospective cohort studies offer methodological advantages over case–
control studies. Additional data from well-designed and well-executed prospective cohort 
studies are required before any conclusion on the protective effect of green tea and/or black 
tea against the development of pancreatic cancer can be reached.  
Oral cavity and pharynx Although numerous epidemiological studies examined the 
association between dietary factors and risk of oral and pharyngeal cancers [101], there are 
limited data on the effect of tea consumption on these malignancies. Combining a series of 
case–control studies in Italy with a total of 119 patients with cancer of the oral cavity and 
6147 hospital controls, La Vecchia et al. reported a reduced, but statistically non-significant, 
risk of oral cancer with black tea consumption [102]. Using a similar approach, Tavani et al. 
combined datasets of two hospital-based case–control studies conducted in Italy and 
Switzerland, respectively, and reported no association between black tea consumption and 
oral cancer risk [103]. Recently, Ren et al. examined the association between black tea 
consumption and the risk of developing oral and pharyngeal cancers in the National 
Institutes of Health (NIH)-American Association of Retired Persons (AARP) Diet and Health 
Study [104]. 
The NIH-AARP cohort study enrolled 481,563 AARP members aged 51–71 years who 
resided in eight states of the United States in 1995–1996. After up to 8 years of follow-up, 392 
study participants developed oral cancer and 178 developed pharyngeal cancer. The study 
demonstrated a statistically significant positive relationship between consumption of hot tea 
and risk of pharyngeal cancer. There was a suggestive positive relationship between hot tea 
intake and risk of oral cancer [104]. Consumption of iced tea was not associated with risk of 
oral or pharyngeal cancer. 
There was one prospective cohort study that examined the association between green tea 
consumption and risk of oral cancer in the Japan Collaborative Cohort Study. The cohort 
consisted of 50,221 Japanese men and women aged 40–79 years at baseline and identified 37 
incident oral cancer cases after 10.3 years of follow-up. The inverse association was slightly 
stronger for women than for men [105]. The inverse relation did not reach statistical 
significance due to the relatively small number of cancer cases included in the analysis. 
A randomized, placebo-controlled, phase II clinical trial was conducted to examine the effect 
of green tea extract on the oral mucosa leukoplakia, a well established precancerous lesion 
of oral cancer [106]. Fifty-nine patients were randomly assigned to either the treatment 
group, who were given 3 g/day of a mixed green tea product composed of dried water 
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extract, polyphenols and pigments, or the placebo group. After 6 months, 37.9% patients in 
the green tea treatment arm showed reduced size of oral lesions whereas 3.4% patients had 
increased lesion size. In contrast, 6.7% patients in the placebo group had decreased and 10% 
patients had increased size of oral mucosa leukoplakia. The differences in the changes of 
lesion sizes between the treatment and placebo arms are statistically significant [106]. 
Recently, Tsao et al. completed another randomized, placebo-controlled phase II trial to 
evaluate the oral cancer prevention potential of green tea extract [107]. Forty-two patients 
with one or more histologically confirmed, bidimentionally measurable oral premalignant 
lesions with high-risk features of malignant transformation that could be sampled by biopsy 
were randomly assigned to receive 500, 750, or 1000 mg/m2 of green tea extract per day or 
placebo orally. The efficacy was determined by the disappearance of all lesions (a complete 
response) or 50% or greater decrease in the sum of products of diameters of all measured 
lesions (a partial response). At 12 weeks after the initiation of the treatment, 39 patients who 
completed the trial were evaluated; 14 (50%) of the 28 patients in the three combined green 
tea extract groups had a favorable response whereas only 2 (18.2%) of the 11 patients in the 
placebo group showed the similar response. A dose-dependent effect was observed; the 
favorable response rates were 58% in patients given 750 or 1000 mg/m2 green tea extract and 
36.4% in those given 500 mg/m2, but only 18.2% in those assigned to the placebo arm [107]. 
Although limited, data from the prospective cohort study suggest a moderate protective 
effect of green tea consumption against the development of oral cancer. Both phase II 
clinical trials further support a protective role of green tea extract against the progression of 
precancerous lesions in the oral cavity towards malignant transformation. Phase III clinical 
trials with large number of patients are required to confirm the efficacy of green tea extract 
against the formation of oral cancer in humans. Data on the effect of black tea consumption 
against the development of oral cancer are too limited to draw any conclusion. One 
prospective study showed a statistically significant inverse association between black tea 
consumption and risk of pharyngeal cancer, more epidemiological studies are warranted to 
evaluate the potential protective effect of either green tea or black tea on the development of 
pharyngeal cancer in humans. 
Large bowel. Numerous epidemiological studies have examined the association between tea 
consumption and colorectal cancer. Sun et al. conducted a meta-analysis that included 25 
epidemiological studies evaluating tea consumption and risk of colorectal cancer in 11 
countries [108]. The inverse association between green tea intake and colon cancer risk was 
mainly observed in 4 case–control studies, but not in 4 cohort studies. There was no 
relationship between green tea intake and rectal cancer risk in 6 case–control or cohort studies. 
Following the meta-analysis, several studies examined and published the results on the 
green tea consumption and colorectal cancer risk. After analyzing the database of the 
Singapore Chinese Health Study, a prospective cohort study of diet and cancer involved 
over 60,000 Chinese men and women aged 45–74 years, Sun et al. found that subjects who 
drank green tea daily had a statistically non-significant increased risk for colorectal cancer 
relative to nondrinkers of green tea. This association was confined to men and was stronger 
for colon cancer than rectal cancer, especially for the advanced stage of colon cancer [109]. 
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These data suggest that substances in green tea can exert an adverse, late-stage effect on the 
development of colorectal cancer. 
Yang et al. prospectively evaluated the association between green tea consumption and 
colorectal cancer risk in a cohort of 69,710 Chinese women aged 40–70 years, most of which 
were Lifelong nonsmokers (97.3%) or nondrinkers of alcoholic beverages (97.7%). 
Information on tea consumption was assessed through inperson interviews at baseline and 
reassessed 2–3 years later in a follow-up survey. During the first 6 years of follow-up, 256 
incident cases of colorectal cancer were identified. Regular tea drinkers had significantly 
reduced risk of colorectal cancer compared with nondrinkers. The reduction in risk was 
most evident among those who consistently reported to drink tea regularly at both the 
baseline and follow-up surveys [110]. 
There were two recent prospective studies on green tea consumption and colorectal cancer 
incidence and mortality in Japan [111, 112]. The first consisted of 96,162 Japanese men and 
women, and 1163 incident cases of colorectal cancer [111]. There was no statistically 
significant association between green tea consumption and incidence of colon and rectal 
cancers combined or separately in either men or women or both. The second cohort 
consisted of 14,001 Japanese men and women. After up to 6 years of follow-up, 43 subjects 
died from colorectal cancer. Given the small number of cases, the results should be 
interpreted with caution. Using validated biomarkers of specific tea polyphenols, Yuan et al. 
prospectively examined the urinary levels of specific tea catechins and their metabolites and 
the risk of developing colorectal cancer in the Shanghai Cohort Study as described above 
[113]. EGC, 4_-O-methyl-epigallocatechin (4_-MeEGC) and EC, and their metabolites in 
baseline urine samples were measured in 162 incident colorectal cancer cases (83 colon and 
79 rectal cancer cases) and 806 matched controls. Individuals with high prediagnostic 
urinary catechin levels had a lower risk of colon cancer. There was no association between 
urinary green tea catechins or their metabolites and risk of rectal cancer. This study 
provided a direct evidence for the chemopreventive effect of tea catechins against the 
development of colon cancer in humans [113]. 
In terms of black tea, the meta-analysis by Sun et al. [108] included 20 studies that examined 
black tea consumption and colorectal cancer risk and found no association. No association 
was found separately in case–control studies or prospective cohort studies. In our analysis 
of the Singapore Chinese Health Study, we did not find any association between black tea 
consumption and risk of colon cancer and rectal cancer combined or separately [109]. More 
recently, Zhang et al. conducted a pooled analysis for black tea intake and colon cancer risk 
on the combined dataset of 13 cohort studies conducted in North America or Western 
Europe. The analysis included 731,441 subjects and 5604 incident colon cancer cases [114]. 
Compared with nondrinkers, consumption of 900 g/day tea (approximately four 8-oz 
cups/day) was associated with a modest, but statistically significantly increased risk of colon 
cancer. This increased risk for colon cancer was only in women, but not in men. 
Epidemiological studies provided suggestive evidence to support a protective role of green 
tea consumption, especially in high amount and long-term duration of consumption, in 
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extract, polyphenols and pigments, or the placebo group. After 6 months, 37.9% patients in 
the green tea treatment arm showed reduced size of oral lesions whereas 3.4% patients had 
increased lesion size. In contrast, 6.7% patients in the placebo group had decreased and 10% 
patients had increased size of oral mucosa leukoplakia. The differences in the changes of 
lesion sizes between the treatment and placebo arms are statistically significant [106]. 
Recently, Tsao et al. completed another randomized, placebo-controlled phase II trial to 
evaluate the oral cancer prevention potential of green tea extract [107]. Forty-two patients 
with one or more histologically confirmed, bidimentionally measurable oral premalignant 
lesions with high-risk features of malignant transformation that could be sampled by biopsy 
were randomly assigned to receive 500, 750, or 1000 mg/m2 of green tea extract per day or 
placebo orally. The efficacy was determined by the disappearance of all lesions (a complete 
response) or 50% or greater decrease in the sum of products of diameters of all measured 
lesions (a partial response). At 12 weeks after the initiation of the treatment, 39 patients who 
completed the trial were evaluated; 14 (50%) of the 28 patients in the three combined green 
tea extract groups had a favorable response whereas only 2 (18.2%) of the 11 patients in the 
placebo group showed the similar response. A dose-dependent effect was observed; the 
favorable response rates were 58% in patients given 750 or 1000 mg/m2 green tea extract and 
36.4% in those given 500 mg/m2, but only 18.2% in those assigned to the placebo arm [107]. 
Although limited, data from the prospective cohort study suggest a moderate protective 
effect of green tea consumption against the development of oral cancer. Both phase II 
clinical trials further support a protective role of green tea extract against the progression of 
precancerous lesions in the oral cavity towards malignant transformation. Phase III clinical 
trials with large number of patients are required to confirm the efficacy of green tea extract 
against the formation of oral cancer in humans. Data on the effect of black tea consumption 
against the development of oral cancer are too limited to draw any conclusion. One 
prospective study showed a statistically significant inverse association between black tea 
consumption and risk of pharyngeal cancer, more epidemiological studies are warranted to 
evaluate the potential protective effect of either green tea or black tea on the development of 
pharyngeal cancer in humans. 
Large bowel. Numerous epidemiological studies have examined the association between tea 
consumption and colorectal cancer. Sun et al. conducted a meta-analysis that included 25 
epidemiological studies evaluating tea consumption and risk of colorectal cancer in 11 
countries [108]. The inverse association between green tea intake and colon cancer risk was 
mainly observed in 4 case–control studies, but not in 4 cohort studies. There was no 
relationship between green tea intake and rectal cancer risk in 6 case–control or cohort studies. 
Following the meta-analysis, several studies examined and published the results on the 
green tea consumption and colorectal cancer risk. After analyzing the database of the 
Singapore Chinese Health Study, a prospective cohort study of diet and cancer involved 
over 60,000 Chinese men and women aged 45–74 years, Sun et al. found that subjects who 
drank green tea daily had a statistically non-significant increased risk for colorectal cancer 
relative to nondrinkers of green tea. This association was confined to men and was stronger 
for colon cancer than rectal cancer, especially for the advanced stage of colon cancer [109]. 
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These data suggest that substances in green tea can exert an adverse, late-stage effect on the 
development of colorectal cancer. 
Yang et al. prospectively evaluated the association between green tea consumption and 
colorectal cancer risk in a cohort of 69,710 Chinese women aged 40–70 years, most of which 
were Lifelong nonsmokers (97.3%) or nondrinkers of alcoholic beverages (97.7%). 
Information on tea consumption was assessed through inperson interviews at baseline and 
reassessed 2–3 years later in a follow-up survey. During the first 6 years of follow-up, 256 
incident cases of colorectal cancer were identified. Regular tea drinkers had significantly 
reduced risk of colorectal cancer compared with nondrinkers. The reduction in risk was 
most evident among those who consistently reported to drink tea regularly at both the 
baseline and follow-up surveys [110]. 
There were two recent prospective studies on green tea consumption and colorectal cancer 
incidence and mortality in Japan [111, 112]. The first consisted of 96,162 Japanese men and 
women, and 1163 incident cases of colorectal cancer [111]. There was no statistically 
significant association between green tea consumption and incidence of colon and rectal 
cancers combined or separately in either men or women or both. The second cohort 
consisted of 14,001 Japanese men and women. After up to 6 years of follow-up, 43 subjects 
died from colorectal cancer. Given the small number of cases, the results should be 
interpreted with caution. Using validated biomarkers of specific tea polyphenols, Yuan et al. 
prospectively examined the urinary levels of specific tea catechins and their metabolites and 
the risk of developing colorectal cancer in the Shanghai Cohort Study as described above 
[113]. EGC, 4_-O-methyl-epigallocatechin (4_-MeEGC) and EC, and their metabolites in 
baseline urine samples were measured in 162 incident colorectal cancer cases (83 colon and 
79 rectal cancer cases) and 806 matched controls. Individuals with high prediagnostic 
urinary catechin levels had a lower risk of colon cancer. There was no association between 
urinary green tea catechins or their metabolites and risk of rectal cancer. This study 
provided a direct evidence for the chemopreventive effect of tea catechins against the 
development of colon cancer in humans [113]. 
In terms of black tea, the meta-analysis by Sun et al. [108] included 20 studies that examined 
black tea consumption and colorectal cancer risk and found no association. No association 
was found separately in case–control studies or prospective cohort studies. In our analysis 
of the Singapore Chinese Health Study, we did not find any association between black tea 
consumption and risk of colon cancer and rectal cancer combined or separately [109]. More 
recently, Zhang et al. conducted a pooled analysis for black tea intake and colon cancer risk 
on the combined dataset of 13 cohort studies conducted in North America or Western 
Europe. The analysis included 731,441 subjects and 5604 incident colon cancer cases [114]. 
Compared with nondrinkers, consumption of 900 g/day tea (approximately four 8-oz 
cups/day) was associated with a modest, but statistically significantly increased risk of colon 
cancer. This increased risk for colon cancer was only in women, but not in men. 
Epidemiological studies provided suggestive evidence to support a protective role of green 
tea consumption, especially in high amount and long-term duration of consumption, in 
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reducing the risk of colon cancer. This effect of green tea on colon carcinogenesis can 
depend on the time of exposure, where late exposure can promote the growth of colon 
tumor cells. Current epidemiological data suggest that black tea consumption can increase, 
instead of decrease, the risk of colorectal cancer. 
Kidney. Several epidemiological studies examined the relationship between tea consumption 
and kidney cancer risk. Mellemgaard et al. conducted a population-based case–control 
study that enrolled 368 renal cell cancer cases and 396 matched controls living in Denmark 
[115]. The study did not find an association between black tea consumption and renal cell 
cancer risk. Bianchi et al. conducted a population-based case–control study of renal cell 
cancer in Iowa (406 cases and 2434 controls), and found no association [116]. 
Similarly, a more recent case–control study of renal cell cancer in Italy including 767 cases 
and 1534 controls did not find any association between tea consumption and risk of renal 
cell cancer [117]. Lee et al. analyzed datasets of the Nurses’ Health Study and the Health 
Professionals Follow-up Study and found that consumption of ˃1 cup/day tea was 
associated with statistically non-significantly reduced risk of renal cell cancer relative to <1 
cup/month [118]. In a pooled analysis, Lee et al. combined data of 13 prospective cohorts 
including more than 774,000 men and women and 1478 incident renal cell cancer cases. 
Compared with nondrinkers, individuals who consumed ≥1 cups/day of tea had a 
statistically borderline significant 15% risk reduction in renal cell cancer after adjustment for 
body mass index, cigarette smoking, hypertension and other potential confounders [119]. 
All these studies were conducted in North America and West Europe and examined the 
effect of presumably black tea on renal cell cancer risk. These findings do not support a 
protective role of black tea on kidney cancer. Additional prospective epidemiological 
studies are warranted to examine the association between green tea consumption and 
kidney cancer risk. 
Glioma. Regular intake of tea was not associated with risk of adult glioma in a case–control 
study [120]. Recently Holick et al. examined the association between coffee, black tea and 
caffeine intake and risk of adult glioma in three prospective cohort studies in the United 
States. The analysis included 335 incident glioma cases. Compared with nondrinkers, there 
was a statistically non-significant, approximately 30% decreased risk of glioma incidence for 
those consuming 4 cups/week of black tea [121]. More data are warranted to draw any 
conclusion on the association between tea consumption and adult glioma risk. 
Lymphoma. Thompson et al. examined the association between black tea consumption and 
risk of non-Hodgkin’s lymphoma in the Iowa Women’s Health Study. The analysis included 
415 incident lymphoma cases during the 20 years of follow-up following baseline interview. 
No association was found between black tea consumption and risk of non-Hodgkin’s 
lymphoma [122]. 
Leukemia. A hospital-based case–control study involving 107 adults with leukemia and 110 
orthopaedic controls in China found that green tea consumption was associated with a 
statistically significant 50% decreased risk of leukemia. The inverse association was dose 
dependent with number of cups of tea per day, number of years of tea consumption, and the 
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amount of dry tea leaves consumed [123]. A similar case–control study enrolled 252 
leukemia patients aged 0–29 years and 637 sex- and age matched control subjects in Taiwan. 
Compared with nondrinkers, high intake of total tea catechins was associated with 
approximately 50% reduced risk. This inverse association was stronger in older (16–29 
years) than in the younger (0–15 years) group [124]. Given the limitations of small study size 
and hospital-based study design, further studies are warranted to confirm these results. 
2.1.3. Possible active tea components and their tissue levels 
Plasma EGCG, EGC and EC exist in free and conjugated (glucuronide and sulfate) forms. 
The plasma tea polyphenol levels in rats and mice in some anticarcinogenesis experiments 
were comparable to the peak levels in humans after consuming two or three cups of tea 
[125].  In a preliminary experiment, after administration of regular green tea in drinking 
fluid to rats, the EGCG was detected in the esophagus (410 ng/g) but not in the lung, the 
EGCG, EGC and EC levels in the small intestine and intestinal contents were rather high (1.5 
- 5.5 mg/g) due to the unabsorbed and biliary excreted glucuronides of polyphenols in the 
intestine. High EGC and EC levels were also observed in the colon tissues (1.8 and 0.3 mg/g 
respectively). Due to possible glucuronidase and esterase activities in the colon, most of the 
EGC and EC were found in the free form and EGCG was found at lower levels. EGCG has 
been usually considered the active anticarcinogenic components in tea because it is the most 
abundant polyphenol in tea.  
Hackett et al., [126] reported that three human volunteers were given 2 g of (+)- catechin and 
the metabolic changes in it were then examined by looking at their blood and urine. About 
55% of the labeled catechin was excreted in urine within 2 h after its uptake. The metabolites 
in urine were (+) - catechin, and glucuronic and sulfate compounds of 3-O-methye- (+)-
catechin. These metabolites were about ¾ of the catechin uptake. 
Matsumoto et al., [127] determined the amount of tea polyphenols in organs and tissues to 
examine the fate of catechin in the digestive canal, such as the stomach; small and large 
intestines of rats. EGCG given orally was transferred from the stomach to the small intestine 
within several hours and moved to the large intestine after 8 hours. Most of the amount of 
catechins taken in orally moved into the digestive tract and were excreted in the feces. Some 
part of the catechins was metabolized by intraintestinal bacteria and about 20% of the 
catechin can have been absorbed by the digestive organs. 
Tea catechins and crude extracts, however, have some beneficial effects on human health, 
such as suppression of high blood pressure [128], reduction of blood glucose levels [129] 
suppression of cholesterol and prevention of fat increase [130]. Tea drinking can also induce 
higher levels of glutathione [131], so that detoxification of reactive forms of carcinogens can 
occur more efficiently, other biochemical mechanisms have been hypothesized for the 
anticancer properties of tea e.g. induction of DNA repair, binding with activated 
carcinogens. Moderate tea consumption (5 cups / day an extract of about 11 g of tea) can be 
readily curable in some types of human cancer [132]. In other studies on the inhibitory 
effects of tea catechins, black tea extract and oolong tea extract and EC, EGC, ECG, EGCG 
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reducing the risk of colon cancer. This effect of green tea on colon carcinogenesis can 
depend on the time of exposure, where late exposure can promote the growth of colon 
tumor cells. Current epidemiological data suggest that black tea consumption can increase, 
instead of decrease, the risk of colorectal cancer. 
Kidney. Several epidemiological studies examined the relationship between tea consumption 
and kidney cancer risk. Mellemgaard et al. conducted a population-based case–control 
study that enrolled 368 renal cell cancer cases and 396 matched controls living in Denmark 
[115]. The study did not find an association between black tea consumption and renal cell 
cancer risk. Bianchi et al. conducted a population-based case–control study of renal cell 
cancer in Iowa (406 cases and 2434 controls), and found no association [116]. 
Similarly, a more recent case–control study of renal cell cancer in Italy including 767 cases 
and 1534 controls did not find any association between tea consumption and risk of renal 
cell cancer [117]. Lee et al. analyzed datasets of the Nurses’ Health Study and the Health 
Professionals Follow-up Study and found that consumption of ˃1 cup/day tea was 
associated with statistically non-significantly reduced risk of renal cell cancer relative to <1 
cup/month [118]. In a pooled analysis, Lee et al. combined data of 13 prospective cohorts 
including more than 774,000 men and women and 1478 incident renal cell cancer cases. 
Compared with nondrinkers, individuals who consumed ≥1 cups/day of tea had a 
statistically borderline significant 15% risk reduction in renal cell cancer after adjustment for 
body mass index, cigarette smoking, hypertension and other potential confounders [119]. 
All these studies were conducted in North America and West Europe and examined the 
effect of presumably black tea on renal cell cancer risk. These findings do not support a 
protective role of black tea on kidney cancer. Additional prospective epidemiological 
studies are warranted to examine the association between green tea consumption and 
kidney cancer risk. 
Glioma. Regular intake of tea was not associated with risk of adult glioma in a case–control 
study [120]. Recently Holick et al. examined the association between coffee, black tea and 
caffeine intake and risk of adult glioma in three prospective cohort studies in the United 
States. The analysis included 335 incident glioma cases. Compared with nondrinkers, there 
was a statistically non-significant, approximately 30% decreased risk of glioma incidence for 
those consuming 4 cups/week of black tea [121]. More data are warranted to draw any 
conclusion on the association between tea consumption and adult glioma risk. 
Lymphoma. Thompson et al. examined the association between black tea consumption and 
risk of non-Hodgkin’s lymphoma in the Iowa Women’s Health Study. The analysis included 
415 incident lymphoma cases during the 20 years of follow-up following baseline interview. 
No association was found between black tea consumption and risk of non-Hodgkin’s 
lymphoma [122]. 
Leukemia. A hospital-based case–control study involving 107 adults with leukemia and 110 
orthopaedic controls in China found that green tea consumption was associated with a 
statistically significant 50% decreased risk of leukemia. The inverse association was dose 
dependent with number of cups of tea per day, number of years of tea consumption, and the 
 
Cancer Chemoprevention by Dietary Polyphenols 255 
amount of dry tea leaves consumed [123]. A similar case–control study enrolled 252 
leukemia patients aged 0–29 years and 637 sex- and age matched control subjects in Taiwan. 
Compared with nondrinkers, high intake of total tea catechins was associated with 
approximately 50% reduced risk. This inverse association was stronger in older (16–29 
years) than in the younger (0–15 years) group [124]. Given the limitations of small study size 
and hospital-based study design, further studies are warranted to confirm these results. 
2.1.3. Possible active tea components and their tissue levels 
Plasma EGCG, EGC and EC exist in free and conjugated (glucuronide and sulfate) forms. 
The plasma tea polyphenol levels in rats and mice in some anticarcinogenesis experiments 
were comparable to the peak levels in humans after consuming two or three cups of tea 
[125].  In a preliminary experiment, after administration of regular green tea in drinking 
fluid to rats, the EGCG was detected in the esophagus (410 ng/g) but not in the lung, the 
EGCG, EGC and EC levels in the small intestine and intestinal contents were rather high (1.5 
- 5.5 mg/g) due to the unabsorbed and biliary excreted glucuronides of polyphenols in the 
intestine. High EGC and EC levels were also observed in the colon tissues (1.8 and 0.3 mg/g 
respectively). Due to possible glucuronidase and esterase activities in the colon, most of the 
EGC and EC were found in the free form and EGCG was found at lower levels. EGCG has 
been usually considered the active anticarcinogenic components in tea because it is the most 
abundant polyphenol in tea.  
Hackett et al., [126] reported that three human volunteers were given 2 g of (+)- catechin and 
the metabolic changes in it were then examined by looking at their blood and urine. About 
55% of the labeled catechin was excreted in urine within 2 h after its uptake. The metabolites 
in urine were (+) - catechin, and glucuronic and sulfate compounds of 3-O-methye- (+)-
catechin. These metabolites were about ¾ of the catechin uptake. 
Matsumoto et al., [127] determined the amount of tea polyphenols in organs and tissues to 
examine the fate of catechin in the digestive canal, such as the stomach; small and large 
intestines of rats. EGCG given orally was transferred from the stomach to the small intestine 
within several hours and moved to the large intestine after 8 hours. Most of the amount of 
catechins taken in orally moved into the digestive tract and were excreted in the feces. Some 
part of the catechins was metabolized by intraintestinal bacteria and about 20% of the 
catechin can have been absorbed by the digestive organs. 
Tea catechins and crude extracts, however, have some beneficial effects on human health, 
such as suppression of high blood pressure [128], reduction of blood glucose levels [129] 
suppression of cholesterol and prevention of fat increase [130]. Tea drinking can also induce 
higher levels of glutathione [131], so that detoxification of reactive forms of carcinogens can 
occur more efficiently, other biochemical mechanisms have been hypothesized for the 
anticancer properties of tea e.g. induction of DNA repair, binding with activated 
carcinogens. Moderate tea consumption (5 cups / day an extract of about 11 g of tea) can be 
readily curable in some types of human cancer [132]. In other studies on the inhibitory 
effects of tea catechins, black tea extract and oolong tea extract and EC, EGC, ECG, EGCG 
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and other tea extracts (0.05 or 0.1%) showed a significant decrease in the number and area of 
preneoplastic glutathione S-transferase placental form (GSTP)-positive foci in the liver of 
rats [133]. 
2.1.4. Antioxidative function of tea polyphenols 
The most noteworthy properties of tea polyphenols and other flavonoids are their 
antioxidative activities. Reactive oxygen species may play important roles in carcinogenesis 
through damaging DNA, altering gene expression, or affecting cell growth and 
differentiation. The anticarcinogenic activities of tea polyphenols are believed to be closely 
related to their antioxidative properties. The findings that green tea preparations inhibited 
12-0-tetradecanoylphorbol- 1 3-acetate-induced hydrogen peroxide formation in mouse 
epidermis and NNK-induced 8-hydroxydeoxyguanosine formation in mouse lung are 
consistent with this concept. Inhibition of tumor promotion-related enzymes such as 
ornithine decarboxylase, protein kinase C, lipoxygenase, and cyclooxygenase by tea 
preparations has also been reported. Although inhibition of carcinogen activation by tea or 
green tea polyphenol fractions could be demonstrated in vitro and, in certain cases, in vivo 
[134], this mechanism was not demonstrated for NNK bioactivation in vivo. Oral 
administration of tea preparations to animals has been reported to moderately enhance the 
activities of glutathione peroxidase, catalase, glutathione S-transferase, NADPH-quinone 
oxidoreductase, uridine diphosphate-glucuronosyltransferase, and methoxyresorufin O-
dealkylase. The effects of a mild induction of these enzymes on carcinogenesis are not clear. 
Mechanisms relating to the quenching of activated carcinogens, antiviral activity, and 
enhancing immune functions have also been suggested, but their relevance to 
carcinogenesis remains to be determined. Inhibition of nitrosation by tea preparations has 
been demonstrated in vitro and in humans [135]; this may be an important factor in 
preventing certain cancers, e.g., gastric cancer, if the endogenously formed N-nitroso 
compounds are causative factors. Other results suggest that the antiproliferative effect of tea 
is important for the anticarcinogenic activity. One may speculate that tea polyphenols 
inhibit growth-related signal transduction pathways [136]. 
2.1.5. Effects of tea on mutation and genotoxicty 
As to the genotoxic profile of tea catechins when tested alone, Chang et al. [137] have shown 
that there is minimal genotoxic concern with a decaffeinated green tea catechin mixture 
(Polyphenon E) that contains about 50% epigallocatechin gallate and 30% other catechins. 
Isbrucker et al. [138] have also found no genotoxic concern with a epigallocatechin gallate 
(GTE) preparation, Teavigo. On the other hand, many studies have demonstrated that tea 
catechins could suppress the genotoxic activity of various carcinogens with both in vitro and 
in vivo systems. 
a. In vivo studies 
Imanishi et al., [139] reported that when green tea or black tea polyphenols was 
administered orally 6, 12 or 18 hours before an intraperitoneal injection of mitomycin C 
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resulted in a statistically significant decrease of micronucleus formation in mouse bone 
marrow, although, post-treatment administration had no effect. 
Hot water extracts of green tea effectively suppressed AFB1 (aflatoxin B1) induced 
chromosome aberrations in bone marrow cells in rats when given green tea extract 24 h 
before injection with AFB1 [140]. Rats administered green tea extract 2 h before or after the 
AFB1 injection showed no suppressive effect. The suppressive effect of green tea extracts on 
AFB1 induced chromosome aberration was directly related to the dose of green tea extract 
(in the range of 0.1 to 2 g/kg). Black tea or coffee given 24 or 2 h before the AFB1 injection 
produced no suppressive effect. 
De boer, [141] showed that the mutagenic potency of several chemicals including the dietary 
heterocyclic amine 2-amino-1-methyl-6-phenyl-imidazo(4,5-b) pyridine (PhIP)(the 
environmentally important aromatic hydrocarbon benzo(a)pyrene) and the food 
contaminant aflatoxin B1 can be modulated by dietary compounds including green tea in 
lacI transgenic rodent. 
Green tea effectively inhibited oxidative DNA damage and cell proliferation in liver of 2-
nitropropane (2NP) treated rats [142]. It was suggested that pyrogallol-related compounds 
of green tea such as EGCG, ECG and EGC are antimutagenic factors in the Escherichia coli 
B/R Wp2 assay system [143-146].  
Significant inhibition activity of the tea catechins ECG and EGCG, against the mutagenicity 
of Trp-P-2 and N-OH-Trp-P-2 has been found by [143] using Salmonella typhimurium, TA98 
and TA100 with and without rat liver S9 mix. EGCG has also an inhibitory effect against the 
mutagenicity of benzo[a]pyrene (B[a]P) diol epoxide in TA100 strain without S9 mix. Green 
tea has  potent suppressive effects against gene expression of the SOS response in salmonella 
typhimurium TA1535/psk 1002 induced by four nitroarenes [147]. 
A study performed by [148] reported that EGCG suppressed the direct-acting mutagenicity 
of 3-hydroxyamino-1-methyl-5H-pyrido-(4,3-b) indole (Trp-p-2(NHOH)) and 2-
hydroxyamino-6-methyldipyrido(1,2-a:3,2-d) imidazole (Glu-p-1(NHOH)) in the Ames 
salmonella test. furthermore, they added that EGCE has also a suppressive effect in the in vivo 
Drosophila mutation assays, i.e., the wing spot test, and the DNA repair test, on several 
carcinogens. 
Kada et al., [144] showed that a homogenate of Japanese green tea gave high 
bioantimutagenic activity against spontaneous mutations resulting from altered DNA-
polymerase III in strain NIG 1125 of Bacillus subtilis. They identified chemically the active 
principles and they obtained 0.85 g EC, 1.44 g EGC, 1.24 g ECG and 4.87 g EGCG from 12 g 
of a crude extract of green tea powder. 
Green tea extract reduced the levels of ischemia/reperfusion induced hydrogen peroxide, 
lipid peroxidation and oxidative DNA damage (formation of 8-hydroxydeoxyguanosine) by 
pretreatment of 0.5 or 2% green tea water extract for 3 weeks, respectively in Mongolian 
gerbils. Moreover, green tea also reduced the number of ischemia/reperfusion- induced 
apoptotic cells and locomotors activity [149]. 
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and other tea extracts (0.05 or 0.1%) showed a significant decrease in the number and area of 
preneoplastic glutathione S-transferase placental form (GSTP)-positive foci in the liver of 
rats [133]. 
2.1.4. Antioxidative function of tea polyphenols 
The most noteworthy properties of tea polyphenols and other flavonoids are their 
antioxidative activities. Reactive oxygen species may play important roles in carcinogenesis 
through damaging DNA, altering gene expression, or affecting cell growth and 
differentiation. The anticarcinogenic activities of tea polyphenols are believed to be closely 
related to their antioxidative properties. The findings that green tea preparations inhibited 
12-0-tetradecanoylphorbol- 1 3-acetate-induced hydrogen peroxide formation in mouse 
epidermis and NNK-induced 8-hydroxydeoxyguanosine formation in mouse lung are 
consistent with this concept. Inhibition of tumor promotion-related enzymes such as 
ornithine decarboxylase, protein kinase C, lipoxygenase, and cyclooxygenase by tea 
preparations has also been reported. Although inhibition of carcinogen activation by tea or 
green tea polyphenol fractions could be demonstrated in vitro and, in certain cases, in vivo 
[134], this mechanism was not demonstrated for NNK bioactivation in vivo. Oral 
administration of tea preparations to animals has been reported to moderately enhance the 
activities of glutathione peroxidase, catalase, glutathione S-transferase, NADPH-quinone 
oxidoreductase, uridine diphosphate-glucuronosyltransferase, and methoxyresorufin O-
dealkylase. The effects of a mild induction of these enzymes on carcinogenesis are not clear. 
Mechanisms relating to the quenching of activated carcinogens, antiviral activity, and 
enhancing immune functions have also been suggested, but their relevance to 
carcinogenesis remains to be determined. Inhibition of nitrosation by tea preparations has 
been demonstrated in vitro and in humans [135]; this may be an important factor in 
preventing certain cancers, e.g., gastric cancer, if the endogenously formed N-nitroso 
compounds are causative factors. Other results suggest that the antiproliferative effect of tea 
is important for the anticarcinogenic activity. One may speculate that tea polyphenols 
inhibit growth-related signal transduction pathways [136]. 
2.1.5. Effects of tea on mutation and genotoxicty 
As to the genotoxic profile of tea catechins when tested alone, Chang et al. [137] have shown 
that there is minimal genotoxic concern with a decaffeinated green tea catechin mixture 
(Polyphenon E) that contains about 50% epigallocatechin gallate and 30% other catechins. 
Isbrucker et al. [138] have also found no genotoxic concern with a epigallocatechin gallate 
(GTE) preparation, Teavigo. On the other hand, many studies have demonstrated that tea 
catechins could suppress the genotoxic activity of various carcinogens with both in vitro and 
in vivo systems. 
a. In vivo studies 
Imanishi et al., [139] reported that when green tea or black tea polyphenols was 
administered orally 6, 12 or 18 hours before an intraperitoneal injection of mitomycin C 
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resulted in a statistically significant decrease of micronucleus formation in mouse bone 
marrow, although, post-treatment administration had no effect. 
Hot water extracts of green tea effectively suppressed AFB1 (aflatoxin B1) induced 
chromosome aberrations in bone marrow cells in rats when given green tea extract 24 h 
before injection with AFB1 [140]. Rats administered green tea extract 2 h before or after the 
AFB1 injection showed no suppressive effect. The suppressive effect of green tea extracts on 
AFB1 induced chromosome aberration was directly related to the dose of green tea extract 
(in the range of 0.1 to 2 g/kg). Black tea or coffee given 24 or 2 h before the AFB1 injection 
produced no suppressive effect. 
De boer, [141] showed that the mutagenic potency of several chemicals including the dietary 
heterocyclic amine 2-amino-1-methyl-6-phenyl-imidazo(4,5-b) pyridine (PhIP)(the 
environmentally important aromatic hydrocarbon benzo(a)pyrene) and the food 
contaminant aflatoxin B1 can be modulated by dietary compounds including green tea in 
lacI transgenic rodent. 
Green tea effectively inhibited oxidative DNA damage and cell proliferation in liver of 2-
nitropropane (2NP) treated rats [142]. It was suggested that pyrogallol-related compounds 
of green tea such as EGCG, ECG and EGC are antimutagenic factors in the Escherichia coli 
B/R Wp2 assay system [143-146].  
Significant inhibition activity of the tea catechins ECG and EGCG, against the mutagenicity 
of Trp-P-2 and N-OH-Trp-P-2 has been found by [143] using Salmonella typhimurium, TA98 
and TA100 with and without rat liver S9 mix. EGCG has also an inhibitory effect against the 
mutagenicity of benzo[a]pyrene (B[a]P) diol epoxide in TA100 strain without S9 mix. Green 
tea has  potent suppressive effects against gene expression of the SOS response in salmonella 
typhimurium TA1535/psk 1002 induced by four nitroarenes [147]. 
A study performed by [148] reported that EGCG suppressed the direct-acting mutagenicity 
of 3-hydroxyamino-1-methyl-5H-pyrido-(4,3-b) indole (Trp-p-2(NHOH)) and 2-
hydroxyamino-6-methyldipyrido(1,2-a:3,2-d) imidazole (Glu-p-1(NHOH)) in the Ames 
salmonella test. furthermore, they added that EGCE has also a suppressive effect in the in vivo 
Drosophila mutation assays, i.e., the wing spot test, and the DNA repair test, on several 
carcinogens. 
Kada et al., [144] showed that a homogenate of Japanese green tea gave high 
bioantimutagenic activity against spontaneous mutations resulting from altered DNA-
polymerase III in strain NIG 1125 of Bacillus subtilis. They identified chemically the active 
principles and they obtained 0.85 g EC, 1.44 g EGC, 1.24 g ECG and 4.87 g EGCG from 12 g 
of a crude extract of green tea powder. 
Green tea extract reduced the levels of ischemia/reperfusion induced hydrogen peroxide, 
lipid peroxidation and oxidative DNA damage (formation of 8-hydroxydeoxyguanosine) by 
pretreatment of 0.5 or 2% green tea water extract for 3 weeks, respectively in Mongolian 
gerbils. Moreover, green tea also reduced the number of ischemia/reperfusion- induced 
apoptotic cells and locomotors activity [149]. 
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Li et al., [150] indicated that green tea, tea pigments, and mixed tea could effectively inhibit 
DMBA (7,12-dimethyl-benz(a)anthracene) induced oral carcinogenesis in hamster. 
Protection from DNA damage and suppression of cell proliferation could be important 
mechanisms of anticarcinogenic effects of the tea preparations. Another study reported that 
green tea consumption inhibited the formation of micronuclei in peripheral blood 
lymphocytes in smokers [151].  
Katiyar et al., [152] demonstrated that green tea polyphenols (GTP) prevent ultraviolet (UV)-
B-induced cyclobutane pyrimidine dimers (CPD), which are considered to be mediators of 
UVB induced immune suppression and DNA damage on human skin. It has been also 
demonstrated that standardized green tea extract protects against psoralen plus ultraviolet 
A-induced phototoxicity to human skin by inhibiting DNA damage and diminishing the 
inflammatory effects of this modality. 
Binding of AFB1 to hepatic nuclear DNA was inhibited in rats given 0.5% instant green tea 
for 2 or 4 weeks before a single injection of AFB1 [153].  
The oral administration of 0.2% green tea or 0.1% black tea for 28 days decreased the extent 
of chromosome damages (micronuclei) in the peripheral blood of mice subsequently treated 
with B[a]P [154]. 
The level of one of the two lung DNA adducts produced by the lung carcinogen NNK 
(4(methylnitrosamino)-1-(3-pyridyl)-1-butanone) during and after carcinogen treatment was 
reduced in mice given 2% green tea as their sole source of drinking water [155]. Green tea 
suppressed 8-OH-2’deoxyguanosine or 8-OH-guanosine, but not 6O-methylguanine levels, 
in lung DNA. 
Recently, it has been demonstrated that the administration of green tea extract 24 hr before 
the dimethylnitrosoamine (DMN) injection significantly suppressed DMN-induced 
chromosomal aberrations and sister chromatid exchanges. The suppression was observed 18 
hr, 24 hr and 48 hr after the DMN treatment but no suppressive effect was observed at the 
early period (6 hr and 12 hr) after the DMN treatment. Furthermore, the suppression was 
observed for all doses of DMN investigated. Mice given green tea 2 hr before the DMN 
injection displayed no suppressive effect. Mice that were given 2% green tea extract as the 
sole source of drinking water for four days before sacrifice displayed significantly 
suppressed DMN-induced chromosomal aberrations and sister chromatid exchanges [156]. 
They conclude that the suppression of DMN-induced chromosomal aberrations and sister 
chromatid exchanges should be considered as a green tea exerting a preventive action.  
b. In vitro studies  
Studies with cell lines had demonstrated that tea polyphenols affect signal transduction 
pathways, inhibit cell proliferation and induce apoptosis, but the effective concentrations 
are usually much higher than those observed in blood and tissue [157].  
Islami et al., [158] described a novel observation that EGCG displayed strong inhibitory 
effects on the proliferation and viability of HTB-94 human chondrosarcoma cells in a dose-
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dependent manner and induced apoptosis. The induction of apoptosis by EGCG via 
activation of caspase-3/cpp32 - like proteases can provide a mechanistic explanation for its 
antitumor effects. 
Supplementation with green tea extract significantly decreased malondialdehyde 
production and DNA damage after Fe(+2) oxidative treatment in jurkat T-cell line [159]. 
EGCE was effective in reducing the mutagenecity of Trp-p-2(NHOH) in mouse FM3A cells 
in culture. EGCE was also effective in inhibiting DNA single strand breaks in vitro caused by 
Glu-p-1(NHOH) [160].   
Jain et al., [161] found that the extract of green tea leaves decreased the mutagenic activity of 
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) to E.coli Wp2 in vitro in a desmutagenic 
manner. 
In cultured mammalian cells, the frequencies of mitomycin C or ultraviolet light-induced 
sister-chromatid exchanges and chromosomal aberrations were suppressed by subsequent 
treatment with tea polyphenols in the presence of liver-metabolizing enzymes (S9 fraction). 
In the absence of such enzymes, however, the tea extracts suppressed sister chromatid 
exchanges and chromosomal aberrations at low concentrations but enhanced them at high 
concentration [162]. 
It was shown that EGCG and EGC rather than ECG and EC were found to induce apoptosis 
in lovo cells. Moreover, EGCG, EGC and ECG caused the arrest at the G1-phase of the cell 
cycle, whereas EC induced the S-phase arrest [163].   
Zhao et al., [164] illustrated that after HL-60 cells were treated by tea polyphenols (250 micro 
g/ml) for 5h, DNA extracted from HL-60 cells showed a typical internucleosomal DNA 
degradation i.e. DNA ladder and apoptotic vehicles were observed. 
Ahmed et al., [165] studied the effect of green tea polyphenols and the major constituent 
epigallocatechin-3-gallate on the induction of apoptosis and regulation of cell cycle in 
human and mouse carcinoma cells and found that treatment of A431 cells with green tea 
polyphenols and its components epigallocatechin-3-gallate, epigallocatechin and 
epicatechin-3-gallate resulted in the formation of internucleosomal DNA fragments, a 
characteristic of apoptosis. Treatment with epigallocatechin-3-gallate also resulted in 
apoptosis in HaCaT, L5178Y, and Du145 cells. The DNA cell cycle analysis showed that in 
A431 cells, epigallocatechin-3-gallate treatment resulted in arrest in the G0/G1 phase of cell 
cycle and a dose-dependent apoptosis. The G0/G1 arrest shown by epigallocatechin-3-
gallate, therefore suggested that this agent might slow down the growth of cancer cells by 
artificially imposing the cell cycle checkpoint. The loss of cell cycle checkpoint results in the 
selection of cells that have a growth advantage and a predisposition for acquiring more 
chromosomal aberrations.   
2.2. Coffee polyphenols 
Caffeic acid and chlorogenic acid are catechol-containing coffee polyphenols that, in a 
similar way to the tea polyphenols, have shown to be demethylating agents. Lee et al., 
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Li et al., [150] indicated that green tea, tea pigments, and mixed tea could effectively inhibit 
DMBA (7,12-dimethyl-benz(a)anthracene) induced oral carcinogenesis in hamster. 
Protection from DNA damage and suppression of cell proliferation could be important 
mechanisms of anticarcinogenic effects of the tea preparations. Another study reported that 
green tea consumption inhibited the formation of micronuclei in peripheral blood 
lymphocytes in smokers [151].  
Katiyar et al., [152] demonstrated that green tea polyphenols (GTP) prevent ultraviolet (UV)-
B-induced cyclobutane pyrimidine dimers (CPD), which are considered to be mediators of 
UVB induced immune suppression and DNA damage on human skin. It has been also 
demonstrated that standardized green tea extract protects against psoralen plus ultraviolet 
A-induced phototoxicity to human skin by inhibiting DNA damage and diminishing the 
inflammatory effects of this modality. 
Binding of AFB1 to hepatic nuclear DNA was inhibited in rats given 0.5% instant green tea 
for 2 or 4 weeks before a single injection of AFB1 [153].  
The oral administration of 0.2% green tea or 0.1% black tea for 28 days decreased the extent 
of chromosome damages (micronuclei) in the peripheral blood of mice subsequently treated 
with B[a]P [154]. 
The level of one of the two lung DNA adducts produced by the lung carcinogen NNK 
(4(methylnitrosamino)-1-(3-pyridyl)-1-butanone) during and after carcinogen treatment was 
reduced in mice given 2% green tea as their sole source of drinking water [155]. Green tea 
suppressed 8-OH-2’deoxyguanosine or 8-OH-guanosine, but not 6O-methylguanine levels, 
in lung DNA. 
Recently, it has been demonstrated that the administration of green tea extract 24 hr before 
the dimethylnitrosoamine (DMN) injection significantly suppressed DMN-induced 
chromosomal aberrations and sister chromatid exchanges. The suppression was observed 18 
hr, 24 hr and 48 hr after the DMN treatment but no suppressive effect was observed at the 
early period (6 hr and 12 hr) after the DMN treatment. Furthermore, the suppression was 
observed for all doses of DMN investigated. Mice given green tea 2 hr before the DMN 
injection displayed no suppressive effect. Mice that were given 2% green tea extract as the 
sole source of drinking water for four days before sacrifice displayed significantly 
suppressed DMN-induced chromosomal aberrations and sister chromatid exchanges [156]. 
They conclude that the suppression of DMN-induced chromosomal aberrations and sister 
chromatid exchanges should be considered as a green tea exerting a preventive action.  
b. In vitro studies  
Studies with cell lines had demonstrated that tea polyphenols affect signal transduction 
pathways, inhibit cell proliferation and induce apoptosis, but the effective concentrations 
are usually much higher than those observed in blood and tissue [157].  
Islami et al., [158] described a novel observation that EGCG displayed strong inhibitory 
effects on the proliferation and viability of HTB-94 human chondrosarcoma cells in a dose-
 
Cancer Chemoprevention by Dietary Polyphenols 259 
dependent manner and induced apoptosis. The induction of apoptosis by EGCG via 
activation of caspase-3/cpp32 - like proteases can provide a mechanistic explanation for its 
antitumor effects. 
Supplementation with green tea extract significantly decreased malondialdehyde 
production and DNA damage after Fe(+2) oxidative treatment in jurkat T-cell line [159]. 
EGCE was effective in reducing the mutagenecity of Trp-p-2(NHOH) in mouse FM3A cells 
in culture. EGCE was also effective in inhibiting DNA single strand breaks in vitro caused by 
Glu-p-1(NHOH) [160].   
Jain et al., [161] found that the extract of green tea leaves decreased the mutagenic activity of 
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) to E.coli Wp2 in vitro in a desmutagenic 
manner. 
In cultured mammalian cells, the frequencies of mitomycin C or ultraviolet light-induced 
sister-chromatid exchanges and chromosomal aberrations were suppressed by subsequent 
treatment with tea polyphenols in the presence of liver-metabolizing enzymes (S9 fraction). 
In the absence of such enzymes, however, the tea extracts suppressed sister chromatid 
exchanges and chromosomal aberrations at low concentrations but enhanced them at high 
concentration [162]. 
It was shown that EGCG and EGC rather than ECG and EC were found to induce apoptosis 
in lovo cells. Moreover, EGCG, EGC and ECG caused the arrest at the G1-phase of the cell 
cycle, whereas EC induced the S-phase arrest [163].   
Zhao et al., [164] illustrated that after HL-60 cells were treated by tea polyphenols (250 micro 
g/ml) for 5h, DNA extracted from HL-60 cells showed a typical internucleosomal DNA 
degradation i.e. DNA ladder and apoptotic vehicles were observed. 
Ahmed et al., [165] studied the effect of green tea polyphenols and the major constituent 
epigallocatechin-3-gallate on the induction of apoptosis and regulation of cell cycle in 
human and mouse carcinoma cells and found that treatment of A431 cells with green tea 
polyphenols and its components epigallocatechin-3-gallate, epigallocatechin and 
epicatechin-3-gallate resulted in the formation of internucleosomal DNA fragments, a 
characteristic of apoptosis. Treatment with epigallocatechin-3-gallate also resulted in 
apoptosis in HaCaT, L5178Y, and Du145 cells. The DNA cell cycle analysis showed that in 
A431 cells, epigallocatechin-3-gallate treatment resulted in arrest in the G0/G1 phase of cell 
cycle and a dose-dependent apoptosis. The G0/G1 arrest shown by epigallocatechin-3-
gallate, therefore suggested that this agent might slow down the growth of cancer cells by 
artificially imposing the cell cycle checkpoint. The loss of cell cycle checkpoint results in the 
selection of cells that have a growth advantage and a predisposition for acquiring more 
chromosomal aberrations.   
2.2. Coffee polyphenols 
Caffeic acid and chlorogenic acid are catechol-containing coffee polyphenols that, in a 
similar way to the tea polyphenols, have shown to be demethylating agents. Lee et al., 
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studied the modulating effects of these two compounds on the in vitro methylation of 
synthetic DNA substrates and also on the methylation status of the promoter region of 
RARβ in two human breast cancer cells lines [166]. The presence of caffeic acid or 
chlorogenic acid inhibited in a concentration-dependent manner the DNA methylation 
catalyzed by DNMT1, predominantly through a non-competitive mechanism. This 
inhibition, similar to other dietary polyphenols, was largely due to the increased formation 
of SAH. Treatment of MCF-7 and MAD-MB-231 human breast cancer cells with these two 
compounds partially inhibited the methylation of the promoter region of RARβ. 
Caffeic acid phenethyl ester (CAPE), which also is a chatechol, kills various types of cancer 
cells but is innocuous to normal cells. There are several studies reporting the in vitro and in 
vivo inhibitory ef1fects of CAPE in multiple cancer models, such as colon cancer [167], lung 
cancer [168], melanoma [169], glioma [170], pancreatic cancer [171], gastric cancer [172], 
cholangiocarcinoma [173], hepatocellular carcinoma [174], and breast cancer [175, 176]. 
2.3. Sulforaphane 
Sulforaphane, a dietary phytochemical obtained from broccoli, has been implicated in 
several physiological processes consistent with anticarcinogenic activity, including 
enhanced xenobiotic metabolism, cell cycle arrest, and apoptosis. Although the effect of 
sulforaphane as a demethylating agent has not been specifically studied, this compound 
was found to down regulate DNMT1 in CaCo-2 colon cancer cells [177]. 
2.4. Isothiocyanates 
Isothiocyanates comprise another class of dietary compounds known to affect the 
epigenome. Isothiocyanates are metabolites of glucosinolates present in a wide variety of 
cruciferous vegetables and demonstrated to have anticancer properties. Treatment of 
prostate cancer cells with phenethyl isothiocyanate, a metabolite of gluconasturtin from 
watercress, was shown to lead to demethylation and re-expression of GSTP1 [178]. On the 
other hand, treatment with different isothiocyanates prevented the esophageous 
tumorigenesis induced by the methylating agent N-nitrosomethylbenzylamine (NMBA) in 
male rats [179]. 
2.5. Curcumin 
Curcumin is a polyphenolic compound derived from the dietary spice turmeric and 
possesses diverse pharmacological effects including antioxidant, anti-inflammatory, anti-
proliferative, and anti-angiogenic activities. Curcumin has been used for centuries in Asia, 
both in traditional medicine and in cooking where curcumin gives natural yellow color to 
the food. It has been well known that curcumin possesses potent antiinflammatory activity 
because of its inhibitory effects on cyclooxygenases 1, 2 (COX-1, COX-2), lipoxygenase 
(LOX), TNF-α, interferon γ (IFN-γ), inducible nitric oxide synthase (iNOS), and NF-κB [180, 
181]. Importantly, experimental evidences suggest that curcumin could exert its inhibitory 
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effects on cancer development and progression. The mechanisms implicated in the 
inhibition of tumorigenesis by curcumin are unclear but could involve a combination of 
anti-oxidant, anti-proliferation, pro-apoptotic, and anti-angiogenic properties through the 
regulation of genes and molecules that are involved in multiple signaling pathways. 
Moreover, preclinical animal experiments and phase I clinical trials have demonstrated 
minimal toxicity of curcumin even at relatively high doses (12 g/day) [182]. However, 
curcumin exhibits poor bioavailability because of poor absorption and rapid metabolism 
[182]. To improve the bioavailability of curcumin, liposomal curcumin, nanoparticle 
curcumin, and structural analogs of curcumin have been synthesized and investigated to 
determine the absorption and anti-cancer activity [183, 184]. The results are promising, 
which further suggest that curcumin or its novel structural analogs could serve as potent 
agents for the prevention and/or treatment of human malignancies, and thus requires more 
phase II and III clinical trials. 
2.6. Rosmarinic acid 
Rosmarinic acid is a natural polyphenol antioxidant carboxylic acid found in many 
Lamiaceae herbs used commonly as culinary herbs such as lemon balm, rosemary, oregano, 
sage, thyme and peppermint. Rosmarinic acid has been recently shown to be a potent 
inhibitor of DNMT1 activity in nuclear extracts from MCF7 breast cancer cells and decrease 
the protein levels of DNMT1. However, this compound was unable to demethylate and 
reactivate known hypermethylated genes such as RASSF1A, GSTP1 and HIN-1 in this cell 
line (185). 
2.7. Resveratrol 
Resveratrol, a phytoalexin made naturally by several plants, has been produced by chemical 
synthesis because of its potential anti-cancer, anti-inflammatory, blood-sugar-lowering and 
other beneficial cardiovascular effects. There is limited evidence about the potential 
demethylating activity of this compound. Resveratrol has shown to be a weak DNMT 
activity inhibitor in nuclear extracts from MCF7 cells, and as rosmarinic acid, was unable to 
reverse the methylation of several tumor suppressor genes [185]. In MCF-7 cells, resveratrol 
improved the action of adenosine analogues to inhibit methylation and to increase 
expression of RARβ2, although without significant effect on its own [186]. 
3. Summary and conclusions 
There is traditional and widespread use of dietary polyphenols all around the world. While 
the anecdotal epidemiological evidence has historically supported the idea of different diet 
and good health, experimental evidence accumulated in the recent years from various 
preclinical and clinical studies clearly support the idea that dietary polyphenols have 
potentially beneficial effects on multitude of health conditions, including cancer. Although 
the health effects of dietary polyphenols in humans are generally considered promising, 
there are definite challenges and limitations of the current data in better understanding the 
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studied the modulating effects of these two compounds on the in vitro methylation of 
synthetic DNA substrates and also on the methylation status of the promoter region of 
RARβ in two human breast cancer cells lines [166]. The presence of caffeic acid or 
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catalyzed by DNMT1, predominantly through a non-competitive mechanism. This 
inhibition, similar to other dietary polyphenols, was largely due to the increased formation 
of SAH. Treatment of MCF-7 and MAD-MB-231 human breast cancer cells with these two 
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Caffeic acid phenethyl ester (CAPE), which also is a chatechol, kills various types of cancer 
cells but is innocuous to normal cells. There are several studies reporting the in vitro and in 
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several physiological processes consistent with anticarcinogenic activity, including 
enhanced xenobiotic metabolism, cell cycle arrest, and apoptosis. Although the effect of 
sulforaphane as a demethylating agent has not been specifically studied, this compound 
was found to down regulate DNMT1 in CaCo-2 colon cancer cells [177]. 
2.4. Isothiocyanates 
Isothiocyanates comprise another class of dietary compounds known to affect the 
epigenome. Isothiocyanates are metabolites of glucosinolates present in a wide variety of 
cruciferous vegetables and demonstrated to have anticancer properties. Treatment of 
prostate cancer cells with phenethyl isothiocyanate, a metabolite of gluconasturtin from 
watercress, was shown to lead to demethylation and re-expression of GSTP1 [178]. On the 
other hand, treatment with different isothiocyanates prevented the esophageous 
tumorigenesis induced by the methylating agent N-nitrosomethylbenzylamine (NMBA) in 
male rats [179]. 
2.5. Curcumin 
Curcumin is a polyphenolic compound derived from the dietary spice turmeric and 
possesses diverse pharmacological effects including antioxidant, anti-inflammatory, anti-
proliferative, and anti-angiogenic activities. Curcumin has been used for centuries in Asia, 
both in traditional medicine and in cooking where curcumin gives natural yellow color to 
the food. It has been well known that curcumin possesses potent antiinflammatory activity 
because of its inhibitory effects on cyclooxygenases 1, 2 (COX-1, COX-2), lipoxygenase 
(LOX), TNF-α, interferon γ (IFN-γ), inducible nitric oxide synthase (iNOS), and NF-κB [180, 
181]. Importantly, experimental evidences suggest that curcumin could exert its inhibitory 
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effects on cancer development and progression. The mechanisms implicated in the 
inhibition of tumorigenesis by curcumin are unclear but could involve a combination of 
anti-oxidant, anti-proliferation, pro-apoptotic, and anti-angiogenic properties through the 
regulation of genes and molecules that are involved in multiple signaling pathways. 
Moreover, preclinical animal experiments and phase I clinical trials have demonstrated 
minimal toxicity of curcumin even at relatively high doses (12 g/day) [182]. However, 
curcumin exhibits poor bioavailability because of poor absorption and rapid metabolism 
[182]. To improve the bioavailability of curcumin, liposomal curcumin, nanoparticle 
curcumin, and structural analogs of curcumin have been synthesized and investigated to 
determine the absorption and anti-cancer activity [183, 184]. The results are promising, 
which further suggest that curcumin or its novel structural analogs could serve as potent 
agents for the prevention and/or treatment of human malignancies, and thus requires more 
phase II and III clinical trials. 
2.6. Rosmarinic acid 
Rosmarinic acid is a natural polyphenol antioxidant carboxylic acid found in many 
Lamiaceae herbs used commonly as culinary herbs such as lemon balm, rosemary, oregano, 
sage, thyme and peppermint. Rosmarinic acid has been recently shown to be a potent 
inhibitor of DNMT1 activity in nuclear extracts from MCF7 breast cancer cells and decrease 
the protein levels of DNMT1. However, this compound was unable to demethylate and 
reactivate known hypermethylated genes such as RASSF1A, GSTP1 and HIN-1 in this cell 
line (185). 
2.7. Resveratrol 
Resveratrol, a phytoalexin made naturally by several plants, has been produced by chemical 
synthesis because of its potential anti-cancer, anti-inflammatory, blood-sugar-lowering and 
other beneficial cardiovascular effects. There is limited evidence about the potential 
demethylating activity of this compound. Resveratrol has shown to be a weak DNMT 
activity inhibitor in nuclear extracts from MCF7 cells, and as rosmarinic acid, was unable to 
reverse the methylation of several tumor suppressor genes [185]. In MCF-7 cells, resveratrol 
improved the action of adenosine analogues to inhibit methylation and to increase 
expression of RARβ2, although without significant effect on its own [186]. 
3. Summary and conclusions 
There is traditional and widespread use of dietary polyphenols all around the world. While 
the anecdotal epidemiological evidence has historically supported the idea of different diet 
and good health, experimental evidence accumulated in the recent years from various 
preclinical and clinical studies clearly support the idea that dietary polyphenols have 
potentially beneficial effects on multitude of health conditions, including cancer. Although 
the health effects of dietary polyphenols in humans are generally considered promising, 
there are definite challenges and limitations of the current data in better understanding the 
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molecular mechanisms responsible for this effect, together with the possible interactions 
between different polyphenols and other dietary constituents. While in vitro models have 
enormously contributed to the understanding of polyphenols mediated regulation of the 
epigenetic network, there is still a paucity of in vivo data for the majority of these dietary 
compounds. Therefore, until sufficient preclinical and clinical data has been gathered on the 
epigenetic changes induced by some of the dietary polyphenols, one should be cautious 
while interpreting and extrapolating the significance of current in vitro evidence. Once such 
evidence is established, the next and more important step would be to determine the most 
effective doses of these ‘dietary nutraceuticals’ in order to obtain various beneficial effects in 
human subjects. 
Additional clinical work is required to examine the safety profile of various doses of dietary 
polyphenols, and more basic science studies are needed to improve our understanding of 
the molecular mechanisms underlying the chemopreventive effect of various dietary 
polyphenols. It is really exciting to witness that we have at least begun to explore the 
molecular mechanistic underpinnings of the “goodness” of certain diets and diet-related 
factors, which have been in existence for centuries. 
The mere fact that currently hundreds of dietary polyphenols are being characterized from 
an “epigenomic” perspective clearly reflects our enthusiasm and trust we pose in the 
concept of safe and natural agents for cancer chemoprevention. Of course, the current 
evidence is thin and it is a long and treacherous road ahead of us; nonetheless, given the 
promise and potential of these polyphenols it is realistic to fathom that some of these 
compounds can become integral for the cancer chemoprevention in future. 
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[18] Singh UP, Singh N, Singh B, Hofseth LJ, Price BL, Nagarkatti M, et al. (2009) Resveratrol 
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molecular mechanisms responsible for this effect, together with the possible interactions 
between different polyphenols and other dietary constituents. While in vitro models have 
enormously contributed to the understanding of polyphenols mediated regulation of the 
epigenetic network, there is still a paucity of in vivo data for the majority of these dietary 
compounds. Therefore, until sufficient preclinical and clinical data has been gathered on the 
epigenetic changes induced by some of the dietary polyphenols, one should be cautious 
while interpreting and extrapolating the significance of current in vitro evidence. Once such 
evidence is established, the next and more important step would be to determine the most 
effective doses of these ‘dietary nutraceuticals’ in order to obtain various beneficial effects in 
human subjects. 
Additional clinical work is required to examine the safety profile of various doses of dietary 
polyphenols, and more basic science studies are needed to improve our understanding of 
the molecular mechanisms underlying the chemopreventive effect of various dietary 
polyphenols. It is really exciting to witness that we have at least begun to explore the 
molecular mechanistic underpinnings of the “goodness” of certain diets and diet-related 
factors, which have been in existence for centuries. 
The mere fact that currently hundreds of dietary polyphenols are being characterized from 
an “epigenomic” perspective clearly reflects our enthusiasm and trust we pose in the 
concept of safe and natural agents for cancer chemoprevention. Of course, the current 
evidence is thin and it is a long and treacherous road ahead of us; nonetheless, given the 
promise and potential of these polyphenols it is realistic to fathom that some of these 
compounds can become integral for the cancer chemoprevention in future. 
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diameter and contains large seeds inside. It tastes very bitter and is considered a blood 
purifier. It can be cut into rings and deep-fried for a snack. It is also often stir fried with 
meat, shrimp or fish. 
In view of the popularity of bitter melon in the Asian tropics and the fact that the results of 
using bitter melon as a remedy for diabetes has yielded conflicting results [2,4,5], more 
research needs to be done on its hypoglycemic activity. In addition, several compounds 
from bitter melon have shown interesting pharmacological activities, including antitumor, 
immunotoxic and anti-HIV properties, which merit further research, and may have strong 
potential in the development of future medicines [2,6-9]. Although different types of 
synthetic drugs are available for the treatment of chronic diseases, such as diabetes and 
cancer, the synthetic agents in use can produce serious side effects and toxicity. Hence there 
is a demand for safer and more effective agents. In many parts of the world, an Ayurvedic 
(traditional Indian) approach has been used for the treatment of a number of diseases, 
including diabetes and cancer and therein exists a hidden wealth of potential for useful 
natural products in the control of diseases. The World Health Organization (WHO) has 
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recommended that this area warrants further evaluation that might reveal effective dietary 
adjuncts, either for the treatment or prevention of specific diseases [10]. With traditional use 
supported by modern scientific evidence of the beneficial function of MC, it is one of the 
most promising plants for drug development. However, its phytochemicals and mechanism 
of action are poorly understood. Extensive research has studied the isolation of several 
classes of active components, including cucurbitane-type triterpenoids and the potential 
biological and pharmacological activities of natural products in MC [7,11]. The aim of this 
chapter is to review the cucurbitane type triterpenoids, particularly kuguacin J, in MC with 
the goal of encouraging future studies. 
1.1. Geographic distribution and monograph 
MC is an herbaceous, tendril-bearing vine growing up to 5 m in length. It bears simple, 
alternate leaves, with 3-7 deeply separated lobes. Each plant bears separate yellow male and 
female flowers [12]. Fruit 2.5-25 cm long, oblong, pendulous, fusiform, usually pointed or 
beaked, ribbed and bearing numerous triangular tubercles, 3 valves are present at the apex 
when mature. MC are perennial climbers cultivated throughout India and in Southern China 
and is now found naturalized in almost all tropical and subtropical regions. It is an important 
vegetable in India, Sri Lanka, Vietnam, Thailand, Malaysia, the Philippines and Southern 
China. It is also cultivated on a small scale in tropical America. MC is grown mainly for the 
production of immature fruit, although the young leaves are edible as a vegetable [3]. The 
young fruit is emerald green, but turns to orange-yellow when ripe. At maturity, the fruit 
splits into irregular valves that curl backwards and release numerous brown or white seeds 
encased in scarlet arils (Figure 1). All parts of the plant, including the fruit, taste bitter. It has 
been used extensively in traditional medicine as a remedy for diabetes.   
 
Figure 1. Flowers, immature fruit and young leaves of Momordica charantia (MC) at a home garden in 
Chiang Mai, Thailand (the picture was taken in March, 2012). 
1.2. Pharmacological activities 
Previous investigations have shown that water extracts of the leaf and fruit of MC exhibited 
high antioxidant activity and that bitter melon fractions are rich in phenolics and have a 
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strong antioxidant activity [13]. The role of free radicals and active oxygen in treating 
chronic diseases including cancer, aging and atheroscerosis has been recognized [14]. 
Therefore, much attention has been focused on the use of antioxidants in protecting against 
the threat of damage of free radicals. The active fractions from the fruit of MC have been 
reported to have significant hypoglycemic and antidiabetic effects [1,5]. Its active 
compounds were reported to be saponins [15,16] and peptides [17,18]. Charantin, an 
antidiabetic compound, is a typical cucurbitane-type triterpenoid in MC and is a potential 
and promising substance for the treatment of diabetes [19]. A number of studies have 
reported the effects of MC unrelated to diabetes. MC has some interesting biological and 
pharmacological activities. Extracts of MC have been reported to possess antitumor activity, 
such as the inhibition of mouse spontaneous mammary tumourigenesis [20] and 
benzo(a)pyrene-induced mouse forestomach tumourigenesis [21]. Besides, antioxidant 
activities [22], the antiviral [9], antidiabetic and immunomodulating properties [23] of this 
plant have also been explored. 
1.3. Ethnomedical uses  
The fruit, leaves and roots of MC have been used in Ayurveda in the treatment of a number 
of diseases. They have been used as a bitter stomachic, a laxative and an anthelmintic [24]. 
The whole extract of the fruit is also advocated in the treatment of diseases of the spleen, 
liver, and in rheumatism and gout [25]. An active ingredient from this plant has been used 
in diabetes mellitus [6,11,26]. In KwaZulu-Natal, the Zulus drink a concoction of the root or 
leaf for the treatment of boils and take an infusion of the runner as a sedative for an irritable 
stomach [27]. It has also been reported that it has been used as a remedy for hypertension 
and is reported to have antidiabetic properties. The leaf is used by the Chagga as an earache 
remedy [28] and in tropical Africa, the leaf is used to treat roundworm [29]. In Uganda, an 
infusion of the leaf and roots is used as an abortifacient and ecbolic [28] and in Tanzania the 
fruit pulp is regarded as being poisonous to weevils, moths and ants and is used as a 
repellant [30]. In the Philippines, the leaves are often used for children’s coughs. It is used in 
the treatment of skin diseases, sterility in women, as a parasiticide, as an antipyretic, and as 
a purgative. MC is also known as the Ampalaya tree, which is a vegetable grown 
throughout the Phillipines [31] and Ampalaya tea is a bitter brew made from the fruit or 
leaves. Ayurveda knowledge has claimed that Amapalaya stimulates digestion, helping 
those with dyspepsia or constipation. The tea seems to help people with diabetes mellitus 
control the disease, and it may provide some antimalarial benefits. Ampalaya has been 
traditionally regarded by Asians, as well as Panamanians and Columbians, as being useful 
in the prevention and treatment of malaria. Laboratory studies have confirmed that various 
species of the bitter fruit have anti-malarial activity, although human studies have not yet 
been published. In the Philippines, the effect of MC capsule preparation on glycemic control 
in type 2 diabetes mellitus has been studied [32]. However, there was no significant effect on 
mean fasting blood sugar, total cholesterol, and weight or on serum creatinine, ALT, AST, 
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1.4. Phytochemicals and cucurbitane triterpenoids 
Since the early 1960’s the constituents of bitter melon have been investigated and several 
classes of primary and secondary metabolites have been isolated from MC fruits, seeds and 
whole plants. It contains biologically active chemicals that include crude fat, crude protein, 
soluble dietary fiber, minerals, essential oil, flavonoids, phenolic acids, glycosides and 
triterpenes. The young fruit is a good source of vitamin C and vitamin A [33-35]. A steroid 
saponin called charantin has been isolated from the fruits and leaves. It also contains a 
polypeptide named gurmarin, which is similar to insulin in composition.  
Among the secondary metabolites of MC, cucurbitane-type triterpinoids are one of the main 
bioactive constituents. The terpenoids, referered to as isoprenoids, are a class of natural 
products and the related compounds have been formally derived from five-carbon isoprene 
units. Terpenoids of different sizes and composition are found in all classes of living things 
and are the largest groups of naturally occurring chemicals. This class has been subdivided 
according to the number of carbon atoms. The triterpenoids are terpenoids with a C30 
skeleton. These C30 constituents are isolated and characterized from various sources in 
nature, particularly in resins and may occur as either esters or glycosides [36,37]. More 
extensive backbone rearrangement of the protostane cation affords the curcubitane skeleton. 
The cucurbitacins are a typical group of cucurbitane-type triterpenoids found in plants and 
belong to the cucumber family (Cucurbitaceae). The natural cucurbitracins are well-known 
for their bitterness and toxicity [38]. The cucurbitane-type triterpenoids and their aglycones 
have shown some biological effects beneficial in treating diabetes and obesity, and possess 
anticancer, anti-HIV and antifeedant properties [7,39]. More than fifty cucurbitacins and 
cucurbitane glycosides from the fruits, seeds, leaves, vines and stems have been reported 
[40-48]. Recently, Chen et al (2008, 2009) isolated and structured elucidation of nineteen 
cucurbitacins named kuguacins A-E from the roots of MC [49] and kuguacins F-S [50] from 
the vines and leaves of MC. They claimed that some of them are artifacts formed during 
the extraction process. The kuguacin C and E showed moderate anti-HIV-1 activity with 
EC50 values of 8.45 and 25.62 g/ml. The kuguacins F-S exhibited weak anti-HIV activities 
in vitro.  
Recently, several triterpenoids from various plants have been reported to feature anti-
proliferative [51-53] and anti-invasive [54,55] bioactive components. More than 50 
triterpenoids have been isolated from bitter melon, but their biological activities have yet to 
be explored in detail. However, it has been shown that Cucurbitacin B (cucB), a triterpenoid 
from Cucurbitaceae vegetables also found in bitter melon seeds, has caused cell cycle arrest 
and apoptosis induction in human colon adenocarcinoma cancer cells [53]. Moreover, 2 
flavonoids and 4 phenolic acids, including rutin, naringin, gentistic acid, benzoic acid, o-
coumaric acid, and t-cinnamic acid, are present in bitter melon leaves [35]. Rutin, a flavonoid 
glycoside, has been reported to successfully show growth inhibition of leukemia and 
ovarian carcinomas, with anti-invasive effects on melanoma [35,56-58]. Triterpenoids and 
flavoniods included in bitter melon leaf extract (BMLE) might be promising components 
with critical roles against cancer cell progression, but the active compound(s) remain to be 
identified. 
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This review presents previously published and current information regarding a cucurbitane 
type triterpenoid, kuguacin J, and provides new insights into the underlying potential of the 
chemical isolation and biological activities of kuguacin J in MC. Molecular mechanisms of 
kuguacin J, as a promising anticancer agent, will be discussed in detail.  
1.5. Isolation and purification of kuguacin J from MC leaf 
Our previous study [59] has compared the effects of the ethanolic extracts from leaves, fruits 
and tendrils of MC on drug accumulation and P-gp activity in vitro. The leaf extract (BMLE) 
showed a concentration-dependent effect on P-gp-mediated vinblastine accumulation and 
effux in drug resistant KB-V1 cells, but had no effect in drug-sensitive KB-3-1 cells, which 
lack P-gp, while there was no change in drug accumulation and efflux in KB-V1 cells in the 
presence of the fruit and tendril extracts [59]. These firstly inspired us to further identify the 
active component(s) of BMLE, which modulate the function of P-gp and the multidrug-
resistant (MDR) phenotype in multidrug-resistant human cervical carcinoma KB-V1 cells 
using Bioassay-guided fractionation. 
In the next study [60], the ethanolic fraction, BMLE, was subsequently extracted with 
solvents increasing in polarity (i.e., ethanol, hexane, diethyl ether, chloroform and ethyl 
acetate). These extraction samples were tested for their abilities to modulate the function of 
P-gp in the multidrug-resistant human cervical carcinoma KB-V1 cells in comparison with 
wild type drug sensitive KB-3-1 cells. Among the extracts tested, the hexane and diethyl 
ether fractions had the most effective MDR reversing properties, and increased intracellular 
[3H]-vinblastine accumulation and decreased the [3H]-vinblastine efflux in KB-V1 cells. The 
percent yield of the diethyl ether fraction was higher than the hexane fraction. Moreover, in 
another of our studies, the growth inhibitory effects on LNCaP cells showed that the diethyl 
ether fraction (DEF) of BMLE displayed the strongest inhibitory effect on the cell growth 
[61]. So, we therefore purified the active component using the diethyl ether fraction as a 
principle material. Bioassay-guided fractionation led us to isolate a purified white crystal. 
The IR, NMR and MS data of the compound was compared with previous reports [62] and it 
was identified as kuguacin J (3,7,23-trihydroxycucurbita-5,24-dien-19-al), (Figure 2). We 
further characterized the anticancer properties of BMLE (in vitro and in vivo) and kuguacin J 
(in vitro) and these will be further discussed in the following sections. 
2. Bitter melon and cancer 
Cancer is a disease in which the cell presents itself with uncontrolled proliferative potential. 
The transition of normal cells towards the cancerous phenotype occurs at various stages 
[63]. Since these defects are mostly due to aberrant signaling cascades involving numerous 
molecular players, targeting them by chemopreventive agents at any stage could be a 
rationalized approach in achieving the control of cancer. 
Carcinogenesis is generally a complex and multi-step process in which distinct molecular 
and cellular alterations occur. In order to simplify the understanding of the different 
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2. Bitter melon and cancer 
Cancer is a disease in which the cell presents itself with uncontrolled proliferative potential. 
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Carcinogenesis is generally a complex and multi-step process in which distinct molecular 
and cellular alterations occur. In order to simplify the understanding of the different 
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possible options for chemoprevention and chemotherapy in cancer development and 
progression, the following stages have been described: (i) initiation, when cells are exposed to 
a carcinogenic agent, (ii) promotion, when abnormal cells persist and initiate a preneoplastic 
stage (iii) progression, final phase of the tumorigenesis, when  uncontrolled cell growth is 
resistant to anticancer drugs (Multidrug Resistance; MDR), and aggressiveness or metastasis 
occur. A cancer chemopreventive agent could be effective at any of the classically defined 
stages of carcinogenesis: initiation, promotion, and/or progression [64,65]. As discussed earlier, 
extracts of bitter melon have been reported to possess anti-tumor activity [20,21] and the 
following sections detail the signaling cascades that are targeted. 
 
Figure 2. Chemical structure of kuguacin J isolated from MC. 
2.1. Anticancer in vitro studies 
Prevention by the use of naturally occurring dietary substances is considered a practical 
approach in reducing the increasing incidence of cancer. The intervention of multi-stage 
carcinogenesis by modulating intracellular signaling pathways may provide the molecular 
basis of chemoprevention with a wide variety of dietary phytochemicals [66,67]. 
Anticancer activities of MC against numerous cancers have revealed that it contains active 
compounds that provide anticancer potential to inhibit cell growth and proliferation, as well 
as to induce apoptotic cell death in several cancer cell lines [68-71]. Our studies [60,61,72,73] 
found that kuguacin J, one of the active compounds contained in MC extracts, exerts 
anticancer properties in various experimental models, which will be discussed further in the 
following sections. 
2.1.1. Antiproliferative and antiapoptotic activities 
Generally, deregulation of cell growth and resistance to apoptosis are the major defects in 
uncontrolled cancer cell growth, hinting that development of approaches that induce cell 
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cycle arrest and apoptotic machineries in cancer cells could be effective measures against 
their proliferation. Recently, dietary phytochemicals are considered promising 
chemopreventive or chemotherapeutic agents [67,74]. Thus, the induction of cell cycle arrest 
or apoptosis using dietary chemopreventive compounds might be an excellent approach to 
inhibit the promotion and progression of carcinogenesis and to remove genetically 
deregulated, premalignant and malignant cells from the body. We have investigated the 
growth inhibitory effect of BMLE and kuguacin J on androgen-dependent and androgen-
independent prostate cancer models [61,72,73]. 
Our study [61] found that BMLE exerted significant growth inhibitory effects on LNCaP via 
the induction of G1 arrest and apoptosis cell death and the alteration of cyclin D1, PCNA, 
Bcl-2/Bax, caspase-3 and cleaved caspase-3 protein levels. The data prompted us to 
characterize the active compound(s) in the extract, which could be valuable in the 
prevention and intervention of cancers. It was found that kuguacin J exerted a marked 
decrease of LNCaP cell proliferation and viability, suggesting that kuguacin J is at least one 
of the active components in BMLE that plays a critical role in the growth inhibition of 
LNCaP. 
The treatment of androgen-sensitive (LNCaP) cells with kuguacin J resulted in a significant 
G1-phase arrest of cell cycle progression [61], which indicates that one of the mechanisms by 
which kuguacin J may act to inhibit the proliferation of cancer cells is the regulation of cell 
cycle progression. We next examined the effect of kuguacin J on cell cycle regulatory 
molecules operative in the G1 phase of the cell cycle. The reduction of cyclinD1, cyclinE, 
Cdk2 and Cdk4 in LNCaP cells by kuguacin J suggests the disruption of the uncontrolled 
cell cycle progression of these cells and that the kuguacin J-induced G1 arrest is mediated 
through the up-regulation of p21 and p27 proteins, which enhances the formation of 
heterotrimeric complexes with the G1-S Cdks and cyclins, thereby inhibiting their activity. 
Additionally, kuguacin J also dramatically suppressed the expression of a proliferation 
marker, PCNA, which is expressed late in the G1 phase and early in the S phase [75]. The 
inhibition of cell proliferation or the induction of cell death in LNCaP by kuguacin J might 
be associated with the G1 arrest machinery. 
G1-phase arrest of cell cycle progression provides an opportunity for cells to either undergo 
repair mechanisms or follow the apoptotic pathway. Apoptosis plays a crucial role in that it 
functions as an essential mechanism of tissue homeostasis, eliminating the mutated 
neoplastic and hyperproliferating neoplastic cells from the system. Acquired resistance 
toward apoptosis is a hallmark of most, and perhaps all, types of cancer. Cancer cells 
become resistant to apoptosis and do not respond to the cytotoxic effects of the 
chemotherapeutic agents [76]. Therefore induction of apoptosis is considered a protective 
mechanism against cancer progression. We thus determined the effect of kuguacin J on the 
induction of apoptosis in LNCaP cells [61]. Kuguacin J treatment caused significant 
induction of apoptosis. Hence, kuguacin J seems to be a potent chemotherapeutic agent for 
prostate cancer inhibition. Moreover, kuguacin J treatment reduced the protein level of 
surviving, which might be associated with kuguacin J-induced cell cycle arrest and 
apoptosis in LNCaP. Kuguacin J treatment could alter the protein levels of key members of 
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cell cycle progression of these cells and that the kuguacin J-induced G1 arrest is mediated 
through the up-regulation of p21 and p27 proteins, which enhances the formation of 
heterotrimeric complexes with the G1-S Cdks and cyclins, thereby inhibiting their activity. 
Additionally, kuguacin J also dramatically suppressed the expression of a proliferation 
marker, PCNA, which is expressed late in the G1 phase and early in the S phase [75]. The 
inhibition of cell proliferation or the induction of cell death in LNCaP by kuguacin J might 
be associated with the G1 arrest machinery. 
G1-phase arrest of cell cycle progression provides an opportunity for cells to either undergo 
repair mechanisms or follow the apoptotic pathway. Apoptosis plays a crucial role in that it 
functions as an essential mechanism of tissue homeostasis, eliminating the mutated 
neoplastic and hyperproliferating neoplastic cells from the system. Acquired resistance 
toward apoptosis is a hallmark of most, and perhaps all, types of cancer. Cancer cells 
become resistant to apoptosis and do not respond to the cytotoxic effects of the 
chemotherapeutic agents [76]. Therefore induction of apoptosis is considered a protective 
mechanism against cancer progression. We thus determined the effect of kuguacin J on the 
induction of apoptosis in LNCaP cells [61]. Kuguacin J treatment caused significant 
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prostate cancer inhibition. Moreover, kuguacin J treatment reduced the protein level of 
surviving, which might be associated with kuguacin J-induced cell cycle arrest and 
apoptosis in LNCaP. Kuguacin J treatment could alter the protein levels of key members of 
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the Bcl-2 family in a manner that favors an increase in the ratio of Bax/Bcl-2 and Bad/Bcl-xL 
and increases the activation of caspase-3 and cleavage of PARP. This may represent the 
mechanism by which cancer cells are susceptibility to kuguacin J mediated apoptosis.  
LNCaP is an androgen-dependent, androgen receptor (AR)-positive prostate cancer cell line. 
AR is known to play a critical role in the development and progression of prostate cancer 
[77]. The ability of AR to cross-talk with several growth factor signaling cascades toward the 
regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells has 
been reported [77]. Inhibition of AR activity could be the major therapeutic goal to delay 
prostate cancer progression. Kuguacin J decreased the expression of AR followed by the 
reduction of the protein level of PSA [61], which is one major AR-dependent target gene. 
The diminishment of PSA represents the effective inhibition of AR activity by kuguacin J 
treatments. The decrease of AR might be involved in the kuguacin J-caused growth 
inhibition of LNCaP through the induction of G1 arrest and apoptosis. 
The tumor suppressor p53 protein is a regulator of genotoxic stress that plays an important 
role in DNA damage response, DNA repair, cell cycle regulation, and in triggering 
apoptosis after cell injury [78]. Induction of apoptosis is considered to be central to the 
tumor-suppressive function of p53 [79]. Kuguacin J-treated LNCaP cells markedly increased 
the expression of the p53 protein [61]. We further investigated whether kuguacin J-induced 
cell cycle arrest and apoptosis of LNCaP cells are p53-dependent using p53 RNA 
interference. We found that kuguacin J induced p53-mediated partly cell cycle arrest, and 
mainly apoptosis, which led to the inhibition of cell growth and may be related to the 
activation of p53 signaling pathway [61].  
Treatment of androgen-independent prostate cancer cells (PC3) with kuguacin J caused a 
significant G1-phase arrest along with a reduction of survivin, cyclinD1, cyclinE, Cdk2 and 
Cdk4 [73]. Kuguacin J also dramatically suppressed the expression of a proliferation marker, 
PCNA, that is expressed in both late G1 phase and early S phase [61,73] . 
Kuguacin J appears to inhibit the growth of the androgen-dependent LNCaP cells to a 
greater degree compared to the androgen-independent PC3 cell line [61,73]. A number of 
differences between PC3 and LNCaP cells may account for this difference in sensitivity. PC3 
is a more aggressively growing cell line and is null for both p53 and the AR. LNCaP is a 
much less aggressive cell line and possesses wild-type p53 and an AR, which although 
mutated, is responsive to androgen. Our study revealed that kuguacin J markedly decreased 
AR expression and induced p53 levels in LNCaP cells. We also found that p53 played a 
critical role in the kuguacin J-mediated induction of apoptosis by LNCaP cells. The data 
could explain the lower induction of apoptosis in PC3 cells compared to LNCaP. The 
induction of G1 arrest by kuguacin J, however, was similar in AR-dependent LNCaP cells 
and AR-independent PC3 cells, suggesting that the AR might not be a critical component in 
mediating the growth-arresting properties of kuguacin J. 
The sensitivity of the human normal prostatic epithelial cell line PNT1A to the cytotoxic 
effects of kuguacin J was much lower than that of the prostate cancer cell lines (LNCaP and 
PC3) [61]. Thus, kuguacin J could be an effective chemopreventive and chemotherapeutic 
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agent against prostate cancer, which might have no or a low side effect on normal cells and 
tissues. 
Our studies [61,73] provide the evidence that shows the significant inhibitory effects on 
carcinogenic progression of LNCaP and PC3 cells via inhibition of cell growth and 
proliferation by kuguacin J. Thus, kuguacin J is able to induce apoptosis/cell cycle arrest in 
pre-initiated/initiated tumor cells, while in more advanced tumors kuguacin J is still able to 
induce apoptosis/cell cycle arrest. Taken together, kuguacin J might be a promising 
candidate as a new chemopreventive agent for both androgen-dependent and androgen-
independent prostate cancer and could be developed as an alternative treatment option in 
cancer therapy. The in vivo study and growth inhibitory effects of kuguacin J on other 
cancers has to be further investigated. 
Because kuguacin J is a purified compound from BMLE, the differences of the anti-tumor 
effects between kuguacin J and BMLE were investigated. The growth inhibition effects of 
kuguacin J on LNCaP are similar to BMLE with the phenomena of cell cycle arrest and 
apoptosis induction and alteration of the expression of cell cycle- and apoptosis-regulators. 
However, kuguacin J is included as only 1.6% of the BMLE, and the effective concentration 
to inhibit cancer cell growth of kuguacin J was 10 times lower than that of BMLE [60,61,73]. 
Therefore, BMLE may include other compounds, which also have anti-tumor function 
towards LNCaP cells.  
2.1.2. Multidrug resistance reversing properties via modulation of P-glycoprotein function 
The development and strategic use of anticancer drugs has become one of the most 
important ways of controlling malignant diseases. However, the emergence of drug 
resistance has made many of the currently available chemotherapeutic agents ineffective. 
Efforts to reverse the drug resistance of tumor cells have been largely unsuccessful [80]. In 
recent years, considerable research has been directed toward understanding the underlying 
mechanisms that confer drug resistance. Many studies using tumor cell lines as model 
systems have demonstrated that the exposure of cells to one drug often results in cross-
resistance to many other structurally, chemically, and functionally distinct agents. This 
phenomenon is broadly known as the MDR phenotype [81-84]. The mechanism of MDR has 
now shown that some of the ATP-binding cassette (ABC) transporter proteins, especially 
ABCB1, or as it is more commonly referred to in literature, P-glycoprotein (P-gp), which is 
normally expressed in tumors derived from epithelial tissues including cancers of the 
kidney, liver, colon, and brain, has been associated with the intrinsic drug resistance of these 
cancers [85]. Some other tumors (for example breast, ovarian and small cell lung cancers) 
exhibit generally low levels of P-gp expression at diagnosis. However, the P-gp expression 
can be induced during the course of treatment, causing the cancer to become resistant to 
anticancer drugs [85]. At present, due in part to the disappointing results associated with the 
many side effects of P-gp modulators that have been used in clinical trials, current research 
efforts have been directed towards the identification of novel compounds with an attention 
toward dietary natural products or dietary herbs. The advantage is that these dietary herbs 
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exhibit little or virtually no side effects and do not further increase the patient’s medication 
burden. 
Our study investigated the effects of bitter melon extracts from leaves, fruits and tendrils on 
drug accumulation and P-gp activity in vitro [59]. We found that the leaf extract showed the 
greatest efficacy on P-gp-mediated vinblastine accumulation and effux in drug resistant KB-
V1 cells, but had no effect in drug-sensitive KB-3-1 cells, which lack P-gp. There was no 
change in drug accumulation and effux in KB-V1 cells in the presence of fruit and tendril 
extracts. The protein expression level of P-gp in KB-V1 cells was not altered by BMLE. 
Therefore, BMLE possibly modulates intracellular drug levels by inhibiting P-gp activity. 
We next identified the active component(s) in BMLE that act to modulate the function of P-
gp and the MDR phenotype in multidrug-resistant human cervical carcinoma using 
Bioassay-guided fractionation and led us to isolate a purified white crystal that was further 
identified as kuguacin J [60]. 
Kuguacin J increased the sensitivity of KB-V1 cells to vinblastine and paclitaxel, but did not 
have this effect on KB-3-1 cells [60]. Moreover, the treatment of KB-V1 and KB-3-1 cells with 
kuguacin J yielded a marked increase in C-AM and Rh123 accumulation in a concentration-
dependent manner in KB-V1 cells, but had no effect on KB-3-1 cells. C-AM and Rh123 are 
known to be good substrates for P-gp, indicating that kuguacin J modulates intracellular 
drug levels by inhibiting P-gp activity. The inhibitory effect of kuguacin J on P-gp function 
by [3H]-vinblastine transportation assays showed that kuguacin J also increased [3H]-
vinblastine accumulation in KB-V1 cells and decreased [3H]-vinblastine efflux from KB-V1 
cells. As our previous study showed, P-gp expression in KB-V1 cells was not affected by 
treating the cells with BMLE [59]. Our data suggests that kuguacin J inhibits P-gp activity, 
but does not inhibit its expression.  
The photoaffinity labeled transport substrate of P-gp, [125I]-IAAP, has been used extensively 
to study the interaction of the modulators at the substrate-binding site of P-gp [86]. It is also 
known that P-gp can be specifically labeled with [125I]-IAAP, and the drug-substrates of P-gp 
can inhibit the photocrosslinking of [125I]-IAAP to P-gp [87]. Kuguacin J inhibited the 
photocrosslinking of [125I]-IAAP to P-gp in a concentration-dependent manner. This is direct 
evidence that kuguacin J interacts with the substrate-binding site of P-gp. We further 
verified the interaction of kuguacin J with P-gp using an ATPase assay, which is another 
useful assay in the study of the interaction of transport-substrates with P-gp, as ATP 
hydrolysis is coupled with the transport function of this transporter [88]. Although 
kuguacin J had a negligible effect on the basal ATPase activity of P-gp, a low concentration 
of kuguacin J slightly stimulated P-gp-mediated ATP hydrolysis. This finding also implies 
that kuguacin J interacts with the substrate-binding site of P-gp. We next investigated the 
effect of kuguacin-J on verapamil-stimulated ATPase activity to further characterize the 
nature of the interactions of kuguacin J. Kuguacin J indeed inhibited the verapamil-
stimulated ATPase activity of P-gp. Furthermore, the kinetic analyses clearly showed that 
kuguacin J competes with verapamil for the substrate-binding site of P-gp. Taken together, 
the biochemical data suggest that kuguacin J inhibits the transport function of P-gp by 
interacting with the substrate-binding site of P-gp where verapamil also binds.  
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These results demonstrate that kuguacin J, an active compound isolated from BMLE, is an 
effective inhibitor of P-gp activity, and could be a candidate molecule for treating cancers 
exhibiting P-gp-mediated MDR. Investigations in animal experiments to determine whether 
kuguacin J has potential as an effective chemosensitizer that could be used in combination 
with conventional chemotherapy, needs to be explored. 
2.1.3. Modulation potential on cancer cell metastasis 
Metastasis, the spreading of malignant cells from the primary site to form a tumor mass at 
distant organs of the body, is the major cause of death in cancer patients. One of the critical 
characteristics of a metastatic cell is its invasion or ability to penetrate and invade the 
extracellular matrix and surrounding tissue. Invasion itself is a multistep process, requiring 
the coordination of various events, including the alteration of cell adhesion, promotion of 
cell migration, and degradation of the extracellular matrix barrier. Specifically, metastatic 
cells adhere to the basement membrane, secrete matrix-degrading enzymes such as matrix 
metalloproteinases (MMPs) to degrade the extracellular matrix barrier, and migrate from its 
original site. Therefore, the inhibition of these steps might be an effective approach in the 
prevention of cancer metastasis. The agents used in cancer metastasis therapy have been 
cytotoxic, with serious side effects that can diminish the quality of life of the cancer patients 
[89]. Recently, many efforts have therefore been made to search for non- or low-cytotoxic 
agents, which can reduce the spread of malignant tumors. One focus is to target cell 
invasion using substances found in medicinal plants [90,91]. 
We have provided clear evidence that BMLE can exert inhibitory potential against the 
metastatic properties of PLS10 cells in vitro [72]. Our results pointed to the beneficial effects 
at non-toxic levels. BMLE might thus afford an advantageous anti-cancer progression agent 
especially for tumor metastasis therapy. Non-cytotoxic BMLE treatment dramatically 
reduced migration and invasion properties and reduced, not only secretion, but also 
expression of MMP-2 and MMP-9 in androgen-independent rat prostate cancer cells. 
Additionally, uPA, which is an upstream enzyme of MMPs also implicated in tumor cell 
invasion, survival, and metastasis [92,93], was similarly reduced by BMLE treatment. Since 
TIMPs have the ability to form tight 1:1 complexes with the active MMP enzymes, changes 
in TIMP levels directly affect MMP activity [94,95]. BMLE treatment induced the expression 
of TIMP-2 that may be involved in the inhibition of tumor cell invasion. In addition, BMLE 
slightly reduced the proteolytic activity of collagenase type IV. Therefore, BMLE might 
mainly reduce the activity of MMPs by suppression of u-PA and induction of TIMP-2, and 
also may partially inhibit MMP activity through direct action. 
The exact nature of the active components of BMLE, which exerts anti-invasion effects, now 
needs to be explored along with further elucidation of the underlying molecular 
mechanisms. Kuguacin J, which already has been investigated for its effects to inhibit P-gp 
function and reverse MDR in cervical carcinoma [60] and to induce G1 arrest and apoptosis 
in human prostate cancer cell lines [61,73], could be a candidate for a purified compound 
with inhibitory activities against cancer cell invasion and metastasis. 
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exhibit little or virtually no side effects and do not further increase the patient’s medication 
burden. 
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needs to be explored along with further elucidation of the underlying molecular 
mechanisms. Kuguacin J, which already has been investigated for its effects to inhibit P-gp 
function and reverse MDR in cervical carcinoma [60] and to induce G1 arrest and apoptosis 
in human prostate cancer cell lines [61,73], could be a candidate for a purified compound 
with inhibitory activities against cancer cell invasion and metastasis. 
 
Carcinogenesis 286 
Our study showed that non-cytotoxic levels of kuguacin J dramatically reduced the 
migration and invasion of androgen-independent human prostate cancer PC3 cells [73]. 
Kuguacin J treatment reduced the secretion of active MMP-2, but did not reduce mRNA 
expression. Importantly, kuguacin J treatment also reduced the expression of MT1-MMP. 
Besides, kuguacin J inhibited the secretion of active MMP-9 and uPA. MMP-9 expression 
also appeared to be reduced by kuguacin J, but the reduction was not significant. The 
activity of purified collagenase type IV was not directly modulated by kuguacin J, indicating 
that kuguacin J-mediated the inhibition of the PC3 MMP enzymes, but was not affected by 
the direct inhibition of their collagenase activities. 
BMLE and kuguacin J exert inhibitory effects in vitro on the progression of androgen-
independent rat and human prostate cancer cells, respectively, by suppressing cancer cell 
invasion and metastasis [72,73]. These provide a basis for the use of BMLE as a dietary 
supplement and kuguacin J as a broader antineoplastic agent for cancer progression. Further 
studies are underway to explore the molecular mechanisms of the action of kuguacin J and 
to determine its properties in vivo. 
2.2. Anticancer in vivo studies 
Kuguacin J has only been recently isolated [62], thus the chemopreventive effects of 
kuguacin J on cancer or the study of carcinogenesis in vivo have not been elucidated yet. An 
important limitation is that the yield of kuguacin J obtained after purification was not 
enough to perform in vivo experiments. On the other hand, bitter melon extract (BME), from 
which kuguacin J was purified, was reported to have anticancer effects in in vivo studies. 
The bitter melon seed or fruit extracts were shown to have anticancer activities in a rat 
colonic aberrant crypt foci model [96] and a mouse mammary tumor model [20]. Extracts of 
bitter melon fruits were reported to inhibit tumor formation of lymphoma cells (L1210 and 
P388) with intraperitoneal injections of BME inhibited tumor formation in CBA/H mice [8]. 
BME also inhibited aberrant crypt foci, which is known as preneoplastic lesion, in the rat 
colon [97]. In addition, seed oil from bitter melon was reported to inhibit aberrant crypt foci 
and carcinogenesis induced by azoxymethane in the rat colon through an elevation of 
peroxisome proliferator-activated receptor gamma expression and an alteration of lipid 
composition [98]. 
Other purified materials from BME were also reported to inhibit cancer and/or 
carcinogenesis. Momordica protein of 30 kDa (MAP30) from MC was reported to inhibit 
breast cancer in the tumor xenograft model. The treatment of human breast cancer-bearing 
SCID mice with MAP30 resulted in significant increases in survival, with 20–25% of the mice 
remaining tumor free for 96 days [99]. Administration of MCP30 decreased PC3 human 
prostate cancer cell growth by the induction of apoptosis in nude mice [71]. Recent studies 
further indicate that the chemical modification and reduction of ribosome-inactivating 
protein in BME, significantly reduced its in vivo immunogenicity, but retained its anti-
proliferative activity as measured by DNA fragmentation and caspase-3 activation [100]. 
Cucurbitane-type triterpenoids, charantosides, from a methanol extract of the fruits of MC 
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also inhibited mouse skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene 
(DMBA) or peroxynitrite plus 12-O-tetradecanoylphorbol-13-acetate (TPA) [45] α-ESA in 
bitter melon seed oil suppressing the growth of DLD-1 human colon cancer cells by 
apoptosis induction via lipid peroxidation [101]. α-ESA, which is converted to conjugated 
linoleic acid in vivo, had a stronger suppressive effect than the conjugated linoleic acid on 
tumor cell growth. 
We also have reported the anti cancer abilities of BMLE in vivo [72,73]. Dietary BMLE 
treatment tended to reduce lung weight and the number of lung metastatic tumors in a 
model in which intravenous inoculation of androgen-independent rat prostate cancer cells 
was injected into nude mice, resulting in a 100% incidence of lung metastasis [72]. Treatment 
of BMLE significantly reduced the percentage of the tumor area in the lungs in a dose-
response manner.  
In another study, while kuguacin J inhibited the migration and invasion of PC3 cells in vitro, 
dietary BMLE did not reduce metastasis to the lymph node but significantly reduced the 
growth of PC3 xenografts [73]. One reason why the differences in the incidence of lymph 
node metastasis between the control and the BMLE-diet fed animals could not be 
determined is that the PC3 xenograph model had a very low incidence of metastasis. Taking 
all the mice together, PC3 cells metastasized to the lymph node with an incidence of only 
3/20, 15%, while metastasis to other organs was not detected. 
Our in vitro data presented that the mechanism of the anticancer effects of kuguacin J were 
similar to BMLE in androgen-dependent and -independent prostate cancer via cell cycle 
arrest, apoptosis and invasion [61,72,73], suggesting that the possibility of in vivo anticancer 
effects of kuguacin J might be similar to BMLE. Therefore, further work using suitable in 
vivo models will be necessary to fully understand the in vivo activity of kuguacin J. 
With respect to in vivo toxicity, MC was shown to be safe with no signs of nephrotoxicity 
and hepatotoxicity without any adverse influence on food intake, growth organ weights and 
hematological parameters in experimental animals when ingested in low doses up to a 
period of 2 months [4,102]. The relatively low toxicity of all parts of this plant has also been 
reported when ingested, while toxicity and even death in laboratory animals has only been 
reported when the extracts were administered intravenously or by intraperitoneal injection 
in high doses [103]. MC has shown abortifacient activity traditionally, as well as 
experimentally [3,7]. The fruit and seeds demonstrated greater toxicity than the leaf or aerial 
parts of the plant. The documented adverse effects of MC are hypoglycemic coma and 
convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in 
gamma-glutamyltransferase and alkaline phosphatase levels in animals, as well as 
headaches [3]. 
3. Conclusion  
A current strategy for the evaluation of anticancer phytochemicals is based in part on: (1) 
cell cycle and apoptosis regulation; (2) anti-oxidative stress and anti-inflammatory activities; 
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Our study showed that non-cytotoxic levels of kuguacin J dramatically reduced the 
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the direct inhibition of their collagenase activities. 
BMLE and kuguacin J exert inhibitory effects in vitro on the progression of androgen-
independent rat and human prostate cancer cells, respectively, by suppressing cancer cell 
invasion and metastasis [72,73]. These provide a basis for the use of BMLE as a dietary 
supplement and kuguacin J as a broader antineoplastic agent for cancer progression. Further 
studies are underway to explore the molecular mechanisms of the action of kuguacin J and 
to determine its properties in vivo. 
2.2. Anticancer in vivo studies 
Kuguacin J has only been recently isolated [62], thus the chemopreventive effects of 
kuguacin J on cancer or the study of carcinogenesis in vivo have not been elucidated yet. An 
important limitation is that the yield of kuguacin J obtained after purification was not 
enough to perform in vivo experiments. On the other hand, bitter melon extract (BME), from 
which kuguacin J was purified, was reported to have anticancer effects in in vivo studies. 
The bitter melon seed or fruit extracts were shown to have anticancer activities in a rat 
colonic aberrant crypt foci model [96] and a mouse mammary tumor model [20]. Extracts of 
bitter melon fruits were reported to inhibit tumor formation of lymphoma cells (L1210 and 
P388) with intraperitoneal injections of BME inhibited tumor formation in CBA/H mice [8]. 
BME also inhibited aberrant crypt foci, which is known as preneoplastic lesion, in the rat 
colon [97]. In addition, seed oil from bitter melon was reported to inhibit aberrant crypt foci 
and carcinogenesis induced by azoxymethane in the rat colon through an elevation of 
peroxisome proliferator-activated receptor gamma expression and an alteration of lipid 
composition [98]. 
Other purified materials from BME were also reported to inhibit cancer and/or 
carcinogenesis. Momordica protein of 30 kDa (MAP30) from MC was reported to inhibit 
breast cancer in the tumor xenograft model. The treatment of human breast cancer-bearing 
SCID mice with MAP30 resulted in significant increases in survival, with 20–25% of the mice 
remaining tumor free for 96 days [99]. Administration of MCP30 decreased PC3 human 
prostate cancer cell growth by the induction of apoptosis in nude mice [71]. Recent studies 
further indicate that the chemical modification and reduction of ribosome-inactivating 
protein in BME, significantly reduced its in vivo immunogenicity, but retained its anti-
proliferative activity as measured by DNA fragmentation and caspase-3 activation [100]. 
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linoleic acid in vivo, had a stronger suppressive effect than the conjugated linoleic acid on 
tumor cell growth. 
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treatment tended to reduce lung weight and the number of lung metastatic tumors in a 
model in which intravenous inoculation of androgen-independent rat prostate cancer cells 
was injected into nude mice, resulting in a 100% incidence of lung metastasis [72]. Treatment 
of BMLE significantly reduced the percentage of the tumor area in the lungs in a dose-
response manner.  
In another study, while kuguacin J inhibited the migration and invasion of PC3 cells in vitro, 
dietary BMLE did not reduce metastasis to the lymph node but significantly reduced the 
growth of PC3 xenografts [73]. One reason why the differences in the incidence of lymph 
node metastasis between the control and the BMLE-diet fed animals could not be 
determined is that the PC3 xenograph model had a very low incidence of metastasis. Taking 
all the mice together, PC3 cells metastasized to the lymph node with an incidence of only 
3/20, 15%, while metastasis to other organs was not detected. 
Our in vitro data presented that the mechanism of the anticancer effects of kuguacin J were 
similar to BMLE in androgen-dependent and -independent prostate cancer via cell cycle 
arrest, apoptosis and invasion [61,72,73], suggesting that the possibility of in vivo anticancer 
effects of kuguacin J might be similar to BMLE. Therefore, further work using suitable in 
vivo models will be necessary to fully understand the in vivo activity of kuguacin J. 
With respect to in vivo toxicity, MC was shown to be safe with no signs of nephrotoxicity 
and hepatotoxicity without any adverse influence on food intake, growth organ weights and 
hematological parameters in experimental animals when ingested in low doses up to a 
period of 2 months [4,102]. The relatively low toxicity of all parts of this plant has also been 
reported when ingested, while toxicity and even death in laboratory animals has only been 
reported when the extracts were administered intravenously or by intraperitoneal injection 
in high doses [103]. MC has shown abortifacient activity traditionally, as well as 
experimentally [3,7]. The fruit and seeds demonstrated greater toxicity than the leaf or aerial 
parts of the plant. The documented adverse effects of MC are hypoglycemic coma and 
convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in 
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headaches [3]. 
3. Conclusion  
A current strategy for the evaluation of anticancer phytochemicals is based in part on: (1) 
cell cycle and apoptosis regulation; (2) anti-oxidative stress and anti-inflammatory activities; 
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(3) drug resistance of cancer cells; and (4) specific molecular targets targeting carcinogenesis 
and metastasis. In our studies, BMLE and one of the tritepenoids included in BMLE, 
kuguacin J, have shown that they possess potent anticancer capabilities to induce 
apoptosis/cell cycle arrest in pre-initiated/initiated tumor cells, while in more advanced 
tumors, these compounds could block resistance to anticancer drugs, tumor progression and 
metastasis (Figure 3). These findings provide evidence of the anticancer effects of BMLE and 
kuguacin J (as summarized in Figure 3) and suggest the strong possibility that these natural 
products can be developed for cancer chemoprevention and chemotherapy.  
 
Figure 3. Summary of reported anticancer effects of bitter melon leaf extract and kuguacin J [59-
61,72,73]. 
The critical points to be investigated in future experiments include the fact that Kuguacin J 
accounts for only approximately 1.6% of BMLE [61]. BMLE is known to include several 
triterpenoids and flavoniods. Recently various triterpenoids have shown promising effects 
when applied as anticancer agents [104,105]. Cucurbitacin B (cucB), a triterpenoid from 
Cucurbitaceae vegetables also found in bitter melon seeds, caused cell cycle arrest and 
apoptosis induction in human colon adenocarcinoma cancer cells [53]. Additionally, Rutin, a 
flavonoid present in bitter melon leaves, has been reported to display growth inhibition of 
leukemia and ovarian carcinoma cells, with anti-invasive effects on melanoma cells [35,56-
58]. Therefore, BMLE may include other bioactive compounds apart from kuguacin J, which 
exert anti-tumor effects, although human studies have not yet been published. Thus, a 
characterization of other active components present in BMLE needs to be further elucidated. 
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In addition, the absorption and metabolism of the bioactive compounds after consumption 
remains to be investigated as to whether a test tube study can be applicable to people. 
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1. Introduction 
Cancer is a multistage disease involving a series of events and generally occurs over an 
extended period. During this period, accumulation of genetic and epigenetic alterations 
leads to the progressive transformation of a normal cell into a malignant cell. Cancer cells 
acquire several abilities that most healthy cells do not possess: they become resistant to 
growth inhibition, proliferate without dependence on growth factors, replicate without 
limit, evade apoptosis, and invade, metastasize and support angiogenesis [1]. Unlike heart 
disease, death rates for cancer remained approximately the same in the United States from 
1975 through 2002. Indeed, it is predicted that by 2020 approximately 15 million new cancer 
cases will be diagnosed worldwide and 12 million cancer patients will die [2]. 
Cancer is a disease characterized by uncontrolled growth and division of genetically altered 
cells and its emergence requires several elements, including self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, tissue invasion and metastasis, and sustained angiogenesis [1, 3]. Cancer is 
thought to evolve along a multi-step process. Cancer cells are the descendants of a normal 
cell in which some kind of internal or external stress causes a change in its genetic code. This 
event is said to initiate the cell to a precancerous state. In a second stage, this precancerous 
cell divides in response to a promoting agent to produce daughter cells, and these daughter 
cells divide to produce more daughter cells, and so on. The genetic instabilities passed down 
through the generations finally result in one cell that no longer requires the promoting agent 
to stimulate its proliferation. A cancer cell is thus born with the ability to make proteins such 
as growth factors that stimulate proliferation. Finally in the third stage of carcinogenesis, 
progression, this cancer cell divides to produce daughter cells, which also divide, and soon 
there is a population of cancer cells with the ability to invade and metastasize [4]. 
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It is now clear that cancer phenotypes result from the dysregulation of more than 500 genes 
at multiple steps in cell signaling pathways. This indicates that inhibition of a single gene 
product or cell signaling pathway is unlikely to prevent or treat cancer. However, most 
current anticancer therapies are based on the modulation of a single target [5, 6]. 
One of the most important findings to have emerged during the past three decades is that 
cancer is a largely preventable disease. Thus, people need to be educated about the risk 
factors for cancer and those that prevent the disease. As many as 90% of all cancers have 
been shown to be due to environmental/acquired factors such as tobacco, diet, radiation and 
infectious organisms, etc., and only the remaining 5–10% of cases are caused by internal 
factors such as inherited mutations, hormones, and immune conditions [7]. 
The ineffective, unsafe, and expensive monotargeted therapies have led to a lack of faith in 
these approaches. Therefore, the current paradigm for cancer treatment is either to combine 
several monotargeted drugs or to design drugs that modulate multiple targets. As a result, 
pharmaceutical companies have been increasingly interested in developing multitargeted 
therapies. Many plant-derived dietary agents, called nutraceuticals, have multitargeting 
properties. In addition, these products are less expensive, safer, and more readily available 
than are synthetic agents [5]. 
Prevention is better than cure and this is very true in case of cancer. Chemoprevention was 
defined as the administration of agents to prevent induction, to inhibit or to delay the 
progression of cancer [8], or as the inhibition or reversal of carcinogenesis at a premalignant 
stage [9]. Chemoprevention involves the use of synthetic or natural compounds to inhibit, 
slow, or reverse carcinogenesis. It is based on the hypothesis that the disruption of biological 
events involved in carcinogenesis will inhibit this process and can be applied to any stage of 
carcinogenesis. Chemoprevention utilizes appropriate pharmacological agents [10,11] or 
dietary agents, consumed in diverse forms like macronutrients, micronutrients, or 
nonnutritive phytochemicals [12–14]. It is estimated that from 10 to 80 percent of cancer 
patients use some form of natural compounds as a part of complementary medicine as part 
of their overall therapy without any real guidance. This explains the growing interest in 
using the natural compounds properly in the treatment of cancer. 
Phytochemicals are one wide class of nutraceuticals found in plants, which are extensively 
researched by scientists for their health-promoting potential. Honey has a wide range of 
phytochemicals including polyphenols which act as antioxidants. Polyphenols and phenolic 
acids found in the honey vary according to the geographical and climatic conditions. Some 
of them were reported as a specific marker for the botanical origin of the honey. 
Considerable differences in both composition and content of phenolic compounds have 
been found in different unifloral honeys [15]. Terpenes, benzyl alcohol, 3, 5-dimethoxy-4-
hydroxybenzoic acid (syringic acid), methyl 3, 5-dimethoxy-4-hydroxybenzoate (methyl 
syringate), 3, 4, 5-trimethoxybenzoic acid, 2-hydroxy-3- phenylpropionic acid, 2-
hydroxybenzoic acid and 1, 4- dihydroxybenzene are some of the phytochemicals a ascribed 
for the antimicrobial activity of honey [16]. Among these phytochemicals, polyphenols were 
reported to have antiproliferative potential.  
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2. Active compounds in propolis 
Polyphenolic compounds are widely distributed in the plant kingdom and display a variety 
of biological activities, including chemoprevention and tumor growth inhibition. Propolis 
and honey have been known to mankind from the remotest of ancient times and have been 
widely used by many cultures for different purposes. Propolis is a complex resinous 
mixture gathered from plants and used by honeybees in their hives as a general-purpose 
sealer and antibiotic. It is made up of a variety of polyphenolic compounds. Some of the 
isolated compounds have shown anti-inflammatory activity, carcinostatic, anti-carcinogenic 
activity and induction of apoptosis. Caffeic acid (CA) and caffeic acid phenethyl ester 
(CAPE) are members of the polyphenolic compounds and present in high concentrations in 
medicinal plants and propolis. CAPE showed a wide variety of biological activities at non-
toxic concentrations. It has shown antibacterial, anti-inflammatory, antioxidant, antitumor 
and anti-proliferative activities [17]. 
CAPE [2-propenoic acid, 3-(3,4-dihydroxy phenyl)-,2-phenethyl ester] (Fig.1) is an active 
component of propolis with a variety of biological activities. CAPE has been used in folk 
medicine as a potent antibacterial, anti-inflammatory, antioxidant, antitumor and 
antiproliferative with a wide variety of biological and pharmacological activities at non-
toxic concentrations in a mammal's organs [18]. 
 
Figure 1. Structure of caffeic acid phenethyl ester (CAPE) 
CAPE is chemopreventive against intestinal, colon and skin cancer, and also has been 
shown to decreases the formation of preneoplastic hepatic lesions when is administrated in 
a rat model of liver carcinogenesis [19-21], but the mechanism of these properties is not 
completely understood. Recently, CAPE, in a concentration dependent fashion, was shown 
to inhibit MCF-7 (hormone receptor positive, HR+) and MDA-MB-231 (a model of triple 
negative BC (TNBC)) tumor growth, either in vitro or in vivo without much effect on normal 
mammary cells [22]. At the same time, CAPE was found to cause pronounced changes in 
bCSC characteristics manifested by inhibition of self renewal, progenitor formation, 
clonal growth in soft agar, and concurrent significant decrease in CD44 content, all signs of 
decreased malignancy potential [23]. Besides CAPE, other caffeic acid esters in propolis may 
have biological effects. 
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Here we will focus on CAPE and its biological effects against cancer in vitro and in vivo. 
Specifically, we will discuss how CAPE can modulate inflammatory pathways and thus 
affect the survival, proliferation, invasion, angiogenesis, and metastasis of the tumor. 
2.1. Regulation of inflammatory pathways by CAPE 
Inflammation is a localized reaction of tissue to infection, irritation, or other injury. 
Inflammation is a necessary response to clear bacterial and viral infections, repair tissue 
insults, and suppress tumor initiation/progression. However, when inflammation persists or 
control mechanisms are dysregulated, diseases such as cancer can develop. Interestingly, 
inflammation functions at all stages of tumor development: initiation, promotion and 
progression including metastasis. During the initiation phase, inflammation induces the 
release of a variety of cytokines and chemokines that promote the activation of 
inflammatory cells and associated factors. This causes further oxidative damage, DNA 
mutations, and other changes in the tissue microenvironment, making it more conducive to 
cell transformation, increased survival, and proliferation [24]. At the molecular level, 
inflammation, transformation, survival and proliferation are regulated by the 
proinflammatory transcription factor Nuclear Factor-κB (NF-κB), a family of ubiquitously 
expressed transcription factors. NF-κB regulates the expression of genes involved in the 
transformation, survival, proliferation, invasion, angiogenesis and metastasis of tumor cells 
[25]. 
TNF-α is also one of the prime signals that induces apoptosis in many different types of 
cells. Whereas acute activation of NF-κB may be therapeutic, chronic activation may lead to 
the development of chronic inflammation, cancer and other chronic diseases. There is a 
strong association between chronic inflammatory conditions and cancer specific to the 
organ. Epidemiological evidence points to a connection between inflammation and a 
predisposition for the development of cancer, i.e., long-term inflammation leads to the 
development of dysplasia. Various factors are known to induce chronic inflammatory 
responses that further cause cancer. These include bacterial, viral, and parasitic infections 
(e.g., Helicobacter pylori, Epstein-Barr virus, human immunodeficiency virus, flukes, 
schistosomes) and chemical irritants (i.e., tumor promoters). Active NF-κB has now been 
identified in tissues of most cancer patients, including those with leukemia and lymphoma 
and cancers of the prostate, breast, oral cavity, liver, pancreas, colon and ovary [26]. 
In the resting stage, NF-κB resides in the cytoplasm as a heterotrimer consisting of p50, p65, 
and the inhibitory subunit IκBα. On activation, the IκBα protein undergoes 
phosphorylation, ubiquitination, and degradation. p50 and p65 are then released, are 
translocated to the nucleus, bind specific DNA sequences present in the promoters of 
various genes, and initiate their transcription. A number of proteins are involved in the NF-
κB signaling pathway. Because of the relevance of the NF-κB signaling pathway in cancer, 
this pathway has been proven to be an attractive target for therapeutic development. 
Active NF-κB complexes can contribute to tumorigenesis by regulating genes that promote 
the growth and survival of cancer cells, during the cell cycle. NF-κB has ability to regulate 
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the G1-phase expression of key proto-oncogenes is subject to regulation by the 
integrated activity of IkappaB kinase (IKK)alpha, IKKbeta, Akt and Chk1. The coordinated 
binding of NF-κB subunits to the Cyclin D1, c-Myc and Skp2 promoters is dynamic with 
distinct changes in promoter occupancy and RelA(p65) phosphorylation occurring through 
G1, S and G2 phases, concomitant with a switch from coactivator to corepressor recruitment. 
Akt activity is required for IKK-dependent phosphorylation of NF-κB subunits in G1 and G2 
phases, where Chk1 is inactive. However, in S-phase, Akt is inactivated, while Chk1 
phosphorylates RelA and associates with IKKalpha, inhibiting the processing of the p100 
(NF-κB2) subunit, which also plays a critical role in the regulation of these genes. This 
reveals a complex regulatory network integrating NF- κB with the DNA-replication 
checkpoint and the expression of critical regulators of cell proliferation [27]. Thus, its 
inhibition could be a novel approach to breaking the vicious cycle of tumor cell proliferation 
[28-30] More than 700 inhibitors of the NF-κB activation pathway have been reported, 
including antioxidants, peptides, small RNA/DNA, microbial and viral proteins, small 
molecules, and engineered dominant-negative or constitutively active polypeptides [31,32].  
Caffeic acid phenethyl ester has been shown to suppress NF-κB activation by suppressing 
the binding of the p50–p65 complex directly to DNA [33-35]. The molecular basis of CAPE 
action was elucidated by Natarajan et al. [36]. Since NF-κB has a role in these activities, they 
examined the effect of CAPE on this transcription factor in an exhaustive manner. They 
preincubated the U-937 cells with CAPE at various concentrations for 2 hours before 
treating with TNF (0.1 nM) for 15 minutes. CAPE inhibited the TNF-dependent activation of 
NF-κB in a dose-dependent manner with maximum effect occurring at 25 μg/mL. NF- κB 
activation induced by the phorbol ester, phorbol-12- myristate 13-acetate (PMA), ceramide, 
okadaic acid and hydrogen peroxide was also inhibited by CAPE. It prevented the 
translocation of the p65 subunit of NF-κB to the nucleus without affecting the TNF-induced 
IκBα degradation. It did not show any inhibitory effects on the other transcription factors 
like AP-1, TFIID and oct-1. With these findings they concluded that CAPE is a potent and a 
specific inhibitor of NF-κB activation and this may provide the molecular basis for its 
multiple immunomodulatory and antiinflammatory activities of CAPE. 
Abdel-Latif et al.[37] have demonstrated for the first time that CAPE is a major component 
of propolis, modulates H. pylori-induced NF-κB, AP-1 DNA binding activity and COX-2 
expression in gastric epithelial cells. In addition, CAPE reduced TNF-α and IL-8 levels and 
suppressed the proliferative response of AGS cells to H. pylori. They found also that 
pretreatment of gastric epithelial cells with CAPE upregulated IkB-a levels and prevented 
nuclear translocation of NF-κB/ p65 in H. pylori-treated AGS cells. NF-κB is present in the 
cytosol in an inactive state bound to the inhibitory IkB protein. H. pylori infection of gastric 
epithelial cells results in phosphorylation and degradation of the IkB, thus allowing nuclear 
translocation of NF-κB. 
It is mechanistically proven that inflammation produces reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). In particular, ROS and RNS lead to oxidative damage and 
nitration of DNA bases, which increases the risk of DNA mutations and further leads to 
cancer. Nitric oxide (NO) is associated with inflammatory reaction and is produced by 
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[28-30] More than 700 inhibitors of the NF-κB activation pathway have been reported, 
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Caffeic acid phenethyl ester has been shown to suppress NF-κB activation by suppressing 
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inducible nitric oxide synthase (iNOS) in certain cells activated by various proinflammatory 
agents. NO acts as a host defense by damaging membranes of pathogenic bacteria and as a 
regulatory molecule with homeostatic activities. However, excessive production of NO is 
pathogenic for host tissue itself because NO, as a reactive radical directly damages functions 
of normal tissue. Thus, effective inhibition of NO accumulation by inflammatory stimuli 
represents a beneficial therapeutic strategy [38,39]. 
Nagaoka et al. [40] reported that CAPE possesses potent NO inhibitory activities and 
suggested that the NO inhibitory effect can directly correlate with anti-inflammatory 
properties of the Netherlands propolis. They suggested that the active principles of the 
Netherlands propolis, i.e., CAPE and its analogues, should block the activation of iNOS 
through the suppression of NF-kB activation and resulted in potent NO inhibition. 
We investigated the anti-inflammatory and antioxidant potential of CAPE on a tumor cell 
line (ZR-75-1). We found that CAPE at the concentration of 15μM inhibited NO production 
by (› 47%) compared to NO level of untreated tumor cells (P‹ 0.05). In addition, superoxide 
dismutase (SOD) was at the highest level in the maintained basal tumor culture cell 
supernatant ( 231.9± 4.2 μU/L). This level reduced intensively to (169.3 ± 3.7 μU/L), in the 
CAPE-treated culture cells, which was significantly less than the level in untreated cells ( 
P‹0.001). On the other hand, malonaldehyde (MDA) level, which is considered to be an 
important parameter for the oxidative damage determination, was inhibited to ( 17.3 ± 2.3 
μmol/L) in the CAPE-treated cells when compared with untreated tumor cells (23.8 ± 2.5 










 Group Parameters 
23.8 ± 2.5 231.9 ± 4.2  19.6 ± 1.9  I 
17.3 ± 2.3 169.3 ± 3.7  10.2 ± 1.3  II 
 
N.S ‹ 0.001  ‹ 0.05  P 
(I). Untreated tumor cells , (II). Treated tumor cells at 15μM CAPE. 
Table 1. Nitric oxide (NO·), Superoxide dismutase (SOD) and Malondialdehyde (MDA) values in 
culture supernatant. 
2.2. Regulation of tumor cell development by CAPE 
Under normal physiological conditions, the human body maintains homeostasis by 
eliminating unwanted, damaged, aged, and misplaced cells. Homeostasis is carried out in a 
genetically programmed manner by a process referred to as apoptosis (programmed cell 
death). Cancer cells are able to evade apoptosis and grow in a rapid and uncontrolled 
manner. One of the most important ways by which cancer cells have gained this ability is 
through mutation in the p53 tumor suppressor gene. Without a functional p53 gene, cells 
lack the DNA-damage-sensing capability that would normally induce the apoptotic cascade 
[41-43]. 
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A complex set of proteins, including caspases, proapoptotic and antiapoptotic B cell 
lymphoma (Bcl)-2 family proteins, cytochrome c, and apoptotic protease activating factor 
(Apaf)-1, execute apoptosis either by an intrinsic or extrinsic pathway. The intrinsic 
pathway is mitochondria dependent, whereas the extrinsic pathway is triggered by death 
receptors (DRs). Some antiapoptotic proteins such as Bcl-2 and B cell lymphoma extra large 
(Bcl-xL) and survivin are overexpressed in a wide variety of cancers. Therefore, selective 
downregulation of antiapoptotic proteins and upregulation of proapoptotic proteins and 
p53 in cancer cells offer promising therapeutic interventions for cancer treatment [44,45]. 
We tested the effect of CAPE on the viability of human breast cancer ZR-75-1 cells derived 
from a malignant ascitic effusion in a 63 year-old, white female with infiltrating ductal 
carcinoma [46]. CAPE induced a significant inhibitory effect on the growth and viability of 
tumor cells in vitro. We observed that this inhibitory action was highly dosage and time-
dependent. The maximum inhibitory action was obtained at 15μM (Figure 2A) on culture 
media. 
 
Figure 2. CAPE induced ZR-75-1 cell death (A); cell viability was observed in tumor cells treated with 
different CAPE concentrations (5, 10, 15 and 20μM), while (B) cells showed maximum alteration of 
viability at 48 hrs. of incubation, indicating that CAPE induced cell death in a dose and time dependent 
manner. The results shown in the histogram were the mean ± S.D. Assay was performed in 12 – well 
plate (2 x 106 ) cells/well, using trypan blue dye for viability detection. 
On the other hand, after 48 hours of administration, the percentage of cell death increased 
significantly to 49.6±6.9 (Figure 1B). No further changes were observed after 72 hours of 
treatment. To investigate the induced effect of apoptosis on cell viability, we analyzed the 
DNA fragmentation using DAPI. The nuclear structure exhibited condensation and 
fragmentation of some nuclei that were caused by 15μM CAPE at 48 hours. Apoptotic cells 
count significantly increased by 27% as compared to control tumor cells (P ‹ 0.01) (Figure 3B) 
[47]. 
Additionally, the microscopic examination did not reveal any signs of morphological 
changes after 12 hours of administration. However, a scattered retraction of the monolayer, 
vacuoles, and the granulation of the cytoplasm were observed after 24 hours. The 
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A complex set of proteins, including caspases, proapoptotic and antiapoptotic B cell 
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from a malignant ascitic effusion in a 63 year-old, white female with infiltrating ductal 
carcinoma [46]. CAPE induced a significant inhibitory effect on the growth and viability of 
tumor cells in vitro. We observed that this inhibitory action was highly dosage and time-
dependent. The maximum inhibitory action was obtained at 15μM (Figure 2A) on culture 
media. 
 
Figure 2. CAPE induced ZR-75-1 cell death (A); cell viability was observed in tumor cells treated with 
different CAPE concentrations (5, 10, 15 and 20μM), while (B) cells showed maximum alteration of 
viability at 48 hrs. of incubation, indicating that CAPE induced cell death in a dose and time dependent 
manner. The results shown in the histogram were the mean ± S.D. Assay was performed in 12 – well 
plate (2 x 106 ) cells/well, using trypan blue dye for viability detection. 
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vacuoles, and the granulation of the cytoplasm were observed after 24 hours. The 
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alterations were further aggravated after 48 hours. The cells were rounded up. Later, they 
became phase-dense and formed floating aggregates, which gradually increased in size and 
most of the cells were detached from the flasks. The cell membranes burst, which was 
followed by a gradual decrease of the cell count. These changes were not reversible. 










Figure 3. Effect of CAPE on expression of apoptotic cells. (A) ZR-75-1 cells without treatment. (B) Cells 
were treated with 15μM CAPE for the indicated time of 48 hrs. Condensation and apoptotic bodies 
were examined by immunofluorescence microscopy. Magnification, X20.  
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Figure 4. CAPE induced cell detaching (A) ZR-75-1 cells kept without treatment during experiments. 
(B) 15μM CAPE treatment after 48 hrs. Morphology changes in cells were examined by phase-contrast 
microscopy. Magnification, X40. 
2.3. Tumor growth inhibition in vivo by CAPE 
The effects of CAPE on the survival of mice bearing tumor are shown in figure 5. The 
median survival time for the untreated group of mice was 21 days. On the other hand, the 
group of mice bearing tumor and treated with 10mg/kg S.C/ every 5 days had a median 
survival time of 29 days. Two mice were completely cured. The median survival time of the 
group treated with 15mg/kg S.C/ every 5 days was found to be 43 days and 3 mice were 
completely cured. However, those mice treated with 5mg /kg S.C/ every 5 days did not 
show any remarkable changes in their survival percentage. It has also been observed that 
giving treatment more than once a week caused sores and increased irritability in the mice, 
vehicle (1:1/DMSO: NaCl). 
We studied the effect of CAPE (15mg/kg S.C/ every 5 days) on the growth of transplanted 
Ehrlich carcinoma into Swiss mice. The solid tumor volume showed a reduced rate in 
CAPE-treated mice and appreciably smaller volume (1.9 ± 0.46) mm³, with respect to the 
untreated group (3.7 ± 0.82) mm³. This value was significant (P‹ 0.01). The difference was 
observed from the beginning of tumor measurement i.e. since the 6th day after tumor 
implantation to the host, and was maintained until the end of observation (Figure 6). This 
finding is one of the characteristic effects of anti-tumor drugs. It is also in accordance with 
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the other findings, which suggest that subcutaneous administration of an aqueous crude 
water-soluble propolis (CWSP) resulted in marked regression of transplanted tumors [48]. 
 
 
Figure 5. Effect of CAPE treatment on the time of survival for mice bearing solid tumor at different 
doses compared with untreated group. 
 
Figure 6. Effect of CAPE (15mg/kg S.C), once/week and twice/week treatment on tumor volume against 
untreated group of mice. Data represented as mean ± S.D.  
The percentage of apoptotic cells with hypodiploid DNA content was determined from 
DNA histograms. Untreated tumor-bearing mice showed a peak pattern which represented 
proliferative and high metastatic tumor activity (Figure 7A). However the mice which had 
their tumor treated at 15mg/kg S.C did not alter the relative size of the peak, but induced a 
significant parallel shift to less-intense fluorescence (D- area). This decrease in the intensity 
and shift may be termed as nuclear apoptosis and fragmentation (Figure 7B). 
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Figure 7. The value in the tumor apoptosis histogram was higher in mice-bearing tumors, which were 
treated with CAPE (15mg/kg/S.C). (B) as compared to mice-bearing tumors untreated with CAPE (A). 
The apoptosis was identified by PI staining (D-area) with increased DNA fragmentation [47]. 
Chung et al., [49] showed that both CA and CAPE selectively inhibit matrix 
metalloproteinases (MMP) 2 and 9. CAPE inhibited strongly MMPs 2 and 9 with IC50 of 2–
5μM, while CA required 10–20 μM for such inhibition. In contrast, MMPs 1, 3, 7 and 
Cathepsin-K were not completely inhibited by either of them. CA and CAPE had a dose-
dependent inhibitory effect on the proliferation of HEPG2 cells. In HepG2 cells, CA at the 
concentration of 200 μg/mL reduced the viability to 61% , while CAPE, at 10 times lower 
concentration, inhibited the viability to 72% as compared to the respective controls. CAPE 
and CA suppressed the MMP 9 expression in HepG cells exposed to phorbol 12-myristate 
13-acetate (PMA). They also confirmed that CA (20 mg/kg) and CAPE (5mg/kg) repressed 
the growth of HepG2 tumor xenografts in nude mice as well as liver metastasis when 
administered subcutaneous or orally. Finally they concluded their observation that CA and 
its derivative CAPE: (1) inhibited the enzymatic activity of MMP-9 that plays an important 
role in cancer invasion and metastasis, (2) blocked the invasive potential through the 
suppression of MMP-9 gene transcription by inhibiting NF-κB function in PMA-stimulated 
HepG2 cells and (3) suppressed the growth of HepG2 cell xenografts in nude mice. 
Therefore, these two drugs were reported as strong candidates for treatment of cancer and 
metastasis via dual mechanisms (dual inhibition of metastasis-specific enzyme activity and 
gene transcription) [50]. 
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2.4. Regulation of tumor cell proliferation by CAPE 
Dysregulated proliferation is one of the major characteristics of tumorigenesis. In normal 
cells, proliferation is regulated by a delicate balance between growth signals and antigrowth 
signals. Cancer cells, however, acquire the ability to generate their own growth signals and 
become insensitive to antigrowth signals [51]. Their growth is controlled by cell cycle 
regulators at the G1/S-phase boundary, in the S phase, and during the G2/M phases of the 
cell cycle. A precise set of proteins called cyclins and cyclin-dependent kinases (CDKs) 
control the progression of cell cycle events. Whereas cyclin binding is required for CDK 
activity, CDK inhibitors (CKIs) such as p21 and p27 prevent CDK activity and prevent cell 
cycle progression. The G1-to-S-phase transition also requires cellular v-myc 
myelocytomatosis viral oncogene homolog (c-Myc), and inhibition of c-Myc expression 
leads to growth arrest [52,53]. 
The expression of c-Myc in turn is regulated by cdc25, a phosphatase that activates CDKs. 
The well-characterized tumor suppressor p53 has been implicated in controlling the G1-to- 
S-phase transition and in blocking cell cycle progression at the G1 phase in response to DNA 
damage [54]. A number of genes controlling cell cycle progression, including the CKI p21, 
are transcribed in a p53-dependent manner [55,56]. 
Rb is a tumor suppressor retinoblastoma protein that, like p53, functions as a negative 
regulator of cell growth [57]. Rb inactivation or deletion has been found in many cancers, 
including retinoblastomas and carcinomas of the lung, breast, bladder, and prostate. By 
binding to and inhibiting transcription factors such as elongation 2 factor (E2F), which are 
necessary for S-phase entry, Rb is believed to inhibit cell cycle progression [58]. On the other 
hand, phosphorylation of Rb (pRb) by CDK/cyclin complexes results in the release of active 
E2F species to stimulate the transcription of genes involved in DNA synthesis and S-phase 
progression [59,60].  
Currently, a number of inhibitors based on cell cycle regulators, including nutraceuticals, 
are being developed as therapeutic intervention for cancer prevention. Nutraceuticals have 
been shown to have potential in cancer prevention for halting cell cycle progression by 
targeting one or more steps in the cell cycle. Most nutraceuticals prevent the transition of 
cancer cells from the G1 to S phase. Some of these nutraceuticals act through p53 and some 
through Rb. Acetyl-keto-beta-boswellic acid was shown to arrest colon cancer cells at the G1 
phase, which was associated with decreases in cyclin-D1, cyclin-E, CDK-2, CDK-4, and pRb 
and an increase in p21[61]. 
In Ehrlich ascites tumor cells, acetoxychavicol acetate was shown to stimulate the 
accumulation of tumor cells in the G1 phase of the cell cycle, which was accompanied by a 
decrease in pRb and an increase in Rb [62]. β-Escin, a triterpene saponin, induced cell cycle 
arrest at the G1/S phase by inducing p21 and reducing pRb in a p53-independent manner in 
HT-29 human colon cancer cells [63]. In gastric cancer cells, curcumin was shown to 
suppress the transition of cells from the G1 to S phase, which was accompanied by a 
decrease in cyclin-D1 and p21-activated kinase 1 activity [64]. 
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The therapeutic goal of cancer treatment is to induce apoptotic death of cancer cells rather 
than necrosis due to the deleterious consequences of the latter, which include leakage of 
lysosomal enzymes to the extracellular media and spawning a substantial inflammatory 
reaction. Several investigators have demonstrated that CAPE has an anti-proliferative effect 
and an apoptosis inducing effect against various tumor cell lines. Cavaliere et al., showed 
that CAPE treatment increased the percentage of cells in G0/G1 and decreased the 
percentage of cells in S and G2/M phase in addition to its ability to inhibit DNA, RNA, and 
protein synthesis , thus delaying cell cycle progression to G2/M phase. CAPE also caused 
high levels of apoptotic cell death of 77.1%, with no signs of significant necrosis in PL104 
cells [65]. Also, Wang et al., demonstrated that CAPE treatment was associated with a strong 
inhibition of proliferation in a dose- and time-dependent manner, along with induction of 
G0/G1 arrest and apoptosis in HCT116 cells [66]. 
2.5. Regulation of tumor cell invasion by CAPE 
Tumor cell invasion and metastasis are interrelated processes involving cell growth, cell 
adhesion, cell migration, and proteolytic degradation of tissue barriers such as the 
extracellular matrix and basement membrane. Several proteolytic enzymes, including 
MMPs (chiefly MMP-2 and MMP-9) [67,68] and intercellular adhesion molecule (ICAM; 
chiefly ICAM-1), participate in the degradation of these barriers [69,70]. A number of studies 
in lung, colon, breast, and pancreatic carcinomas have demonstrated overexpression of 
MMPs in malignant tissues compared with adjacent normal tissues [71-78]. Apart from 
MMPs, cysteine proteases [79] and serine proteases [80] such as urokinase-type plasminogen 
activator (u-PA) have also been involved in the invasion and metastasis of cancer cells. Since 
both u-PA and u-PA receptor (u-PAR) contain binding sites for NF-κB and activator protein 
(AP)-1 in their promoter regions [81-83], inhibition of these transcription factors will 
eventually result in the inhibition of u-PA–u-PAR complex and subsequent suppression of 
invasive behavior. 
Furthermore, Hwang et al. [84] investigated the effect of CAPE on tumor invasion and 
metastasis in HT 1080 fibrosarcoma cells by determining the regulation of matrix 
metalloproteinases (MMPs). HT 1080 cells were treated with increasing concentration of 
CAPE and the m-RNA transcripts of MMP-2 and MMP-9 were analyzed using semi-
quantitative RT-PCR. Both MMP- 2 and 9 proteins levels were significantly suppressed in 
a dose dependent manner. Gelatin zymography also indicated constitutively expressed 
MMP-2 and 9 proteins in HT 1080 cells, which gradually reduced after treating with 
CAPE. To further corroborate the down regulation of MMP-2, activation studies of pro-
MMP2 were performed using organomercuric compound, 4-aminophenylmercuric acetate 
(APMA), and the result indicated the down regulation of MMP-2 by CAPE. It has been 
shown that mRNA levels of tissue inhibitor of matrix metalloproteinases (TIMPs) and 
membrane type-matrix metalloproteinases (MT-1 MMPs) were also reduced significantly. 
CAPE also inhibited the cell invasion, cell migration and colony formation of tumor cells. 
Thus CAPE acts as a vital antimetastatic agent, by inhibiting the metastatic and invasive 
potential of malignant cells. 
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2.6. Regulation of tumor cell angiogenesis by CAPE 
Angiogenesis, the process during which new blood vessels are formed from preexisting 
ones, can be classified as either physiological or pathological. Physiological angiogenesis 
provides a driving force for organ development in ontogeny, is necessary for ovulation, and is 
a prerequisite for wound healing; pathological angiogenesis occurs during tumor growth at 
primary and metastatic sites [85]. The angiogenic cascade during tumor development consists 
of the release of angiogenic factors, binding of angiogenic factors to receptors on endothelial 
cells (ECs), EC activation, degradation of the basement membrane by proteases, and migration 
and proliferation of ECs. Adhesion molecules then help to pull the sprouting blood vessels 
forward, and ECs are finally organized into a network of new blood vessels [86].  
The signaling pathway governing tumor angiogenesis is exceedingly complex, involving 
various angiogenic mediators. The major signaling mediators include VEGF, platelet-
derived growth factor, fibroblast growth factors (FGFs), epidermal growth factor, ephrins, 
angiopoietins, endothelins, integrins, cadherins, and notch [87]. 
 
P2  P1 Treated Group
n = 10 
Tumor Group
n = 10 
Normal Group
n = 10 
Group 
Parameters 
P‹ 0.01  P‹ 0.001 142.1 
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88.2 – 216.1 
130.9 
 






P‹ 0. 01  P = 0.01 1.9 
 
 













P1 Tumor group Vs Normal group 
P2 Treated group Vs Tumor group 
Table 2. Levels of MMP-9 and Endostatin serum in normal mice group, tumor bearing group and 
treated tumor group. 
We found that the untreated mice bearing Ehrlich tumor elicited a highly significant 
increase of serum MMP-9 level (181.9 ng/ml), which was reduced (142.1 ng/ml) in mice 
treated with CAPE at a dose of 15mg/kg (P‹ 0.01) close to the normal mice serum level. 
However, in the untreated mice bearing tumor serum endostatin (sE) was significantly 
lowered (1.4 ng/ml) compared with the normal mice. In CAPE-treated mice serum endostatin 
level was significantly higher (1.9 ng/ml) than the serum level in the untreated group (Table 
2)[47]. On the other hand, there was a negative correlation between (sMMP-9 and sE) and the 
total white blood cells (WBCs), hemoglobin (HB) and the platelet count of mice (Table 3)[47]. 
Based on these findings, we concluded that; the endogenous inhibitor of the angiogenic serum 
(endostatin) has been shown to be overexpressed, significantly higher in treated mice 
compared to untreated mice  (1.9 ng/ml), and nearly to the value of normal serum mice (Table 
2). These findings may help to utilize endostatin itself in the therapy. It also indicates that 
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CAPE has the potential of an anti-metastatic agent. It may mediate CAPE effects by inhibiting 
the cell proliferation. The findings of this study are in accordance with Schuch et al. [88] who, 
claimed that endostatin microbeads significantly inhibit the growth of subcutaneous 
choloromas in SCID mice as compared to control mice. On the other hand, MMP-9 and 
endostatin did not correlate with the white blood cells (WBCs), hemoglobin (HB) and platelet 
count (Table 3). It may be concluded that MMP-9 and endostatin are independent factors. 
 





MMP-9  R= 0.11, ›0.05  R= 0.19, ›0.05  R= 0.24, ›0.05 
Endostatin  R= 0.09, ›0.05  R= 0.1, ›0.05  R= 0.04, ›0.05 
Table 3. Correlation between investigated angiogenic factors and, hemoglobin (HB), white blood cells 
count (WBCs) and platelets count in tumor treated mice. 
3. Conclusion 
These findings obtained suggest that CAPE is a potent agent, which has antioxidant 
properties. In vitro findings support that CAPE could be potentially useful in the control of 
tumor cell proliferation as well as, an apoptotic-inducing agent. Furthermore, CAPE exhibits 
anti-metastatic and anti-angiogenic properties. CAPE could be potentially useful in the 
control of tumor growth in experimental models. Its action is accompanied by the shifting 
and elevating of the angiostatic and inhibiting angiogenic factors. Finally, it has been 
demonstrated that CAPE has many biological and pharmacological properties with 
predictive future applications in human clinical trials.  
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2.6. Regulation of tumor cell angiogenesis by CAPE 
Angiogenesis, the process during which new blood vessels are formed from preexisting 
ones, can be classified as either physiological or pathological. Physiological angiogenesis 
provides a driving force for organ development in ontogeny, is necessary for ovulation, and is 
a prerequisite for wound healing; pathological angiogenesis occurs during tumor growth at 
primary and metastatic sites [85]. The angiogenic cascade during tumor development consists 
of the release of angiogenic factors, binding of angiogenic factors to receptors on endothelial 
cells (ECs), EC activation, degradation of the basement membrane by proteases, and migration 
and proliferation of ECs. Adhesion molecules then help to pull the sprouting blood vessels 
forward, and ECs are finally organized into a network of new blood vessels [86].  
The signaling pathway governing tumor angiogenesis is exceedingly complex, involving 
various angiogenic mediators. The major signaling mediators include VEGF, platelet-
derived growth factor, fibroblast growth factors (FGFs), epidermal growth factor, ephrins, 
angiopoietins, endothelins, integrins, cadherins, and notch [87]. 
 
P2  P1 Treated Group
n = 10 
Tumor Group
n = 10 
Normal Group
n = 10 
Group 
Parameters 
P‹ 0.01  P‹ 0.001 142.1 
 
84.5 – 196.3 
181.9 
 
88.2 – 216.1 
130.9 
 






P‹ 0. 01  P = 0.01 1.9 
 
 













P1 Tumor group Vs Normal group 
P2 Treated group Vs Tumor group 
Table 2. Levels of MMP-9 and Endostatin serum in normal mice group, tumor bearing group and 
treated tumor group. 
We found that the untreated mice bearing Ehrlich tumor elicited a highly significant 
increase of serum MMP-9 level (181.9 ng/ml), which was reduced (142.1 ng/ml) in mice 
treated with CAPE at a dose of 15mg/kg (P‹ 0.01) close to the normal mice serum level. 
However, in the untreated mice bearing tumor serum endostatin (sE) was significantly 
lowered (1.4 ng/ml) compared with the normal mice. In CAPE-treated mice serum endostatin 
level was significantly higher (1.9 ng/ml) than the serum level in the untreated group (Table 
2)[47]. On the other hand, there was a negative correlation between (sMMP-9 and sE) and the 
total white blood cells (WBCs), hemoglobin (HB) and the platelet count of mice (Table 3)[47]. 
Based on these findings, we concluded that; the endogenous inhibitor of the angiogenic serum 
(endostatin) has been shown to be overexpressed, significantly higher in treated mice 
compared to untreated mice  (1.9 ng/ml), and nearly to the value of normal serum mice (Table 
2). These findings may help to utilize endostatin itself in the therapy. It also indicates that 
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CAPE has the potential of an anti-metastatic agent. It may mediate CAPE effects by inhibiting 
the cell proliferation. The findings of this study are in accordance with Schuch et al. [88] who, 
claimed that endostatin microbeads significantly inhibit the growth of subcutaneous 
choloromas in SCID mice as compared to control mice. On the other hand, MMP-9 and 
endostatin did not correlate with the white blood cells (WBCs), hemoglobin (HB) and platelet 
count (Table 3). It may be concluded that MMP-9 and endostatin are independent factors. 
 





MMP-9  R= 0.11, ›0.05  R= 0.19, ›0.05  R= 0.24, ›0.05 
Endostatin  R= 0.09, ›0.05  R= 0.1, ›0.05  R= 0.04, ›0.05 
Table 3. Correlation between investigated angiogenic factors and, hemoglobin (HB), white blood cells 
count (WBCs) and platelets count in tumor treated mice. 
3. Conclusion 
These findings obtained suggest that CAPE is a potent agent, which has antioxidant 
properties. In vitro findings support that CAPE could be potentially useful in the control of 
tumor cell proliferation as well as, an apoptotic-inducing agent. Furthermore, CAPE exhibits 
anti-metastatic and anti-angiogenic properties. CAPE could be potentially useful in the 
control of tumor growth in experimental models. Its action is accompanied by the shifting 
and elevating of the angiostatic and inhibiting angiogenic factors. Finally, it has been 
demonstrated that CAPE has many biological and pharmacological properties with 
predictive future applications in human clinical trials.  
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